<SEC-DOCUMENT>0001178913-22-003074.txt : 20220812
<SEC-HEADER>0001178913-22-003074.hdr.sgml : 20220812
<ACCEPTANCE-DATETIME>20220812073040
ACCESSION NUMBER:		0001178913-22-003074
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		30
CONFORMED PERIOD OF REPORT:	20220630
FILED AS OF DATE:		20220812
DATE AS OF CHANGE:		20220812

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Chemomab Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001534248
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				813676773
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38807
		FILM NUMBER:		221157820

	BUSINESS ADDRESS:	
		STREET 1:		KIRYAT ATIDIM, BUILDING 7
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6158002
		BUSINESS PHONE:		972-77-331-0156

	MAIL ADDRESS:	
		STREET 1:		KIRYAT ATIDIM, BUILDING 7
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6158002

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Anchiano Therapeutics Ltd.
		DATE OF NAME CHANGE:	20180906

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioCancell Ltd.
		DATE OF NAME CHANGE:	20111104
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>zk2228232.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--INTEGIX by Ez-XBRL--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:cmmb="http://www.anchiano.com/20220630"  ><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/><title>Chemomab Therapeutics Ltd. - 1534248 - 2022</title></head><body>
        <div style="display:none">
        <ix:header><ix:hidden><ix:footnote id="FN20220809003109592" xml:lang="en-US">Number of shares has been retroactively adjusted to reflect the share reverse split effected on March 16, 2021 (refer to Note 1B).</ix:footnote>
<ix:footnote id="FN20220809022016820" xml:lang="en-US">20 Ordinary Shares are equal to 1 American Depositary Share (ADS).</ix:footnote>
<ix:footnote id="FN20220719183112561" xml:lang="en-US">Number of shares has been retroactively adjusted to reflect the share reverse split effected on March 16, 2021 (refer to Note 1B).</ix:footnote>
<ix:nonNumeric name="dei:AmendmentFlag" contextRef="C_20220101to20220630"  id="FFact_288" >false</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="C_20220101to20220630"  id="FFact_289" >--12-31</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="C_20220101to20220630"  id="FFact_290" >Q2</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="C_20220101to20220630"  id="FFact_292" >0001534248</ix:nonNumeric></ix:hidden>
<ix:references>
        <link:schemaRef xlink:type="simple" xlink:href="cmmb-20220630.xsd"/>
        </ix:references><ix:resources><xbrli:context id="C_20220401to20220630"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210401to20210630"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20220630"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20210630"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20201231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220630"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210630"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20210331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20210331"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20210331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210331"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210401to20210630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210401to20210630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20210331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210401to20210630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220331"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20220331"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20220331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20220331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20220331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210316"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-03-16</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210316_usgaapBusinessAcquisitionAxis_cmmbMergerAgreementWithChemomabIsraeliLimitedCompanyAndClinicalStageBiotechCompanyMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cmmb:MergerAgreementWithChemomabIsraeliLimitedCompanyAndClinicalStageBiotechCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-03-16</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210314to20210316_usgaapBusinessAcquisitionAxis_cmmbMergerAgreementWithChemomabIsraeliLimitedCompanyAndClinicalStageBiotechCompanyMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cmmb:MergerAgreementWithChemomabIsraeliLimitedCompanyAndClinicalStageBiotechCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-03-14</xbrli:startDate>
        <xbrli:endDate>2021-03-16</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210314to20210316_srtTitleOfIndividualAxis_cmmbFormerChemomabSecurityHoldersMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cmmb:FormerChemomabSecurityHoldersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-03-14</xbrli:startDate>
        <xbrli:endDate>2021-03-16</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210316_srtTitleOfIndividualAxis_cmmbFormerChemomabSecurityHoldersMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cmmb:FormerChemomabSecurityHoldersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-03-16</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210301to20210315"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-03-01</xbrli:startDate>
        <xbrli:endDate>2021-03-15</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210401to20210430_usgaapStatementClassOfStockAxis_cmmbAmericanDepositorySharesMember_usgaapSubsidiarySaleOfStockAxis_cmmbAtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmmb:AmericanDepositorySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:AtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-04-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210501to20220630_usgaapStatementClassOfStockAxis_cmmbAmericanDepositorySharesMember_usgaapSubsidiarySaleOfStockAxis_cmmbAtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmmb:AmericanDepositorySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:AtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-05-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220630_usgaapStatementClassOfStockAxis_cmmbAmericanDepositorySharesMember_usgaapSubsidiarySaleOfStockAxis_cmmbAtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmmb:AmericanDepositorySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:AtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220401to20220425_srtRangeAxis_srtMaximumMember_usgaapStatementClassOfStockAxis_cmmbAmericanDepositorySharesMember_usgaapSubsidiarySaleOfStockAxis_cmmbAtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmmb:AmericanDepositorySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:AtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-04-25</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210314to20210316"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-03-14</xbrli:startDate>
        <xbrli:endDate>2021-03-16</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210315"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-03-15</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20220630_usgaapStatementClassOfStockAxis_cmmbAmericanDepositarySharesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmmb:AmericanDepositarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20220630_usgaapStatementClassOfStockAxis_cmmbOrdinarySharesNoParValuePerShareMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmmb:OrdinarySharesNoParValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220811"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-08-11</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:unit id="Share"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD_per_share"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<ix:relationship fromRefs="Fxbrl_20220720153627242" toRefs="FN20220809003109592"/><ix:relationship fromRefs="Fxbrl_20220720153627242" toRefs="FN20220809022016820"/><ix:relationship fromRefs="Fxbrl_20220720153632498" toRefs="FN20220809003109592"/><ix:relationship fromRefs="Fxbrl_20220720153632498" toRefs="FN20220809022016820"/><ix:relationship fromRefs="Fxbrl_20220720153639507" toRefs="FN20220809003109592"/><ix:relationship fromRefs="Fxbrl_20220720153639507" toRefs="FN20220809022016820"/><ix:relationship fromRefs="Fxbrl_20220720153641684" toRefs="FN20220809003109592"/><ix:relationship fromRefs="Fxbrl_20220720153641684" toRefs="FN20220809022016820"/><ix:relationship fromRefs="Fxbrl_20220801220211119" toRefs="FN20220809003109592"/><ix:relationship fromRefs="Fxbrl_20220801220211119" toRefs="FN20220809022016820"/><ix:relationship fromRefs="Fxbrl_20220801220307005" toRefs="FN20220809003109592"/><ix:relationship fromRefs="Fxbrl_20220801220307005" toRefs="FN20220809022016820"/><ix:relationship fromRefs="Fxbrl_20220801220408934" toRefs="FN20220809003109592"/><ix:relationship fromRefs="Fxbrl_20220801220408934" toRefs="FN20220809022016820"/><ix:relationship fromRefs="Fxbrl_20220801220459941" toRefs="FN20220809003109592"/><ix:relationship fromRefs="Fxbrl_20220801220459941" toRefs="FN20220809022016820"/><ix:relationship fromRefs="Fxbrl_20220809022126183" toRefs="FN20220809003109592"/><ix:relationship fromRefs="Fxbrl_20220809022126183" toRefs="FN20220809022016820"/><ix:relationship fromRefs="Fxbrl_20220809022138581" toRefs="FN20220809003109592"/><ix:relationship fromRefs="Fxbrl_20220809022138581" toRefs="FN20220809022016820"/><ix:relationship fromRefs="Fxbrl_20220809022148798" toRefs="FN20220809003109592"/><ix:relationship fromRefs="Fxbrl_20220809022148798" toRefs="FN20220809022016820"/><ix:relationship fromRefs="Fxbrl_20220809022201676" toRefs="FN20220809003109592"/><ix:relationship fromRefs="Fxbrl_20220809022201676" toRefs="FN20220809022016820"/><ix:relationship fromRefs="Fxbrl_20220809022343739" toRefs="FN20220809003109592"/><ix:relationship fromRefs="Fxbrl_20220809022343739" toRefs="FN20220809022016820"/><ix:relationship fromRefs="Fxbrl_20220809022355319" toRefs="FN20220809003109592"/><ix:relationship fromRefs="Fxbrl_20220809022355319" toRefs="FN20220809022016820"/><ix:relationship fromRefs="Fxbrl_20220809022408661" toRefs="FN20220809003109592"/><ix:relationship fromRefs="Fxbrl_20220809022408661" toRefs="FN20220809022016820"/><ix:relationship fromRefs="Fxbrl_20220809022503184" toRefs="FN20220809003109592"/><ix:relationship fromRefs="Fxbrl_20220809022503184" toRefs="FN20220809022016820"/><ix:relationship fromRefs="Fxbrl_20220504161436664" toRefs="FN20220719183112561"/><ix:relationship fromRefs="Fxbrl_20220504161607482" toRefs="FN20220719183112561"/><ix:relationship fromRefs="Fxbrl_20220504161812745" toRefs="FN20220719183112561"/><ix:relationship fromRefs="Fxbrl_20220504161847247" toRefs="FN20220719183112561"/><ix:relationship fromRefs="Fxbrl_20220504162054050" toRefs="FN20220719183112561"/><ix:relationship fromRefs="Fxbrl_20220504162109962" toRefs="FN20220719183112561"/><ix:relationship fromRefs="Fxbrl_20220505093740414" toRefs="FN20220719183112561"/><ix:relationship fromRefs="Fxbrl_20220505093821193" toRefs="FN20220719183112561"/><ix:relationship fromRefs="Fxbrl_20220505093843525" toRefs="FN20220719183112561"/><ix:relationship fromRefs="Fxbrl_20220505093917037" toRefs="FN20220719183112561"/><ix:relationship fromRefs="Fxbrl_20220505094011117" toRefs="FN20220719183112561"/><ix:relationship fromRefs="Fxbrl_20220505094033172" toRefs="FN20220719183112561"/><ix:relationship fromRefs="Fxbrl_20220505094051101" toRefs="FN20220719183112561"/><ix:relationship fromRefs="Fxbrl_20220509163909641" toRefs="FN20220719183112561"/><ix:relationship fromRefs="Fxbrl_20220509165714258" toRefs="FN20220719183112561"/><ix:relationship fromRefs="Fxbrl_20220719171018175_xbrl_20220509172328807" toRefs="FN20220719183112561"/><ix:relationship fromRefs="Fxbrl_20220719171018175_xbrl_20220509163550193" toRefs="FN20220719183112561"/><ix:relationship fromRefs="Fxbrl_20220719171029396_xbrl_20220509165714258" toRefs="FN20220719183112561"/><ix:relationship fromRefs="Fxbrl_20220719171029396_xbrl_20220509163909641" toRefs="FN20220719183112561"/></ix:resources></ix:header></div><div>
  <div>
    <hr style="border:none;border-bottom:1px solid black;border-top:4px solid black;height:10px;color:#ffffff;background-color:#ffffff;text-align:center;margin-left:auto;margin-right:auto;margin-top:0pt;text-align:center" />
  </div>
  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:18pt;margin-bottom:0pt;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>UNITED STATES</strong></span></span><br /><span style="font-size:14pt"><span style="font-family:Times New Roman,Times,serif"><strong>SECURITIES AND EXCHANGE COMMISSION</strong></span></span><br /><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>WASHINGTON, DC 20549</strong></span></span></p>
  <div>
    <div>
      <div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:center;line-height:1.25"><span style="font-size:14pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">FORM <ix:nonNumeric id="FFact_1" name="dei:DocumentType" contextRef="C_20220101to20220630">10-Q</ix:nonNumeric></span><span>&#160;</span></span></span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(Mark One)</span></span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonNumeric id="FFact_2" name="dei:DocumentQuarterlyReport" contextRef="C_20220101to20220630" format="ixt:fixed-true">&#9746;</ix:nonNumeric></span>&#160;<span style="font-weight:bold">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></span></span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">For the quarterly period ended <ix:nonNumeric id="FFact_3" name="dei:DocumentPeriodEndDate" contextRef="C_20220101to20220630" format="ixt:date-monthname-day-year-en">June 30, <ix:nonNumeric id="Fxbrl_20220509210752112" name="dei:DocumentFiscalYearFocus" contextRef="C_20220101to20220630">2022</ix:nonNumeric></ix:nonNumeric></span>&#160;</span></span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>OR</span></span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonNumeric id="FFact_4" name="dei:DocumentTransitionReport" contextRef="C_20220101to20220630" format="ixt:fixed-false">&#9744;</ix:nonNumeric></span>&#160;<span style="font-weight:bold">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></span></span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>For the transition period from to</span></span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">Commission File Number: <ix:nonNumeric id="FFact_5" name="dei:EntityFileNumber" contextRef="C_20220101to20220630">001-38807</ix:nonNumeric></span>&#160;</span></span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:center;line-height:1.25"><span style="font-size:16pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold"><ix:nonNumeric id="FFact_6" name="dei:EntityRegistrantName" contextRef="C_20220101to20220630">Chemomab Therapeutics Ltd.</ix:nonNumeric></span><span>&#160;</span></span></span></span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(Exact Name of Registrant as Specified in its Charter)</span></span></span></span></div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:49%;vertical-align:bottom">
                <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold"><ix:nonNumeric id="FFact_7" name="dei:EntityIncorporationStateCountryCode" contextRef="C_20220101to20220630" format="ixt-sec:edgarprovcountryen">Israel</ix:nonNumeric></span>&#160;</span></span></span></span></div>
              </td>
              <td style="width:2%;vertical-align:bottom">
                <div style="text-align:center;line-height:1.25">&#160;</div>
              </td>
              <td style="width:49%;vertical-align:bottom">
                <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold"><ix:nonNumeric id="FFact_8" name="dei:EntityTaxIdentificationNumber" contextRef="C_20220101to20220630">81-3676773</ix:nonNumeric></span>&#160;</span></span></span></span></div>
              </td>
            </tr>
            <tr>
              <td style="width:49%;vertical-align:bottom">
                <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(State or other jurisdiction of</span></span></span></span></div>
                <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">incorporation or organization)</span>&#160;</span></span></span></span></div>
              </td>
              <td style="width:2%;vertical-align:bottom">
                <div style="text-align:center;line-height:1.25">&#160;</div>
                <div style="line-height:1.25">&#160;</div>
              </td>
              <td style="width:49%;vertical-align:bottom">
                <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(I.R.S. Employer </span></span></span></span></div>
                <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">Identification No.)</span>&#160;</span></span></span></span></div>
              </td>
            </tr>
            <tr>
              <td style="width:49%;vertical-align:bottom">&#160;</td>
              <td style="width:2%;vertical-align:bottom">
                <div style="text-align:center;line-height:1.25">&#160;</div>
              </td>
              <td style="width:49%;vertical-align:bottom">
                <div style="text-align:center;line-height:1.25">&#160;</div>
              </td>
            </tr>
            <tr>
              <td colspan="3" style="width:100%;vertical-align:bottom">
                <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold"><ix:nonNumeric id="FFact_9" name="dei:EntityAddressAddressLine1" contextRef="C_20220101to20220630">Kiryat Atidim</ix:nonNumeric>, <ix:nonNumeric id="FFact_10" name="dei:EntityAddressAddressLine2" contextRef="C_20220101to20220630">Building 7</ix:nonNumeric></span>&#160;</span></span></span></span></div>
              </td>
            </tr>
            <tr>
              <td colspan="3" style="width:100%;vertical-align:bottom">
                <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold"><ix:nonNumeric id="FFact_11" name="dei:EntityAddressCityOrTown" contextRef="C_20220101to20220630">Tel Aviv</ix:nonNumeric>, <ix:nonNumeric id="FFact_12" name="dei:EntityAddressCountry" contextRef="C_20220101to20220630" format="ixt-sec:countrynameen">Israel</ix:nonNumeric>&#160;<ix:nonNumeric id="FFact_13" name="dei:EntityAddressPostalZipCode" contextRef="C_20220101to20220630">6158002</ix:nonNumeric></span>&#160;</span></span></span></span></div>
              </td>
            </tr>
            <tr>
              <td colspan="3" style="width:100%;vertical-align:bottom">
                <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">(Address of principal executive offices including zip code)</span>&#160;</span></span></span></span></div>
                <div style="line-height:1.25">&#160;</div>
              </td>
            </tr>

        </table>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Registrant&#8217;s telephone number, including area code: +<ix:nonNumeric id="FFact_14" name="dei:CityAreaCode" contextRef="C_20220101to20220630">972</ix:nonNumeric>-<ix:nonNumeric id="FFact_15" name="dei:LocalPhoneNumber" contextRef="C_20220101to20220630">77-331-0156</ix:nonNumeric></span></span></span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold">&#160;</div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Securities registered pursuant to Section 12(b) of the Exchange Act:</span></span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table border="0" cellpadding="2" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">

            <tr>
              <td style="width:40%;vertical-align:middle;border-top:2px solid rgb(0, 0, 0);border-left:2px solid rgb(0, 0, 0)">
                <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">Title of each class</span>&#160;</span></span></span></span></div>
                <div style="line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div>
              </td>
              <td style="width:20%;vertical-align:middle;border-top:2px solid rgb(0, 0, 0);border-left:2px solid rgb(0, 0, 0)">
                <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">Trading Symbol(s)</span>&#160;</span></span></span></span></div>
                <div style="line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div>
              </td>
              <td style="width:40%;vertical-align:middle;border-top:2px solid rgb(0, 0, 0);border-left:2px solid rgb(0, 0, 0);border-right:2px solid rgb(0, 0, 0)">
                <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">Name of each exchange on which registered</span>&#160;</span></span></span></span></div>
                <div style="line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width:40%;vertical-align:top;border-top:2px solid rgb(0, 0, 0);border-left:2px solid rgb(0, 0, 0)">
                <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonNumeric id="FFact_16" name="dei:Security12bTitle" contextRef="C_20220101to20220630_usgaapStatementClassOfStockAxis_cmmbAmericanDepositarySharesMember">American Depositary Shares, each representing twenty (20)</ix:nonNumeric></span></span></span></span></div>
                <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>ordinary shares, no par value per share</span>&#160;</span></span></span></div>
                <div style="line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div>
              </td>
              <td style="width:20%;vertical-align:top;border-top:2px solid rgb(0, 0, 0);border-left:2px solid rgb(0, 0, 0)">
                <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonNumeric id="FFact_17" name="dei:TradingSymbol" contextRef="C_20220101to20220630_usgaapStatementClassOfStockAxis_cmmbAmericanDepositarySharesMember">CMMB</ix:nonNumeric>&#160;</span></span></span></span></div>
                <div style="line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div>
              </td>
              <td style="width:40%;vertical-align:top;border-top:2px solid rgb(0, 0, 0);border-left:2px solid rgb(0, 0, 0);border-right:2px solid rgb(0, 0, 0)">
                <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonNumeric id="FFact_18" name="dei:SecurityExchangeName" contextRef="C_20220101to20220630_usgaapStatementClassOfStockAxis_cmmbAmericanDepositarySharesMember" format="ixt-sec:exchnameen">Nasdaq</ix:nonNumeric> Capital Market</span></span></span></span></div>
                <div style="line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width:40%;vertical-align:top;border-top:2px solid rgb(0, 0, 0);border-left:2px solid rgb(0, 0, 0);border-bottom:2px solid rgb(0, 0, 0)">
                <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonNumeric id="FFact_19" name="dei:Security12bTitle" contextRef="C_20220101to20220630_usgaapStatementClassOfStockAxis_cmmbOrdinarySharesNoParValuePerShareMember">Ordinary shares, no par value per share</ix:nonNumeric>&#160;</span></span></span></span></div>
                <div style="line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div>
              </td>
              <td style="width:20%;vertical-align:top;border-top:2px solid rgb(0, 0, 0);border-left:2px solid rgb(0, 0, 0);border-bottom:2px solid rgb(0, 0, 0)">
                <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonNumeric id="Fxbrl_20220810212313319" name="dei:TradingSymbol" contextRef="C_20220101to20220630_usgaapStatementClassOfStockAxis_cmmbOrdinarySharesNoParValuePerShareMember">n/a </ix:nonNumeric></span></span></span></span></div>
                <div style="line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div>
              </td>
              <td style="width:40%;vertical-align:top;border-width:2px;border-style:solid;border-color:rgb(0, 0, 0)">
                <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonNumeric id="Fxbrl_20220810204332751" name="dei:SecurityExchangeName" contextRef="C_20220101to20220630_usgaapStatementClassOfStockAxis_cmmbOrdinarySharesNoParValuePerShareMember" format="ixt-sec:exchnameen">Nasdaq</ix:nonNumeric> Capital Market*</span></span></span></span></div>
                <div style="line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>*Not for trading; only in connection with the registration of American Depository Shares</span></span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
          <div style="page-break-after:always">
            <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" />
          </div>
        </div>
        <div style="text-align:justify;text-indent:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</span></span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;<ix:nonNumeric id="FFact_22" name="dei:EntityCurrentReportingStatus" contextRef="C_20220101to20220630">Yes</ix:nonNumeric>&#160;<span>&#9746;</span> No <span>&#9744;</span></span></span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;text-indent:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</span></span></span></span></div>
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;</span></span></span></span>
          <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonNumeric id="FFact_23" name="dei:EntityInteractiveDataCurrent" contextRef="C_20220101to20220630">Yes</ix:nonNumeric>&#160;<span>&#9746;</span> No <span>&#9744;</span></span></span></span></span></div>
        </div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;text-indent:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:18.8%;vertical-align:top">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Large accelerated filer</span></span></span></span></div>
              </td>
              <td style="width:2%;vertical-align:top">
                <div style="line-height:1.25;font-family:'Segoe UI Symbol', sans-serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#9744;</span></span></span></span></div>
              </td>
              <td style="width:54.8%;vertical-align:top">
                <div style="line-height:1.25">&#160;</div>
              </td>
              <td style="width:21.82%;vertical-align:top">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Accelerated filer</span></span></span></span></div>
              </td>
              <td style="width:2.58%;vertical-align:top">
                <div style="line-height:1.25;font-family:'Segoe UI Symbol', sans-serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#9744;</span></span></span></span></div>
              </td>
            </tr>
            <tr>
              <td style="width:18.8%;vertical-align:top">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonNumeric id="FFact_24" name="dei:EntityFilerCategory" contextRef="C_20220101to20220630" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric>&#160;</span></span></span></span></div>
              </td>
              <td style="width:2%;vertical-align:top">
                <div style="line-height:1.25;font-family:'Segoe UI Symbol', sans-serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#9746;</span></span></span></span></div>
              </td>
              <td style="width:54.8%;vertical-align:top">
                <div style="line-height:1.25">&#160;</div>
              </td>
              <td style="width:21.82%;vertical-align:top">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Smaller reporting company</span></span></span></span></div>
              </td>
              <td style="width:2.58%;vertical-align:top">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonNumeric id="FFact_25" name="dei:EntitySmallBusiness" contextRef="C_20220101to20220630" format="ixt:fixed-true">&#9746;</ix:nonNumeric></span>&#160;</span></span></span></span></div>
              </td>
            </tr>
            <tr>
              <td style="width:18.8%;vertical-align:top">
                <div style="line-height:1.25">&#160;</div>
              </td>
              <td style="width:2%;vertical-align:top">
                <div style="line-height:1.25">&#160;</div>
              </td>
              <td style="width:54.8%;vertical-align:top">
                <div style="line-height:1.25">&#160;</div>
              </td>
              <td style="width:21.82%;vertical-align:top">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Emerging growth company</span></span></span></span></div>
              </td>
              <td style="width:2.58%;vertical-align:top">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonNumeric id="FFact_26" name="dei:EntityEmergingGrowthCompany" contextRef="C_20220101to20220630" format="ixt:fixed-true">&#9746;</ix:nonNumeric></span>&#160;</span></span></span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;text-indent:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span><ix:nonNumeric id="FFact_27" name="dei:EntityExTransitionPeriod" contextRef="C_20220101to20220630" format="ixt:fixed-false">&#9744;</ix:nonNumeric></span>&#160;</span></span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-indent:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></span></span></span></div>
        <div style="line-height:1.25">
          <div style="text-align:center;line-height:1.25">&#160;</div>
          <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Yes <span>&#9744;</span> No <span><ix:nonNumeric id="FFact_28" name="dei:EntityShellCompany" contextRef="C_20220101to20220630" format="ixt:fixed-false">&#9746;</ix:nonNumeric></span></span></span></span></span></div>
        </div>
        <div style="line-height:1.25">&#160;</div>
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>As of August 11, 2022, the registrant had <ix:nonFraction id="Fxbrl_20220720131522106" name="dei:EntityCommonStockSharesOutstanding" contextRef="C_20220811" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">11,431,656</ix:nonFraction> American Depositary Shares outstanding.</span></span></span></span></div>
      </div>
    </div>
  </div>
  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify;margin-left:20pt">&#160;</p>
  <hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;page-break-after:always" />
  <div>&#160;</div>
<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CHEMOMAB THERAPEUTICS LTD.</span></span></div><div><div><div style="line-height:1.25">&#160;</div><div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">QUARTERLY REPORT ON FORM 10-Q</span></span></div><div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">FOR THE QUARTER ENDED JUNE 30, 2022</span></span></div><div style="line-height:1.25">&#160;</div><div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TABLE OF CONTENTS</span></span></div><div style="line-height:1.25">&#160;</div><table border="0" cellpadding="2" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)"><tr><td style="width:97.65%;vertical-align:bottom"><div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#PARTI.FINANCIALINFORMATIO">PART I. &#8211; FINANCIAL INFORMATION</a></span></span></div></td><td style="width:2.35%;vertical-align:bottom"><div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1</span></span></div></td></tr><tr><td style="width:97.65%;vertical-align:bottom"><div style="text-indent:28pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#Item1.">Item 1.Financial Statements</a></span></span></div></td><td style="width:2.35%;vertical-align:bottom"><div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1</span></span></div></td></tr><tr><td style="width:97.65%;vertical-align:bottom"><div style="text-indent:28pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#Item2.">Item 2.Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></span></div></td><td style="width:2.35%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">13</span></span></td></tr><tr><td style="width:97.65%;vertical-align:bottom"><div style="text-indent:28pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#Item3">Item 3.Quantitative and Qualitative Disclosures About Market Risk</a></span></span></div></td><td style="width:2.35%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">21</span></span></td></tr><tr><td style="width:97.65%;vertical-align:bottom"><div style="text-indent:28pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#Item4.">Item 4.Controls and Procedures</a></span></span></div></td><td style="width:2.35%;vertical-align:bottom"><div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">22</span></span></div></td></tr><tr><td style="width:97.65%;vertical-align:bottom"><div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#PARTII">PART II. &#8211; OTHER INFORMATION</a></span></span></div></td><td style="width:2.35%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">23</span></span></td></tr><tr><td style="width:97.65%;vertical-align:bottom"><div style="text-indent:28pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#Item1.LegalProceedings">Item 1.Legal Proceedings</a></span></span></div></td><td style="width:2.35%;vertical-align:bottom"><div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">23</span></span></div></td></tr><tr><td style="width:97.65%;vertical-align:bottom"><div style="text-indent:28pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#Item1A.RiskFactors">Item 1A.Risk Factors</a></span></span></div></td><td style="width:2.35%;vertical-align:bottom"><div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">23</span></span></div></td></tr><tr><td style="width:97.65%;vertical-align:bottom"><div style="text-indent:28pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#Item2.UnregisteredSalesof">Item 2.Unregistered Sales of Equity Securities and Use of Proceeds</a></span></span></div></td><td style="width:2.35%;vertical-align:bottom"><div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">23</span></span></div></td></tr><tr><td style="width:97.65%;vertical-align:bottom"><div style="text-indent:28pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#Item3.DefaultsUponSeniorS">Item 3.Defaults Upon Senior Securities</a></span></span></div></td><td style="width:2.35%;vertical-align:bottom"><div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">23</span></span></div></td></tr><tr><td style="width:97.65%;vertical-align:bottom"><div style="text-indent:28pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#Item4.MineSafetyDisclosur">Item 4.Mine Safety Disclosures</a></span></span></div></td><td style="width:2.35%;vertical-align:bottom"><div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">23</span></span></div></td></tr><tr><td style="width:97.65%;vertical-align:bottom"><div style="text-indent:28pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#Item5.OtherInformation.">Item 5.Other Information</a></span></span></div></td><td style="width:2.35%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">23</span></span></td></tr><tr><td style="width:97.65%;vertical-align:bottom"><div style="text-indent:28pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#Item6.Exhibits.">Item 6.Exhibits</a></span></span></div></td><td style="width:2.35%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">24</span></span></td></tr><tr><td style="width:97.65%;vertical-align:bottom"><div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#SIGNATURES">SIGNATURES</a></span></span></div></td><td style="width:2.35%;vertical-align:bottom"><div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">25</span></span></div></td></tr></table><div style="line-height:1.25">&#160;</div><div style="clear:both;margin-top:10pt;margin-bottom:10pt"><div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div><div style="line-height:1.25">&#160;</div><div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">CAUTIONARY NOTE ABOUT FORWARD-LOOKING STATEMENTS</span>&#160;</span></span></div><div style="line-height:1.25">&#160;</div><div style="text-align:justify;text-indent:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">This quarterly report contains forward-looking statements. All statements other than statements of historical fact are &#8220;forward-looking statements&#8221; for purposes of this Quarterly Report on Form 10-Q. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms including &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; or the negative of these terms or other similar expressions. Forward-looking statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Actual results or events could differ materially from those set forth or implied by such forward-looking statements and related assumptions due to certain factors, including, without limitation, the risks set forth under the caption &#8220;Risk Factors&#8221; below, which are incorporated herein by reference as well as those business risks and factors described elsewhere in this report and in our other filings with the Securities and Exchange Commission (the &#8220;SEC&#8221;), specifically our most recent Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. All forward-looking statements speak only as of the date made, and we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.</span></span></div><div style="line-height:1.25">&#160;</div><div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">CERTAIN TERMS USED IN THIS QUARTERLY REPORT ON FORM 10-Q</span>&#160;</span></span></div><div style="line-height:1.25">&#160;</div><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As used in this Quarterly Report on Form 10-Q, unless the context otherwise requires:</span></span></div><div style="line-height:1.25">&#160;</div><div><table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:6pt;width:100%;text-align:left;color:#000000"><tr><td style="width:35.7pt;vertical-align:top"><div style="line-height:1.25;font-family:Symbol,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#9679;</span></span></span></div><div style="line-height:1.25">&#160;</div></td><td style="width:auto;vertical-align:top"><div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">references to &#8220;Chemomab Therapeutics Ltd.&#8221;, &#8220;Chemomab,&#8221; the &#8220;Company,&#8221; &#8220;us,&#8221; &#8220;we&#8221; and &#8220;our&#8221; refer to Chemomab Therapeutics Ltd. an Israeli company and its consolidated subsidiaries, although with respect to the presentation of financial results for historical periods that preceded the Merger (as defined below), these terms refer to the financial results of Chemomab Ltd., which was the accounting acquirer in the Merger;</span></span></div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:6pt;width:100%;text-align:left;color:#000000"><tr><td style="width:35.7pt;vertical-align:top"><div style="line-height:1.25;font-family:Symbol,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#9679;</span></span></span></div></td><td style="width:auto;vertical-align:top"><div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">references to &#8220;ordinary shares,&#8221; &#8220;our shares&#8221; and similar expressions refer to the Company&#8217;s ordinary shares, no nominal (par) value;</span></span></div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:6pt;width:100%;text-align:left;color:#000000"><tr><td style="width:35.7pt;vertical-align:top"><div style="line-height:1.25;font-family:Symbol,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#9679;</span></span></span></div></td><td style="width:auto;vertical-align:top"><div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">references to &#8220;ADS&#8221; refer to the American Depositary Shares listed on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;CMMB,&#8221; each representing twenty (20) ordinary shares; references to &#8220;dollars,&#8221; &#8220;U.S. dollars&#8221; and &#8220;$&#8221; are to U.S. Dollars;</span></span></div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:6pt;width:100%;text-align:left;color:#000000"><tr><td style="width:35.7pt;vertical-align:top;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#9679;</span></span></span></td><td style="width:auto;vertical-align:top"><div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">references to &#8220;NIS&#8221; are to New Israeli Shekels;</span></span></div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:6pt;width:100%;text-align:left;color:#000000"><tr><td style="width:35.7pt;vertical-align:top;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#9679;</span></span></span></td><td style="width:auto;vertical-align:top"><div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">references to the &#8220;SEC&#8221; are to the U.S. Securities and Exchange Commission; and</span></span></div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:6pt;width:100%;text-align:left;color:#000000"><tr><td style="width:35.7pt;vertical-align:top;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#9679;</span></span></span></td><td style="width:auto;vertical-align:top"><div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">references to the &#8220;Merger&#8221; refer to the merger involving Anchiano Therapeutics Ltd. and Chemomab Ltd., whereby a wholly owned subsidiary of Anchiano Therapeutics Ltd. merged with and into Chemomab Ltd., with Chemomab Ltd. surviving as a wholly owned subsidiary of Anchiano Therapeutics Ltd. Upon consummation of the Merger, Anchiano Therapeutics Ltd. changed its name to &#8220;Chemomab Therapeutics Ltd.&#8221; and the business conducted by Chemomab Ltd. became primarily the business conducted by the Company.</span></span></div></td></tr></table></div><div>&#160;</div><div style="clear:both;margin-top:10pt;margin-bottom:10pt"><div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>&#160;<div><div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><a id="PARTI.FINANCIALINFORMATIO"></a><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">PART I. &#8211; FINANCIAL INFORMATION</span></span></div><div style="line-height:1.25">&#160;</div><div style="line-height:1.25"><a id="Item1."></a><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Item 1. Financial Statements</span>&#160;</span></span></div><div style="line-height:1.25">&#160;</div><table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"><tr><td style="width:100%;vertical-align:top"><div style="text-align:center;margin-right:14.2pt;margin-left:14.2pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:12pt;font-weight:bold"><span style="font-size:12pt"><span><span style="font-family:Times New Roman,Times,serif">Chemomab Therapeutics Ltd. and</span></span></span></div><div style="text-align:center;margin-right:14.2pt;margin-left:14.2pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:12pt;font-weight:bold"><span style="font-size:12pt"><span><span style="font-family:Times New Roman,Times,serif">its subsidiaries</span></span></span></div><div style="line-height:1.25;font-size:12pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25">&#160;</span></span></span></div><div style="text-align:center;margin-right:14.2pt;margin-left:14.2pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:12pt;font-weight:bold"><span style="font-size:12pt"><span><span style="font-family:Times New Roman,Times,serif">Condensed Consolidated Interim</span></span></span></div><div style="text-align:center;margin-right:14.2pt;margin-left:14.2pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:12pt;font-weight:bold"><span style="font-size:12pt"><span><span style="font-family:Times New Roman,Times,serif">Financial Statements</span></span></span></div><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25">&#160;</span></span></span></div><div style="text-align:center;margin-right:14.2pt;margin-left:14.2pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:12pt;font-weight:bold"><span style="font-size:12pt"><span><span style="font-family:Times New Roman,Times,serif">As of June 30, 2022</span></span></span></div><div style="line-height:1.25;font-size:12pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25">&#160;</span></span></span></div><div style="text-align:center;margin-right:14.2pt;margin-left:14.2pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:12pt;font-weight:bold"><span style="font-size:12pt"><span><span style="font-family:Times New Roman,Times,serif">(Unaudited)</span></span></span></div></td></tr></table></div></div></div><div><div><div><table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"><tr><td style="width:100%;vertical-align:top"><div style="text-align:center;margin-right:14.2pt;margin-left:14.2pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:12pt;font-weight:bold">&#160;</div></td></tr></table><div style="line-height:1.25">&#160;</div><div style="clear:both;margin-top:10pt;margin-bottom:10pt"><div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div><div style="text-align:right;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd.</span></span></span></span></div><div style="text-align:right;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>and its subsidiaries</span></span></span></span></div><div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div><div style="line-height:1.25"><div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span>Unaudited Condensed Consolidated Interim Financial Statements as of June 30, 2022</span></span></span></span></span><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" /></div></div><div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div><div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Contents</span></span></span></span></div><div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div><div style="text-align:right;text-indent:12pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Page</span></span></span></span></div><div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div><div style="line-height:1.25"><table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;color:#000000;width:100%" width="100%"><tr><td style="font-family:Times New Roman, Times, serif"><div><div style="text-align:left;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><a href="#BalanceSheets">Condensed Consolidated Interim Balance Sheets</a></span></span></span></span></div></div></td><td style="font-family:Times New Roman, Times, serif;width:10%"><div style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>3</span></span></span></span></div></td></tr><tr><td rowspan="1" style="font-family:Times New Roman, Times, serif">&#160;</td><td rowspan="1" style="text-align:right;font-family:Times New Roman, Times, serif;width:10%">&#160;</td></tr><tr><td rowspan="1" style="font-family:Times New Roman, Times, serif"><div style="text-align:left;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><a href="#ofOperationsUnaudited">Condensed Consolidated Interim Statements of Operations</a></span></span></span></span></div></td><td rowspan="1" style="text-align:right;font-family:Times New Roman, Times, serif;width:10%"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>4</span></span></span></span></td></tr><tr><td rowspan="1" style="font-family:Times New Roman, Times, serif">&#160;</td><td rowspan="1" style="text-align:right;font-family:Times New Roman, Times, serif;width:10%">&#160;</td></tr><tr><td rowspan="1" style="font-family:Times New Roman, Times, serif"><div style="text-align:left;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><a href="#CondensedConsolidatedInterimStatementsofChangesinEquity"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Condensed Consolidated Interim Statements of Changes in Equity</span></span></span></span></a></span></span></span></span></div></td><td rowspan="1" style="text-align:right;font-family:Times New Roman, Times, serif;width:10%"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>5 - 6</span></span></span></span></td></tr><tr><td rowspan="1" style="font-family:Times New Roman, Times, serif">&#160;</td><td rowspan="1" style="text-align:right;font-family:Times New Roman, Times, serif;width:10%">&#160;</td></tr><tr><td rowspan="1"><div style="text-align:left;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><a href="#Cashflows">Condensed Consolidated Interim Statements of Cash Flow</a><span>&#160;</span></span></span></span></span></div></td><td rowspan="1" style="text-align:right;font-family:Times New Roman, Times, serif;width:10%"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>7</span></span></span></span></td></tr><tr><td rowspan="1" style="font-family:Times New Roman, Times, serif">&#160;</td><td rowspan="1" style="text-align:right;font-family:Times New Roman, Times, serif;width:10%">&#160;</td></tr><tr><td rowspan="1" style="font-family:Times New Roman, Times, serif"><div style="text-align:left;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><a href="#NOTESTOCONDENSEDCONSOLIDATEDINTERIMFINANCIALSTATEMENTS"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Notes to the Condensed Consolidated Interim Financial Statements</span></span></span></span></a></span></span></span></span></div></td><td rowspan="1" style="text-align:right;font-family:Times New Roman, Times, serif;width:10%"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>8 - 12</span></span></span></span></td></tr></table></div><div style="line-height:1.25;font-family:Times New Roman, Times, serif;text-align:center"><br /><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2</span></span><br />&#160;</div><div style="clear:both;margin-top:0pt;margin-bottom:0pt"><div><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;page-break-after:always;background-color:#000000" /></div></div></div></div><div style="line-height:1.25;font-family:'Times New Roman',Times,serif;margin-bottom:0pt">&#160;</div></div>
  <div>
    <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chemomab Therapeutics Ltd.</span></span></div>
    <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">and its subsidiaries</span></span></div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
      <div style="line-height:1.25;font-weight:bold"><a id="BalanceSheets"></a> <span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Condensed Consolidated Balance Sheets</span></span>
        <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" />
      </div>
    </div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In USD thousands (except share amounts)</span></span></div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
    <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

        <tr>
          <td rowspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td rowspan="1" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="2" rowspan="1" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">
            <div style="text-align:right;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30,</span></span></div>
          </td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="2" rowspan="1" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">
            <div style="text-align:right;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
          </td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td rowspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td rowspan="1" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note</span></span></div>
          </td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="2" rowspan="1" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
            <div style="line-height:1.25">
              <div style="text-align:right;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
            </div>
          </td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="2" rowspan="1" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
            <div style="line-height:1.25">
              <div style="text-align:right;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
            </div>
          </td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">
            <div style="line-height:1.25;font-weight:bold">&#160;</div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">
            <div style="text-align:right;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unaudited</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">
            <div style="text-align:right;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Audited</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td rowspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Assets</span></span></div>
          </td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td rowspan="1" style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="2" rowspan="1" style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="2" rowspan="1" style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Current assets</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash and cash equivalents</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_30" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,883</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_31" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,186</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Short term bank deposits</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_32" name="us-gaap:DepositsAssetsCurrent" contextRef="C_20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,841</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_33" name="us-gaap:DepositsAssetsCurrent" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,975</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other receivables and prepaid expenses</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_34" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,106</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_35" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,527</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total current assets</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_36" name="us-gaap:AssetsCurrent" contextRef="C_20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">54,830</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_37" name="us-gaap:AssetsCurrent" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62,688</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-current assets</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Long term prepaid expenses</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220504175928392" name="us-gaap:PrepaidExpenseNoncurrent" contextRef="C_20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">821</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25;font-family:'Times New Roman', serif;font-size:9pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_40" name="us-gaap:PrepaidExpenseNoncurrent" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">908</ix:nonFraction></span></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property and equipment, net</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_42" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">355</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right" valign="bottom">
            <div style="line-height:1.25;font-family:'Times New Roman', serif;font-size:9pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_43" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">357</ix:nonFraction></span></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Restricted cash</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_44" name="us-gaap:RestrictedCashNoncurrent" contextRef="C_20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">77</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_45" name="us-gaap:RestrictedCashNoncurrent" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating lease right-of-use assets</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_46" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">295</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_47" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">345</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td rowspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td rowspan="1" style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total non-current assets</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_48" name="us-gaap:AssetsNoncurrent" contextRef="C_20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,548</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-family:'Times New Roman', serif;font-size:9pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_49" name="us-gaap:AssetsNoncurrent" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,665</ix:nonFraction></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:4px" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total assets</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:4px" valign="bottom">&#160;</td>
          <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:4px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:4px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_50" name="us-gaap:Assets" contextRef="C_20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56,378</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:4px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_51" name="us-gaap:Assets" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,353</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Current liabilities</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Trade payables</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_52" name="us-gaap:AccountsPayableTradeCurrent" contextRef="C_20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,433</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_53" name="us-gaap:AccountsPayableTradeCurrent" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,336</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accrued expenses</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_54" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,712</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_55" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">555</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Employee and related expenses</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_56" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,117</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_57" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">653</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating lease liabilities</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_58" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">132</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_59" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">106</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total current liabilities</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_60" name="us-gaap:LiabilitiesCurrent" contextRef="C_20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,394</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_61" name="us-gaap:LiabilitiesCurrent" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,650</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-current liabilities</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating lease liabilities - long term</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_62" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">148</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_63" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">237</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total non-current liabilities</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_64" name="us-gaap:LiabilitiesNoncurrent" contextRef="C_20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">148</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_65" name="us-gaap:LiabilitiesNoncurrent" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">237</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Commitments and contingent liabilities</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom"><ix:nonFraction id="Fxbrl_20220801213051011" name="us-gaap:CommitmentsAndContingencies" contextRef="C_20220630" unitRef="USD" xsi:nil="true"></ix:nonFraction></td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom"><ix:nonFraction id="Fxbrl_20220801213059987" name="us-gaap:CommitmentsAndContingencies" contextRef="C_20211231" unitRef="USD" xsi:nil="true"></ix:nonFraction></td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;text-align:center" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total liabilities</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;text-align:center;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_66" name="us-gaap:Liabilities" contextRef="C_20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,542</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_67" name="us-gaap:Liabilities" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,887</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;text-align:center" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64.66%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Shareholders' equity</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:middle;width:64.66%" valign="bottom">
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Ordinary shares <ix:nonFraction id="Fxbrl_20220505092446513" name="us-gaap:CommonStockNoParValue" contextRef="C_20211231" unitRef="USD_per_share" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="Fxbrl_20220719155003261" name="us-gaap:CommonStockNoParValue" contextRef="C_20220630" unitRef="USD_per_share" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> par value - Authorized: <ix:nonFraction id="Fxbrl_20220505092709497" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20211231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20220719155025581" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20220630" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">650,000,000</ix:nonFraction></ix:nonFraction> shares as of June 30, 2022 and as of December 31, 2021;</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:center;width:9.08%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%" valign="bottom">
            <div style="line-height:1.25;font-weight:bold">
              <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">-</p>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%" valign="bottom">
            <div style="line-height:1.25">
              <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">-</p>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td rowspan="1" style="vertical-align:middle;width:64.66%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issued and outstanding: <ix:nonFraction id="Fxbrl_20220808225957738" name="us-gaap:CommonStockSharesIssued" contextRef="C_20220630" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20220719155109723" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20220630" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">228,633,120</ix:nonFraction></ix:nonFraction> ordinary shares as of June 30, 2022 and <ix:nonFraction id="Fxbrl_20220808230014261" name="us-gaap:CommonStockSharesIssued" contextRef="C_20211231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20220719155156785" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20211231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">228,090,300</ix:nonFraction></ix:nonFraction> as of December 31, 2021</span></span></div>
          </td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220505093047469" name="us-gaap:CommonStockValue" contextRef="C_20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220505093055381" name="us-gaap:CommonStockValue" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64.66%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additional paid in capital</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_78" name="us-gaap:AdditionalPaidInCapital" contextRef="C_20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">99,303</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_79" name="us-gaap:AdditionalPaidInCapital" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">97,639</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64.66%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accumulated deficit</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_80" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">47,467</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_81" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">36,173</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64.66%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64.66%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total shareholders&#8217; equity</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220719200901554_Fact_84" name="us-gaap:StockholdersEquity" contextRef="C_20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">51,836</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220719200901554_Fact_85" name="us-gaap:StockholdersEquity" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,466</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64.66%;padding-bottom:4px" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total liabilities and shareholders&#8217; equity</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:4px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;padding-bottom:4px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:4px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_84" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56,378</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:4px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_85" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,353</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>

    </table>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying notes are an integral part of the condensed consolidated interim financial statements.</span></span></div>
    <div style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</div>
    <div style="clear:both;margin-top:0pt;margin-bottom:10pt">
      <div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:#000000;font-weight:normal;font-style:normal">3</span></span></span></div>
      <div style="page-break-after:always">
        <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" />
      </div>
    </div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
  </div>

  <div>
    <div style="text-align:right;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd.</span></span></span></span></div>
    <div style="text-align:right;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>and its subsidiaries</span></span></span></span></div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
      <div style="line-height:1.25;font-weight:bold"><a id="ofOperationsUnaudited"></a><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Condensed Consolidated Interim Statements of Operations (Unaudited)</span></span></span></span>
        <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" />
      </div>
    </div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>In USD thousands&#160;</span></span></span></span>(except share and per share amounts)</span></span></div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
    <div>
      <div>
        <table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

            <tr>
              <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:46%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:8%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">
                <div style="text-align:right;line-height:1.25;font-weight:bold">Three months</div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">
                <div style="text-align:right;line-height:1.25;font-weight:bold">Three months</div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">
                <div style="text-align:right;line-height:1.25;font-weight:bold">Six months</div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">
                <div style="text-align:right;line-height:1.25;font-weight:bold">Six months</div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:46%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:8%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">
                <div style="text-align:right;line-height:1.25;font-weight:bold">Ended</div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">
                <div style="text-align:right;line-height:1.25;font-weight:bold">Ended</div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">
                <div style="text-align:right;line-height:1.25;font-weight:bold">Ended</div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">
                <div style="text-align:right;line-height:1.25;font-weight:bold">Ended</div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:46%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:8%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:top" valign="bottom">
                <div style="text-align:right;line-height:1.25;font-family:'Times New Roman', serif;font-size:9pt"><span style="font-family:'Times New Roman',Times,serif;font-size:10pt;font-weight:bold">June 30</span><span style="font-size:10pt;font-family:'Times New Roman', Times, serif">,</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:top" valign="bottom">
                <div style="text-align:right;line-height:1.25;font-family:'Times New Roman', serif;font-size:9pt"><span style="font-family:'Times New Roman',Times,serif;font-size:10pt;font-weight:bold">June 30</span><span style="font-size:10pt;font-family:'Times New Roman', Times, serif">,</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:top" valign="bottom">
                <div style="text-align:right;line-height:1.25"><span style="font-family:'Times New Roman',Times,serif;font-weight:bold">June 30</span><span style="font-family:'Times New Roman',Times,serif">,</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:top" valign="bottom">
                <div style="text-align:right;line-height:1.25;font-family:'Times New Roman', serif;font-size:9pt"><span style="font-family:'Times New Roman',Times,serif;font-size:10pt;font-weight:bold">June 30</span><span style="font-size:10pt;font-family:'Times New Roman', Times, serif">,</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;width:46%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;width:1%" valign="bottom">&#160;</td>
              <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);width:8%" valign="bottom">
                <div style="line-height:1.25">
                  <div style="text-align:center;line-height:1.25;font-weight:bold">Note</div>
                </div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;width:1%" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                <div style="line-height:1.25">
                  <div style="text-align:right;line-height:1.25;font-weight:bold">2022</div>
                </div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;width:1%" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                <div style="line-height:1.25">
                  <div style="text-align:right;line-height:1.25;font-weight:bold">2021</div>
                </div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;width:1%" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                <div style="line-height:1.25">
                  <div style="text-align:right;line-height:1.25;font-weight:bold">2022</div>
                </div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;width:1%" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                <div style="line-height:1.25">
                  <div style="text-align:right;line-height:1.25;font-weight:bold">2021</div>
                </div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:46%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:8%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);width:46%" valign="bottom">
                <div style="line-height:1.25;font-weight:bold">Operating expenses</div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
              <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);width:8%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:46%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:8%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);width:46%" valign="bottom">
                <div style="line-height:1.25">Research and development</div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
              <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);width:8%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:8%" valign="bottom">
                <div style="line-height:1.25;font-weight:bold"><ix:nonFraction id="FFact_88" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20220401to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,914</ix:nonFraction></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:8%" valign="bottom">
                <div style="line-height:1.25"><ix:nonFraction id="FFact_89" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20210401to20210630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,307</ix:nonFraction></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:8%" valign="bottom">
                <div style="line-height:1.25;font-weight:bold"><ix:nonFraction id="Fxbrl_20220719164443341" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,659</ix:nonFraction></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:8%" valign="bottom">
                <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20220719164445428" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20210101to20210630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,464</ix:nonFraction></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:46%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:8%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;background-color:rgb(204, 238, 255);width:46%" valign="bottom">
                <div style="line-height:1.25">General and administrative</div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
              <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);width:8%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:8%" valign="bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25;font-weight:bold"><ix:nonFraction id="FFact_92" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20220401to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,340</ix:nonFraction></div>
                </div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:8%" valign="bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><ix:nonFraction id="FFact_93" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20210401to20210630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,446</ix:nonFraction></div>
                </div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:8%" valign="bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25;font-weight:bold"><ix:nonFraction id="Fxbrl_20220719164450381" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,915</ix:nonFraction></div>
                </div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:8%" valign="bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20220719164452278" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20210101to20210630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,988</ix:nonFraction></div>
                </div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:46%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:8%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);width:46%" valign="bottom">
                <div style="line-height:1.25;font-weight:bold">Total operating expenses</div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
              <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);width:8%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:8%" valign="bottom">
                <div style="line-height:1.25;font-weight:bold"><ix:nonFraction id="FFact_96" name="us-gaap:OperatingExpenses" contextRef="C_20220401to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,254</ix:nonFraction></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:8%" valign="bottom">
                <div style="line-height:1.25"><ix:nonFraction id="FFact_97" name="us-gaap:OperatingExpenses" contextRef="C_20210401to20210630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,753</ix:nonFraction></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:8%" valign="bottom">
                <div style="line-height:1.25;font-weight:bold"><ix:nonFraction id="Fxbrl_20220719164501750" name="us-gaap:OperatingExpenses" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,574</ix:nonFraction></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:8%" valign="bottom">
                <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20220719164503934" name="us-gaap:OperatingExpenses" contextRef="C_20210101to20210630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,452</ix:nonFraction></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:46%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:8%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;background-color:rgb(204, 238, 255);width:46%" valign="bottom">
                <div style="line-height:1.25">Financing expense, net</div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
              <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);width:8%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:8%" valign="bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25;font-weight:bold"><ix:nonFraction id="Fxbrl_20220719180539700_xbrl_20220719164540689" name="cmmb:FinanceIncomeExpensesNet" contextRef="C_20220401to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">480</ix:nonFraction></div>
                </div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:8%" valign="bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20220719180539700_xbrl_20220719164542506" name="cmmb:FinanceIncomeExpensesNet" contextRef="C_20210401to20210630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">17</ix:nonFraction></div>
                </div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:8%" valign="bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25;font-weight:bold"><ix:nonFraction id="Fxbrl_20220719180539700_xbrl_20220719164544402" name="cmmb:FinanceIncomeExpensesNet" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">264</ix:nonFraction></div>
                </div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:8%" valign="bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20220719180539700_xbrl_20220719164546402" name="cmmb:FinanceIncomeExpensesNet" contextRef="C_20210101to20210630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">22</ix:nonFraction></div>
                </div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:46%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:8%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td rowspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:46%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold">Loss before taxes</div>
              </td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td rowspan="1" style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:8%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25;font-weight:bold"><ix:nonFraction id="Fxbrl_20220808224756229" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20220401to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">6,734</ix:nonFraction></div>
              </td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20220808224804527" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20210401to20210630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,770</ix:nonFraction></div>
              </td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25;font-weight:bold"><ix:nonFraction id="Fxbrl_20220808224806687" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">11,838</ix:nonFraction></div>
              </td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20220808224808919" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20210101to20210630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">4,474</ix:nonFraction></div>
              </td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td rowspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:46%" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td rowspan="1" style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:8%" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:46%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">
                <div style="line-height:1.25">Taxes on income (benefit)</div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">
                <div style="line-height:1.25;font-weight:bold;text-align:center">&#160;</div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom">
                <div style="line-height:1.25;font-weight:bold">&#160;</div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                <div style="line-height:1.25;font-weight:bold">(<ix:nonFraction id="Fxbrl_20220728231430174" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20220401to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">544</ix:nonFraction></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom">
                <div style="line-height:1.25;font-weight:bold">)</div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                <div style="line-height:1.25"><ix:nonFraction id="FFact_101" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20210401to20210630" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                <div style="line-height:1.25;font-weight:bold">(<ix:nonFraction id="Fxbrl_20220728231438213" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">544</ix:nonFraction></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom">
                <div style="line-height:1.25;font-weight:bold">)</div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20220719164514240" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20210101to20210630" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:46%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:46%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25;font-weight:bold">Net loss for the period</div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25;font-weight:bold"><ix:nonFraction id="FFact_104" name="us-gaap:NetIncomeLoss" contextRef="C_20220401to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">6,190</ix:nonFraction></div>
                </div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><ix:nonFraction id="FFact_105" name="us-gaap:NetIncomeLoss" contextRef="C_20210401to20210630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,770</ix:nonFraction></div>
                </div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25;font-weight:bold"><ix:nonFraction id="Fxbrl_20220719164519088" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">11,294</ix:nonFraction></div>
                </div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20220719164521040" name="us-gaap:NetIncomeLoss" contextRef="C_20210101to20210630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">4,474</ix:nonFraction></div>
                </div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td rowspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:46%" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td rowspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:46%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25">Basic and diluted loss per Ordinary Share (*) (**)</div>
              </td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25;font-weight:bold"><ix:nonFraction id="Fxbrl_20220801220211119" name="us-gaap:EarningsPerShareBasic" contextRef="C_20220401to20220630" unitRef="USD_per_share" scale="0" decimals="3" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20220809022126183" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20220401to20220630" unitRef="USD_per_share" scale="0" decimals="3" format="ixt:num-dot-decimal">0.027</ix:nonFraction></ix:nonFraction></div>
              </td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20220801220307005" name="us-gaap:EarningsPerShareBasic" contextRef="C_20210401to20210630" unitRef="USD_per_share" scale="0" decimals="3" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20220809022138581" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20210401to20210630" unitRef="USD_per_share" scale="0" decimals="3" format="ixt:num-dot-decimal">0.013</ix:nonFraction></ix:nonFraction></div>
              </td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25;font-weight:bold"><ix:nonFraction id="Fxbrl_20220801220408934" name="us-gaap:EarningsPerShareBasic" contextRef="C_20220101to20220630" unitRef="USD_per_share" scale="0" decimals="3" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20220809022148798" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20220101to20220630" unitRef="USD_per_share" scale="0" decimals="3" format="ixt:num-dot-decimal">0.050</ix:nonFraction></ix:nonFraction></div>
              </td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20220801220459941" name="us-gaap:EarningsPerShareBasic" contextRef="C_20210101to20210630" unitRef="USD_per_share" scale="0" decimals="3" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20220809022201676" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20210101to20210630" unitRef="USD_per_share" scale="0" decimals="3" format="ixt:num-dot-decimal">0.024</ix:nonFraction></ix:nonFraction></div>
              </td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td rowspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:46%" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td rowspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:46%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25">Weighted average number of Ordinary Shares outstanding, basic, and diluted (*) (**)</div>
              </td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25;font-weight:bold"><ix:nonFraction id="Fxbrl_20220720153627242" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20220401to20220630" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20220809022343739" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20220401to20220630" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">228,173,276</ix:nonFraction></ix:nonFraction></div>
              </td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20220720153632498" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20210401to20210630" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20220809022355319" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20210401to20210630" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">216,266,993</ix:nonFraction></ix:nonFraction></div>
              </td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25;font-weight:bold"><ix:nonFraction id="Fxbrl_20220720153639507" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20220101to20220630" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20220809022408661" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20220101to20220630" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">228,132,249</ix:nonFraction></ix:nonFraction></div>
              </td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:8%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20220720153641684" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20210101to20210630" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20220809022503184" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20210101to20210630" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">186,840,022</ix:nonFraction></ix:nonFraction></div>
              </td>
              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            </tr>

        </table>&#160;<div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(*) Number of shares has been retroactively adjusted to reflect the share reverse split effected on March 16, 2021 (refer to Note 1B).</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(**) 20 Ordinary Shares are equal to 1 American Depositary Share (ADS).</span></span></div>
      </div>
    </div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>The accompanying notes are an integral part of the condensed consolidated interim financial statements.</span></span></span></span></div>
    <div style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</div>
    <div style="clear:both;margin-top:0pt;margin-bottom:10pt">
      <div style="text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="color:#000000;font-weight:normal;font-style:normal">4</span></span></span></span></span></div>
      <div style="page-break-after:always">
        <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" />
      </div>
    </div>
    <div style="text-align:right;line-height:1.25">&#160;</div>
  </div>

  <div>
    <div style="text-align:right;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd.</span></span></span></span></div>
    <div style="text-align:right;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>and its subsidiaries</span></span></span></span></div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
      <div style="line-height:1.25;font-weight:bold"><a id="CondensedConsolidatedInterimStatementsofChangesinEquity"></a><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Condensed Consolidated Interim Statements of Changes in Equity (Unaudited)</span></span></span></span>
        <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" />
      </div>
    </div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>In USD thousands (except share amounts)</span></span></span></span></div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
    <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

        <tr>
          <td rowspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="6" rowspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">&#160;<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Ordinary</span></span></span></span></div>
            <div style="line-height:1.25">
              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Shares</span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="2" rowspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Additional</span></span></span></span></div>
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>paid in</span></span></span></span></div>
            <div style="line-height:1.25">
              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>capital</span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="2" rowspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Accumulated</span></span></span></span></div>
            <div style="line-height:1.25">
              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Deficit</span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="2" rowspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
            <div style="line-height:1.25">
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Total</span><span>&#160;</span></span></span></span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span style="font-weight:bold">Shareholders&#8217;</span></span></span></span></span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span style="font-weight:bold">equity</span></span></span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td rowspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;font-weight:bold;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="2" rowspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;text-align:center;font-weight:bold;border-bottom:#000000 solid 2px" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Number</span></span></span></span></td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;font-weight:bold;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;font-weight:bold;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="2" rowspan="1" style="vertical-align:top;font-family:'Times New Roman',Times,serif;text-align:center;font-weight:bold;border-bottom:#000000 solid 2px" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>USD</span></span></span></span></td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;font-weight:bold;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;font-weight:bold;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="2" rowspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;text-align:center;font-weight:bold;border-bottom:#000000 solid 2px" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>USD</span></span></span></span></td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;font-weight:bold;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;font-weight:bold;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="2" rowspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;text-align:center;font-weight:bold;border-bottom:#000000 solid 2px" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>USD</span></span></span></span></td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;font-weight:bold;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;font-weight:bold;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="2" rowspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;text-align:center;font-weight:bold;border-bottom:#000000 solid 2px" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>USD</span></span></span></span></td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;font-weight:bold;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>For the six-month period ended on June 30, 2022</span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td rowspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="2" rowspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="2" rowspan="1" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="2" rowspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="2" rowspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="2" rowspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:40%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Balance as of January 1, 2022</span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220719171142064_xbrl_20220504161436664" name="us-gaap:SharesOutstanding" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">228,090,300</ix:nonFraction></span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220719171142064_xbrl_20220505093740414" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220719171142064_xbrl_20220504161607482" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">97,639</ix:nonFraction></span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(<ix:nonFraction id="Fxbrl_20220719171142064_xbrl_20220504161812745" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">36,173</ix:nonFraction></span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220719171142064_xbrl_20220504161847247" name="us-gaap:StockholdersEquity" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,466</ix:nonFraction></span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:40%" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Share-based compensation</span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>-</span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220719171155021_xbrl_20220505093821193" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20220101to20220331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220719171155021_xbrl_20220504161917493" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20220101to20220331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">874</ix:nonFraction></span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220719171155021_xbrl_20220505093815054" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20220101to20220331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220719171155021_xbrl_20220504161939600" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20220101to20220331" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">874</ix:nonFraction></span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:40%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Net loss for the period</span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>-</span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220719171210751_xbrl_20220505093843525" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20220331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220719171210751_xbrl_20220505093847704" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20220331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(<ix:nonFraction id="Fxbrl_20220719171210751_xbrl_20220504162015389" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20220331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">5,104</ix:nonFraction></span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(<ix:nonFraction id="Fxbrl_20220719171210751_xbrl_20220504162029289" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20220331" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">5,104</ix:nonFraction></span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:40%;padding-bottom:4px" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Balance as of March 31, 2022</span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220719171143948_xbrl_20220504161436664" name="us-gaap:SharesOutstanding" contextRef="C_20220331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">228,090,300</ix:nonFraction></span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220719171143948_xbrl_20220505093740414" name="us-gaap:StockholdersEquity" contextRef="C_20220331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220719171143948_xbrl_20220504161607482" name="us-gaap:StockholdersEquity" contextRef="C_20220331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">98,513</ix:nonFraction></span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(<ix:nonFraction id="Fxbrl_20220719171143948_xbrl_20220504161812745" name="us-gaap:StockholdersEquity" contextRef="C_20220331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">41,277</ix:nonFraction></span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220719171143948_xbrl_20220504161847247" name="us-gaap:StockholdersEquity" contextRef="C_20220331" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,236</ix:nonFraction></span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td rowspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:40%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:40%" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Share-based compensation</span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>-</span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220719171157157_xbrl_20220505093821193" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220719171157157_xbrl_20220504161917493" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">761</ix:nonFraction></span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220719171157157_xbrl_20220505093815054" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220719171157157_xbrl_20220504161939600" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20220401to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">761</ix:nonFraction></span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:40%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Exercise of options</span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220719171227712" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">542,820</ix:nonFraction></span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220719171215975_xbrl_20220505093843525" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220719171215975_xbrl_20220505093847704" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29</ix:nonFraction></span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220719171215975_xbrl_20220504162015389" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220719171215975_xbrl_20220504162029289" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220401to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29</ix:nonFraction></span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:40%;padding-bottom:2px" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Net loss for the period</span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>-</span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220719171212527_xbrl_20220505093843525" name="us-gaap:NetIncomeLoss" contextRef="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220719171212527_xbrl_20220505093847704" name="us-gaap:NetIncomeLoss" contextRef="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(<ix:nonFraction id="Fxbrl_20220719171212527_xbrl_20220504162015389" name="us-gaap:NetIncomeLoss" contextRef="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">6,190</ix:nonFraction></span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(<ix:nonFraction id="Fxbrl_20220719171212527_xbrl_20220504162029289" name="us-gaap:NetIncomeLoss" contextRef="C_20220401to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">6,190</ix:nonFraction></span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:40%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Balance as of June 30, 2022</span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220719171146108_xbrl_20220504161436664" name="us-gaap:SharesOutstanding" contextRef="C_20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">228,633,120</ix:nonFraction></span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220719171146108_xbrl_20220505093740414" name="us-gaap:StockholdersEquity" contextRef="C_20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220719171146108_xbrl_20220504161607482" name="us-gaap:StockholdersEquity" contextRef="C_20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">99,303</ix:nonFraction></span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(<ix:nonFraction id="Fxbrl_20220719171146108_xbrl_20220504161812745" name="us-gaap:StockholdersEquity" contextRef="C_20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">47,467</ix:nonFraction></span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220719171146108_xbrl_20220504161847247" name="us-gaap:StockholdersEquity" contextRef="C_20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">51,836</ix:nonFraction></span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>

    </table>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
    <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
      <div style="text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="color:#000000;font-weight:normal;font-style:normal">5</span></span></span></span></span></div>
      <div style="page-break-after:always">
        <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" />
      </div>
    </div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
    <div style="text-align:right;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd.</span></span></span></span></div>
    <div style="text-align:right;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>and its subsidiaries</span></span></span></span></div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
      <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Condensed Consolidated Interim Statements of Changes in Equity (Unaudited)</span></span></span></span>
        <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" />
      </div>
    </div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>In USD thousands (except share amounts)</span></span></span></span></div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
    <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

        <tr>
          <td rowspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="6" rowspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
            <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Ordinary</span></span></span></span></div>
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Shares (*)</span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
          <td colspan="2" rowspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
            <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Additional</span></span></span></span></div>
            <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>paid in</span></span></span></span></div>
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>capital</span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
          <td colspan="2" rowspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
            <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Accumulated</span></span></span></span></div>
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Deficit</span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
          <td colspan="2" rowspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-family:'Times New Roman',serif;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Total</span><span>&#160;</span></span></span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman',serif;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span style="font-weight:bold">Shareholders&#8217; </span></span></span></span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman',serif;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span style="font-weight:bold">equity</span></span></span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td rowspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="2" rowspan="1" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
            <div style="line-height:1.25">
              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Number</span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="2" rowspan="1" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
            <div style="line-height:1.25">
              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>USD</span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="2" rowspan="1" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
            <div style="line-height:1.25">
              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>USD</span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="2" rowspan="1" style="vertical-align:top;font-family:'Times New Roman',Times,serif;text-align:center;border-bottom:2px solid rgb(0, 0, 0);font-weight:bold" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>USD</span></span></span></span></td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;font-weight:bold;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;font-weight:bold" valign="bottom">&#160;</td>
          <td colspan="2" rowspan="1" style="vertical-align:top;font-family:'Times New Roman',Times,serif;text-align:center;border-bottom:2px solid rgb(0, 0, 0);font-weight:bold" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>USD</span></span></span></span></td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>For the six-month period ended on June 30, 2021</span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td rowspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="2" rowspan="1" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="2" rowspan="1" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="2" rowspan="1" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="2" rowspan="1" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="2" rowspan="1" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:40%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Balance as of January 1, 2021 (*)</span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220504161436664" name="us-gaap:SharesOutstanding" contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">9,274,838</ix:nonFraction></span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220505093740414" name="us-gaap:StockholdersEquity" contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220504161607482" name="us-gaap:StockholdersEquity" contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,497</ix:nonFraction></span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(<ix:nonFraction id="Fxbrl_20220504161812745" name="us-gaap:StockholdersEquity" contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">23,695</ix:nonFraction></span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220504161847247" name="us-gaap:StockholdersEquity" contextRef="C_20201231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,802</ix:nonFraction></span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:40%" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Share-based compensation</span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>-</span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220505093821193" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20210101to20210331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220504161917493" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20210101to20210331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43</ix:nonFraction></span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220505093815054" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20210101to20210331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220504161939600" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20210101to20210331" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43</ix:nonFraction></span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:40%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Effect of reverse capitalization transaction</span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220719171018175_xbrl_20220509163550193" name="cmmb:EffectOfReverseCapitalizationTransactionShares" contextRef="C_20210101to20210331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">152,299,702</ix:nonFraction></span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220719171018175_xbrl_20220509172328807" name="cmmb:EffectOfReverseCapitalizationTransaction" contextRef="C_20210101to20210331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220719171018175_xbrl_20220509172946846" name="cmmb:EffectOfReverseCapitalizationTransaction" contextRef="C_20210101to20210331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,476</ix:nonFraction></span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220719171018175_xbrl_20220509164008995" name="cmmb:EffectOfReverseCapitalizationTransaction" contextRef="C_20210101to20210331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220719171018175_xbrl_20220509163651908" name="cmmb:EffectOfReverseCapitalizationTransaction" contextRef="C_20210101to20210331" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,476</ix:nonFraction></span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:40%" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Issuance of shares and warrants, net of issuance costs</span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220719171029396_xbrl_20220509163909641" name="cmmb:StockAndWarrantIssuedDuringPeriodNewIssues" contextRef="C_20210101to20210331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">52,385,400</ix:nonFraction></span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220719171029396_xbrl_20220509165714258" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20210101to20210331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220719171029396_xbrl_20220509163916692" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20210101to20210331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,547</ix:nonFraction></span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220719171029396_xbrl_20220509164000245" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20210101to20210331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220719171029396_xbrl_20220509163919739" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20210101to20210331" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,547</ix:nonFraction></span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:40%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Net loss for the period</span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>-</span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220505093843525" name="us-gaap:NetIncomeLoss" contextRef="C_20210101to20210331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220505093847704" name="us-gaap:NetIncomeLoss" contextRef="C_20210101to20210331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(<ix:nonFraction id="Fxbrl_20220504162015389" name="us-gaap:NetIncomeLoss" contextRef="C_20210101to20210331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,704</ix:nonFraction></span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(<ix:nonFraction id="Fxbrl_20220504162029289" name="us-gaap:NetIncomeLoss" contextRef="C_20210101to20210331" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,704</ix:nonFraction></span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:40%;padding-bottom:4px" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Balance as of March 31, 2021</span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220504162054050" name="us-gaap:SharesOutstanding" contextRef="C_20210331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">213,959,940</ix:nonFraction></span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220505093917037" name="us-gaap:StockholdersEquity" contextRef="C_20210331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220504162134224" name="us-gaap:StockholdersEquity" contextRef="C_20210331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80,563</ix:nonFraction></span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(<ix:nonFraction id="Fxbrl_20220504162140381" name="us-gaap:StockholdersEquity" contextRef="C_20210331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">25,399</ix:nonFraction></span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220504162145961" name="us-gaap:StockholdersEquity" contextRef="C_20210331" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55,164</ix:nonFraction></span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td rowspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:40%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:40%" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Share-based compensation</span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>-</span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220505094011117" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20210401to20210630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220504162242016" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20210401to20210630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">527</ix:nonFraction></span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220505094006095" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20210401to20210630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220504162250216" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20210401to20210630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">527</ix:nonFraction></span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:40%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Issuance of shares, net of issuance costs</span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220509163909641" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20210401to20210630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">13,996,120</ix:nonFraction></span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220509165714258" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20210401to20210630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220509163916692" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20210401to20210630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,118</ix:nonFraction></span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220509164000245" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20210401to20210630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220509163919739" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20210401to20210630" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">15,118</ix:nonFraction></span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:40%;padding-bottom:2px" valign="bottom">
            <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Net loss for the period</span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>-</span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220505094033172" name="us-gaap:NetIncomeLoss" contextRef="C_20210401to20210630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220505094023997" name="us-gaap:NetIncomeLoss" contextRef="C_20210401to20210630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(<ix:nonFraction id="Fxbrl_20220504162305425" name="us-gaap:NetIncomeLoss" contextRef="C_20210401to20210630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,770</ix:nonFraction></span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(<ix:nonFraction id="Fxbrl_20220504162313633" name="us-gaap:NetIncomeLoss" contextRef="C_20210401to20210630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,770</ix:nonFraction></span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:40%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Balance as of June 30, 2021</span></span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220504162109962" name="us-gaap:SharesOutstanding" contextRef="C_20210630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">227,956,060</ix:nonFraction></span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220505094051101" name="us-gaap:StockholdersEquity" contextRef="C_20210630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220504162332928" name="us-gaap:StockholdersEquity" contextRef="C_20210630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">96,208</ix:nonFraction></span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(<ix:nonFraction id="Fxbrl_20220504162338080" name="us-gaap:StockholdersEquity" contextRef="C_20210630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">28,169</ix:nonFraction></span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220504162343720" name="us-gaap:StockholdersEquity" contextRef="C_20210630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,039</ix:nonFraction></span></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>

    </table>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(*) Number of shares has been retroactively adjusted to reflect the share reverse split effected on March 16, 2021 (refer to Note 1B).</span></span></span></span></div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>The accompanying notes are an integral part of the condensed consolidated interim financial statements.</span></span></span></span></div>
    <div style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</div>
    <div style="clear:both;margin-top:0pt;margin-bottom:10pt">
      <div style="text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="color:#000000;font-weight:normal;font-style:normal">6</span></span></span></span></span></div>
      <div style="page-break-after:always">
        <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" />
      </div>
    </div>
    <div style="font-family:'Times New Roman',Times,serif">
      <div style="line-height:1.25">&#160;</div>
    </div>
  </div>

  <div>
    <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chemomab Therapeutics Ltd.</span></span></div>
    <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">and its subsidiaries</span></span></div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
      <div style="line-height:1.25;font-weight:bold"><a id="Cashflows"></a> <span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Condensed Consolidated Interim Statements of Cash flows (Unaudited)</span></span>
        <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" />
      </div>
    </div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In USD thousands</span></span></div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
    <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

        <tr>
          <td rowspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;font-weight:bold;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="2" rowspan="1" style="vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold;border-bottom:#000000 solid 2px" valign="bottom">
            <div>
              <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Six months</span></span></div>
            </div>
            <div>
              <div style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ended</span></span></div>
              <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30,</span></span></div>
              <div style="line-height:1.25">
                <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
              </div>
            </div>
          </td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;font-weight:bold;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;font-weight:bold;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="2" rowspan="1" style="vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold;border-bottom:#000000 solid 2px" valign="bottom">
            <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Six months</span></span></div>
            <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Ended</span></span></div>
            <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30,</span></span></div>
            <div style="line-height:1.25">
              <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
            </div>
          </td>
          <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;font-weight:bold;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash flows from operating activities</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">
            <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss for the period</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_193" name="us-gaap:ProfitLoss" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">11,294</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_194" name="us-gaap:ProfitLoss" contextRef="C_20210101to20210630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">4,474</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">
            <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Adjustments for operating activities:</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Depreciation</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_195" name="us-gaap:Depreciation" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_196" name="us-gaap:Depreciation" contextRef="C_20210101to20210630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">
            <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Change in other receivables and prepaid expenses</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_197" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,483</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220719185926153" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_20210101to20210630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,529</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Change in operating lease liability</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220719190053059" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">15</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220504154924941" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="C_20210101to20210630" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">
            <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Change in trade payables</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_199" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">97</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_200" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="C_20210101to20210630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">312</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Change in accrued expenses</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_201" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,157</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_202" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_20210101to20210630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">993</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">
            <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Change in employees and related expenses</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_203" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">464</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_204" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="C_20210101to20210630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">200</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based compensation</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_205" name="us-gaap:ShareBasedCompensation" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,635</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_206" name="us-gaap:ShareBasedCompensation" contextRef="C_20210101to20210630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">570</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_207" name="us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,882</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220719185858022" name="us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" contextRef="C_20210101to20210630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,426</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net cash used in operating activities</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_209" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">9,412</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_210" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20210101to20210630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">6,900</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash flows from investing activities</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">
            <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Increase in deposits</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220801194023381_Fact_211" name="cmmb:PaymentsToPurchaseOfDeposits" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220801194023381_xbrl_20220719190124821" name="cmmb:PaymentsToPurchaseOfDeposits" contextRef="C_20210101to20210630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,500</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Decrease in deposits</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_211" name="cmmb:ProceedsFromSaleOfDeposits" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,134</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220719190124821" name="cmmb:ProceedsFromSaleOfDeposits" contextRef="C_20210101to20210630" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">
            <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Sale of asset held for sale</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220719180938189_Fact_211" name="us-gaap:ProceedsFromSaleOfPropertyHeldForSale" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220719180938189_Fact_212" name="us-gaap:ProceedsFromSaleOfPropertyHeldForSale" contextRef="C_20210101to20210630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,000</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Purchase of property and equipment</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_215" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_216" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_20210101to20210630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">105</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px" valign="bottom">
            <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net cash provided by (used in) investing activities</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_217" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,109</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_218" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_20210101to20210630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">20,605</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">
            <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash flows from financing activities</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash acquired in reverse recapitalization</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220504155015779" name="cmmb:CashAcquiredInReverseRecapitalization" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_221" name="cmmb:CashAcquiredInReverseRecapitalization" contextRef="C_20210101to20210630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,427</ix:nonFraction></span></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">
            <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercise of options</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220719180719914_Fact_209" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220719180719914_Fact_210" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_20210101to20210630" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issuance of shares, net of issuance costs</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220719180724993_Fact_209" name="cmmb:IssuanceOfSharesNetOfIssuanceCosts" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20220719180724993_Fact_210" name="cmmb:IssuanceOfSharesNetOfIssuanceCosts" contextRef="C_20210101to20210630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,243</ix:nonFraction></span></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px" valign="bottom">
            <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issuance of shares and warrants, net of issuance costs</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_227" name="us-gaap:ProceedsFromOtherEquity" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_228" name="us-gaap:ProceedsFromOtherEquity" contextRef="C_20210101to20210630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,557</ix:nonFraction></span></span></span></div>
            </div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net cash provided by financing activities</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_229" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_230" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20210101to20210630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,227</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Change in cash, cash equivalents and restricted cash</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_231" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">5,281</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_232" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_20210101to20210630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,722</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash, cash equivalents and restricted cash at beginning of period</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_233" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,241</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_234" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20201231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,727</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash, cash equivalents and restricted cash at end of period</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_235" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,960</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_236" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20210630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,449</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Supplemental disclosure of non-cash investing and financing activities:</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px" valign="bottom">
            <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Liabilities assumed, net of non-cash assets received in reverse merger</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220505095521944" name="cmmb:LiabilitiesAssumedNetOfNonCashAssetsReceivedInReverseMerger" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_237" name="cmmb:LiabilitiesAssumedNetOfNonCashAssetsReceivedInReverseMerger" contextRef="C_20210101to20210630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Receivable related to exercise of options</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220719180738568_Fact_209" name="cmmb:AccountReceivableDueToExerciseOfOptions" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220719180738568_Fact_210" name="cmmb:AccountReceivableDueToExerciseOfOptions" contextRef="C_20210101to20210630" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px" valign="bottom">
            <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accrued share issuance expenses</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220505095540169" name="cmmb:AccruedShareIssuanceExpenses" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_239" name="cmmb:AccruedShareIssuanceExpenses" contextRef="C_20210101to20210630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">135</ix:nonFraction></span></span></div>
            </div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>

    </table>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying notes are an integral part of the condensed consolidated interim financial statements.</span></span></div>
    <div style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</div>
    <div style="clear:both;margin-top:0pt;margin-bottom:10pt">
      <div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:#000000;font-weight:normal;font-style:normal">7</span></span></span></div>
      <div style="page-break-after:always">
        <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" />
      </div>
    </div>
  </div>

  <div>
    <p style="margin-top:0px;margin-bottom:0px;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center">&#160;</p>
    <p style="margin-top:0px;margin-bottom:0px;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><strong><span style="text-decoration:underline"><span style="color:black">CHEMOMAB THERAPEUTICS LTD&#160;AND ITS SUBSIDIARIES</span></span></strong></span></span></span></span></span></p>
    <p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><strong><span style="text-decoration:underline"><span><span style="color:black">(FORMERLY ANCHIANO THERAPEUTICS LTD)</span></span></span></strong></span></span></span></span></span></span></span></p>
    <div style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><a id="NOTESTOCONDENSEDCONSOLIDATEDINTERIMFINANCIALSTATEMENTS"></a> <span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><strong><span style="text-decoration:underline"><span><span style="color:black">NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS</span></span></span></strong></span></span></span></span></span></span></span>
      <p style="margin:0pt">&#160;</p>
    </div>
  </div>
  <ix:nonNumeric id="Fxbrl_20220505134250696" name="us-gaap:NatureOfOperations" contextRef="C_20220101to20220630" escape="true">
    <div>
      <div>
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><span><span>Note 1 - General.</span></span></strong></span></span></span></span></div>
        <div>
          <div>
            <div>
              <div>
                <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                <div>
                  <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                      <tr>
                        <td style="width:72pt;vertical-align:top;font-family:'Times New Roman',Times,serif">
                          <div style="margin-left:36pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>A.</span></span></span></span></span></span></div>
                        </td>
                        <td style="width:auto;vertical-align:top;font-family:'Times New Roman',Times,serif">
                          <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chemomab Therapeutics Ltd. (the &#8220;Company") is an Israeli -based company incorporated under the laws of the State of Israel in September 2011. The Company&#8217;s registered office is located in Kiryat Atidim, Tel Aviv, Israel. The Company is a clinical-stage biotech company discovering and developing innovative therapeutics for conditions with high-unmet medical need that involve inflammation and fibrosis.</span></span></p>
                        </td>
                      </tr>

                  </table>
                </div>
                <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                <div>
                  <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                      <tr>
                        <td style="width:72pt;vertical-align:top;font-family:'Times New Roman',Times,serif">
                          <div style="margin-left:36pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>B.</span></span></span></span></span></span></div>
                        </td>
                        <td style="width:auto;vertical-align:top;font-family:'Times New Roman',Times,serif">
                          <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On March&#160;16, 2021, the Company, then known as Anchiano Therapeutics Ltd. (&#8220;Anchiano&#8221;), completed its merger with Chemomab Ltd., a privately-held Israeli limited company (&#8220;Chemomab Ltd.&#8221;). Pursuant to the Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) dated as of December&#160;14, 2020, by and among Anchiano, CMB Acquisition Ltd., an Israeli limited company and wholly-owned subsidiary of Anchiano (&#8220;Merger Sub&#8221;), and Chemomab Ltd., Merger Sub merged with and into Chemomab Ltd., with Chemomab Ltd. being the surviving entity and becoming a wholly owned subsidiary of Anchiano (the &#8220;Merger&#8221;).&#160; Upon consummation of the Merger, the Company changed its name from &#8220;Anchiano Therapeutics Ltd.&#8221; to &#8220;Chemomab Therapeutics Ltd.&#8221; and the business conducted by Chemomab Ltd. became primarily the business conducted by the Company.</span></span></p>
                        </td>
                      </tr>

                  </table>
                </div>
                <div style="text-align:justify;margin-left:72pt;line-height:1.25">&#160;</div>
                <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For accounting purposes, Chemomab Ltd. is considered to have acquired Anchiano based upon the terms of the Merger as well as other factors including: (i) Chemomab Ltd.'s former shareholders owned approximately<span><span><span><span><span><span>&#160;<ix:nonFraction id="Fxbrl_20220801194753103" name="cmmb:ShareholdingPercentageImmediatelyFollowingMerger" contextRef="C_20210314to20210316_srtTitleOfIndividualAxis_cmmbFormerChemomabSecurityHoldersMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">90</ix:nonFraction>% </span></span></span></span></span></span>of the combined Company&#8217;s outstanding ordinary shares immediately following the closing of the Merger and (ii) Chemomab Ltd. management holds key management positions of the combined Company. The Merger has been accounted for as an asset acquisition (reverse recapitalization transaction) rather than a business combination, as the assets acquired and the liabilities assumed by Chemomab Ltd. do not meet the definition of a business under accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;). The net assets acquired in connection with the Merger were recorded at their estimated acquisition date fair market value as of March 16, 2021, the date of completion of the Merger.</span></span></div>
                <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Immediately prior to the effective date of the Merger, all preferred shares of Chemomab Ltd. were converted into ordinary shares of Chemomab Ltd. on a one-for-one basis.</span></span></span></span></span></span></div>
                <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>In connection with the Merger, and following the effective time of the Merger, the Company effected a reverse share split of the Company&#8217;s ordinary shares at a ratio of <ix:nonFraction id="Fxbrl_20220801211724341" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="C_20210314to20210316" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">4</ix:nonFraction>:<ix:nonFraction id="Fxbrl_20220801211728344" name="cmmb:NumberOfOrdinarySharesForEachPreferredShareConvertedPriorToDateOfMerger" contextRef="C_20210314to20210316" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">1</ix:nonFraction> (the &#8220;Reverse Split&#8221;) and increased the number of ordinary shares underlying each American Depositary Share ("ADS") from 5 to 20. At the effective time of the Merger, each Chemomab Ltd. ordinary share outstanding immediately prior to the effective time of the Merger automatically converted into the right to receive approximately <ix:nonFraction id="Fxbrl_20220719155933012" name="cmmb:NumberOfAdsIssuedAndOutstandingAfterMerger" contextRef="C_20210316_usgaapBusinessAcquisitionAxis_cmmbMergerAgreementWithChemomabIsraeliLimitedCompanyAndClinicalStageBiotechCompanyMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">12.86</ix:nonFraction> ADSs, each representing <ix:nonFraction id="Fxbrl_20220801195039967" name="cmmb:NumberOfOrdinarySharesConsistedInDS" contextRef="C_20210314to20210316_usgaapBusinessAcquisitionAxis_cmmbMergerAgreementWithChemomabIsraeliLimitedCompanyAndClinicalStageBiotechCompanyMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">20</ix:nonFraction> Anchiano ordinary shares, plus a warrant to purchase ADSs that may become exercisable only under certain circumstances.</span></span></span></span></span></span></div>
                <div style="text-align:justify;margin-left:72pt;line-height:1.25">&#160;</div>
                <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The exchange ratio was calculated by a formula that was determined through arms-length negotiations between the Company and Chemomab Ltd. The combined Company assumed all of the outstanding options of Chemomab Ltd., vested and unvested, under the Chemomab Share Incentive Plan (the &#8220;2015 Plan&#8221;), with such options representing the right to purchase a number of ADSs equal to approximately 12.86 multiplied by the number of Chemomab Ltd. ordinary shares previously represented by such options.</span></span></div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div>
        <div><ix:exclude>
          <div>
            <div>
              <p style="margin:0pt">&#160;</p>
              <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">8</span></span></p><div><hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div><p style="margin:0pt">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="text-decoration:underline"><strong>CHEMOMAB THERAPEUTICS LTD AND ITS SUBSIDIARIES<br />(FORMERLY ANCHIANO THERAPEUTICS LTD)<br />NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS</strong></span></span></span></p><p style="margin:0pt">&#160;</p>
              <p style="margin:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><strong><span>Note 1 - General.</span></strong><strong><span><span style="color:black"> (Cont.)</span></span></strong></span></span></span></span></span></span></span></p>
            </div>
          </div>
        </ix:exclude></div>
        <div>
          <div>
            <p style="margin:0pt">&#160;</p>
            <p style="margin-top:0pt;margin-left:72pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>The accompanying unaudited condensed consolidated financial statements and notes to the unaudited condensed consolidated financial statements give retroactive effect to the exchange ratio and the Reverse Split for all periods presented.</span></span></span></span></span></span></p>
            <div>
              <div>
                <div style="text-align:justify;margin-left:72pt;line-height:1.25">&#160;</div>
                <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>The equity structure reflects the legal acquirer's equity structure. The balance sheet has been adjusted to reflect the par value of the outstanding shares of the legal acquirer, including the number of shares issued in the Merger. Any difference is recognized as an adjustment to the additional paid in capital.</span></span></span></span></span></span></div>
                <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Immediately after completion of the Merger, on March 16, 2021, the Company had <ix:nonFraction id="Fxbrl_20220719160013200" name="cmmb:NumberOfSharesDilutedAfterMerger" contextRef="C_20210316_usgaapBusinessAcquisitionAxis_cmmbMergerAgreementWithChemomabIsraeliLimitedCompanyAndClinicalStageBiotechCompanyMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">8,078,727</ix:nonFraction> ADS issued and outstanding (<ix:nonFraction id="Fxbrl_20220719160028273" name="cmmb:SharesConvertiblePerShareOfAcquireeEntity" contextRef="C_20210314to20210316_usgaapBusinessAcquisitionAxis_cmmbMergerAgreementWithChemomabIsraeliLimitedCompanyAndClinicalStageBiotechCompanyMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">9,003,357</ix:nonFraction> on a fully diluted basis). In addition, immediately after the Merger, Chemomab Ltd. former shareholders owned approximately <ix:nonFraction id="Fxbrl_20220719160036138" name="cmmb:ShareholdingPercentageImmediatelyFollowingMerger" contextRef="C_20210314to20210316_srtTitleOfIndividualAxis_cmmbFormerChemomabSecurityHoldersMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">90</ix:nonFraction>% of the number of issued and outstanding ordinary shares of the Company and the shareholders of the Company immediately prior to the Merger owned approximately 10% </span></span></span></span></span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">of the number of issued and outstanding ordinary shares of the Company (all on a fully diluted basis).</span></span></div>
                <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>On March 16, 2021, immediately prior to the effectiveness of the Merger, Anchiano had <ix:nonFraction id="Fxbrl_20220719160047972" name="cmmb:NumberOfOrdinarySharesForEachPreferredShareConvertedPriorToDateOfMerger" contextRef="C_20210314to20210316_srtTitleOfIndividualAxis_cmmbFormerChemomabSecurityHoldersMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">65,675,904</ix:nonFraction> ordinary shares outstanding (prior to the effect of the Reverse Split) and a market capitalization of $<ix:nonFraction id="Fxbrl_20220719160056244" name="us-gaap:Capital" contextRef="C_20210316" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">58.7</ix:nonFraction> million. The estimated fair value of the net assets of Anchiano on March 16, 2021, prior to the Merger, was approximately $<ix:nonFraction id="Fxbrl_20220719160102341" name="cmmb:RetainedEarningsAccumulatedDeficits" contextRef="C_20210316_srtTitleOfIndividualAxis_cmmbFormerChemomabSecurityHoldersMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal" sign="-">2.5</ix:nonFraction> million. The fair value of ordinary shares on the Merger closing date, prior to the Merger, was above the fair value of the Company&#8217;s net assets. As the Company&#8217;s net assets were predominantly composed of cash offset against current liabilities, the fair value of the Company&#8217;s net assets as of March 16, 2021, prior to the Merger, is considered to be the best indicator of the fair value and, therefore, the estimated preliminary purchase consideration.</span></span></span></span></span></span></div>
                <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>The following table summarizes the net assets acquired based on their estimated fair values as of March 16, 2021, immediately prior to completion of the Merger (in thousands):</span></span></span></span></span></span></div>
                <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                <div>
                  <div style="margin-left:72pt">
                    <ix:nonNumeric id="Fxbrl_20220801194203792" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" contextRef="C_20220101to20220630" escape="true">
                      <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:90%">

                          <tr>
                            <td style="vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;width:88%" valign="bottom">
                              <div style="text-indent:-12pt;margin-left:12pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Cash and cash equivalents</span></span></span></span></span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>$</span></span></span></span></span></span></div>
                            </td>
                            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><ix:nonFraction id="FFact_251" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" contextRef="C_20210316" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,427</ix:nonFraction></span></span></span></span></span></span></div>
                            </td>
                            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%" valign="bottom">
                              <div style="text-indent:-12pt;margin-left:12pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Asset held for sale</span></span></span></span></span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><ix:nonFraction id="FFact_252" name="cmmb:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale" contextRef="C_20210316" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,000</ix:nonFraction></span></span></span></span></span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%;background-color:rgb(204, 238, 255)" valign="bottom">
                              <div style="text-indent:-12pt;margin-left:12pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Prepaid and other assets</span></span></span></span></span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><ix:nonFraction id="FFact_253" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" contextRef="C_20210316" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">236</ix:nonFraction></span></span></span></span></span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%;padding-bottom:2px" valign="bottom">
                              <div style="text-indent:-12pt;margin-left:12pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Accrued liabilities</span></span></span></span></span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>(<ix:nonFraction id="FFact_254" name="cmmb:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" contextRef="C_20210316" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,187</ix:nonFraction></span></span></span></span></span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>)</span></span></span></span></span></span></div>
                            </td>
                          </tr>
                          <tr>
                            <td colspan="1" style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%;background-color:rgb(204, 238, 255)" valign="bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Net acquired assets</span></span></span></span></span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>$</span></span></span></span></span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><ix:nonFraction id="FFact_255" name="cmmb:EstimatedFairValueOfNetAssetsAcquired" contextRef="C_20210316" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,476</ix:nonFraction></span></span></span></span></span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                          </tr>

                      </table>
                    </ix:nonNumeric>
                  </div>
                </div>
                <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
                <div>
                  <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                      <tr>
                        <td style="width:72pt;vertical-align:top;font-family:'Times New Roman',Times,serif">
                          <div style="margin-left:36pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>C.</span></span></span></span></span></span></div>
                        </td>
                        <td style="width:auto;vertical-align:top;font-family:'Times New Roman',Times,serif">
                          <div style="text-align:justify;line-height:1.25">In connection with the Merger, on March 15, 2021, Anchiano entered into Securities Purchase Agreements with certain purchasers for the issuance and sale by Anchiano in a private placement (the &#8220;Private Placement&#8221;) of approximately<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span> $<ix:nonFraction id="Fxbrl_20220719160118070" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" contextRef="C_20210301to20210315" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">45.5</ix:nonFraction> million </span></span></span></span></span></span>of its ADSs and accompanying warrants to purchase ADSs. The warrants have an exercise price of approximately<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span> $<ix:nonFraction id="Fxbrl_20220808231241599" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20210315" unitRef="USD_per_share" scale="0" decimals="2" format="ixt:num-dot-decimal">17.35</ix:nonFraction>&#160;</span></span></span></span></span></span>per ADS, expire<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>&#160;<ix:nonNumeric id="Fxbrl_20220719160132552" name="cmmb:WarrantsExercisablePeriod" contextRef="C_20210301to20210315" format="ixt-sec:durwordsen">five years</ix:nonNumeric>&#160;</span></span></span></span></span></span>from the date of issuance, and if exercised in full, will provide additional proceeds to the Company of approximately<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span> $<ix:nonFraction id="Fxbrl_20220719160138785" name="us-gaap:ProceedsFromWarrantExercises" contextRef="C_20210301to20210315" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.5</ix:nonFraction> million. </span></span></span></span></span></span>The Private Placement closed on March 22, 2021.</div>
                        </td>
                      </tr>

                  </table>
                </div>
              </div>
            </div>
            <div style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</div>
            <div><ix:exclude>
              <div>
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">9</span></span></p><div><hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div><p style="margin:0pt">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="text-decoration:underline"><strong>CHEMOMAB THERAPEUTICS LTD AND ITS SUBSIDIARIES<br />(FORMERLY ANCHIANO THERAPEUTICS LTD)<br />NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS</strong></span></span></span></p><p style="margin:0pt">&#160;</p>
              </div>
              <div>
                <p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><strong><span>Note 1 - General.</span></strong><strong><span><span style="color:black"> (Cont.)</span></span></strong></span></span></span></span></span></span></span></p>
              </div>
            </ix:exclude></div>
            <div style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</div>
            <div>
              <div>
                <div>
                  <div>
                    <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                        <tr>
                          <td style="width:72pt;vertical-align:top;font-family:'Times New Roman',Times,serif">
                            <div style="margin-left:36pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>D.</span></span></span></span></span></span></div>
                          </td>
                          <td style="width:auto;vertical-align:top;font-family:'Times New Roman',Times,serif">
                            <div style="text-align:justify;line-height:1.25">Pursuant to an Asset Purchase and Assignment Agreement dated as of March 16, 2021, as amended on March 31, 2021, between the Company&#8217;s wholly owned subsidiary, Anchiano Therapeutics, Inc., a Delaware corporation (&#8220;Anchiano Delaware&#8221;) and Kestrel Therapeutics, Inc., a Delaware corporation (&#8220;Kestrel&#8221;), Anchiano Delaware agreed to sell to Kestrel all of the its rights and obligations in its business to the extent related to the research, development and commercialization of the Compounds and Products (as such terms are defined in the Collaboration and License Agreement entered into as of September 13, 2019, by and between ADT Pharmaceuticals, LLC and Anchiano Delaware), also known as the pan-RAS and PDE10/&#946;-catenin programs. In consideration of the sale and transfer of the Compounds and Products, Kestrel paid the Company a total of $<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><ix:nonFraction id="Fxbrl_20220801230315934" name="cmmb:AmountOfTotalSaleAndTransferOfCompoundsAndProductsKestrelPaid" contextRef="C_20210301to20210315" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction> million.</span></span></span></span></span></span></div>
                          </td>
                        </tr>

                    </table>
                  </div>
                  <div style="text-align:justify;margin-left:72pt;line-height:1.25">&#160;</div>
                  <div>
                    <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                        <tr>
                          <td style="width:72pt;vertical-align:top;font-family:'Times New Roman',Times,serif">
                            <div style="margin-left:36pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>E.</span></span></span></span></span></span></div>
                          </td>
                          <td style="width:auto;vertical-align:top;font-family:'Times New Roman',Times,serif">
                            <div style="text-align:justify;line-height:1.25">On April 30, 2021, the Company entered into an At the Market Offering Agreement (the "ATM Agreement") with Cantor Fitzgerald &#38; Co., ("Cantor"). According to the ATM Agreement, the Company may offer and sell, from time to time, its ADSs having an aggregate offering price of up to<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>&#160;$<ix:nonFraction id="Fxbrl_20220719160218493" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="C_20210401to20210430_usgaapStatementClassOfStockAxis_cmmbAmericanDepositorySharesMember_usgaapSubsidiarySaleOfStockAxis_cmmbAtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">75.0</ix:nonFraction> </span></span></span></span></span></span>million through Cantor pursuant to the ATM Agreement. From April 30, 2021 through June 30, 2022, the Company sold<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span> <ix:nonFraction id="Fxbrl_20220719160226621" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="C_20210501to20220630_usgaapStatementClassOfStockAxis_cmmbAmericanDepositorySharesMember_usgaapSubsidiarySaleOfStockAxis_cmmbAtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">699,806</ix:nonFraction> ADSs at an average price of $<ix:nonFraction id="Fxbrl_20220719160233894" name="us-gaap:SaleOfStockPricePerShare" contextRef="C_20220630_usgaapStatementClassOfStockAxis_cmmbAmericanDepositorySharesMember_usgaapSubsidiarySaleOfStockAxis_cmmbAtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember" unitRef="USD_per_share" scale="0" decimals="2" format="ixt:num-dot-decimal">22.75</ix:nonFraction> </span></span></span></span></span></span>per ADS under the ATM Agreement, resulting in gross proceeds of approximately<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span> $<ix:nonFraction id="Fxbrl_20220719160245351" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" contextRef="C_20210501to20220630_usgaapStatementClassOfStockAxis_cmmbAmericanDepositorySharesMember_usgaapSubsidiarySaleOfStockAxis_cmmbAtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.9</ix:nonFraction> </span></span></span></span></span></span>million<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>. </span></span></span></span></span></span>The offer and sale of ADSs under the ATM Agreement has been registered under the Company&#8217;s effective registration statement on Form S-3 (File No. 333-255658), together with a prospectus forming a part thereof, filed with the SEC under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). Sales, if any, of ADS pursuant to the ATM Agreement may be made in any transactions that are deemed to be &#8220;at the market&#8221; offerings as defined in Rule 415(a)(4) under the Securities Act. The Company is not obligated to sell any ADSs under the ATM Agreement.</div>
                          </td>
                        </tr>

                    </table>
                  </div>
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                  <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On April 25, 2022, the Company filed with the SEC a prospectus supplement to the above mentioned registration statement for the issuance and sale of up to</span></span><span><span><span><span><span><span> $<ix:nonFraction id="Fxbrl_20220720110354187" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="C_20220401to20220425_srtRangeAxis_srtMaximumMember_usgaapStatementClassOfStockAxis_cmmbAmericanDepositorySharesMember_usgaapSubsidiarySaleOfStockAxis_cmmbAtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">18,125,000</ix:nonFraction> </span></span></span></span></span></span>of the Company's ADSs under the ATM Agreement, which is within the $75 million maximum permitted under the ATM Agreement.</span></span></div>
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                  <div>
                    <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                        <tr>
                          <td style="width:72pt;vertical-align:top;font-family:'Times New Roman',Times,serif">
                            <div style="margin-left:36pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>F.</span></span></span></span></span></span></div>
                          </td>
                          <td style="width:auto;vertical-align:top;font-family:'Times New Roman',Times,serif">
                            <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Since January 2020, the COVID-19 outbreak has dramatically expanded into a worldwide pandemic creating macro-economic uncertainty and disruption in the business and financial markets. Many countries around the world, including Israel, have been taking measures designated to limit the continued spread of the Coronavirus, including the closure of workplaces, restricting travel, prohibiting assembling, closing international borders and quarantining populated areas. The Company's clinical trial sites have been affected by the COVID-19 pandemic, and as a result, commencement of the enrollment of Company&#8217;s clinical trials of CM-101 in PSC was delayed and the enrollment rate has been affected as well. As a result, the Company extended patients recruiting to additional territories with significant recruitment potential. In addition, after enrollment in these trials, patients may drop out of the Company's trials because of the COVID-19 possible implications.</span></span></span></span></span></span></div>
                          </td>
                        </tr>

                    </table>
                  </div>
                  <div style="text-align:justify;margin-left:72pt;line-height:1.25">&#160;</div>
                  <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Based on management&#8217;s assessment, the extent to which the coronavirus will further impact the Company&#8217;s operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration and severity of the outbreak, and the actions that may be required to contain the coronavirus or treat its impact. The Company is carefully monitoring the restrictions due to the COVID-19 outbreak and will adjust activities accordingly.</span></span></span></span></span></span>
                    <p style="margin:0pt">&#160;</p>
                  </div>
                  <div><ix:exclude>
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">10</span></span></p><div><hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div><p style="margin:0pt">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="text-decoration:underline"><strong>CHEMOMAB THERAPEUTICS LTD AND ITS SUBSIDIARIES<br />(FORMERLY ANCHIANO THERAPEUTICS LTD)<br />NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS</strong></span></span></span></p><p style="margin:0pt">&#160;</p>
                      <p style="margin:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span><span><span>Note 1 - General. (Cont.)</span></span></span></span></strong></span></span></p>
                    </div>
                  </ix:exclude></div>
                  <div style="text-align:justify;margin-left:72pt;line-height:1.25">
                    <p style="margin:0pt">&#160;</p><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>On March 27, 2020 and December 27, 2020, the President of the United States signed and enacted into law the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) and the Consolidated Appropriations Act, 2021 (CAA). Among other provisions, the CARES Act and the CAA provide relief to U.S. federal corporate taxpayers through temporary adjustments to net operating loss rules, changes to limitations on interest expense deductibility, and the acceleration of available refunds for minimum tax credit carryforwards. The CARES Act also includes provisions for a carryback of any net operating loss (NOL) arising in a taxable year beginning after December 31, 2017, and before January 1, 2021, to each of the five taxable years preceding the taxable year in which the loss arises (carryback period).</span></span></span></span></span></span>
                  </div>
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                  <div style="text-align:justify;margin-left:72pt;line-height:1.25">
                    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chemomab Therapeutics Inc., a wholly owned subsidiary of the Company, filed an application with the US Internal Revenue Service to carryback net operating losses. The Company expects to receive the refund during the second half of 2022.</span></span></p>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
  </ix:nonNumeric>
  <div>
    <div>
      <div>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right">&#160;</p>
      </div>
    </div>
  </div>

  <div>
    <ix:nonNumeric id="Fxbrl_20220505134338955" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="C_20220101to20220630" escape="true">
      <div>
        <p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong><span>Note 2 - Basis of Presentation and Significant Accounting Policies </span></strong></span></span></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
        <ix:nonNumeric id="Fxbrl_20220505104021668" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="C_20220101to20220630" escape="true">
          <div>
            <p style="margin-top:0pt;margin-left:36pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>A.&#160; &#160; &#160; &#160; &#160; Basis of Preparation</strong></span></span></span></p>
            <p style="margin-top:0pt;margin-left:48px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
            <p style="margin-top:0pt;margin-left:36pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">The condensed interim consolidated financial statements included in this quarterly report are unaudited. These financial statements have been prepared in accordance with U.S. GAAP and applicable rules and regulations of the SEC regarding interim financial reporting and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for a fair statement of the Company&#8217;s financial position as of June 30, 2022, and its results of operations for the three and six months ended June 30, 2022, and 2021, changes in shareholders&#8217; equity for the six months ended June 30, 2022 and 2021, and cash flows for the six months ended June 30, 2022 and 2021. The results of operations for the three and six months ended June 30, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022 or for any other future annual or interim period. These financial statements should be read in conjunction with the audited financial statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC. The Company&#8217;s significant accounting policies are disclosed in the audited financial statements for the year ended December 31, 2021 included in the Company&#8217;s Annual Report on Form 10-K. Since the date of such financial statements, there have been no changes to the Company&#8217;s significant accounting policies.</p>
          </div>
        </ix:nonNumeric>
        <p style="margin-top:0pt;margin-left:48px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
        <ix:nonNumeric id="Fxbrl_20220505104106171" name="us-gaap:UseOfEstimates" contextRef="C_20220101to20220630" escape="true">
          <div>
            <p style="margin-top:0pt;margin-left:36pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>B.&#160; &#160; &#160; &#160; &#160; Use of estimates</strong></span></span></span></p>
            <p style="margin:0pt">&#160;</p>
            <p style="margin-top:0pt;margin-left:36pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.</span></span></span></p>
          </div>
        </ix:nonNumeric>
      </div>
    </ix:nonNumeric>
  </div>
  <div style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">
    <p style="margin:0pt">&#160;</p>
    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">11</span></span></p><div><hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div><p style="margin:0pt">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="text-decoration:underline"><strong>CHEMOMAB THERAPEUTICS LTD AND ITS SUBSIDIARIES<br />(FORMERLY ANCHIANO THERAPEUTICS LTD)<br />NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS</strong></span></span></span></p><p style="margin:0pt">&#160;</p>
  </div>

  <ix:nonNumeric id="Fxbrl_20220728222325384" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="C_20220101to20220630" escape="true">
    <div>
      <div style="margin-top:0px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note 3 - Contingencies</span></span></strong></div>
      <div>
        <div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>During 2022, </span></span>the Israeli tax authority ("ITA&#8221;) notified the Company that it had initiated a routine VAT audit to include tax years 2017 through 2020. The ITA raised several claims, mainly in respect with the recoverability of VAT with respect to Merger Agreement related expenses and the classification of the Company as a holding company. On July 2022, the ITA proposed a settlement, which the Company rejected. As a result, the ITA issued an assessment. The Company plans to appeal the ITA&#8217;s assessment. The Company has recorded a provision which is inherently subjective due to the inherent uncertainty of these matters and the judicial process. Therefore, the final outcome may differ from the estimated liability recorded by the Company during the period<span><span>.</span></span></span></span></div>
        </div>
      </div>
    </div>
  </ix:nonNumeric>
  <div>&#160;</div>
  <div>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center">12</p>
    <hr style="background:rgb(0, 0, 0);width:100%;border-top:1.5pt solid black;page-break-after:always;margin-bottom:8pt" />
  </div>
<div><div><div style="line-height:1.25"><div style="text-align:justify;line-height:1.25"><a id="Item2."></a><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Item 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span>&#160;</span></span></div></div><div style="line-height:1.25">&#160;</div><div style="text-align:justify;line-height:1.25;font-style:italic;text-indent:50px"><span style="font-size:10pt;text-indent:40px"><span style="font-family:Times New Roman, Times, serif;text-indent:40px">You should read the following discussion and analysis of our financial condition and results of operations together with our condensed consolidated financial statements and the related notes included elsewhere in this Quarterly Report on Form 10-Q, as well as our audited consolidated financial statements and related notes for the year ended December 31, 2021, as filed in our Annual Report on Form 10-K for the year ended December 31, 2021 (the &#8220;2021 Annual Report&#8221;). Some of the information contained in this discussion and analysis, particularly with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. You should read &#8220;Risk Factors&#8221; in Item 1A of our 2021 Annual Report for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. </span></span></div><div style="line-height:1.25;text-indent:40px">&#160;</div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt;text-indent:40px"><span style="font-family:Times New Roman, Times, serif;text-indent:40px"><span style="font-style:italic;text-indent:40px">References to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and &#8220;Chemomab&#8221; in this &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; below refer to the Company after the Merger, and, with respect to historical periods preceding the Merger, refer to Chemomab Ltd., whose business became the business of the Company upon consummation of the Merger.</span>&#160;</span></span></div><div style="line-height:1.25">&#160;</div><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Overview </span>&#160;</span></span></div><div style="line-height:1.25">&#160;</div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt;text-indent:50px"><span style="font-family:Times New Roman, Times, serif;text-indent:50px">The Company is a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, the Company developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.</span></span></div><div style="line-height:1.25;text-indent:50px">&#160;</div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt;text-indent:50px"><span style="font-family:Times New Roman, Times, serif;text-indent:50px">The Company has pioneered the therapeutic targeting of CCL24, a chemokine that promotes various types of cellular processes that regulate inflammatory and fibrotic activities through the CCR3 receptor. The chemokine is expressed in various types of cells, including immune cells, endothelial cells and epithelial cells. We have developed a novel CCL24 inhibiting product candidate with dual anti-fibrotic and anti-inflammatory activity that modulates the complex interplays of both of these inflammatory and fibrotic mechanisms that drive abnormal states of fibrosis and clinical fibrotic diseases. This innovative approach is being developed for difficult to treat rare diseases, also known as orphan indications or diseases, such as primary sclerosing cholangitis, or PSC, and systemic sclerosis, or SSc, for which patients have no established disease modifying standard of care treatment options.</span></span></div><div style="line-height:1.25">&#160;</div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CM-101, the Company&#8217;s lead clinical product candidate, is a first-in-class humanized monoclonal antibody that attenuates the basic function of the soluble chemokine CCL24, also known as eotaxin-2, as a regulator of major inflammatory and fibrotic pathways. We have demonstrated that CM-101 interferes with the underlying biology of inflammation and fibrosis through a novel and differentiated mechanism of action. Based on these findings, the Company is actively developing CM-101 in Phase 2 clinical studies directed toward two distinct clinical indications including patients with liver, skin, and/or lung fibrosis. We are currently conducting a Phase 2 clinical study in PSC, a rare obstructive and cholestatic liver disease. In addition, we are planning a Phase 2 clinical trial in SSc focused on establishing biological proof-of-concept on clinically relevant aspects of this complex disease in this patient population. Although our primary focus relates to these two rare indications, an additional Phase 2 clinical study is currently ongoing in non-alcoholic steatohepatitis, or NASH. This trial is expected to provide important safety and PK data to support the development of a CM-101 subcutaneous formulation.</span></span></div><div style="line-height:1.25">&#160;</div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fibrosis is the abnormal and excessive accumulation of collagen and extracellular matrix, the non-cellular component in all tissues and organs, that provides structural and biochemical support to surrounding cells. When present in excessive amounts, collagen and extracellular matrix lead to scarring and thickening of connective tissues, affecting tissue properties and potentially leading to organ failure. Fibrosis can occur in many different tissues, including lung, liver, kidney, muscle, skin, and the gastrointestinal tract, resulting in a wide array of progressive fibrotic conditions. Fibrosis and inflammation are intrinsically linked. While a healthy inflammatory response is necessary for efficient tissue repair; after injury, an excessive, uncontrolled inflammatory response can lead to tissue fibrosis.</span></span></div><div style="line-height:1.25">&#160;</div><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Recent Developments</span>&#160;</span></span></div><div style="line-height:1.25">&#160;</div><div style="line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">New Executive Appointments</span></span></div><div style="line-height:1.25">&#160;</div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On June 16, 2022, our board of directors (&#8220;Board of Directors&#8221;) appointed Ms. Jill M. Quigley, JD, as a Class I director and as a member of the audit committee of the Board of Directors (the &#8220;Audit Committee&#8221;). Additionally, our Board of Directors determined Ms. Quigley to be an independent director and designated her as the Audit Committee financial expert. Ms. Quigley is a highly accomplished biotechnology executive with broad experience in public company executive management, global operations, legal affairs, finances, and board membership. Ms. Quigley, as a Class I director, will serve in such capacity until the Company&#8217;s annual general meeting to be convened in 2025. Ms. Quigley&#8217;s appointment followed Mr. Joel Maryles&#8217; decision on May 31, 2022 not to stand for re-election as a Class I director at the Company&#8217;s annual general meeting in 2022. Following the appointment of Ms. Quigley and departure of Mr. Maryles, the current composition of the Audit Committee is Dr. Claude Nicaise (chair), Dr. Alan Moses and Ms. Quigley.</span></span></div><div style="line-height:1.25">&#160;</div><div style="clear:both;margin-top:10pt;margin-bottom:10pt"><div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">13</span></span></span></div><div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On June 14, 2022, Mr. Ilan Vaknin, PhD, joined Chemomab as Vice President of Research &#38; Development. Dr. Vaknin has more than 20 years of highly relevant experience in immunology, antibody development, biomarkers and drug development, including more than a decade in senior science roles at the biotechnology company Compugen.</span></span></div><div style="line-height:1.25">&#160;</div><div style="line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">New CM-101 U.S. Patent</span></span></div><div style="line-height:1.25">&#160;</div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On June 21, 2022, the United States Patent and Trademark Office issued a new patent the United States Patent and Trademark Office issued Chemomab a new patent that covers the use of CM-101 and other anti-CCL24 antibodies and binding fragments for the treatment of a range of fibro-inflammatory liver diseases, including PSC and other cholestatic-associated disorders. Liver diseases are an important target for CCL24-associated diseases--CM-101 is currently in a Phase 2 trial for the treatment of PSC, a potentially lethal disease affecting the bile ducts of the liver, and a Phase 2 liver fibrosis study of CM-101 is now concluding. In addition, there are a number of other liver diseases where CM-101 might have therapeutic value. This new method of use patent adds to the protections provided by CM-101&#8217;s core composition of matter patents that have already issued in the U.S., Europe and other major global territories, U.S. Patent No.11365246, &#8220;Anti CCL24 (eotaxin 2) Antibodies for Use in the Treatment of Hepatic Disease&#8221; has a filing date of March 8, 2018, and a grant date of June 21, 2022, with corresponding first to expire claims in 2038 and a possible patent term extension of up to an additional five years, as provided under the Drug Price Competition and Patent Restoration Act (35 U.S.C. &#167;156).</span></span></div><div style="line-height:1.25">&#160;</div><div style="line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Revisions to Chemomab&#8217;s Clinical Programs</span></span></div><div style="line-height:1.25">&#160;</div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On March 9, 2022, we announced that, following a comprehensive strategic review, we were revising our current clinical programs. The changes are designed to optimize the clinical development of lead product candidate CM-101 by maximizing the clinical information obtained, generating additional important data to support future advancement to registration trials, and decreasing the overall risk in the CM-101 clinical development program in the lead indications of PSC and SSc, as well as potentially in additional indications where the scientific rationale is strong. The key top-line changes that are being implemented in the clinical development programs include the following:</span></span></div><div style="line-height:1.25">&#160;</div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt;text-indent:50px"><span style="font-family:Times New Roman, Times, serif;text-indent:50px"><span style="font-weight:bold">Expanding our commitment to PSC with an enlarged clinical trial that adds an important dose finding component.</span> We are significantly expanding the Phase 2 clinical trial in PSC by implementing a dose finding component to the CM-101 development program. We will be increasing the size of the study to 93patients by adding two additional dose cohorts to the current 10 mg/kg cohort, a lower dose cohort to evaluate 5 mg/kg, and a higher dose cohort to evaluate 20 mg/kg. Additionally, we are changing the trial&#8217;s primary outcome to an evaluation of CM-101&#8217;s safety and tolerability. Each cohort will enroll 25 patients with PSC and the placebo cohort will enroll 18 patients. In addition, we plan to add an open-label extension to the trial to evaluate the safety, tolerability and durability of effect over a total of 48 weeks of treatment duration. We have begun regulatory submissions to support trial expansion and other relevant changes.</span></span></div><div style="line-height:1.25;text-indent:50px">&#160;</div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt;text-indent:50px"><span style="font-family:Times New Roman, Times, serif;text-indent:50px">We will be performing a blinded interim safety analysis of the currently enrolling dose cohort in the PSC study, expected to be completed before the end of this year. The primary purpose of this safety analysis is to support review by the Data Monitoring Committee, a prerequisite to opening enrollment in this trial to the planned higher dose cohort of 20mg/kg. </span></span></div><div style="line-height:1.25">&#160;</div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt;text-indent:50px"><span style="font-family:Times New Roman, Times, serif;text-indent:50px">Based on our ongoing efforts to expand the number of clinical trial sites, the current development landscape of trials in PSC, and the increased size of the study, we anticipate that the top-line data from this Phase 2 trial in PSC will be available in the second half of 2024.</span></span></div><div style="line-height:1.25;text-indent:50px">&#160;</div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt;text-indent:50px"><span style="font-family:Times New Roman, Times, serif;text-indent:50px"><span style="font-weight:bold;text-indent:50px">Focusing our clinical efforts in systemic sclerosis on establishing earlier biological proof-of-concept in clinically relevant aspects of this complex disease. </span>We are focusing our SSc trial towards establishing biological proof of concept in this patient population. We are revising the design of our planned SSc trial in a way that we believe should enable an expedited path to data supporting proof of the relevance of CCL-24 biology, provide further elucidation of the different mechanisms of action of CM-101, and potentially detect a CM-101 clinical efficacy signal for treating the skin, lung and vascular damage seen in SSc patients. We expect to launch the trial by the end of 2022.</span></span></div><div style="line-height:1.25;text-indent:50px">&#160;</div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt;text-indent:50px"><span style="font-family:Times New Roman, Times, serif;text-indent:50px"><span style="font-weight:bold;text-indent:50px">Early Conclusion of enrollment in our safety, pharmacokinetic and biomarker liver fibrosis study, yielding a data readout targeted near the end of 2022.</span> We concluded enrollment in our safety, tolerability and biomarker trial that is evaluating a subcutaneous formulation of CM-101 in NASH patients with liver fibrosis. We believe that the data from this trial could provide useful insights in support of the CM-101 development program and that the early completion of this study should be sufficient to achieve our key objectives: characterizing the safety and tolerability of CM-101 in NASH patients, assessing possible early signs of biomarker activity in these patients, and providing the tolerability and pharmacokinetic data needed to assess next steps in the development of our current subcutaneous formulation, while allowing us to focus our resources on our lead indications of PSC and SSc.</span></span></div><div style="line-height:1.25">&#160;</div><div style="clear:both;margin-top:10pt;margin-bottom:10pt"><div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">14</span></span></span></div><div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We expect that the changes we are making to the CM-101 development program will provide important data on clinical dose response relationships to inform the broader development program and to identify the optimal dose to advance into late development in PSC. The modifications are also expected to generate proof of mechanism data on biologically relevant aspects of SSc, a complex rheumatological disorder, to best inform the development path for a novel, first-in-class therapeutic like CM-101, along with relevant safety and tolerability data to support the evaluation of higher doses and inform decisions on next steps in the development of our current subcutaneous formulation.</span></span></div><div style="line-height:1.25">&#160;</div><div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-style:italic">Shelf Registration Statement and ATM Offering</span>&#160;</span></span></div><div style="line-height:1.25">&#160;</div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt;text-indent:50px"><span style="font-family:Times New Roman, Times, serif;text-indent:50px">On April 30, 2021, we filed a shelf registration statement on Form S-3 with the SEC (File No. 333-255658) for the issuance and sale by us of up to $200,000,000 of our ordinary shares, ADSs, debt securities, warrants and units comprising any combination of the foregoing securities (the &#8220;Shelf Registration Statement&#8221;). On the same date, we entered into a sales agreement (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald, pursuant to which we may offer and sell, from time to time, at our option, through or to Cantor Fitzgerald, up to an aggregate of $75,000,000 of our ADSs (the &#8220;ATM Facility&#8221;). During the period from April 30, 2021 through the date of this quarterly report on Form 10-Q, we had sold an aggregate of 699,806 ADSs pursuant to the Sales Agreement for a total gross consideration of approximately $15.9 million.</span></span></div><div style="line-height:1.25;text-indent:50px">&#160;</div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt;text-indent:50px"><span style="font-family:Times New Roman, Times, serif;text-indent:50px">On April 25, 2022, we filed a prospectus supplement with the SEC for the issuance and sale of up to $18,125,000 of our ADSs in connection with the reactivation of the ATM Facility and pursuant to General Instruction I.B.6 of Form S-3, which, subject to certain exceptions, limits the amount of securities we are able to offer and sell under such registration statement to one-third of our unaffiliated public float. Any ADSs offered, or to be offered, and sold under the Sales Agreement were issued and sold, or will be issued and sold, pursuant to the Shelf Registration Statement and the applicable prospectus or prospectus supplement by methods deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) promulgated under the Securities Act, or if specified by us, by any other method permitted by law.</span></span></div><div style="line-height:1.25">&#160;</div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During the period from April 25, 2022 through the date of this quarterly report on Form 10-Q, we did not sell ADSs pursuant to the Sales Agreement.</span></span></div><div style="line-height:1.25">&#160;</div><div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-style:italic">Impact of COVID-19</span>&#160;</span></span></div><div style="line-height:1.25">&#160;</div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt;text-indent:50px"><span style="font-family:Times New Roman, Times, serif;text-indent:50px">Since March 2020, the COVID-19 pandemic has dramatically expanded into a worldwide pandemic, creating macro-economic uncertainty and disruption in the business and financial markets. The continuing implications of the COVID-19 pandemic on Chemomab remain uncertain and will depend on future developments, including any adverse impact due to additional variants of the virus; its impact on our employees; the range of government mandated restrictions and other measures; and the success of the COVID-19 vaccines and their effectiveness against the virus and related variants. Furthermore, our clinical trial sites have been affected by the COVID-19 pandemic, and as a result, commencement of the enrollment in our clinical trials of CM-101 in PSC was delayed, and the enrollment rate has been affected as well. As a result, we expanded our patient recruiting efforts to additional territories. In addition, after enrollment in these trials, patients might still discontinue participation in these trials because of possible COVID-19 implications.</span></span></div><div style="line-height:1.25;text-indent:50px">&#160;</div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt;text-indent:50px"><span style="font-family:Times New Roman, Times, serif;text-indent:50px">Based on management&#8217;s assessment, the extent to which the COVID-19 pandemic will continue to impact our operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the ultimate duration and changing severity of the outbreak, and the actions that may be required to continue to contain COVID-19 or address its impact. We are monitoring the remaining limitations on patient recruitment due to the effects of the COVID-19 pandemic and if necessary, will adjust activities accordingly.</span></span></div><div style="line-height:1.25">&#160;</div><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Corporate Information</span>&#160;</span></span></div><div style="line-height:1.25">&#160;</div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We were incorporated on September 22, 2011 under the laws of the State of Israel. In March 2021, in connection with the Merger, we changed our name from Anchiano Therapeutics Ltd. to Chemomab Therapeutics Ltd. Our principal executive offices are located at Kiryat Atidim, Building 7, Tel Aviv, Israel 6158002, and our phone number is +972-77-331-0156. Our website is: <span style="font-style:italic"><span style="text-decoration:underline">www.chemomab.com</span>. </span>The information contained on, or that can be accessed through, our website is not incorporated by reference into this Quarterly Report on Form 10-Q. We have included our website address as an inactive textual reference only.</span></span></div><div style="line-height:1.25">&#160;</div><div style="clear:both;margin-top:10pt;margin-bottom:10pt"><div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">15</span></span></span></div><div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Components of Operating Results</span>&#160;</span></span></div><div style="line-height:1.25">&#160;</div><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold;font-style:italic">Revenues</span>&#160;</span></span></div><div style="line-height:1.25">&#160;</div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">To date, we have not generated any revenue. We do not expect to generate any revenue unless and until we obtain regulatory approval and commercialize a product candidate, or until we receive revenue from a collaboration such as a co-development or out-licensing agreement. There can be no assurance that we will receive such regulatory approvals, and if any product candidate is approved, that we will be successful in commercializing it.</span></span></div><div style="line-height:1.25">&#160;</div><div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold;font-style:italic">Research and Development Expenses</span>&#160;</span></span></div><div style="line-height:1.25">&#160;</div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development expenses consist primarily of costs incurred in connection with the development of our product candidates. These expenses include:</span></span></div><div><table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-top:11pt;width:100%;text-align:left;color:#000000"><tr><td style="width:18pt">&#160;</td><td style="width:36pt;vertical-align:top;align:right"><div style="margin-left:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></div></td><td style="width:auto;vertical-align:top"><div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">expenses incurred under agreements with contract research organizations or contract manufacturing organizations, as well as investigative sites and consultants that conduct our clinical trials, preclinical studies and other scientific development services;</span></span></div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-top:11pt;width:100%;text-align:left;color:#000000"><tr><td style="width:18pt">&#160;</td><td style="width:36pt;vertical-align:top;align:right"><div style="margin-left:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></div></td><td style="width:auto;vertical-align:top"><div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">manufacturing scale-up expenses and the cost of acquiring and manufacturing preclinical and clinical trial materials;</span></span></div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-top:11pt;width:100%;text-align:left;color:#000000"><tr><td style="width:18pt">&#160;</td><td style="width:36pt;vertical-align:top;align:right"><div style="margin-left:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></div></td><td style="width:auto;vertical-align:top"><div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">employee-related expenses, including salaries, related benefits, travel and share-based compensation expenses for employees engaged in research and development functions, as well as external costs, such as fees paid to outside consultants engaged in such activities;</span></span></div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-top:11pt;width:100%;text-align:left;color:#000000"><tr><td style="width:18pt">&#160;</td><td style="width:36pt;vertical-align:top;align:right"><div style="margin-left:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></div></td><td style="width:auto;vertical-align:top"><div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">license maintenance fees and milestone fees incurred in connection with various license agreements;</span></span></div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-top:11pt;width:100%;text-align:left;color:#000000"><tr><td style="width:18pt">&#160;</td><td style="width:36pt;vertical-align:top;align:right"><div style="margin-left:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></div></td><td style="width:auto;vertical-align:top"><div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">costs related to compliance with regulatory requirements; and</span></span></div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-top:11pt;width:100%;text-align:left;color:#000000"><tr><td style="width:18pt">&#160;</td><td style="width:36pt;vertical-align:top;align:right"><div style="margin-left:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></div></td><td style="width:auto;vertical-align:top"><div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">depreciation and other expenses.</span></span></div></td></tr></table></div><div style="line-height:1.25">&#160;</div><div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif;text-indent:50px"><span style="font-size:10pt;text-indent:50px"><span style="font-family:Times New Roman, Times, serif;text-indent:50px">We recognize external development costs based on an evaluation of the progress to completion of specific tasks using information provided to us by our service providers.</span></span></div><div style="line-height:1.25;text-indent:50px">&#160;</div><div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif;text-indent:50px"><span style="font-size:10pt;text-indent:50px"><span style="font-family:Times New Roman, Times, serif;text-indent:50px">We do not allocate employee costs or facility expenses, including depreciation or other indirect costs, to specific programs because these costs are deployed across multiple programs and, as such, are not separately classified. We use our internal resources primarily to oversee research, as well as for managing our preclinical development, process development, manufacturing and clinical development activities. Our employees work across multiple programs and, therefore, we do not track costs by program.</span></span></div><div style="line-height:1.25;text-indent:50px">&#160;</div><div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif;text-indent:50px"><span style="font-size:10pt;text-indent:50px"><span style="font-family:Times New Roman, Times, serif;text-indent:50px">Research and development activities are fundamental to our business. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. As a result, we expect that our research and development expenses will increase substantially over the next several quarters and years as we continue to advance the development of our product candidates. We also expect to incur additional expenses related to milestone and royalty payments payable to third parties with whom we have entered into license agreements to acquire the rights to its product candidates.</span></span></div><div style="line-height:1.25">&#160;</div><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold;font-style:italic">General and Administrative Expenses</span>&#160;</span></span></div><div style="line-height:1.25">&#160;</div><div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif;text-indent:50px"><span style="font-size:10pt;text-indent:50px"><span style="font-family:Times New Roman, Times, serif;text-indent:50px">General and administrative expenses consist primarily of salaries, related benefits and share-based compensation expenses for personnel in executive and administrative functions. General and administrative expenses also include professional fees for legal, consulting, accounting and audit services.</span></span></div><div style="line-height:1.25;text-indent:50px">&#160;</div><div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif;text-indent:50px"><span style="font-size:10pt;text-indent:50px"><span style="font-family:Times New Roman, Times, serif;text-indent:50px">We anticipate that our general and administrative expenses will increase in the future as we increase headcount and general activities to support our continued research activities and development of our product candidates as well as expanding our presence in the United States. We also anticipate that we will incur increased headcount, accounting, audit, legal, regulatory, compliance, director and officer insurance costs, as well as investor and public relations expenses associated with being a public company. We expect that the additional costs for these services will substantially increase our general and administrative expenses. Additionally, if and when we believe that regulatory approval of a product candidate appears likely, we expect to incur an increase in payroll and related expenses as a result of our preparation for commercial operations, especially as it relates to the sales and marketing of any product candidate.</span></span></div><div style="line-height:1.25">&#160;</div><div style="clear:both;margin-top:10pt;margin-bottom:10pt"><div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">16</span></span></span></div><div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Results of Operations</span>&#160;</span></span></div><div style="line-height:1.25">&#160;</div><div style="line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Three and Six Months Ended June 30, 2022 Compared to the Three and Six Months Ended June 30, 2021</span></span></div><div style="line-height:1.25">&#160;</div><div style="line-height:1.25;text-indent:50px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Below is a summary of our results of operations for the periods indicated:</span></span></div><div style="line-height:1.25">&#160;</div><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-style:italic">Three Months Ended June 30, 2022 Compared to the Three Months Ended June 30, 2021</span>&#160;</span></span></div><div style="line-height:1.25">&#160;</div><table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%"><tr><td style="vertical-align:bottom" valign="bottom"><div style="line-height:1.25">&#160;</div></td><td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td><td colspan="6" style="vertical-align:bottom" valign="bottom"><div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Three months ended</span></span></span></div></td><td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td><td colspan="2" style="vertical-align:bottom" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td><td colspan="2" style="vertical-align:bottom" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td></tr><tr><td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td><td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"><div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">June 30,</span></span></span></div></td><td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td><td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"><div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Increase/(decrease)</span></span></span></div></td><td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td></tr><tr><td style="vertical-align:bottom;padding-bottom:2px" valign="bottom"><div style="line-height:1.25">&#160;</div></td><td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td><td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"><div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2022</span></span></span></div></td><td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td><td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"><div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div></td><td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center;font-weight:bold" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:#000000 solid 2px" valign="bottom"><div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">%</span></span></span></div></td><td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td></tr><tr><td style="vertical-align:bottom" valign="bottom"><div style="line-height:1.25">&#160;</div></td><td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td><td colspan="6" style="vertical-align:bottom" valign="bottom"><div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-style:italic">(in thousands)</span></span></span></div></td><td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td><td colspan="2" style="vertical-align:bottom" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;text-align:right" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td></tr><tr><td style="vertical-align:bottom;background-color:#CCEEFF" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating expenses:</span></span></div></td><td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="2" style="vertical-align:bottom;background-color:#CCEEFF" valign="bottom">&#160;</td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="2" style="vertical-align:bottom;background-color:#CCEEFF" valign="bottom">&#160;</td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="2" style="vertical-align:bottom;background-color:#CCEEFF" valign="bottom">&#160;</td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom" valign="bottom">&#160;</td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right" valign="bottom">&#160;</td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td></tr><tr><td style="vertical-align:bottom;width:52%" valign="bottom"><div style="text-indent:10pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div></td><td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,914</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div></td><td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,307</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div></td><td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,607</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">123</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#CCEEFF;width:52%" valign="bottom"><div style="text-indent:10pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">General and administrative</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,340</span></span></div></td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,446</span></span></div></td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,894</span></span></div></td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">131</span></span></div></td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div></td></tr><tr><td style="vertical-align:bottom;width:52%" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating loss</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(6,254</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(2,753</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,501</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">127</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#CCEEFF;width:52%;padding-bottom:2px" valign="bottom"><div style="text-indent:10pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financing expense, net</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;border-bottom:#000000 solid 2px" valign="bottom">&#160;</td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;border-bottom:#000000 solid 2px" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">480</span></span></div></td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;border-bottom:#000000 solid 2px" valign="bottom">&#160;</td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;border-bottom:#000000 solid 2px" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">17</span></span></div></td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;border-bottom:#000000 solid 2px" valign="bottom">&#160;</td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;border-bottom:#000000 solid 2px" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">463</span></span></div></td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;border-bottom:#000000 solid 2px" valign="bottom">&#160;</td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;border-bottom:#000000 solid 2px" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,724</span></span></div></td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div></td></tr><tr><td style="vertical-align:bottom;width:52%;padding-bottom:2px" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income Tax </span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(544</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(544</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">100</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div></td></tr><tr><td style="vertical-align:bottom;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div></td><td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(6,190</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div></td><td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(2,770</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div></td><td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(3,420</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">123</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div></td></tr></table><div style="line-height:1.25">&#160;</div><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-style:italic">Six Months Ended June 30, 2022 Compared to the Six Months Ended June 30, 2021</span><br />&#160;</span></span></div><table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%"><tr><td style="vertical-align:bottom" valign="bottom"><div style="line-height:1.25">&#160;</div></td><td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td><td colspan="6" style="vertical-align:bottom" valign="bottom"><div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Six months ended</span></span></span></div></td><td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td><td colspan="2" style="vertical-align:bottom" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td><td colspan="2" style="vertical-align:bottom" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td></tr><tr><td style="vertical-align:bottom;padding-bottom:2px" valign="bottom"><div style="line-height:1.25">&#160;</div></td><td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td><td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"><div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">June 30,</span></span></span></div></td><td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td><td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"><div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Increase/(decrease)</span></span></span></div></td><td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td></tr><tr><td style="vertical-align:bottom;padding-bottom:2px" valign="bottom"><div style="line-height:1.25">&#160;</div></td><td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td><td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"><div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2022</span></span></span></div></td><td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td><td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"><div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div></td><td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">$</span></span></span></td><td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:#000000 solid 2px" valign="bottom"><div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">%</span></span></span></div></td><td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td></tr><tr><td style="vertical-align:bottom" valign="bottom"><div style="line-height:1.25">&#160;</div></td><td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td><td colspan="6" style="vertical-align:bottom" valign="bottom"><div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-style:italic">(in thousands)</span></span></span></div></td><td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td><td colspan="2" style="vertical-align:bottom" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;text-align:right" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td></tr><tr><td style="vertical-align:bottom;background-color:#CCEEFF" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating expenses:</span></span></div></td><td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="2" style="vertical-align:bottom;background-color:#CCEEFF" valign="bottom">&#160;</td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="2" style="vertical-align:bottom;background-color:#CCEEFF" valign="bottom">&#160;</td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="2" style="vertical-align:bottom;background-color:#CCEEFF" valign="bottom">&#160;</td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom" valign="bottom">&#160;</td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right" valign="bottom">&#160;</td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td></tr><tr><td style="vertical-align:bottom;width:52%" valign="bottom"><div style="text-indent:10pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div></td><td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,659</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div></td><td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,464</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div></td><td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,195</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">130</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#CCEEFF;width:52%" valign="bottom"><div style="text-indent:10pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">General and administrative</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,915</span></span></div></td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,988</span></span></div></td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,927</span></span></div></td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">198</span></span></div></td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div></td></tr><tr><td style="vertical-align:bottom;width:52%" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating loss</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(11,574</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(4,452</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(7,122</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">160</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div></td></tr><tr><td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255)" valign="bottom"><div style="text-indent:10pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financing expense, net</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">264</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">22</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">242</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,100</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div></td></tr><tr><td style="vertical-align:bottom;width:52%;padding-bottom:2px" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income Tax (benefit)</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(544</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(544</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">100</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div></td></tr><tr><td style="vertical-align:bottom;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div></td><td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(11,294</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div></td><td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(4,474</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div></td><td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(6,820</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">152</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div></td></tr></table><div style="line-height:1.25">&#160;</div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our results of operations have varied in the past and can be expected to vary in the future due to numerous factors. We believe that period-to-period comparisons of our operating results are not necessarily meaningful and should not be relied upon as indications of future performance.</span></span></div><div style="line-height:1.25">&#160;</div><div style="clear:both;margin-top:10pt;margin-bottom:10pt"><div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">17</span></span></span></div><div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-style:italic">Research and development expenses</span>&#160;</span></span></div><div style="line-height:1.25">&#160;</div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt;text-indent:50px"><span style="font-family:Times New Roman, Times, serif;text-indent:50px">Research and development expenses increased by approximately $1.6 million, or 123%, for the three months ended June 30, 2022, as compared to the same period in 2021. The increase was primarily due to increased clinical and pre-clinical activities.</span></span></div><div style="line-height:1.25;text-indent:50px">&#160;</div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt;text-indent:50px"><span style="font-family:Times New Roman, Times, serif;text-indent:50px">Research and development expenses increased by approximately $3.2 million, or 130%, for the six months ended June 30, 2022, as compared to the same period in 2021 also due primarily to increased clinical and pre-clinical activities. </span></span></div><div style="line-height:1.25">&#160;</div><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;<span style="font-style:italic">General and administrative expenses</span>&#160;</span></span></div><div style="line-height:1.25">&#160;</div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt;text-indent:50px"><span style="font-family:Times New Roman, Times, serif;text-indent:50px">General and administrative expenses increased by approximately $1.9 million, or 131%, for the three months ended June 30, 2022, as compared to the same period in 2021. The increase was primarily due to increase in salaries and related benefits expenses of $1.1 million mainly related to key additions to the senior management team, as well as increase in non-cash share-based expenses in the amount of $0.2 million and provision for expenses recorded in relation to an audit by the Israeli Tax Authority.</span></span></div><div style="line-height:1.25;text-indent:50px">&#160;</div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt;text-indent:50px"><span style="font-family:Times New Roman, Times, serif;text-indent:50px">General and administrative expenses increased by approximately $3.9 million, or 198%, for the six months ended June 30, 2022, as compared to the same period in 2021. The increase was primarily due to the increase in non-cash share-based expenses in the amount of $1.0 million as well as increase in salaries and related benefits expenses of $1.6 million mainly related to key additions to the senior management team, and provision for expenses recorded in relation to an audit by the Israeli Tax Authority.</span></span></div><div style="line-height:1.25">&#160;</div><div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-style:italic">Financing expenses, net</span>&#160;</span></span></div><div style="line-height:1.25">&#160;</div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt;text-indent:50px"><span style="font-family:Times New Roman, Times, serif;text-indent:50px">Financing expenses, net increased by approximately $463 thousand for the three months ended June 30, 2022 from the same period in 2021. Financing expense, net for the three months ended June 30, 2022 was primarily related to foreign currency exchange rate loss. Financing expense, net for the three months ended June 30, 2021 was primarily related to foreign currency exchange rate loss which was partially offset by interest income from bank deposits.</span></span></div><div style="line-height:1.25;text-indent:50px">&#160;</div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt;text-indent:50px"><span style="font-family:Times New Roman, Times, serif;text-indent:50px">Financing expenses, net increased by approximately $242 thousand for the six months ended June 30, 2022 from the same period in 2021. Financing expense, net for the six months ended June 30, 2022 was primarily related to foreign currency exchange rate loss which was partially offset by interest income from bank deposits. Financing expense, net for the six months ended June 30, 2021 was primarily related to foreign currency exchange rate loss.</span></span></div><div style="line-height:1.25">&#160;</div><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Liquidity and Capital Resources</span>&#160;</span></span></div><div style="line-height:1.25">&#160;</div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt;text-indent:50px"><span style="font-family:Times New Roman, Times, serif;text-indent:50px">Since inception, we have not generated any revenue and have incurred significant operating losses and negative cash flows from our operations, resulting in an accumulated deficit at June 30, 2022 of $47.5 million. We have funded our operations to date primarily with proceeds from the sale of our ADSs, and, prior to the Merger, other equity securities. Cash in excess of immediate requirements is invested primarily with a view to liquidity and capital preservation.</span></span></div><div style="line-height:1.25;text-indent:50px">&#160;</div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt;text-indent:50px"><span style="font-family:Times New Roman, Times, serif;text-indent:50px">During the period from April 30, 2021 through June 30, 2022, we sold an aggregate of 699,806 ADSs pursuant to the Sales Agreement for total gross consideration of $15.9 million. As of June 30, 2022, we had an aggregate of approximately $51.8 million of cash, cash equivalents and short-term deposits.</span></span></div><div style="line-height:1.25">&#160;</div><div style="clear:both;margin-top:10pt;margin-bottom:10pt"><div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">18</span></span></span></div><div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Developing product candidates, conducting clinical trials and commercializing products are expensive, and we will need to raise substantial additional funds to achieve our strategic objectives. We believe that our existing cash resources, including from the ADSs sold pursuant to the Sales Agreement, will be sufficient to fund our projected cash requirements through the end of 2023. Nevertheless, we will require significant additional financing in the future to fund our operations, including if and when we progress into additional clinical trials, obtain regulatory approval for any of our product candidates and commercialize the same. We believe that we will need to raise significant additional funds before we have any cash flow from operations, if at all. Our future capital requirements will depend on many factors, including:</span></span></div><div style="line-height:1.25">&#160;</div><div><table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:6pt;width:100%;text-align:left;color:#000000"><tr><td style="width:54pt;vertical-align:top;align:right"><div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></div></td><td style="width:auto;vertical-align:top"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">the progress and costs of our preclinical studies, clinical trials and other research and development activities;</span></span></div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:6pt;width:100%;text-align:left;color:#000000"><tr><td style="width:54pt;vertical-align:top;align:right"><div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></div></td><td style="width:auto;vertical-align:top"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">the scope, prioritization and number of our clinical trials and other research and development programs;</span></span></div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:6pt;width:100%;text-align:left;color:#000000"><tr><td style="width:54pt;vertical-align:top;align:right"><div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></div></td><td style="width:auto;vertical-align:top"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">the amount of revenues and contributions we receive under future licensing, development and commercialization arrangements with respect to our product candidates;</span></span></div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:6pt;width:100%;text-align:left;color:#000000"><tr><td style="width:54pt;vertical-align:top;align:right"><div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></div></td><td style="width:auto;vertical-align:top"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">the costs of the development and expansion of our operational infrastructure;</span></span></div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:6pt;width:100%;text-align:left;color:#000000"><tr><td style="width:54pt;vertical-align:top;align:right"><div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></div></td><td style="width:auto;vertical-align:top"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">the costs and timing of obtaining regulatory approval for our product candidates;</span></span></div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:6pt;width:100%;text-align:left;color:#000000"><tr><td style="width:54pt;vertical-align:top;align:right"><div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></div></td><td style="width:auto;vertical-align:top"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">the costs of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights;</span></span></div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:6pt;width:100%;text-align:left;color:#000000"><tr><td style="width:54pt;vertical-align:top;align:right"><div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></div></td><td style="width:auto;vertical-align:top"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">the costs and timing of securing manufacturing arrangements for clinical or commercial production;</span></span></div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:6pt;width:100%;text-align:left;color:#000000"><tr><td style="width:54pt;vertical-align:top;align:right"><div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></div></td><td style="width:auto;vertical-align:top"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">the costs of contracting with third parties to provide sales and marketing capabilities for us;</span></span></div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:6pt;width:100%;text-align:left;color:#000000"><tr><td style="width:54pt;vertical-align:top;align:right"><div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></div></td><td style="width:auto;vertical-align:top"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">the costs of acquiring or undertaking development and commercialization efforts for any future products, product candidates or platforms;</span></span></div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:6pt;width:100%;text-align:left;color:#000000"><tr><td style="width:54pt;vertical-align:top;align:right"><div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></div></td><td style="width:auto;vertical-align:top"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">the magnitude of our general and administrative expenses; and</span></span></div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:6pt;width:100%;text-align:left;color:#000000"><tr><td style="width:54pt;vertical-align:top;align:right"><div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></div></td><td style="width:auto;vertical-align:top"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif;margin-bottom:0pt">any cost that we may incur under future in- and out-licensing arrangements relating to our product candidates. </span></span></div></td></tr></table></div><div style="text-align:justify;line-height:1.25;text-indent:50px;margin-top:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We currently do not have any commitments for future external funding. In the future, we will need to raise additional funds, and we may decide to raise additional funds even before we need such funds if the conditions for raising capital are favorable. Until we can generate significant recurring revenues, we expect to satisfy our future cash needs through debt or equity financings, credit facilities or by out-licensing applications of our product candidates. The sale of equity or convertible debt securities may result in dilution to our existing shareholders. The incurrence of indebtedness would result in increased fixed obligations and could also subject us to covenants that restrict our operations. We cannot be certain that additional funding, whether through grants from the Israel Innovation Authority, financings, credit facilities or out-licensing arrangements, will be available to us on acceptable terms, if at all. If sufficient funds are not available, we may be required to delay, reduce the scope of or eliminate research or development plans for, or commercialization efforts with respect to, one or more applications of our product candidates, or obtain funds through arrangements with collaborators or others that may require us to relinquish rights to certain potential products that we might otherwise seek to develop or commercialize independently.</span></span></div><div style="line-height:1.25">&#160;</div><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold;font-style:italic">Cash Flows</span>&#160;</span></span></div><div style="line-height:1.25">&#160;</div><div style="text-indent:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The table below shows a summary of our cash flow activities for the periods indicated:</span></span></div><div style="line-height:1.25">&#160;</div><table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%"><tr><td style="vertical-align:bottom" valign="bottom"><div style="line-height:1.25">&#160;</div></td><td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td><td colspan="6" style="vertical-align:bottom" valign="bottom"><div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Six months ended</span></span></span></div></td><td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td><td colspan="2" style="vertical-align:bottom" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td><td colspan="2" style="vertical-align:bottom" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td></tr><tr><td style="vertical-align:bottom;padding-bottom:2px" valign="bottom"><div style="text-align:center;line-height:1.25">&#160;</div></td><td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td><td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"><div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">June 30,</span></span></span></div></td><td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td><td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"><div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Increase/(decrease)</span></span></span></div></td><td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td></tr><tr><td style="vertical-align:bottom;padding-bottom:2px" valign="bottom"><div style="text-align:center;line-height:1.25">&#160;</div></td><td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td><td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"><div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div></td><td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td><td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"><div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div></td><td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;<span style="font-weight:bold">$</span></span></span></td><td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="text-align:right;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:#000000 solid 2px" valign="bottom"><div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">%</span></span></span></div></td><td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td></tr><tr><td style="vertical-align:bottom" valign="bottom"><div style="line-height:1.25">&#160;</div></td><td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td><td colspan="6" style="vertical-align:bottom" valign="bottom"><div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-style:italic">(in thousands)</span></span></span></div></td><td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td><td colspan="2" style="vertical-align:bottom" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="text-align:right;vertical-align:bottom" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;text-align:right" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td></tr><tr><td style="vertical-align:bottom;background-color:#CCEEFF;width:52%" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net cash used in operating activities</span></span></div></td><td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div></td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(9,412</span></span></div></td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div></td><td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div></td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(6,900</span></span></div></td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div></td><td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div></td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(2,512</span></span></div></td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div></td><td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">36</span></span></div></td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div></td></tr><tr><td style="vertical-align:bottom;width:52%" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net cash provided by (used in) investing activities</span></span></div></td><td colspan="1" style="text-align:right;vertical-align:bottom;width:1%" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,109</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="text-align:right;vertical-align:bottom;width:1%" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(20,605</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div></td><td colspan="1" style="text-align:right;vertical-align:bottom;width:1%" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">24,714</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="text-align:right;vertical-align:bottom;width:1%" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(120</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#CCEEFF;width:52%;padding-bottom:2px" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net cash provided by financing activities</span></span></div></td><td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;border-bottom:#000000 solid 2px" valign="bottom">&#160;</td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;border-bottom:#000000 solid 2px" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">22</span></span></div></td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;border-bottom:#000000 solid 2px" valign="bottom">&#160;</td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;border-bottom:#000000 solid 2px" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">61,227</span></span></div></td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;border-bottom:#000000 solid 2px" valign="bottom">&#160;</td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;border-bottom:#000000 solid 2px" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(61,205</span></span></div></td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div></td><td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;border-bottom:#000000 solid 2px" valign="bottom">&#160;</td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;border-bottom:#000000 solid 2px" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(100</span></span></div></td><td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)%</span></span></div></td></tr><tr><td style="vertical-align:bottom;width:52%;padding-bottom:4px" valign="bottom"><div style="line-height:1.25"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net increase (decrease) in cash, cash equivalents and restricted cash</span></span></div></div></td><td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div></td><td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(5,281</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div></td><td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div></td><td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">33,722</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div></td><td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(39,003</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div></td><td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(116</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)%</span></span></div></td></tr></table><div style="line-height:1.25">&#160;</div><div style="clear:both;margin-top:10pt;margin-bottom:10pt"><div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">19</span></span></span></div><div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-style:italic">Operating activities</span>&#160;</span></span></div><div style="line-height:1.25">&#160;</div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net cash used in operating activities increased by $2.5 million, or 36%, for the six months ended June 30 2022 compared to the same period in 2021. The increase was primarily related to the increase in net loss of $6.8 million, offset by an increase in accrued expenses of $2.2 million, decrease in other receivables of $1.0 million and changes in non-cash activities adjustment of $1.1 million.</span></span></div><div style="line-height:1.25">&#160;</div><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-style:italic">Investing activities</span>&#160;</span></span></div><div style="line-height:1.25">&#160;</div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net cash provided by investing activities for the six months ended June 30, 2022 increased by approximately $24.7 million compared to same period in 2021. The increase is primarily related to an increase in short term bank deposits. Net cash used in investing activities for the six months ended June 30, 2021 was primarily related to the deposit of proceeds received from a private placement in bank deposits.</span></span></div><div style="line-height:1.25">&#160;</div><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-style:italic">Financing activities</span>&#160;</span></span></div><div style="line-height:1.25">&#160;</div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt;text-indent:50px"><span style="font-family:Times New Roman, Times, serif;text-indent:50px">Net cash provided by financing activities for the six months ended June 30, 2022 decreased by approximately $61.2 million, as compared to the same period in 2021. The decrease is primarily related to a decrease in proceeds from the issuance of ADSs of approximately $58.7 million (net of expenses), and cash acquired in the Merger of approximately $2.4 million, in each case in the six months ended on June 30, 2021.</span></span></div><div style="line-height:1.25;text-indent:50px">&#160;</div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt;text-indent:50px"><span style="font-family:Times New Roman, Times, serif;text-indent:50px">Financing activities for the six months ended June 30, 2021 reflect proceeds received from the private placement as well as sales of the Company's ADSs under the ATM program. </span></span></div><div style="line-height:1.25">&#160;</div><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Contractual Commitments</span>&#160;</span></span></div><div style="line-height:1.25">&#160;</div><div style="line-height:1.25;text-indent:50px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s contractual commitments at June 30, 2022 were as follows (in thousands):</span></span><br />&#160;</div><div style="line-height:1.25"><table border="0" cellpadding="0" cellspacing="0" style="width:70%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;margin:auto"><tr><td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255)" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Remainder of 2022</span></span></div></td><td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div></td><td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,021</span></span></div></td><td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td></tr><tr><td colspan="2" style="vertical-align:top" valign="bottom"><div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,741</span></span></div></td><td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td></tr><tr><td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255)" valign="bottom"><div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div></td><td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%" valign="bottom">&#160;</td><td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">146</span></span></div></td><td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td></tr><tr><td colspan="2" rowspan="1" style="vertical-align:top;padding-bottom:2px" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025-2027</span></span></div></td><td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td><td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td><td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">- </span></span></td><td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td></tr><tr><td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);padding-bottom:4px" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total</span></span></div></td><td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td><td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px" valign="bottom">&#160;</td><td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div></td><td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10,908</span></span></div></td><td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td></tr></table></div><div style="line-height:1.25"><br /><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Critical Accounting Policies</span>&#160;</span></span></div><div style="line-height:1.25">&#160;</div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt;text-indent:50px"><span style="font-family:Times New Roman, Times, serif;text-indent:50px">The Company&#8217;s financial statements are prepared in accordance with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;). The preparation of the Company&#8217;s financial statements and related disclosures in accordance with GAAP requires it to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue, costs and expenses, and the disclosure of contingent assets and liabilities in the Company&#8217;s financial statements. The Company bases its estimates on historical experience, known trends and events and various other factors that it believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. The Company evaluates its estimates and assumptions on an ongoing basis. The Company&#8217;s actual results may differ from these estimates under different assumptions or conditions.</span></span></div><div style="line-height:1.25;text-indent:50px">&#160;</div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt;text-indent:50px"><span style="font-family:Times New Roman, Times, serif;text-indent:50px">While the Company&#8217;s significant accounting policies are described in more detail in Note 2 to the Company&#8217;s consolidated financial statements included elsewhere in the 2021 Annual Report, the Company believes that the following accounting estimates are those that include a higher degree of judgment or complexity and are reasonably likely to have a material impact on our financial condition or results of operations and are therefore considered critical accounting estimates.</span></span></div><div style="line-height:1.25">&#160;</div><div style="clear:both;margin-top:10pt;margin-bottom:10pt"><div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">20</span></span></span></div><div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-style:italic">Share-Based Compensation</span>&#160;</span></span></div><div style="line-height:1.25">&#160;</div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt;text-indent:50px"><span style="font-family:Times New Roman, Times, serif;text-indent:50px">We apply Accounting Standard Codification (ASC) 718-10, &#8220;Share-Based Payment,&#8221; which requires the measurement and recognition of compensation expenses for all share-based payment awards made to employees and directors, including employee options under Chemomab&#8217;s option plans based on estimated fair values.</span></span></div><div style="line-height:1.25;text-indent:50px">&#160;</div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt;text-indent:50px"><span style="font-family:Times New Roman, Times, serif;text-indent:50px">ASC 718-10 requires that we estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The fair value of the award is recognized as an expense over the requisite service periods in Chemomab&#8217;s statements of comprehensive loss. Chemomab recognizes share-based award forfeitures as they occur, rather than estimate by applying a forfeiture rate.</span></span></div><div style="line-height:1.25;text-indent:50px">&#160;</div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt;text-indent:50px"><span style="font-family:Times New Roman, Times, serif;text-indent:50px">In June 2018, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2018-07, &#8220;Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting&#8221;, which simplifies the accounting for nonemployee share-based payment transactions by aligning the measurement and classification guidance, with certain exceptions, to that for share-based payment awards to employees. The amendments expand the scope of the accounting standard for share-based payment awards to include share-based payment awards granted to non-employees in exchange for goods or services used or consumed in an entity&#8217;s own operations and supersedes the guidance related to equity-based payments to non-employees. We adopted these amendments on January 1, 2019.</span></span></div><div style="line-height:1.25;text-indent:50px">&#160;</div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt;text-indent:50px"><span style="font-family:Times New Roman, Times, serif;text-indent:50px">We recognize compensation expenses for the fair value of non-employee awards over the requisite service period of each award.</span></span></div><div style="line-height:1.25;text-indent:50px">&#160;</div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt;text-indent:50px"><span style="font-family:Times New Roman, Times, serif;text-indent:50px">We estimate the fair value of options granted as equity awards using a Black-Scholes options pricing model. The option-pricing model requires a number of assumptions, of which the most significant are share price, expected volatility and the expected option term (the time from the grant date until the options are exercised or expire). The Company determines the fair value per share of the underlying stock by taking into consideration its most recent sales of stock, as well as additional factors that the Company deems relevant. The Company&#8217;s board determined the fair value of ordinary shares based on valuations performed using the Option Pricing Method subject to relevant facts and circumstances. The Company has historically been a private company and lacks company-specific historical and implied volatility information of its stock. Expected volatility is estimated based on volatility of similar companies in the biotechnology sector. The Company has historically not paid dividends and has no foreseeable plans to issue dividends. The risk-free interest rate is based on the yield from governmental zero-coupon bonds with an equivalent term. The expected option term is calculated for options granted to employees and directors using the &#8220;simplified&#8221; method. Grants to non-employees are based on the contractual term. Changes in the determination of each of the inputs can affect the fair value of the options granted and the results of operations of the Company.</span></span></div><div style="line-height:1.25">&#160;</div><div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Recently-Issued Accounting Pronouncements</span>&#160;</span></span></div><div style="line-height:1.25">&#160;</div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Certain recently-issued accounting pronouncements are discussed in Note 2, Summary of Significant Accounting Policies, to the audited consolidated financial statements in our 2021 Annual Report.</span></span></div><div style="line-height:1.25">&#160;</div><div style="line-height:1.25"><a id="Item3"></a> <span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Item 3. Quantitative and Qualitative Disclosures About Market Risk.</span>&#160;</span></span></div><div style="line-height:1.25">&#160;</div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We are an emerging growth company as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and are not required to provide the information under this item.</span></span></div><div style="line-height:1.25">&#160;</div><div style="clear:both;margin-top:10pt;margin-bottom:10pt"><div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">21</span></span></span></div><div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div><div style="line-height:1.25"><a id="Item4."></a> <span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Item 4. Controls and Procedures.</span>&#160;</span></span></div><div style="line-height:1.25">&#160;</div><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Evaluation of Disclosure Controls and Procedures</span>&#160;</span></span></div><div style="line-height:1.25">&#160;</div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt;text-indent:50px"><span style="font-family:Times New Roman, Times, serif;text-indent:50px">Disclosure controls and procedures are designed to ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.</span></span></div><div style="line-height:1.25;text-indent:50px">&#160;</div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt;text-indent:50px"><span style="font-family:Times New Roman, Times, serif;text-indent:50px">Under the supervision and with the participation of our management, including our principal executive officer and principal financial and accounting officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of June 30, 2022. Based on such evaluation, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures were effective as of June 30, 2022.</span></span></div><div style="line-height:1.25">&#160;</div><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Changes in Internal Control over Financial Reporting</span>&#160;</span></span></div><div style="line-height:1.25">&#160;</div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt;text-indent:50px"><span style="font-family:Times New Roman, Times, serif;text-indent:50px">We consummated the Merger on March 16, 2021, which has been accounted for as a reverse capitalization for accounting purposes, and, upon consummation of the Merger, we reconstituted our Board of Directors and our senior management team. The Company&#8217;s management has been in the process of strengthening the Company&#8217;s internal control over financial reporting since the Merger, including during the quarter ended June 30, 2022, including adopting new policies and procedures appropriate to the Company&#8217;s current business and management team. The foregoing actions are being taken solely in connection with the changes effected in connection with the Merger and not as the result of any material weakness or deficiency in the Company&#8217;s internal control over financial reporting.</span></span></div><div style="line-height:1.25;text-indent:50px">&#160;</div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt;text-indent:50px"><span style="font-family:Times New Roman, Times, serif;text-indent:50px">Except as described above, there have been no changes in our internal control over financial reporting that occurred during the last fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></span></div><div style="line-height:1.25">&#160;</div><div style="clear:both;margin-top:10pt;margin-bottom:10pt"><div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">22</span></span></span></div><div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div><div style="text-align:center;line-height:1.25"><a id="PARTII"></a> <span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">PART II. &#8211; OTHER INFORMATION</span>&#160;</span></span></div><div style="line-height:1.25">&#160;</div><div style="line-height:1.25"><a id="Item1.LegalProceedings"></a> <span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Item 1.</span>&#160;<span style="font-weight:bold">Legal Proceedings</span>&#160;</span></span></div><div style="line-height:1.25">&#160;</div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">From time to time, we may become involved in legal proceedings relating to claims arising from the ordinary course of business. Our management believes that there are currently no claims or actions pending against us, the ultimate disposition of which could have a material adverse effect on our results of operations, financial condition or cash flows.</span></span></div><div style="line-height:1.25">&#160;</div><div style="line-height:1.25"><a id="Item1A.RiskFactors"></a> <span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Item 1A.</span>&#160;<span style="font-weight:bold">Risk Factors</span>&#160;</span></span></div><div style="line-height:1.25">&#160;</div><div style="text-align:justify;line-height:1.25;text-indent:50px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">There have been no material changes from the information set forth in &#8220;Item 1A. Risk Factors&#8221; in our 2021 Annual Report.</span></span></div><div style="line-height:1.25">&#160;</div><div style="line-height:1.25"><a id="Item2.UnregisteredSalesof"></a><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Item 2.</span>&#160;<span style="font-weight:bold">Unregistered Sales of Equity Securities and Use of Proceeds.</span>&#160;</span></span></div><div style="line-height:1.25">&#160;</div><div style="line-height:1.25;text-indent:50px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">None.</span></span></div><div style="line-height:1.25">&#160;</div><div style="line-height:1.25"><a id="Item3.DefaultsUponSeniorS"></a><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Item 3.</span>&#160;<span style="font-weight:bold">Defaults Upon Senior Securities.</span>&#160;</span></span></div><div style="line-height:1.25">&#160;</div><div style="line-height:1.25;text-indent:50px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Not applicable.</span></span></div><div style="line-height:1.25">&#160;</div><div style="line-height:1.25"><a id="Item4.MineSafetyDisclosur"></a><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Item 4.</span>&#160;<span style="font-weight:bold">Mine Safety Disclosures.</span>&#160;</span></span></div><div style="line-height:1.25">&#160;</div><div style="line-height:1.25;text-indent:50px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Not applicable.</span></span></div><div style="line-height:1.25">&#160;</div><div style="line-height:1.25"><a id="Item5.OtherInformation."></a><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Item 5.</span>&#160;<span style="font-weight:bold">Other Information.</span>&#160;</span></span></div><div style="line-height:1.25">&#160;</div><div style="line-height:1.25;text-indent:50px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">None.</span></span></div><div style="line-height:1.25">&#160;</div><div style="clear:both;margin-top:10pt;margin-bottom:10pt"><div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">23</span></span></span></div><div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div><div style="line-height:1.25"><a id="Item6.Exhibits."></a><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Item 6.</span>&#160;<span style="font-weight:bold">Exhibits.</span>&#160;</span></span></div><div style="line-height:1.25">&#160;</div><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(a) The following documents are filed as exhibits to this Quarterly Report or incorporated by reference herein.</span></span></div><div style="line-height:1.25">&#160;</div><table border="0" cellpadding="2" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"><tr><td style="width:10%;vertical-align:bottom;border-bottom:#000000 2px solid"><div style="line-height:1.25;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exhibit</span></span></div><div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Number</span>&#160;</span></span></div></td><td style="width:1%;vertical-align:bottom"><div style="line-height:1.25">&#160;</div></td><td style="width:89%;vertical-align:bottom;border-bottom:#000000 2px solid"><div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Description</span>&#160;</span></span></div></td></tr><tr><td style="width:10%;vertical-align:bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_31-1.htm">31.1*</a></span></span></div></td><td style="width:1%;vertical-align:bottom">&#160;</td><td style="width:89%;vertical-align:bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_31-1.htm">Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act</a></span></span></div></td></tr><tr><td style="width:10%;vertical-align:bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_31-2.htm">31.2*</a></span></span></div></td><td style="width:1%;vertical-align:bottom">&#160;</td><td style="width:89%;vertical-align:bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_31-2.htm">Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act</a></span></span></div></td></tr><tr><td style="width:10%;vertical-align:bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_32-1.htm">32.1**</a></span></span></div></td><td style="width:1%;vertical-align:bottom">&#160;</td><td style="width:89%;vertical-align:bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_32-1.htm">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></span></div></td></tr><tr><td style="width:10%;vertical-align:bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_32-2.htm">32.2**</a></span></span></div></td><td style="width:1%;vertical-align:bottom">&#160;</td><td style="width:89%;vertical-align:bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_32-2.htm">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></span></div></td></tr><tr><td style="width:10%;vertical-align:bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">101. INS*</span></span></div></td><td style="width:1%;vertical-align:bottom"><div style="line-height:1.25">&#160;</div></td><td style="width:89%;vertical-align:bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Inline XBRL Instance Document</span></span></div></td></tr><tr><td style="width:10%;vertical-align:bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">101. SCH*</span></span></div></td><td style="width:1%;vertical-align:bottom"><div style="line-height:1.25">&#160;</div></td><td style="width:89%;vertical-align:bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Inline XBRL Taxonomy Extension Schema Document</span></span></div></td></tr><tr><td style="width:10%;vertical-align:bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">101. CAL*</span></span></div></td><td style="width:1%;vertical-align:bottom"><div style="line-height:1.25">&#160;</div></td><td style="width:89%;vertical-align:bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></span></div></td></tr><tr><td style="width:10%;vertical-align:bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">101. DEF*</span></span></div></td><td style="width:1%;vertical-align:bottom"><div style="line-height:1.25">&#160;</div></td><td style="width:89%;vertical-align:bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></span></div></td></tr><tr><td style="width:10%;vertical-align:bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">101. LAB*</span></span></div></td><td style="width:1%;vertical-align:bottom"><div style="line-height:1.25">&#160;</div></td><td style="width:89%;vertical-align:bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Inline XBRL Taxonomy Extension Label Linkbase Document</span></span></div></td></tr><tr><td style="width:10%;vertical-align:bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">101. PRE*</span></span></div></td><td style="width:1%;vertical-align:bottom"><div style="line-height:1.25">&#160;</div></td><td style="width:89%;vertical-align:bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></span></div></td></tr><tr><td style="width:10%;vertical-align:bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">104*</span></span></div></td><td style="width:1%;vertical-align:bottom"><div style="line-height:1.25">&#160;</div></td><td style="width:89%;vertical-align:bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></span></div></td></tr><tr><td style="width:10%;vertical-align:bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">*</span></span></div></td><td style="width:1%;vertical-align:bottom"><div style="line-height:1.25">&#160;</div></td><td style="width:89%;vertical-align:bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Filed herewith.</span></span></div></td></tr><tr><td style="width:10%;vertical-align:bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">**</span></span></div></td><td style="width:1%;vertical-align:bottom"><div style="line-height:1.25">&#160;</div></td><td style="width:89%;vertical-align:bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Furnished herewith.</span></span></div></td></tr></table>&#160;<div><div style="line-height:1.25">&#160;</div><div style="clear:both;margin-top:10pt;margin-bottom:10pt"><div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">24</span></span></span></div><div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div></div><div style="line-height:1.25">&#160;</div><div style="text-align:center;line-height:1.25"><a id="SIGNATURES"></a><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">SIGNATURES</span>&#160;</span></span></div><div style="line-height:1.25">&#160;</div><div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </span></span></span></div><div style="line-height:1.25">&#160;</div><table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"><tr><td style="width:49%;vertical-align:bottom"><div style="line-height:1.25">&#160;</div></td><td colspan="2" style="width:51%;vertical-align:bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CHEMOMAB THERAPEUTICS LTD.</span></span></div></td></tr><tr><td style="width:49%;vertical-align:bottom">&#160;</td><td style="width:5%;vertical-align:bottom">&#160;</td><td style="width:46%;vertical-align:bottom"><div style="line-height:1.25">&#160;</div></td></tr><tr><td style="width:49%;vertical-align:bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Date: August 12, 2022</span></span></div></td><td style="width:5%;vertical-align:bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">By:</span></span></div></td><td style="width:46%;vertical-align:top;border-bottom:#000000 2px solid"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">/s/ Dale Pfost</span></span></div></td></tr><tr><td style="width:49%;vertical-align:bottom">&#160;</td><td style="width:5%;vertical-align:bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Name:</span></span></div></td><td style="width:46%;vertical-align:bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dale Pfost </span></span></div></td></tr><tr><td style="width:49%;vertical-align:bottom"><div style="line-height:1.25">&#160;</div></td><td style="width:5%;vertical-align:bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Title:</span></span></div></td><td style="width:46%;vertical-align:bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chief Executive Officer</span></span></div></td></tr><tr><td style="width:49%;vertical-align:bottom"><div style="line-height:1.25">&#160;</div></td><td style="width:5%;vertical-align:bottom"><div style="line-height:1.25">&#160;</div></td><td style="width:46%;vertical-align:bottom">&#160;</td></tr><tr><td style="width:49%;vertical-align:bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Date: August 12, 2022</span></span></div></td><td style="width:5%;vertical-align:bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">By:</span></span></div></td><td style="width:46%;vertical-align:bottom;border-bottom:#000000 2px solid"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">/s/ Donald Marvin</span></span></div></td></tr><tr><td style="width:49%;vertical-align:bottom"><div style="line-height:1.25">&#160;</div></td><td style="width:5%;vertical-align:bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Name:</span></span></div></td><td style="width:46%;vertical-align:bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Donald Marvin </span></span></div></td></tr><tr><td style="width:49%;vertical-align:bottom"><div style="line-height:1.25">&#160;</div></td><td style="width:5%;vertical-align:bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Title:</span></span></div></td><td style="width:46%;vertical-align:bottom"><div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chief Financial Officer</span></span></div></td></tr></table><div style="line-height:1.25">&#160;</div><div style="line-height:1.25;text-align:center"><br /><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">25</span></span></span></div><div style="line-height:1.25"><hr style="border:none;border-bottom:4px solid black;border-top:1px solid black;height:10px;color:#ffffff;background-color:#ffffff;text-align:center;margin-left:auto;margin-right:auto;text-align:center" /></div><div style="line-height:1.25"><div style="text-align:right;line-height:1.25">&#160;</div></div></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>exhibit_31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using Broadridge PROfile 22.7.2.5063
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div> <br>
    </div>
    <div>
      <div>
        <div>
          <div style="line-height: 1.25;">
            <div style="text-align: right; line-height: 1.25; font-weight: bold;"><u>Exhibit 31.1</u></div>
          </div>
          <div style="line-height: 1.25;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">CERTIFICATION PURSUANT TO</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">RULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">AS ADOPTED PURSUANT TO</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</div>
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </div>
          <div style="line-height: 1.25;">
            <div style="text-align: justify; line-height: 1.25;">I, Dale Pfost, certify that:</div>
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 4.6%; vertical-align: top;">
                  <div style="line-height: 1.25;">1.</div>
                </td>
                <td style="width: 95.4%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">I have reviewed this Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 of Chemomab Therapeutics Ltd.;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 4.6%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 95.4%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 4.6%; vertical-align: top;">
                  <div style="line-height: 1.25;">2.</div>
                </td>
                <td style="width: 95.4%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the
                    circumstances under which such statements were made, not misleading with respect to the period end covered by this report;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 4.6%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 95.4%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 4.6%; vertical-align: top;">
                  <div style="line-height: 1.25;">3.</div>
                </td>
                <td style="width: 95.4%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of
                    operations and cash flows of the registrant as of, and for, the period end presented in this report;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 4.6%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 95.4%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 4.6%; vertical-align: top;">
                  <div style="line-height: 1.25;">4.</div>
                </td>
                <td style="width: 95.4%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
                    15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;">&#160;</div>
          </div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 8.84%; vertical-align: top;">
                  <div style="text-align: center; line-height: 1.25;">&#160;&#160; a.</div>
                </td>
                <td style="width: 91.16%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to
                    the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period end in which this report is being prepared;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 8.84%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 91.16%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 8.84%; vertical-align: top;">
                  <div style="text-align: center; line-height: 1.25;">&#160;&#160; b.</div>
                </td>
                <td style="width: 91.16%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance
                    regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 8.84%; vertical-align: top;">
                  <div style="text-align: center; line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 91.16%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 8.84%; vertical-align: top;">
                  <div style="text-align: center; line-height: 1.25;">&#160;&#160; c.</div>
                </td>
                <td style="width: 91.16%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and
                    procedures, as of the end of the period end covered by this report based on such evaluation; and</div>
                </td>
              </tr>
              <tr>
                <td style="width: 8.84%; vertical-align: top;">
                  <div style="text-align: center; line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 91.16%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 8.84%; vertical-align: top;">
                  <div style="text-align: center; line-height: 1.25;">&#160;&#160; d.</div>
                </td>
                <td style="width: 91.16%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s
                    fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
          </div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 4.6%; vertical-align: top;">
                  <div style="text-align: center; line-height: 1.25;">5.</div>
                </td>
                <td style="width: 95.4%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the
                    audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
          </div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 8.84%; vertical-align: top;">
                  <div style="text-align: center; line-height: 1.25;">&#160;&#160; a.</div>
                </td>
                <td style="width: 91.16%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the
                    registrant&#8217;s ability to record, process, summarize and report financial information; and</div>
                </td>
              </tr>
              <tr>
                <td style="width: 8.84%; vertical-align: top;">
                  <div style="text-align: center; line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 91.16%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 8.84%; vertical-align: top;">
                  <div style="text-align: center; line-height: 1.25;">&#160;&#160; b.</div>
                </td>
                <td style="width: 91.16%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;">&#160;</div>
          </div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 40.38%; vertical-align: top;">
                  <div style="line-height: 1.25;">Date: August 12, 2022</div>
                </td>
                <td style="width: 59.62%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 40.38%; vertical-align: top; border-bottom: #000000 2px solid;">
                  <div style="line-height: 1.25; font-style: italic;">/s/ Dale Pfost</div>
                </td>
                <td style="width: 59.62%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 40.38%; vertical-align: top;">
                  <div style="line-height: 1.25;">Dale Pfost</div>
                </td>
                <td style="width: 59.62%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 40.38%; vertical-align: top;">
                  <div style="line-height: 1.25;">Chief Executive Officer</div>
                  <div style="line-height: 1.25;">(<font style="font-style: italic;">principal executive officer)</font></div>
                </td>
                <td style="width: 59.62%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
          </div>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;">
              <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <br>
        </div>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>exhibit_31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using Broadridge PROfile 22.7.2.5063
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div> <br>
    </div>
    <div>
      <div>
        <div>
          <div style="line-height: 1.25;">
            <div style="text-align: right; line-height: 1.25;"><font style="font-weight: bold;"><u>Exhibit 31.2</u></font></div>
          </div>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;">&#160;</div>
          </div>
          <div style="line-height: 1.25;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">CERTIFICATION PURSUANT TO</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">RULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">AS ADOPTED PURSUANT TO</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</div>
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </div>
          <div style="line-height: 1.25;">
            <div style="text-align: justify; line-height: 1.25;">I, Donald Marvin, certify that:</div>
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 4.6%; vertical-align: top;">
                  <div style="line-height: 1.25;">1.</div>
                </td>
                <td style="width: 95.4%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">I have reviewed this Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 of Chemomab Therapeutics Ltd.;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 4.6%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 95.4%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 4.6%; vertical-align: top;">
                  <div style="line-height: 1.25;">2.</div>
                </td>
                <td style="width: 95.4%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the
                    circumstances under which such statements were made, not misleading with respect to the period end covered by this report;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 4.6%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 95.4%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 4.6%; vertical-align: top;">
                  <div style="line-height: 1.25;">3.</div>
                </td>
                <td style="width: 95.4%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of
                    operations and cash flows of the registrant as of, and for, the period end presented in this report;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 4.6%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 95.4%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 4.6%; vertical-align: top;">
                  <div style="line-height: 1.25;">4.</div>
                </td>
                <td style="width: 95.4%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
                    15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;">&#160;</div>
          </div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 8.84%; vertical-align: top;">
                  <div style="text-align: center; line-height: 1.25;">&#160;&#160; a.</div>
                </td>
                <td style="width: 91.16%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to
                    the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period end in which this report is being prepared;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 8.84%; vertical-align: top;">
                  <div style="text-align: center; line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 91.16%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 8.84%; vertical-align: top;">
                  <div style="text-align: center; line-height: 1.25;">&#160;&#160; b.</div>
                </td>
                <td style="width: 91.16%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance
                    regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 8.84%; vertical-align: top;">
                  <div style="text-align: center; line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 91.16%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 8.84%; vertical-align: top;">
                  <div style="text-align: center; line-height: 1.25;">&#160;&#160; c.</div>
                </td>
                <td style="width: 91.16%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and
                    procedures, as of the end of the period end covered by this report based on such evaluation; and</div>
                </td>
              </tr>
              <tr>
                <td style="width: 8.84%; vertical-align: top;">
                  <div style="text-align: center; line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 91.16%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 8.84%; vertical-align: top;">
                  <div style="text-align: center; line-height: 1.25;">&#160;&#160; d.</div>
                </td>
                <td style="width: 91.16%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s
                    fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
          </div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 4.6%; vertical-align: top;">
                  <div style="line-height: 1.25;">5.</div>
                </td>
                <td style="width: 95.4%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the
                    audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
          </div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 8.84%; vertical-align: top;">
                  <div style="text-align: center; line-height: 1.25;">&#160;&#160; a.</div>
                </td>
                <td style="width: 91.16%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the
                    registrant&#8217;s ability to record, process, summarize and report financial information; and</div>
                </td>
              </tr>
              <tr>
                <td style="width: 8.84%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 91.16%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 8.84%; vertical-align: top;">
                  <div style="text-align: center; line-height: 1.25;">&#160;&#160; b.</div>
                </td>
                <td style="width: 91.16%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;">&#160;</div>
          </div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 40.42%; vertical-align: top;">
                  <div style="line-height: 1.25;">Date: August 12, 2022</div>
                </td>
                <td style="width: 59.58%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 40.42%; vertical-align: top; border-bottom: #000000 2px solid;">
                  <div style="line-height: 1.25; font-style: italic;">/s/ Donald Marvin</div>
                </td>
                <td style="width: 59.58%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 40.42%; vertical-align: top;">
                  <div style="line-height: 1.25;">Donald Marvin</div>
                </td>
                <td style="width: 59.58%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 40.42%; vertical-align: top;">
                  <div style="line-height: 1.25;">Chief Financial Officer</div>
                  <div style="line-height: 1.25;">(<font style="font-style: italic;">principal financial and accounting officer)</font></div>
                </td>
                <td style="width: 59.58%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
          </div>
          <div style="line-height: 1.25;">
            <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
          <br>
        </div>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>exhibit_32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using Broadridge PROfile 22.7.2.5063
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div> <br>
    </div>
    <div>
      <div>
        <div>
          <div style="text-align: right; line-height: 1.25; font-weight: bold;"><u>Exhibit 32.1</u></div>
          <div style="text-align: center; line-height: 1.25;">&#160;</div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">CERTIFICATION PURSUANT TO</div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">18 U.S.C. SECTION 1350,</div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">AS ADOPTED PURSUANT TO</div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</div>
          <div style="text-align: center; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25;">In connection with the Quarterly Report of Chemomab Therapeutics Ltd. (the &#8220;Company&#8221;) on Form 10-Q for the quarter ended June 30, 2022, as filed with the Securities and Exchange Commission on
            the date hereof (the &#8220;Report&#8221;), I, Dale Pfost, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 4.62%; vertical-align: top;">
                  <div style="line-height: 1.25;">(1)</div>
                </td>
                <td style="width: 95.38%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</div>
                </td>
              </tr>
              <tr>
                <td style="width: 4.62%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 95.38%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 4.62%; vertical-align: top;">
                  <div style="line-height: 1.25;">(2)</div>
                </td>
                <td style="width: 95.38%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 40.48%; vertical-align: top; border-bottom: #000000 2px solid;">
                  <div style="line-height: 1.25; font-style: italic;">/s/ Dale Pfost</div>
                </td>
                <td style="width: 59.52%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 40.48%; vertical-align: top;">
                  <div style="line-height: 1.25;">Dale Pfost</div>
                </td>
                <td style="width: 59.52%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 40.48%; vertical-align: top;">
                  <div style="line-height: 1.25;">Chief Executive Officer</div>
                  <div style="line-height: 1.25;">(<font style="font-style: italic;">principal executive officer)</font></div>
                </td>
                <td style="width: 59.52%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 40.48%; vertical-align: top;">
                  <div>
                    <div style="line-height: 1.25;">Chemomab Therapeutics Ltd.</div>
                  </div>
                </td>
                <td style="width: 59.52%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 40.48%; vertical-align: top;">
                  <div style="line-height: 1.25;">August 12, 2022</div>
                </td>
                <td style="width: 59.52%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25;">
            <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25;">&#160;</div>
        </div>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>exhibit_32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using Broadridge PROfile 22.7.2.5063
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div> <br>
    </div>
    <div>
      <div style="text-align: center;">
        <div>
          <div style="text-align: right; line-height: 1.25; font-weight: bold;"><u>Exhibit 32.2</u></div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25; font-weight: bold;">CERTIFICATION PURSUANT TO</div>
          <div style="line-height: 1.25; font-weight: bold;">18 U.S.C. SECTION 1350,</div>
          <div style="line-height: 1.25; font-weight: bold;">AS ADOPTED PURSUANT TO</div>
          <div style="line-height: 1.25; font-weight: bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25;">In connection with the Quarterly Report of Chemomab Therapeutics Ltd. (the &#8220;Company&#8221;) on Form 10-Q for the quarter ended June 30, 2022, as filed with the Securities and Exchange Commission on
            the date hereof (the &#8220;Report&#8221;), I, Donald Marvin, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 4.62%; vertical-align: top;">
                  <div style="line-height: 1.25;">(1)</div>
                </td>
                <td style="width: 95.38%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</div>
                </td>
              </tr>
              <tr>
                <td style="width: 4.62%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 95.38%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 4.62%; vertical-align: top;">
                  <div style="line-height: 1.25;">(2)</div>
                </td>
                <td style="width: 95.38%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 40.48%; vertical-align: top; border-bottom: #000000 2px solid;">
                  <div style="line-height: 1.25; font-style: italic;">/s/ Donald Marvin</div>
                </td>
                <td style="width: 59.52%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 40.48%; vertical-align: top;">
                  <div style="line-height: 1.25;">Donald Marvin</div>
                </td>
                <td style="width: 59.52%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 40.48%; vertical-align: top;">
                  <div style="line-height: 1.25;">Chief Financial Officer</div>
                  <div style="line-height: 1.25;">(<font style="font-style: italic;">principal financial and accounting officer)</font></div>
                </td>
                <td style="width: 59.52%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 40.48%; vertical-align: top;">
                  <div style="line-height: 1.25;">Chemomab Therapeutics Ltd.</div>
                </td>
                <td style="width: 59.52%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 40.48%; vertical-align: top;">
                  <div style="line-height: 1.25;">August 12, 2022</div>
                </td>
                <td style="width: 59.52%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
        </div>
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"><font style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" id="DSPFPageNumber">&#160;</font></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>cmmb-20220630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<schema xmlns:cmmb="http://www.anchiano.com/20220630" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" targetNamespace="http://www.anchiano.com/20220630" elementFormDefault="qualified">
  <!-- INTEGIX by Ez-XBRL -->
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd"/>
  <import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd"/>
  <import namespace="http://xbrl.sec.gov/naics/2022" schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd"/>
  <import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd"/>
  <import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"/>
  <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd"/>
  <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.anchiano.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>0001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets" id="StatementCondensedConsolidatedBalanceSheets">
        <link:definition>0002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
        <link:definition>0003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations" id="StatementUnauditedCondensedConsolidatedStatementsOfOperations">
        <link:definition>0004 - Statement - Condensed Consolidated Interim Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/InterimStatementsOfChangesInEquity" id="InterimStatementsOfChangesInEquity">
        <link:definition>0005 - Statement - Condensed Consolidated Interim Statements of Changes in Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" id="StatementUnauditedCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>0006 - Statement - Condensed Consolidated Interim Statements of Cash flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/General." id="General.">
        <link:definition>0007 - Disclosure - General</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/BasisOfPresentationAndSignificantAccountingPolicies" id="BasisOfPresentationAndSignificantAccountingPolicies">
        <link:definition>0008 - Disclosure - Basis of Presentation and Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/Contingencies" id="Contingencies">
        <link:definition>0009 - Disclosure - Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" id="BasisOfPresentationAndSignificantAccountingPoliciesPolicies">
        <link:definition>0010 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/General.Tables" id="General.Tables">
        <link:definition>0011 - Disclosure - General (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/General.Details" id="General.Details">
        <link:definition>0012 - Disclosure - General (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/General.-EstimatedFairValueOfAssetsAcquiredDetails" id="General.-EstimatedFairValueOfAssetsAcquiredDetails">
        <link:definition>0013 - Disclosure - General - Estimated fair value of assets acquired (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="cmmb-20220630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="cmmb-20220630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="cmmb-20220630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="cmmb-20220630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
    </appinfo>
  </annotation>
  <element name="AccountReceivableDueToExerciseOfOptions" id="cmmb_AccountReceivableDueToExerciseOfOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AccruedShareIssuanceExpenses" id="cmmb_AccruedShareIssuanceExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AmericanDepositarySharesMember" id="cmmb_AmericanDepositarySharesMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AmericanDepositorySharesMember" id="cmmb_AmericanDepositorySharesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AmountOfTotalSaleAndTransferOfCompoundsAndProductsKestrelPaid" id="cmmb_AmountOfTotalSaleAndTransferOfCompoundsAndProductsKestrelPaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember" id="cmmb_AtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale" id="cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" id="cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="CashAcquiredInReverseRecapitalization" id="cmmb_CashAcquiredInReverseRecapitalization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DrFrostMember" id="cmmb_DrFrostMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EffectOfReverseCapitalizationTransaction" id="cmmb_EffectOfReverseCapitalizationTransaction" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="EffectOfReverseCapitalizationTransactionShares" id="cmmb_EffectOfReverseCapitalizationTransactionShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EstimatedFairValueOfNetAssetsAcquired" id="cmmb_EstimatedFairValueOfNetAssetsAcquired" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="FinanceIncomeExpensesNet" id="cmmb_FinanceIncomeExpensesNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="FormerChemomabSecurityHoldersMember" id="cmmb_FormerChemomabSecurityHoldersMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IssuanceOfSharesNetOfIssuanceCosts" id="cmmb_IssuanceOfSharesNetOfIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="LiabilitiesAssumedNetOfNonCashAssetsReceivedInReverseMerger" id="cmmb_LiabilitiesAssumedNetOfNonCashAssetsReceivedInReverseMerger" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="MergerAgreementWithChemomabIsraeliLimitedCompanyAndClinicalStageBiotechCompanyMember" id="cmmb_MergerAgreementWithChemomabIsraeliLimitedCompanyAndClinicalStageBiotechCompanyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MrMarvinMember" id="cmmb_MrMarvinMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NatureOfOperationsDisclosureAbstract" id="cmmb_NatureOfOperationsDisclosureAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfAdsIssuedAndOutstandingAfterMerger" id="cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfOrdinarySharesConsistedInDS" id="cmmb_NumberOfOrdinarySharesConsistedInDS" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfOrdinarySharesForEachPreferredShareConvertedPriorToDateOfMerger" id="cmmb_NumberOfOrdinarySharesForEachPreferredShareConvertedPriorToDateOfMerger" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfSharesDilutedAfterMerger" id="cmmb_NumberOfSharesDilutedAfterMerger" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OneEmployeeOneOfficerConsultantAndSixBoardMember" id="cmmb_OneEmployeeOneOfficerConsultantAndSixBoardMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OrdinarySharesMember" id="cmmb_OrdinarySharesMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OrdinarySharesNoParValuePerShareMember" id="cmmb_OrdinarySharesNoParValuePerShareMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PaymentsForInvestmentInDeposits" id="cmmb_PaymentsForInvestmentInDeposits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="PaymentsToPurchaseOfDeposits" id="cmmb_PaymentsToPurchaseOfDeposits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ProceedsFromInvestmentInDepositsInvestingActivities" id="cmmb_ProceedsFromInvestmentInDepositsInvestingActivities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ProceedsFromReceivablesOnAccountOfShares" id="cmmb_ProceedsFromReceivablesOnAccountOfShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ProceedsFromSaleOfDeposits" id="cmmb_ProceedsFromSaleOfDeposits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RetainedEarningsAccumulatedDeficits" id="cmmb_RetainedEarningsAccumulatedDeficits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="SecuritiesPurchaseAgreementsForOfferingAndSaleByAnchianoMember" id="cmmb_SecuritiesPurchaseAgreementsForOfferingAndSaleByAnchianoMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareholdingPercentageImmediatelyFollowingMerger" id="cmmb_ShareholdingPercentageImmediatelyFollowingMerger" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SharesConvertiblePerShareOfAcquireeEntity" id="cmmb_SharesConvertiblePerShareOfAcquireeEntity" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockAndWarrantIssuedDuringPeriodNewIssues" id="cmmb_StockAndWarrantIssuedDuringPeriodNewIssues" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockAndWarrantsIssuedDuringPeriodValueNewIssues" id="cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="TwoThousandFifteenPlanMember" id="cmmb_TwoThousandFifteenPlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantsExercisablePeriod" id="cmmb_WarrantsExercisablePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>cmmb-20220630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="cmmb-20220630.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20220630.xsd#StatementUnauditedCondensedConsolidatedStatementsOfOperations" roleURI="http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20220630.xsd#StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaap_DepositsAssetsCurrent_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_23"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0" xlink:to="loc_us-gaap_AssetsCurrent_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_DepositsAssetsCurrent_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0" xlink:to="loc_us-gaap_AssetsNoncurrent_5" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_5" xlink:to="loc_us-gaap_DepositsAssetsNoncurrent_5" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_5" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_6" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_5" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_7" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_5" xlink:to="loc_us-gaap_PrepaidExpenseNoncurrent_8" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_11" xlink:to="loc_us-gaap_Liabilities_12" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_12" xlink:to="loc_us-gaap_LiabilitiesCurrent_12" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_12" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_12" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_12" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_13" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_12" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_14" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_12" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_15" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_12" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_17" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_17" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_17" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_11" xlink:to="loc_us-gaap_CommitmentsAndContingencies_20" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_11" xlink:to="loc_us-gaap_StockholdersEquity_21" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_21" xlink:to="loc_us-gaap_CommonStockValue_21" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_21" xlink:to="loc_us-gaap_AdditionalPaidInCapital_22" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_21" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_23" order="20" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_FinanceIncomeExpensesNet" xlink:label="loc_cmmb_FinanceIncomeExpensesNet_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xlink:to="loc_cmmb_FinanceIncomeExpensesNet_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xlink:to="loc_us-gaap_OperatingExpenses_2" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_2" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_3" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6" order="10" use="optional" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyHeldForSale" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyHeldForSale_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_12"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_ProceedsFromSaleOfDeposits" xlink:label="loc_cmmb_ProceedsFromSaleOfDeposits_13"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_PaymentsToPurchaseOfDeposits" xlink:label="loc_cmmb_PaymentsToPurchaseOfDeposits_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_16"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_CashAcquiredInReverseRecapitalization" xlink:label="loc_cmmb_CashAcquiredInReverseRecapitalization_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="loc_us-gaap_ProceedsFromOtherEquity_18"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_IssuanceOfSharesNetOfIssuanceCosts" xlink:label="loc_cmmb_IssuanceOfSharesNetOfIssuanceCosts_19"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_ProfitLoss_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_2" xlink:to="loc_us-gaap_Depreciation_2" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_2" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_2" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_4" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_5" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_6" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_2" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_7" order="50" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_2" xlink:to="loc_us-gaap_ShareBasedCompensation_8" order="60" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_11" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_11" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyHeldForSale_11" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_11" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_12" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_11" xlink:to="loc_cmmb_ProceedsFromSaleOfDeposits_13" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_11" xlink:to="loc_cmmb_PaymentsToPurchaseOfDeposits_14" order="30" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_16" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_16" xlink:to="loc_cmmb_CashAcquiredInReverseRecapitalization_16" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_16" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_17" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_16" xlink:to="loc_us-gaap_ProceedsFromOtherEquity_18" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_16" xlink:to="loc_cmmb_IssuanceOfSharesNetOfIssuanceCosts_19" order="30" use="optional" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>cmmb-20220630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="cmmb-20220630.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20220630.xsd#InterimStatementsOfChangesInEquity" roleURI="http://www.anchiano.com/role/InterimStatementsOfChangesInEquity"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20220630.xsd#General.Details" roleURI="http://www.anchiano.com/role/General.Details"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/DocumentDocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_AmericanDepositarySharesMember" xlink:label="loc_cmmb_AmericanDepositarySharesMember_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_OrdinarySharesNoParValuePerShareMember" xlink:label="loc_cmmb_OrdinarySharesNoParValuePerShareMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="loc_dei_EntityInformationFormerLegalOrRegisteredName_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_dei_NoTradingSymbolFlag_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_39"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1" xlink:to="loc_us-gaap_ClassOfStockDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_cmmb_AmericanDepositarySharesMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_cmmb_OrdinarySharesNoParValuePerShareMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1" xlink:to="loc_us-gaap_ClassOfStockDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentType_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityCentralIndexKey_8" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentPeriodEndDate_9" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_CurrentFiscalYearEndDate_10" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentFiscalYearFocus_11" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_12" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_AmendmentFlag_13" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentQuarterlyReport_14" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentTransitionReport_15" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityFileNumber_16" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityRegistrantName_17" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityIncorporationStateCountryCode_18" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityTaxIdentificationNumber_19" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityAddressAddressLine1_20" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityAddressAddressLine2_21" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityAddressCityOrTown_22" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityAddressPostalZipCode_23" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityAddressCountry_24" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_CityAreaCode_25" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_LocalPhoneNumber_26" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityInformationFormerLegalOrRegisteredName_27" order="210" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_Security12bTitle_28" order="220" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_TradingSymbol_29" order="230" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_NoTradingSymbolFlag_30" order="240" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_SecurityExchangeName_31" order="250" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityCurrentReportingStatus_32" order="260" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityInteractiveDataCurrent_33" order="270" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityFilerCategory_34" order="280" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntitySmallBusiness_35" order="290" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityEmergingGrowthCompany_36" order="300" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityExTransitionPeriod_37" order="310" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityShellCompany_38" order="320" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_39" order="330" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/InterimStatementsOfChangesInEquity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_14"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_EffectOfReverseCapitalizationTransaction" xlink:label="loc_cmmb_EffectOfReverseCapitalizationTransaction_15"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_EffectOfReverseCapitalizationTransactionShares" xlink:label="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_16"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues" xlink:label="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_17"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_StockAndWarrantIssuedDuringPeriodNewIssues" xlink:label="loc_cmmb_StockAndWarrantIssuedDuringPeriodNewIssues_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_19"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_CommonStockMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_RetainedEarningsMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockholdersEquity_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SharesOutstanding_9" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_10" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_11" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_12" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_13" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_14" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cmmb_EffectOfReverseCapitalizationTransaction_15" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_16" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_17" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cmmb_StockAndWarrantIssuedDuringPeriodNewIssues_18" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetIncomeLoss_19" order="120" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/General.Details">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_MergerAgreementWithChemomabIsraeliLimitedCompanyAndClinicalStageBiotechCompanyMember" xlink:label="loc_cmmb_MergerAgreementWithChemomabIsraeliLimitedCompanyAndClinicalStageBiotechCompanyMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_FormerChemomabSecurityHoldersMember" xlink:label="loc_cmmb_FormerChemomabSecurityHoldersMember_5"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_OneEmployeeOneOfficerConsultantAndSixBoardMember" xlink:label="loc_cmmb_OneEmployeeOneOfficerConsultantAndSixBoardMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_10"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_TwoThousandFifteenPlanMember" xlink:label="loc_cmmb_TwoThousandFifteenPlanMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_14"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_AmericanDepositorySharesMember" xlink:label="loc_cmmb_AmericanDepositorySharesMember_14"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_OrdinarySharesMember" xlink:label="loc_cmmb_OrdinarySharesMember_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_24"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_AtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember" xlink:label="loc_cmmb_AtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_ShareholdingPercentageImmediatelyFollowingMerger" xlink:label="loc_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_29"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_NumberOfOrdinarySharesForEachPreferredShareConvertedPriorToDateOfMerger" xlink:label="loc_cmmb_NumberOfOrdinarySharesForEachPreferredShareConvertedPriorToDateOfMerger_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_31"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_NumberOfOrdinarySharesConsistedInDS" xlink:label="loc_cmmb_NumberOfOrdinarySharesConsistedInDS_32"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger" xlink:label="loc_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_33"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_NumberOfSharesDilutedAfterMerger" xlink:label="loc_cmmb_NumberOfSharesDilutedAfterMerger_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Capital" xlink:label="loc_us-gaap_Capital_35"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_SharesConvertiblePerShareOfAcquireeEntity" xlink:label="loc_cmmb_SharesConvertiblePerShareOfAcquireeEntity_36"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_RetainedEarningsAccumulatedDeficits" xlink:label="loc_cmmb_RetainedEarningsAccumulatedDeficits_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_45"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_46"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_47"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_WarrantsExercisablePeriod" xlink:label="loc_cmmb_WarrantsExercisablePeriod_48"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_49"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_AmountOfTotalSaleAndTransferOfCompoundsAndProductsKestrelPaid" xlink:label="loc_cmmb_AmountOfTotalSaleAndTransferOfCompoundsAndProductsKestrelPaid_50"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" xlink:to="loc_cmmb_MergerAgreementWithChemomabIsraeliLimitedCompanyAndClinicalStageBiotechCompanyMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_5" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5" xlink:to="loc_cmmb_FormerChemomabSecurityHoldersMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5" xlink:to="loc_cmmb_OneEmployeeOneOfficerConsultantAndSixBoardMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_5" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1" xlink:to="loc_us-gaap_PlanNameAxis_10" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_10" xlink:to="loc_us-gaap_PlanNameDomain_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_10" xlink:to="loc_cmmb_TwoThousandFifteenPlanMember_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_10" xlink:to="loc_us-gaap_PlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_14" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_14" xlink:to="loc_us-gaap_ClassOfStockDomain_14" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_14" xlink:to="loc_cmmb_AmericanDepositorySharesMember_14" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_14" xlink:to="loc_cmmb_OrdinarySharesMember_15" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_14" xlink:to="loc_us-gaap_ClassOfStockDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1" xlink:to="loc_srt_RangeAxis_19" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_19" xlink:to="loc_srt_RangeMember_19" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_19" xlink:to="loc_srt_MinimumMember_19" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_19" xlink:to="loc_srt_MaximumMember_20" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_19" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_24" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_24" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_24" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_24" xlink:to="loc_cmmb_AtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember_24" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_24" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0" xlink:to="loc_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_29" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0" xlink:to="loc_cmmb_NumberOfOrdinarySharesForEachPreferredShareConvertedPriorToDateOfMerger_30" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_31" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0" xlink:to="loc_cmmb_NumberOfOrdinarySharesConsistedInDS_32" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0" xlink:to="loc_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_33" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0" xlink:to="loc_cmmb_NumberOfSharesDilutedAfterMerger_34" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0" xlink:to="loc_us-gaap_Capital_35" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0" xlink:to="loc_cmmb_SharesConvertiblePerShareOfAcquireeEntity_36" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0" xlink:to="loc_cmmb_RetainedEarningsAccumulatedDeficits_37" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_38" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_39" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_40" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_41" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_42" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_43" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_44" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_45" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0" xlink:to="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_46" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_47" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0" xlink:to="loc_cmmb_WarrantsExercisablePeriod_48" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_49" order="210" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0" xlink:to="loc_cmmb_AmountOfTotalSaleAndTransferOfCompoundsAndProductsKestrelPaid_50" order="220" use="optional"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>cmmb-20220630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_AccountReceivableDueToExerciseOfOptions" xlink:label="loc_cmmb_AccountReceivableDueToExerciseOfOptions_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_AccountReceivableDueToExerciseOfOptions" xlink:label="loc_cmmb_AccountReceivableDueToExerciseOfOptions_2"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_AccountReceivableDueToExerciseOfOptions" xlink:label="loc_cmmb_AccountReceivableDueToExerciseOfOptions_3"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_AccountReceivableDueToExerciseOfOptions" xlink:label="loc_cmmb_AccountReceivableDueToExerciseOfOptions_4"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_AccruedShareIssuanceExpenses" xlink:label="loc_cmmb_AccruedShareIssuanceExpenses_5"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_AccruedShareIssuanceExpenses" xlink:label="loc_cmmb_AccruedShareIssuanceExpenses_6"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_AmericanDepositarySharesMember" xlink:label="loc_cmmb_AmericanDepositarySharesMember_7"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_AmericanDepositarySharesMember" xlink:label="loc_cmmb_AmericanDepositarySharesMember_8"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_AmericanDepositorySharesMember" xlink:label="loc_cmmb_AmericanDepositorySharesMember_9"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_AmericanDepositorySharesMember" xlink:label="loc_cmmb_AmericanDepositorySharesMember_10"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_AmericanDepositorySharesMember" xlink:label="loc_cmmb_AmericanDepositorySharesMember_11"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_AmountOfTotalSaleAndTransferOfCompoundsAndProductsKestrelPaid" xlink:label="loc_cmmb_AmountOfTotalSaleAndTransferOfCompoundsAndProductsKestrelPaid_12"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_AmountOfTotalSaleAndTransferOfCompoundsAndProductsKestrelPaid" xlink:label="loc_cmmb_AmountOfTotalSaleAndTransferOfCompoundsAndProductsKestrelPaid_13"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_AmountOfTotalSaleAndTransferOfCompoundsAndProductsKestrelPaid" xlink:label="loc_cmmb_AmountOfTotalSaleAndTransferOfCompoundsAndProductsKestrelPaid_14"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_AtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember" xlink:label="loc_cmmb_AtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember_15"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_AtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember" xlink:label="loc_cmmb_AtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember_16"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_AtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember" xlink:label="loc_cmmb_AtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember_17"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale" xlink:label="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_18"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale" xlink:label="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_19"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale" xlink:label="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_20"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:label="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_21"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:label="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_22"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:label="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_23"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_CashAcquiredInReverseRecapitalization" xlink:label="loc_cmmb_CashAcquiredInReverseRecapitalization_24"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_CashAcquiredInReverseRecapitalization" xlink:label="loc_cmmb_CashAcquiredInReverseRecapitalization_25"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_CashAcquiredInReverseRecapitalization" xlink:label="loc_cmmb_CashAcquiredInReverseRecapitalization_26"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_DrFrostMember" xlink:label="loc_cmmb_DrFrostMember_27"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_DrFrostMember" xlink:label="loc_cmmb_DrFrostMember_28"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_EffectOfReverseCapitalizationTransaction" xlink:label="loc_cmmb_EffectOfReverseCapitalizationTransaction_29"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_EffectOfReverseCapitalizationTransaction" xlink:label="loc_cmmb_EffectOfReverseCapitalizationTransaction_30"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_EffectOfReverseCapitalizationTransactionShares" xlink:label="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_31"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_EffectOfReverseCapitalizationTransactionShares" xlink:label="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_32"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_EffectOfReverseCapitalizationTransactionShares" xlink:label="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_33"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_EstimatedFairValueOfNetAssetsAcquired" xlink:label="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_34"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_EstimatedFairValueOfNetAssetsAcquired" xlink:label="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_35"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_EstimatedFairValueOfNetAssetsAcquired" xlink:label="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_36"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_FinanceIncomeExpensesNet" xlink:label="loc_cmmb_FinanceIncomeExpensesNet_37"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_FinanceIncomeExpensesNet" xlink:label="loc_cmmb_FinanceIncomeExpensesNet_38"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_FinanceIncomeExpensesNet" xlink:label="loc_cmmb_FinanceIncomeExpensesNet_39"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_FinanceIncomeExpensesNet" xlink:label="loc_cmmb_FinanceIncomeExpensesNet_40"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_FormerChemomabSecurityHoldersMember" xlink:label="loc_cmmb_FormerChemomabSecurityHoldersMember_41"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_FormerChemomabSecurityHoldersMember" xlink:label="loc_cmmb_FormerChemomabSecurityHoldersMember_42"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_IssuanceOfSharesNetOfIssuanceCosts" xlink:label="loc_cmmb_IssuanceOfSharesNetOfIssuanceCosts_43"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_IssuanceOfSharesNetOfIssuanceCosts" xlink:label="loc_cmmb_IssuanceOfSharesNetOfIssuanceCosts_44"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_IssuanceOfSharesNetOfIssuanceCosts" xlink:label="loc_cmmb_IssuanceOfSharesNetOfIssuanceCosts_45"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_IssuanceOfSharesNetOfIssuanceCosts" xlink:label="loc_cmmb_IssuanceOfSharesNetOfIssuanceCosts_46"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_LiabilitiesAssumedNetOfNonCashAssetsReceivedInReverseMerger" xlink:label="loc_cmmb_LiabilitiesAssumedNetOfNonCashAssetsReceivedInReverseMerger_47"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_LiabilitiesAssumedNetOfNonCashAssetsReceivedInReverseMerger" xlink:label="loc_cmmb_LiabilitiesAssumedNetOfNonCashAssetsReceivedInReverseMerger_48"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_LiabilitiesAssumedNetOfNonCashAssetsReceivedInReverseMerger" xlink:label="loc_cmmb_LiabilitiesAssumedNetOfNonCashAssetsReceivedInReverseMerger_49"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_MergerAgreementWithChemomabIsraeliLimitedCompanyAndClinicalStageBiotechCompanyMember" xlink:label="loc_cmmb_MergerAgreementWithChemomabIsraeliLimitedCompanyAndClinicalStageBiotechCompanyMember_50"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_MergerAgreementWithChemomabIsraeliLimitedCompanyAndClinicalStageBiotechCompanyMember" xlink:label="loc_cmmb_MergerAgreementWithChemomabIsraeliLimitedCompanyAndClinicalStageBiotechCompanyMember_51"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_MergerAgreementWithChemomabIsraeliLimitedCompanyAndClinicalStageBiotechCompanyMember" xlink:label="loc_cmmb_MergerAgreementWithChemomabIsraeliLimitedCompanyAndClinicalStageBiotechCompanyMember_52"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_MrMarvinMember" xlink:label="loc_cmmb_MrMarvinMember_53"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_MrMarvinMember" xlink:label="loc_cmmb_MrMarvinMember_54"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_NatureOfOperationsDisclosureAbstract" xlink:label="loc_cmmb_NatureOfOperationsDisclosureAbstract_55"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_NatureOfOperationsDisclosureAbstract" xlink:label="loc_cmmb_NatureOfOperationsDisclosureAbstract_56"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger" xlink:label="loc_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_57"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger" xlink:label="loc_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_58"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_NumberOfOrdinarySharesConsistedInDS" xlink:label="loc_cmmb_NumberOfOrdinarySharesConsistedInDS_59"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_NumberOfOrdinarySharesConsistedInDS" xlink:label="loc_cmmb_NumberOfOrdinarySharesConsistedInDS_60"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_NumberOfOrdinarySharesConsistedInDS" xlink:label="loc_cmmb_NumberOfOrdinarySharesConsistedInDS_61"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_NumberOfOrdinarySharesForEachPreferredShareConvertedPriorToDateOfMerger" xlink:label="loc_cmmb_NumberOfOrdinarySharesForEachPreferredShareConvertedPriorToDateOfMerger_62"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_NumberOfOrdinarySharesForEachPreferredShareConvertedPriorToDateOfMerger" xlink:label="loc_cmmb_NumberOfOrdinarySharesForEachPreferredShareConvertedPriorToDateOfMerger_63"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_NumberOfOrdinarySharesForEachPreferredShareConvertedPriorToDateOfMerger" xlink:label="loc_cmmb_NumberOfOrdinarySharesForEachPreferredShareConvertedPriorToDateOfMerger_64"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_NumberOfSharesDilutedAfterMerger" xlink:label="loc_cmmb_NumberOfSharesDilutedAfterMerger_65"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_NumberOfSharesDilutedAfterMerger" xlink:label="loc_cmmb_NumberOfSharesDilutedAfterMerger_66"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_OneEmployeeOneOfficerConsultantAndSixBoardMember" xlink:label="loc_cmmb_OneEmployeeOneOfficerConsultantAndSixBoardMember_67"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_OneEmployeeOneOfficerConsultantAndSixBoardMember" xlink:label="loc_cmmb_OneEmployeeOneOfficerConsultantAndSixBoardMember_68"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_OneEmployeeOneOfficerConsultantAndSixBoardMember" xlink:label="loc_cmmb_OneEmployeeOneOfficerConsultantAndSixBoardMember_69"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_OrdinarySharesMember" xlink:label="loc_cmmb_OrdinarySharesMember_70"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_OrdinarySharesMember" xlink:label="loc_cmmb_OrdinarySharesMember_71"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_OrdinarySharesNoParValuePerShareMember" xlink:label="loc_cmmb_OrdinarySharesNoParValuePerShareMember_72"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_OrdinarySharesNoParValuePerShareMember" xlink:label="loc_cmmb_OrdinarySharesNoParValuePerShareMember_73"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_PaymentsForInvestmentInDeposits" xlink:label="loc_cmmb_PaymentsForInvestmentInDeposits_74"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_PaymentsForInvestmentInDeposits" xlink:label="loc_cmmb_PaymentsForInvestmentInDeposits_75"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_PaymentsForInvestmentInDeposits" xlink:label="loc_cmmb_PaymentsForInvestmentInDeposits_76"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_PaymentsToPurchaseOfDeposits" xlink:label="loc_cmmb_PaymentsToPurchaseOfDeposits_77"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_PaymentsToPurchaseOfDeposits" xlink:label="loc_cmmb_PaymentsToPurchaseOfDeposits_78"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_PaymentsToPurchaseOfDeposits" xlink:label="loc_cmmb_PaymentsToPurchaseOfDeposits_79"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_ProceedsFromInvestmentInDepositsInvestingActivities" xlink:label="loc_cmmb_ProceedsFromInvestmentInDepositsInvestingActivities_80"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_ProceedsFromInvestmentInDepositsInvestingActivities" xlink:label="loc_cmmb_ProceedsFromInvestmentInDepositsInvestingActivities_81"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_ProceedsFromInvestmentInDepositsInvestingActivities" xlink:label="loc_cmmb_ProceedsFromInvestmentInDepositsInvestingActivities_82"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_ProceedsFromReceivablesOnAccountOfShares" xlink:label="loc_cmmb_ProceedsFromReceivablesOnAccountOfShares_83"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_ProceedsFromReceivablesOnAccountOfShares" xlink:label="loc_cmmb_ProceedsFromReceivablesOnAccountOfShares_84"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_ProceedsFromSaleOfDeposits" xlink:label="loc_cmmb_ProceedsFromSaleOfDeposits_85"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_ProceedsFromSaleOfDeposits" xlink:label="loc_cmmb_ProceedsFromSaleOfDeposits_86"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_ProceedsFromSaleOfDeposits" xlink:label="loc_cmmb_ProceedsFromSaleOfDeposits_87"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_RetainedEarningsAccumulatedDeficits" xlink:label="loc_cmmb_RetainedEarningsAccumulatedDeficits_88"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_RetainedEarningsAccumulatedDeficits" xlink:label="loc_cmmb_RetainedEarningsAccumulatedDeficits_89"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_RetainedEarningsAccumulatedDeficits" xlink:label="loc_cmmb_RetainedEarningsAccumulatedDeficits_90"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_SecuritiesPurchaseAgreementsForOfferingAndSaleByAnchianoMember" xlink:label="loc_cmmb_SecuritiesPurchaseAgreementsForOfferingAndSaleByAnchianoMember_91"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_SecuritiesPurchaseAgreementsForOfferingAndSaleByAnchianoMember" xlink:label="loc_cmmb_SecuritiesPurchaseAgreementsForOfferingAndSaleByAnchianoMember_92"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_ShareholdingPercentageImmediatelyFollowingMerger" xlink:label="loc_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_93"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_ShareholdingPercentageImmediatelyFollowingMerger" xlink:label="loc_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_94"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_SharesConvertiblePerShareOfAcquireeEntity" xlink:label="loc_cmmb_SharesConvertiblePerShareOfAcquireeEntity_95"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_SharesConvertiblePerShareOfAcquireeEntity" xlink:label="loc_cmmb_SharesConvertiblePerShareOfAcquireeEntity_96"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_SharesConvertiblePerShareOfAcquireeEntity" xlink:label="loc_cmmb_SharesConvertiblePerShareOfAcquireeEntity_97"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_StockAndWarrantIssuedDuringPeriodNewIssues" xlink:label="loc_cmmb_StockAndWarrantIssuedDuringPeriodNewIssues_98"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_StockAndWarrantIssuedDuringPeriodNewIssues" xlink:label="loc_cmmb_StockAndWarrantIssuedDuringPeriodNewIssues_99"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_StockAndWarrantIssuedDuringPeriodNewIssues" xlink:label="loc_cmmb_StockAndWarrantIssuedDuringPeriodNewIssues_100"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues" xlink:label="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_101"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues" xlink:label="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_102"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues" xlink:label="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_103"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_TwoThousandFifteenPlanMember" xlink:label="loc_cmmb_TwoThousandFifteenPlanMember_104"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_TwoThousandFifteenPlanMember" xlink:label="loc_cmmb_TwoThousandFifteenPlanMember_105"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_TwoThousandFifteenPlanMember" xlink:label="loc_cmmb_TwoThousandFifteenPlanMember_106"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_WarrantsExercisablePeriod" xlink:label="loc_cmmb_WarrantsExercisablePeriod_107"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_WarrantsExercisablePeriod" xlink:label="loc_cmmb_WarrantsExercisablePeriod_108"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_WarrantsExercisablePeriod" xlink:label="loc_cmmb_WarrantsExercisablePeriod_109"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_110"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_111"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_112"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_113"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_114"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_115"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_116"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_117"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_118"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_119"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_120"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_121"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_122"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_123"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_124"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_125"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_126"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_127"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_128"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_129"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_130"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_131"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_132"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_133"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_134"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_135"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_136"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_137"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_138"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_139"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_140"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_141"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_142"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_143"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_144"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_145"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_146"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_147"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_148"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_149"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_150"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_151"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_152"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_153"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_154"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_155"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_156"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_157"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_158"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="loc_dei_EntityInformationFormerLegalOrRegisteredName_159"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_160"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_161"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_162"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_163"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_164"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_165"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_dei_NoTradingSymbolFlag_166"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_167"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_168"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_169"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_170"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_171"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_172"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_173"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_174"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_175"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_176"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_177"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_178"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_179"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_180"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_181"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_182"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_183"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_184"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_185"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_186"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_187"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_188"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_189"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_190"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_191"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_192"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_193"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_194"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_195"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Capital" xlink:label="loc_us-gaap_Capital_196"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_197"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_198"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_199"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_200"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_201"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_202"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_203"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_204"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_205"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_206"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_207"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNoParValue" xlink:label="loc_us-gaap_CommonStockNoParValue_208"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_209"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_210"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_211"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_212"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_213"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_214"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaap_DepositsAssetsCurrent_215"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent_216"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_217"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_218"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_219"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_220"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_221"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_222"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_223"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_224"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_225"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_226"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_227"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_228"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_229"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_230"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_231"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_232"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_233"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_234"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_235"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_236"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_237"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_238"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_239"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_240"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_241"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_242"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_243"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_244"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_245"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_246"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_247"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_248"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_249"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_250"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_251"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_252"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_253"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_254"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_255"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_256"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_257"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_258"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_259"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_260"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_261"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_262"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="loc_us-gaap_ProceedsFromOtherEquity_263"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="loc_us-gaap_ProceedsFromOtherEquity_264"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyHeldForSale" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyHeldForSale_265"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyHeldForSale" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyHeldForSale_266"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_267"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_268"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_269"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_270"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_271"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_272"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_273"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_274"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_275"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_276"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_277"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_278"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_279"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_280"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_281"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_282"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_283"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_284"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_285"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_286"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_287"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_288"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_289"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_290"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_291"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_292"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_293"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_294"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_295"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_296"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_297"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_298"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_299"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_300"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_301"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_302"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_303"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_304"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_305"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_306"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_307"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_308"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_309"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_310"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_311"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_312"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_313"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_314"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_315"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_316"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_317"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_318"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_319"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_320"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_321"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_322"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_323"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_324"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_325"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_326"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_327"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_328"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_AccountReceivableDueToExerciseOfOptions_0" xml:lang="en-US">Represent the amount of account receivable due to exercise of options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_AccountReceivableDueToExerciseOfOptions_1" xml:lang="en-US">Account Receivable Due To Exercise Of Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_AccountReceivableDueToExerciseOfOptions_2" xml:lang="en-US">Account receivable Due to Exercise of Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_AccountReceivableDueToExerciseOfOptions_3" xml:lang="en-US">Receivable related to exercise of options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_AccruedShareIssuanceExpenses_0" xml:lang="en-US">The amount of accrued issuance expenses non-cash investing and financing activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_AccruedShareIssuanceExpenses_1" xml:lang="en-US">Accrued share issuance expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_AmericanDepositarySharesMember_0" xml:lang="en-US">American Depositary Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_AmericanDepositarySharesMember_1" xml:lang="en-US">American Depositary Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_AmericanDepositorySharesMember_0" xml:lang="en-US">This member stands for American Depository Shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_AmericanDepositorySharesMember_1" xml:lang="en-US">American Depository Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_AmericanDepositorySharesMember_2" xml:lang="en-US">American Depositary Share ("ADS") [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_AmountOfTotalSaleAndTransferOfCompoundsAndProductsKestrelPaid_0" xml:lang="en-US">Represents the amount of total sale and transfer of compounds and products kestrel paid.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_AmountOfTotalSaleAndTransferOfCompoundsAndProductsKestrelPaid_1" xml:lang="en-US">Amount Of Total Sale And Transfer Of Compounds And Products Kestrel Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_AmountOfTotalSaleAndTransferOfCompoundsAndProductsKestrelPaid_2" xml:lang="en-US">Amount of total sale and transfer of compounds and products kestrel paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_AtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember_0" xml:lang="en-US">This member stands for At the Market Offering Agreement with Cantor Fitzgerald &amp; Co.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_AtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember_1" xml:lang="en-US">At Market Offering Agreement With Cantor Fitzgerald And Co [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_AtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember_2" xml:lang="en-US">At The Market Offering Agreement With Cantor Fitzgerald &amp; Co. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_0" xml:lang="en-US">The amount of of asset held for sale recogized prior to the completion of merger.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_1" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Asset Held For Sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_2" xml:lang="en-US">Asset held for sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_0" xml:lang="en-US">Amount of accrued liabilities to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_1" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accrued Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_2" xml:lang="en-US">Accrued liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_CashAcquiredInReverseRecapitalization_0" xml:lang="en-US">represents cash acquired from acquisition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_CashAcquiredInReverseRecapitalization_1" xml:lang="en-US">Cash acquired in reverse recapitalization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_CashAcquiredInReverseRecapitalization_2" xml:lang="en-US">Cash acquired in reverse recapitalization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_DrFrostMember_0" xml:lang="en-US">Dr. Frost [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_DrFrostMember_1" xml:lang="en-US">Dr. Frost [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_EffectOfReverseCapitalizationTransaction_0" xml:lang="en-US">The amount of effect due reverse capitalization transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_EffectOfReverseCapitalizationTransaction_1" xml:lang="en-US">Effect of reverse capitalization transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_EffectOfReverseCapitalizationTransactionShares_0" xml:lang="en-US">The number of shares isued due to effect of reverse capitalization transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_EffectOfReverseCapitalizationTransactionShares_1" xml:lang="en-US">Effect Of Reverse Capitalization Transaction Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_EffectOfReverseCapitalizationTransactionShares_2" xml:lang="en-US">Effect of reverse capitalization transaction (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_EstimatedFairValueOfNetAssetsAcquired_0" xml:lang="en-US">The amount of estimated fair value of the net assets acquired.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_EstimatedFairValueOfNetAssetsAcquired_1" xml:lang="en-US">Estimated Fair Value Of Net Assets Acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_EstimatedFairValueOfNetAssetsAcquired_2" xml:lang="en-US">Net acquired assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_FinanceIncomeExpensesNet_0" xml:lang="en-US">The net amount of finance income earned and finance expenses incurred during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cmmb_FinanceIncomeExpensesNet_1" xml:lang="en-US">Financing expense, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_FinanceIncomeExpensesNet_2" xml:lang="en-US">Finance Income Expenses Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_FinanceIncomeExpensesNet_3" xml:lang="en-US">Financing expenses (income), net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_FormerChemomabSecurityHoldersMember_0" xml:lang="en-US">This represents former Chemomab security holders.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_FormerChemomabSecurityHoldersMember_1" xml:lang="en-US">Former Chemomab Security Holders [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_IssuanceOfSharesNetOfIssuanceCosts_0" xml:lang="en-US">Issuance of shares net, of issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_IssuanceOfSharesNetOfIssuanceCosts_1" xml:lang="en-US">Issuance Of Shares Net Of Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_IssuanceOfSharesNetOfIssuanceCosts_2" xml:lang="en-US">Issuance of shares net, of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_IssuanceOfSharesNetOfIssuanceCosts_3" xml:lang="en-US">Issuance of shares, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_LiabilitiesAssumedNetOfNonCashAssetsReceivedInReverseMerger_0" xml:lang="en-US">The amount of liabilities assumed, net of non-cash assets received in reverse merger.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_LiabilitiesAssumedNetOfNonCashAssetsReceivedInReverseMerger_1" xml:lang="en-US">Liabilities Assumed Net Of Non Cash Assets Received In Reverse Merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_LiabilitiesAssumedNetOfNonCashAssetsReceivedInReverseMerger_2" xml:lang="en-US">Liabilities assumed, net of non-cash assets received in reverse merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_MergerAgreementWithChemomabIsraeliLimitedCompanyAndClinicalStageBiotechCompanyMember_0" xml:lang="en-US">This represents Merger Agreement with Chemomab, an Israeli limited company and a clinical-stage biotech company inclued proposed merger of CMB Acquisition Ltd, wholly owned subsidiary of our company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_MergerAgreementWithChemomabIsraeliLimitedCompanyAndClinicalStageBiotechCompanyMember_1" xml:lang="en-US">Merger Agreement With Chemomab Israeli Limited Company And Clinical Stage Biotech Company [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_MergerAgreementWithChemomabIsraeliLimitedCompanyAndClinicalStageBiotechCompanyMember_2" xml:lang="en-US">Merger agreement with Chemomab, an Israeli limited company and a clinical-stage biotech company [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_MrMarvinMember_0" xml:lang="en-US">Mr. Marvin [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_MrMarvinMember_1" xml:lang="en-US">Mr. Marvin [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_NatureOfOperationsDisclosureAbstract_0" xml:lang="en-US">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_NatureOfOperationsDisclosureAbstract_1" xml:lang="en-US">Nature Of Operations Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_0" xml:lang="en-US">Number of ADS issued and outstanding after the merger.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_1" xml:lang="en-US">Number of ADS issued and outstanding after the merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_NumberOfOrdinarySharesConsistedInDS_0" xml:lang="en-US">Represent the number of ordinary shares consisted in one American depository share (ADS).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_NumberOfOrdinarySharesConsistedInDS_1" xml:lang="en-US">Number Of Ordinary Shares Consisted In D S</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_NumberOfOrdinarySharesConsistedInDS_2" xml:lang="en-US">Number of ordinary shares represented by each ADS (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_NumberOfOrdinarySharesForEachPreferredShareConvertedPriorToDateOfMerger_0" xml:lang="en-US">Number of shares of common stock for each preferred share converted before merger.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_NumberOfOrdinarySharesForEachPreferredShareConvertedPriorToDateOfMerger_1" xml:lang="en-US">Number Of Ordinary Shares For Each Preferred Share Converted Prior To Date Of Merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_NumberOfOrdinarySharesForEachPreferredShareConvertedPriorToDateOfMerger_2" xml:lang="en-US">Number of common shares for each preferred share converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_NumberOfSharesDilutedAfterMerger_0" xml:lang="en-US">The number of shares diluted after the merger.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_NumberOfSharesDilutedAfterMerger_1" xml:lang="en-US">Number of shares diluted after the merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_OneEmployeeOneOfficerConsultantAndSixBoardMember_0" xml:lang="en-US">One employee one officer consultant and six Board [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_OneEmployeeOneOfficerConsultantAndSixBoardMember_1" xml:lang="en-US">One Employee One Officer Consultant And Six Board [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_OneEmployeeOneOfficerConsultantAndSixBoardMember_2" xml:lang="en-US">One employee one officer consultant and six Board [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_OrdinarySharesMember_0" xml:lang="en-US">Ordinary Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_OrdinarySharesMember_1" xml:lang="en-US">Ordinary Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_OrdinarySharesNoParValuePerShareMember_0" xml:lang="en-US">Ordinary Shares, No Par Value Per Share [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_OrdinarySharesNoParValuePerShareMember_1" xml:lang="en-US">Ordinary Shares, No Par Value Per Share [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_PaymentsForInvestmentInDeposits_0" xml:lang="en-US">The amount of payments for investm,ents in deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cmmb_PaymentsForInvestmentInDeposits_1" xml:lang="en-US">Investment in bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_PaymentsForInvestmentInDeposits_2" xml:lang="en-US">Payments for Investment in Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_PaymentsToPurchaseOfDeposits_0" xml:lang="en-US">The cash outflow to purchase of deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cmmb_PaymentsToPurchaseOfDeposits_1" xml:lang="en-US">Increase in deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_PaymentsToPurchaseOfDeposits_2" xml:lang="en-US">Payments To Purchase Of Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ProceedsFromInvestmentInDepositsInvestingActivities_0" xml:lang="en-US">Represents the proceeds from investment in deposits, investing activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ProceedsFromInvestmentInDepositsInvestingActivities_1" xml:lang="en-US">Proceeds From Investment In Deposits Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_ProceedsFromInvestmentInDepositsInvestingActivities_2" xml:lang="en-US">Investment in deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ProceedsFromReceivablesOnAccountOfShares_0" xml:lang="en-US">The amount of receivables on account of shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ProceedsFromReceivablesOnAccountOfShares_1" xml:lang="en-US">Proceeds from receivables on account of shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ProceedsFromSaleOfDeposits_0" xml:lang="en-US">The cash inflow from the sale of deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ProceedsFromSaleOfDeposits_1" xml:lang="en-US">Proceeds From Sale Of Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_ProceedsFromSaleOfDeposits_2" xml:lang="en-US">Decrease in deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_RetainedEarningsAccumulatedDeficits_0" xml:lang="en-US">The cumulative amount of the reporting entity's undistributed earnings or deficits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cmmb_RetainedEarningsAccumulatedDeficits_1" xml:lang="en-US">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_RetainedEarningsAccumulatedDeficits_2" xml:lang="en-US">Retained Earnings Accumulated Deficits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_SecuritiesPurchaseAgreementsForOfferingAndSaleByAnchianoMember_0" xml:lang="en-US">Represent sthe information pertaining to Securities Purchase Agreements with certain purchasers for the offering and sale by Anchiano .</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_SecuritiesPurchaseAgreementsForOfferingAndSaleByAnchianoMember_1" xml:lang="en-US">Securities Purchase Agreements for the offering and sale by Anchiano [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_0" xml:lang="en-US">shareholding percentage immediately following the merger.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_1" xml:lang="en-US">Shareholding percentage immediately following the merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_SharesConvertiblePerShareOfAcquireeEntity_0" xml:lang="en-US">Represents the shares convertible in merger.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_SharesConvertiblePerShareOfAcquireeEntity_1" xml:lang="en-US">Shares Convertible Per Share Of Acquiree Entity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_SharesConvertiblePerShareOfAcquireeEntity_2" xml:lang="en-US">Number of shares after merger for each share of Chemomab</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_StockAndWarrantIssuedDuringPeriodNewIssues_0" xml:lang="en-US">it represents number of shares and warrants issued during period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_StockAndWarrantIssuedDuringPeriodNewIssues_1" xml:lang="en-US">Stock And Warrant Issued During Period New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_StockAndWarrantIssuedDuringPeriodNewIssues_2" xml:lang="en-US">Issuance of shares and warrants, net of issuance costs (In shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_0" xml:lang="en-US">Value of stock issued in lieu contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_1" xml:lang="en-US">Stock And Warrants Issued During Period Value New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_2" xml:lang="en-US">Issuance of shares and warrants, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_TwoThousandFifteenPlanMember_0" xml:lang="en-US">2015 Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_TwoThousandFifteenPlanMember_1" xml:lang="en-US">Two Thousand Fifteen Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_TwoThousandFifteenPlanMember_2" xml:lang="en-US">2015 Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_WarrantsExercisablePeriod_0" xml:lang="en-US">Represent the warrants exercisable period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_WarrantsExercisablePeriod_1" xml:lang="en-US">Warrants exercisable period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_WarrantsExercisablePeriod_2" xml:lang="en-US">Warrants exercisable period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_0" xml:lang="en-US">Taxes Expenses (Income)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_1" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_2" xml:lang="en-US">Taxes Expenses (Income)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_3" xml:lang="en-US">Taxes on income (benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0" xml:lang="en-US">Change in other receivables and prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0" xml:lang="en-US">Purchase of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0" xml:lang="en-US">Loss before taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2" xml:lang="en-US">Loss before taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_NetIncomeLoss_0" xml:lang="en-US">Net loss for the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss_1" xml:lang="en-US">Net loss for the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss_2" xml:lang="en-US">Net loss for the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_OperatingExpenses_0" xml:lang="en-US">Total operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses_1" xml:lang="en-US">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses_2" xml:lang="en-US">Total operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesOutstanding_0" xml:lang="en-US">Ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesOutstanding_1" xml:lang="en-US">Beginning balance (In shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesOutstanding_2" xml:lang="en-US">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity_0" xml:lang="en-US">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity_1" xml:lang="en-US">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity_2" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity_3" xml:lang="en-US">Total shareholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag_0" xml:lang="en-US">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode_0" xml:lang="en-US">City Area Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate_0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus_0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus_0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate_0" xml:lang="en-US">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentQuarterlyReport_0" xml:lang="en-US">Document Quarterly Report</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentTransitionReport_0" xml:lang="en-US">Document Transition Report</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType_0" xml:lang="en-US">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1_0" xml:lang="en-US">Entity Address, Address Line One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine2_0" xml:lang="en-US">Entity Address, Address Line Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown_0" xml:lang="en-US">Entity Address, City or Town</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCountry_0" xml:lang="en-US">Entity Address, Country</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode_0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey_0" xml:lang="en-US">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCurrentReportingStatus_0" xml:lang="en-US">Entity Current Reporting Status</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany_0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityExTransitionPeriod_0" xml:lang="en-US">Entity Ex Transition Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFileNumber_0" xml:lang="en-US">Entity File Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory_0" xml:lang="en-US">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode_0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityInformationFormerLegalOrRegisteredName_0" xml:lang="en-US">Entity Information, Former Legal or Registered Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityInteractiveDataCurrent_0" xml:lang="en-US">Entity Interactive Data Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName_0" xml:lang="en-US">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityShellCompany_0" xml:lang="en-US">Entity Shell Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness_0" xml:lang="en-US">Entity Small Business</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityTaxIdentificationNumber_0" xml:lang="en-US">Entity Tax Identification Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber_0" xml:lang="en-US">Local Phone Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_NoTradingSymbolFlag_0" xml:lang="en-US">No Trading Symbol Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_Security12bTitle_0" xml:lang="en-US">Title of 12(b) Security</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_SecurityExchangeName_0" xml:lang="en-US">Name of Exchange on which Security is Registered</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol_0" xml:lang="en-US">Trading Symbol</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember_0" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember_0" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis_0" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualAxis_0" xml:lang="en-US">Title of Individual [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_0" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent_0" xml:lang="en-US">Trade payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_0" xml:lang="en-US">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapital_0" xml:lang="en-US">Additional paid in capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_0" xml:lang="en-US">Additional paid in capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_1" xml:lang="en-US">Adjustments for operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0" xml:lang="en-US">Adjustments for operating activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets_0" xml:lang="en-US">Assets [Default Label]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets_1" xml:lang="en-US">Total assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract_0" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent_0" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent_1" xml:lang="en-US">Total current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract_0" xml:lang="en-US">Current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsNoncurrent_0" xml:lang="en-US">Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsNoncurrent_1" xml:lang="en-US">Total non-current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract_0" xml:lang="en-US">Non-current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0" xml:lang="en-US">Basis of Preparation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_0" xml:lang="en-US">Business Acquisition [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_0" xml:lang="en-US">Prepaid and other assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Capital_0" xml:lang="en-US">Market capitalization amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1" xml:lang="en-US">Change in cash, cash equivalents and restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1" xml:lang="en-US">Warrant exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies_0" xml:lang="en-US">Commitments and contingent liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" xml:lang="en-US">Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember_0" xml:lang="en-US">Ordinary shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockNoParValue_0" xml:lang="en-US">Common Stock, No Par Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued_0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_0" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue_0" xml:lang="en-US">Ordinary shares no par value - Authorized: 650,000,000 shares as of September 30, 2021 and 500,000,000 shares as of December 31, 2020; Issued and outstanding: 227,956,060 ordinary shares at September 30, 2021 and 9,274,838 ordinary shares at December 31, 2020</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValue_1" xml:lang="en-US">Ordinary shares no par value - Authorized: 650,000,000 shares as of March 31, 2022 and as of December 31, 2021; Issued and outstanding: 228,090,300 ordinary shares at March 31, 2022 as of December 31, 2021</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockValue_2" xml:lang="en-US">Ordinary shares no par value - Authorized: 650,000,000 shares as of June 30, 2022 and as of December 31, 2021; Issued and outstanding: 228,633,120 ordinary shares as of June 30, 2022 and 228,090,300 as of December 31, 2021</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepositsAssetsCurrent_0" xml:lang="en-US">Short term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepositsAssetsNoncurrent_0" xml:lang="en-US">Long term deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation_0" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic_0" xml:lang="en-US">Basic and diluted loss per Ordinary Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic_1" xml:lang="en-US">Basic loss per Ordinary Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted_0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted_1" xml:lang="en-US">Diluted loss per Ordinary Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_0" xml:lang="en-US">Employee and related expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_0" xml:lang="en-US">General and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract_0" xml:lang="en-US">Income Statement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_0" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_1" xml:lang="en-US">Taxes on Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_0" xml:lang="en-US">Change in trade payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_0" xml:lang="en-US">Change in accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_0" xml:lang="en-US">Change in employees and related expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_0" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_1" xml:lang="en-US">Change in operating lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_2" xml:lang="en-US">Change in operating lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities_0" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities_1" xml:lang="en-US">Total liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_0" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_1" xml:lang="en-US">Total liabilities and shareholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS' EQUITY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent_0" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent_1" xml:lang="en-US">Total current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_0" xml:lang="en-US">Current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrent_0" xml:lang="en-US">Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesNoncurrent_1" xml:lang="en-US">Total non-current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract_0" xml:lang="en-US">Non-current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NatureOfOperations_0" xml:lang="en-US">Nature of Operations [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NatureOfOperations_1" xml:lang="en-US">General.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1" xml:lang="en-US">Net cash provided by financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0" xml:lang="en-US">Cash flows from financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1" xml:lang="en-US">Net cash provided by (used in) investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0" xml:lang="en-US">Cash flows from investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xml:lang="en-US">Net cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0" xml:lang="en-US">Cash flows from operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract_0" xml:lang="en-US">Operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_0" xml:lang="en-US">Operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_0" xml:lang="en-US">Operating lease liabilities - long term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_0" xml:lang="en-US">Operating lease right-of-use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis_0" xml:lang="en-US">Plan Name [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0" xml:lang="en-US">Other receivables and prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseNoncurrent_0" xml:lang="en-US">Long term prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromOtherEquity_0" xml:lang="en-US">Proceeds from Other Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromOtherEquity_1" xml:lang="en-US">Issuance of shares and warrants, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyHeldForSale_0" xml:lang="en-US">Proceeds from Sale of Property Held-for-sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyHeldForSale_1" xml:lang="en-US">Sale of asset held for sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_0" xml:lang="en-US">Exercise of options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_1" xml:lang="en-US">Exercise of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_2" xml:lang="en-US">Exercise of options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_0" xml:lang="en-US">Proceeds from Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_1" xml:lang="en-US">Proceeds from exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfitLoss_0" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProfitLoss_1" xml:lang="en-US">Net loss for the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_0" xml:lang="en-US">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_0" xml:lang="en-US">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashNoncurrent_0" xml:lang="en-US">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems_0" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0" xml:lang="en-US">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember_0" xml:lang="en-US">Accumulated deficit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_0" xml:lang="en-US">Aggregate offering price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_0" xml:lang="en-US">Gross proceeds from sale under agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0" xml:lang="en-US">Shares issued under agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_0" xml:lang="en-US">Average price of shares issued under agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_0" xml:lang="en-US">Schedule of net assets acquired based on their estimated fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation_0" xml:lang="en-US">Share-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation_1" xml:lang="en-US">Share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0" xml:lang="en-US">Share based payment options vesting period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0" xml:lang="en-US">Dividend yield</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0" xml:lang="en-US">Expected term (years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0" xml:lang="en-US">Expected volatility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0" xml:lang="en-US">Risk-free interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_0" xml:lang="en-US">Number of shares authorized, increase</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0" xml:lang="en-US">Options to purchase ADs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Exercise price per ADs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1" xml:lang="en-US">Value of ADS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis_0" xml:lang="en-US">Class of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_0" xml:lang="en-US">Equity Components [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems_0" xml:lang="en-US">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_0" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_0" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable_0" xml:lang="en-US">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_0" xml:lang="en-US">Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_1" xml:lang="en-US">Isuuance and sale value of ADSs and warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0" xml:lang="en-US">Shareholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_0" xml:lang="en-US">Reverse stock split conversion ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0" xml:lang="en-US">Option to purchase shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0" xml:lang="en-US">Issuance of shares, net of issuance costs, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1" xml:lang="en-US">Issuance of shares, net of issuance costs (In shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1" xml:lang="en-US">Exercise of Options (In shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_0" xml:lang="en-US">Issuance of shares, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0" xml:lang="en-US">Share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0" xml:lang="en-US">Exercise of Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventLineItems_0" xml:lang="en-US">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract_0" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_0" xml:lang="en-US">Subsequent Events</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTable_0" xml:lang="en-US">Subsequent Event [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_0" xml:lang="en-US">Sale of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfArrangementAxis_0" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates_0" xml:lang="en-US">Use of estimates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1" xml:lang="en-US">Weighted average number of Ordinary Shares outstanding, diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0" xml:lang="en-US">Weighted average number of Ordinary Shares outstanding, basic, and diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1" xml:lang="en-US">Weighted average number of Ordinary Shares outstanding, basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AccountReceivableDueToExerciseOfOptions_1" xlink:to="lab_cmmb_AccountReceivableDueToExerciseOfOptions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AccountReceivableDueToExerciseOfOptions_2" xlink:to="lab_cmmb_AccountReceivableDueToExerciseOfOptions_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AccountReceivableDueToExerciseOfOptions_3" xlink:to="lab_cmmb_AccountReceivableDueToExerciseOfOptions_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AccountReceivableDueToExerciseOfOptions_4" xlink:to="lab_cmmb_AccountReceivableDueToExerciseOfOptions_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AccruedShareIssuanceExpenses_5" xlink:to="lab_cmmb_AccruedShareIssuanceExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AccruedShareIssuanceExpenses_6" xlink:to="lab_cmmb_AccruedShareIssuanceExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AmericanDepositarySharesMember_7" xlink:to="lab_cmmb_AmericanDepositarySharesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AmericanDepositarySharesMember_8" xlink:to="lab_cmmb_AmericanDepositarySharesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AmericanDepositorySharesMember_9" xlink:to="lab_cmmb_AmericanDepositorySharesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AmericanDepositorySharesMember_10" xlink:to="lab_cmmb_AmericanDepositorySharesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AmericanDepositorySharesMember_11" xlink:to="lab_cmmb_AmericanDepositorySharesMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AmountOfTotalSaleAndTransferOfCompoundsAndProductsKestrelPaid_12" xlink:to="lab_cmmb_AmountOfTotalSaleAndTransferOfCompoundsAndProductsKestrelPaid_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AmountOfTotalSaleAndTransferOfCompoundsAndProductsKestrelPaid_13" xlink:to="lab_cmmb_AmountOfTotalSaleAndTransferOfCompoundsAndProductsKestrelPaid_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AmountOfTotalSaleAndTransferOfCompoundsAndProductsKestrelPaid_14" xlink:to="lab_cmmb_AmountOfTotalSaleAndTransferOfCompoundsAndProductsKestrelPaid_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember_15" xlink:to="lab_cmmb_AtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember_16" xlink:to="lab_cmmb_AtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember_17" xlink:to="lab_cmmb_AtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_18" xlink:to="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_19" xlink:to="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_20" xlink:to="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_21" xlink:to="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_22" xlink:to="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_23" xlink:to="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CashAcquiredInReverseRecapitalization_24" xlink:to="lab_cmmb_CashAcquiredInReverseRecapitalization_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CashAcquiredInReverseRecapitalization_25" xlink:to="lab_cmmb_CashAcquiredInReverseRecapitalization_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CashAcquiredInReverseRecapitalization_26" xlink:to="lab_cmmb_CashAcquiredInReverseRecapitalization_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_DrFrostMember_27" xlink:to="lab_cmmb_DrFrostMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_DrFrostMember_28" xlink:to="lab_cmmb_DrFrostMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EffectOfReverseCapitalizationTransaction_29" xlink:to="lab_cmmb_EffectOfReverseCapitalizationTransaction_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EffectOfReverseCapitalizationTransaction_30" xlink:to="lab_cmmb_EffectOfReverseCapitalizationTransaction_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_31" xlink:to="lab_cmmb_EffectOfReverseCapitalizationTransactionShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_32" xlink:to="lab_cmmb_EffectOfReverseCapitalizationTransactionShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_33" xlink:to="lab_cmmb_EffectOfReverseCapitalizationTransactionShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_34" xlink:to="lab_cmmb_EstimatedFairValueOfNetAssetsAcquired_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_35" xlink:to="lab_cmmb_EstimatedFairValueOfNetAssetsAcquired_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_36" xlink:to="lab_cmmb_EstimatedFairValueOfNetAssetsAcquired_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_FinanceIncomeExpensesNet_37" xlink:to="lab_cmmb_FinanceIncomeExpensesNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_FinanceIncomeExpensesNet_38" xlink:to="lab_cmmb_FinanceIncomeExpensesNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_FinanceIncomeExpensesNet_39" xlink:to="lab_cmmb_FinanceIncomeExpensesNet_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_FinanceIncomeExpensesNet_40" xlink:to="lab_cmmb_FinanceIncomeExpensesNet_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_FormerChemomabSecurityHoldersMember_41" xlink:to="lab_cmmb_FormerChemomabSecurityHoldersMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_FormerChemomabSecurityHoldersMember_42" xlink:to="lab_cmmb_FormerChemomabSecurityHoldersMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IssuanceOfSharesNetOfIssuanceCosts_43" xlink:to="lab_cmmb_IssuanceOfSharesNetOfIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IssuanceOfSharesNetOfIssuanceCosts_44" xlink:to="lab_cmmb_IssuanceOfSharesNetOfIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IssuanceOfSharesNetOfIssuanceCosts_45" xlink:to="lab_cmmb_IssuanceOfSharesNetOfIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IssuanceOfSharesNetOfIssuanceCosts_46" xlink:to="lab_cmmb_IssuanceOfSharesNetOfIssuanceCosts_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_LiabilitiesAssumedNetOfNonCashAssetsReceivedInReverseMerger_47" xlink:to="lab_cmmb_LiabilitiesAssumedNetOfNonCashAssetsReceivedInReverseMerger_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_LiabilitiesAssumedNetOfNonCashAssetsReceivedInReverseMerger_48" xlink:to="lab_cmmb_LiabilitiesAssumedNetOfNonCashAssetsReceivedInReverseMerger_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_LiabilitiesAssumedNetOfNonCashAssetsReceivedInReverseMerger_49" xlink:to="lab_cmmb_LiabilitiesAssumedNetOfNonCashAssetsReceivedInReverseMerger_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_MergerAgreementWithChemomabIsraeliLimitedCompanyAndClinicalStageBiotechCompanyMember_50" xlink:to="lab_cmmb_MergerAgreementWithChemomabIsraeliLimitedCompanyAndClinicalStageBiotechCompanyMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_MergerAgreementWithChemomabIsraeliLimitedCompanyAndClinicalStageBiotechCompanyMember_51" xlink:to="lab_cmmb_MergerAgreementWithChemomabIsraeliLimitedCompanyAndClinicalStageBiotechCompanyMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_MergerAgreementWithChemomabIsraeliLimitedCompanyAndClinicalStageBiotechCompanyMember_52" xlink:to="lab_cmmb_MergerAgreementWithChemomabIsraeliLimitedCompanyAndClinicalStageBiotechCompanyMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_MrMarvinMember_53" xlink:to="lab_cmmb_MrMarvinMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_MrMarvinMember_54" xlink:to="lab_cmmb_MrMarvinMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_55" xlink:to="lab_cmmb_NatureOfOperationsDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_56" xlink:to="lab_cmmb_NatureOfOperationsDisclosureAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_57" xlink:to="lab_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_58" xlink:to="lab_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfOrdinarySharesConsistedInDS_59" xlink:to="lab_cmmb_NumberOfOrdinarySharesConsistedInDS_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfOrdinarySharesConsistedInDS_60" xlink:to="lab_cmmb_NumberOfOrdinarySharesConsistedInDS_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfOrdinarySharesConsistedInDS_61" xlink:to="lab_cmmb_NumberOfOrdinarySharesConsistedInDS_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfOrdinarySharesForEachPreferredShareConvertedPriorToDateOfMerger_62" xlink:to="lab_cmmb_NumberOfOrdinarySharesForEachPreferredShareConvertedPriorToDateOfMerger_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfOrdinarySharesForEachPreferredShareConvertedPriorToDateOfMerger_63" xlink:to="lab_cmmb_NumberOfOrdinarySharesForEachPreferredShareConvertedPriorToDateOfMerger_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfOrdinarySharesForEachPreferredShareConvertedPriorToDateOfMerger_64" xlink:to="lab_cmmb_NumberOfOrdinarySharesForEachPreferredShareConvertedPriorToDateOfMerger_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfSharesDilutedAfterMerger_65" xlink:to="lab_cmmb_NumberOfSharesDilutedAfterMerger_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfSharesDilutedAfterMerger_66" xlink:to="lab_cmmb_NumberOfSharesDilutedAfterMerger_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_OneEmployeeOneOfficerConsultantAndSixBoardMember_67" xlink:to="lab_cmmb_OneEmployeeOneOfficerConsultantAndSixBoardMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_OneEmployeeOneOfficerConsultantAndSixBoardMember_68" xlink:to="lab_cmmb_OneEmployeeOneOfficerConsultantAndSixBoardMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_OneEmployeeOneOfficerConsultantAndSixBoardMember_69" xlink:to="lab_cmmb_OneEmployeeOneOfficerConsultantAndSixBoardMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_OrdinarySharesMember_70" xlink:to="lab_cmmb_OrdinarySharesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_OrdinarySharesMember_71" xlink:to="lab_cmmb_OrdinarySharesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_OrdinarySharesNoParValuePerShareMember_72" xlink:to="lab_cmmb_OrdinarySharesNoParValuePerShareMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_OrdinarySharesNoParValuePerShareMember_73" xlink:to="lab_cmmb_OrdinarySharesNoParValuePerShareMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PaymentsForInvestmentInDeposits_74" xlink:to="lab_cmmb_PaymentsForInvestmentInDeposits_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PaymentsForInvestmentInDeposits_75" xlink:to="lab_cmmb_PaymentsForInvestmentInDeposits_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PaymentsForInvestmentInDeposits_76" xlink:to="lab_cmmb_PaymentsForInvestmentInDeposits_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PaymentsToPurchaseOfDeposits_77" xlink:to="lab_cmmb_PaymentsToPurchaseOfDeposits_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PaymentsToPurchaseOfDeposits_78" xlink:to="lab_cmmb_PaymentsToPurchaseOfDeposits_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PaymentsToPurchaseOfDeposits_79" xlink:to="lab_cmmb_PaymentsToPurchaseOfDeposits_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ProceedsFromInvestmentInDepositsInvestingActivities_80" xlink:to="lab_cmmb_ProceedsFromInvestmentInDepositsInvestingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ProceedsFromInvestmentInDepositsInvestingActivities_81" xlink:to="lab_cmmb_ProceedsFromInvestmentInDepositsInvestingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ProceedsFromInvestmentInDepositsInvestingActivities_82" xlink:to="lab_cmmb_ProceedsFromInvestmentInDepositsInvestingActivities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ProceedsFromReceivablesOnAccountOfShares_83" xlink:to="lab_cmmb_ProceedsFromReceivablesOnAccountOfShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ProceedsFromReceivablesOnAccountOfShares_84" xlink:to="lab_cmmb_ProceedsFromReceivablesOnAccountOfShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ProceedsFromSaleOfDeposits_85" xlink:to="lab_cmmb_ProceedsFromSaleOfDeposits_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ProceedsFromSaleOfDeposits_86" xlink:to="lab_cmmb_ProceedsFromSaleOfDeposits_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ProceedsFromSaleOfDeposits_87" xlink:to="lab_cmmb_ProceedsFromSaleOfDeposits_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RetainedEarningsAccumulatedDeficits_88" xlink:to="lab_cmmb_RetainedEarningsAccumulatedDeficits_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RetainedEarningsAccumulatedDeficits_89" xlink:to="lab_cmmb_RetainedEarningsAccumulatedDeficits_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RetainedEarningsAccumulatedDeficits_90" xlink:to="lab_cmmb_RetainedEarningsAccumulatedDeficits_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SecuritiesPurchaseAgreementsForOfferingAndSaleByAnchianoMember_91" xlink:to="lab_cmmb_SecuritiesPurchaseAgreementsForOfferingAndSaleByAnchianoMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SecuritiesPurchaseAgreementsForOfferingAndSaleByAnchianoMember_92" xlink:to="lab_cmmb_SecuritiesPurchaseAgreementsForOfferingAndSaleByAnchianoMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_93" xlink:to="lab_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_94" xlink:to="lab_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SharesConvertiblePerShareOfAcquireeEntity_95" xlink:to="lab_cmmb_SharesConvertiblePerShareOfAcquireeEntity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SharesConvertiblePerShareOfAcquireeEntity_96" xlink:to="lab_cmmb_SharesConvertiblePerShareOfAcquireeEntity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SharesConvertiblePerShareOfAcquireeEntity_97" xlink:to="lab_cmmb_SharesConvertiblePerShareOfAcquireeEntity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockAndWarrantIssuedDuringPeriodNewIssues_98" xlink:to="lab_cmmb_StockAndWarrantIssuedDuringPeriodNewIssues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockAndWarrantIssuedDuringPeriodNewIssues_99" xlink:to="lab_cmmb_StockAndWarrantIssuedDuringPeriodNewIssues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockAndWarrantIssuedDuringPeriodNewIssues_100" xlink:to="lab_cmmb_StockAndWarrantIssuedDuringPeriodNewIssues_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_101" xlink:to="lab_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_102" xlink:to="lab_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_103" xlink:to="lab_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TwoThousandFifteenPlanMember_104" xlink:to="lab_cmmb_TwoThousandFifteenPlanMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TwoThousandFifteenPlanMember_105" xlink:to="lab_cmmb_TwoThousandFifteenPlanMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TwoThousandFifteenPlanMember_106" xlink:to="lab_cmmb_TwoThousandFifteenPlanMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_WarrantsExercisablePeriod_107" xlink:to="lab_cmmb_WarrantsExercisablePeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_WarrantsExercisablePeriod_108" xlink:to="lab_cmmb_WarrantsExercisablePeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_WarrantsExercisablePeriod_109" xlink:to="lab_cmmb_WarrantsExercisablePeriod_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_110" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_111" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_112" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_113" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_114" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_115" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_116" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_117" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_118" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_119" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_120" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_121" xlink:to="lab_us-gaap_NetIncomeLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_122" xlink:to="lab_us-gaap_NetIncomeLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_123" xlink:to="lab_us-gaap_NetIncomeLoss_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_124" xlink:to="lab_us-gaap_OperatingExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_125" xlink:to="lab_us-gaap_OperatingExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_126" xlink:to="lab_us-gaap_OperatingExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_127" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_128" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_129" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_130" xlink:to="lab_us-gaap_SharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_131" xlink:to="lab_us-gaap_SharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_132" xlink:to="lab_us-gaap_SharesOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_133" xlink:to="lab_us-gaap_StockholdersEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_134" xlink:to="lab_us-gaap_StockholdersEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_135" xlink:to="lab_us-gaap_StockholdersEquity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_136" xlink:to="lab_us-gaap_StockholdersEquity_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_137" xlink:to="lab_dei_AmendmentFlag_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_138" xlink:to="lab_dei_CityAreaCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_139" xlink:to="lab_dei_CurrentFiscalYearEndDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_140" xlink:to="lab_dei_DocumentFiscalPeriodFocus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_141" xlink:to="lab_dei_DocumentFiscalYearFocus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_142" xlink:to="lab_dei_DocumentPeriodEndDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport_143" xlink:to="lab_dei_DocumentQuarterlyReport_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport_144" xlink:to="lab_dei_DocumentTransitionReport_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_145" xlink:to="lab_dei_DocumentType_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_146" xlink:to="lab_dei_EntityAddressAddressLine1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2_147" xlink:to="lab_dei_EntityAddressAddressLine2_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_148" xlink:to="lab_dei_EntityAddressCityOrTown_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry_149" xlink:to="lab_dei_EntityAddressCountry_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_150" xlink:to="lab_dei_EntityAddressPostalZipCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_151" xlink:to="lab_dei_EntityCentralIndexKey_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_152" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_153" xlink:to="lab_dei_EntityCurrentReportingStatus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_154" xlink:to="lab_dei_EntityEmergingGrowthCompany_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod_155" xlink:to="lab_dei_EntityExTransitionPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_156" xlink:to="lab_dei_EntityFileNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_157" xlink:to="lab_dei_EntityFilerCategory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_158" xlink:to="lab_dei_EntityIncorporationStateCountryCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationFormerLegalOrRegisteredName_159" xlink:to="lab_dei_EntityInformationFormerLegalOrRegisteredName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent_160" xlink:to="lab_dei_EntityInteractiveDataCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_161" xlink:to="lab_dei_EntityRegistrantName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_162" xlink:to="lab_dei_EntityShellCompany_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_163" xlink:to="lab_dei_EntitySmallBusiness_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber_164" xlink:to="lab_dei_EntityTaxIdentificationNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_165" xlink:to="lab_dei_LocalPhoneNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_NoTradingSymbolFlag_166" xlink:to="lab_dei_NoTradingSymbolFlag_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_167" xlink:to="lab_dei_Security12bTitle_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_168" xlink:to="lab_dei_SecurityExchangeName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_169" xlink:to="lab_dei_TradingSymbol_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_170" xlink:to="lab_srt_MaximumMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_171" xlink:to="lab_srt_MinimumMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_172" xlink:to="lab_srt_RangeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis_173" xlink:to="lab_srt_TitleOfIndividualAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_174" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrent_175" xlink:to="lab_us-gaap_AccountsPayableTradeCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_176" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_177" xlink:to="lab_us-gaap_AdditionalPaidInCapital_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_178" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_179" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_180" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_181" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_182" xlink:to="lab_us-gaap_Assets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_183" xlink:to="lab_us-gaap_Assets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_184" xlink:to="lab_us-gaap_AssetsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_185" xlink:to="lab_us-gaap_AssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_186" xlink:to="lab_us-gaap_AssetsCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_187" xlink:to="lab_us-gaap_AssetsCurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent_188" xlink:to="lab_us-gaap_AssetsNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent_189" xlink:to="lab_us-gaap_AssetsNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_190" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_191" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_192" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_193" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_194" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_195" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Capital_196" xlink:to="lab_us-gaap_Capital_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_197" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_198" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_199" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_200" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_201" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_202" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_203" xlink:to="lab_us-gaap_CommitmentsAndContingencies_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_204" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_205" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_206" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_207" xlink:to="lab_us-gaap_CommonStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNoParValue_208" xlink:to="lab_us-gaap_CommonStockNoParValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_209" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_210" xlink:to="lab_us-gaap_CommonStockSharesIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_211" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_212" xlink:to="lab_us-gaap_CommonStockValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_213" xlink:to="lab_us-gaap_CommonStockValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_214" xlink:to="lab_us-gaap_CommonStockValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositsAssetsCurrent_215" xlink:to="lab_us-gaap_DepositsAssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositsAssetsNoncurrent_216" xlink:to="lab_us-gaap_DepositsAssetsNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_217" xlink:to="lab_us-gaap_Depreciation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_218" xlink:to="lab_us-gaap_EarningsPerShareBasic_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_219" xlink:to="lab_us-gaap_EarningsPerShareBasic_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_220" xlink:to="lab_us-gaap_EarningsPerShareDiluted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_221" xlink:to="lab_us-gaap_EarningsPerShareDiluted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_222" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_223" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_224" xlink:to="lab_us-gaap_IncomeStatementAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_225" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_226" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_227" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_228" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_229" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_230" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_231" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_232" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_233" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_234" xlink:to="lab_us-gaap_Liabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_235" xlink:to="lab_us-gaap_Liabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_236" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_237" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_238" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_239" xlink:to="lab_us-gaap_LiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_240" xlink:to="lab_us-gaap_LiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_241" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_242" xlink:to="lab_us-gaap_LiabilitiesNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_243" xlink:to="lab_us-gaap_LiabilitiesNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_244" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations_245" xlink:to="lab_us-gaap_NatureOfOperations_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations_246" xlink:to="lab_us-gaap_NatureOfOperations_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_247" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_248" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_249" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_250" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_251" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_252" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_253" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_254" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_255" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_256" xlink:to="lab_us-gaap_OperatingExpensesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_257" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_258" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_259" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_260" xlink:to="lab_us-gaap_PlanNameAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_261" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseNoncurrent_262" xlink:to="lab_us-gaap_PrepaidExpenseNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromOtherEquity_263" xlink:to="lab_us-gaap_ProceedsFromOtherEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromOtherEquity_264" xlink:to="lab_us-gaap_ProceedsFromOtherEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyHeldForSale_265" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyHeldForSale_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyHeldForSale_266" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyHeldForSale_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_267" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_268" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_269" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises_270" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises_271" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_272" xlink:to="lab_us-gaap_ProfitLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_273" xlink:to="lab_us-gaap_ProfitLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_274" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_275" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent_276" xlink:to="lab_us-gaap_RestrictedCashNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_277" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_278" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_279" xlink:to="lab_us-gaap_RetainedEarningsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_280" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_281" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_282" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare_283" xlink:to="lab_us-gaap_SaleOfStockPricePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_284" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_285" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_286" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_287" xlink:to="lab_us-gaap_ShareBasedCompensation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_288" xlink:to="lab_us-gaap_ShareBasedCompensation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_289" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_290" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_291" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_292" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_293" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_294" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_295" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_296" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_297" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_298" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_299" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_300" xlink:to="lab_us-gaap_StatementClassOfStockAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_301" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_302" xlink:to="lab_us-gaap_StatementLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_303" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_304" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_305" xlink:to="lab_us-gaap_StatementTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_306" xlink:to="lab_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_307" xlink:to="lab_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_308" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_309" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_310" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_311" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_312" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_313" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_314" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_315" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_316" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_317" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_318" xlink:to="lab_us-gaap_SubsequentEventLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_319" xlink:to="lab_us-gaap_SubsequentEventsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_320" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_321" xlink:to="lab_us-gaap_SubsequentEventTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_322" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_323" xlink:to="lab_us-gaap_TypeOfArrangementAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_324" xlink:to="lab_us-gaap_UseOfEstimates_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_325" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_326" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_327" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_328" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>cmmb-20220630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20220630.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20220630.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20220630.xsd#BalanceSheetsParenthetical" roleURI="http://www.anchiano.com/role/BalanceSheetsParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20220630.xsd#StatementUnauditedCondensedConsolidatedStatementsOfOperations" roleURI="http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20220630.xsd#InterimStatementsOfChangesInEquity" roleURI="http://www.anchiano.com/role/InterimStatementsOfChangesInEquity"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20220630.xsd#StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20220630.xsd#General." roleURI="http://www.anchiano.com/role/General."/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20220630.xsd#BasisOfPresentationAndSignificantAccountingPolicies" roleURI="http://www.anchiano.com/role/BasisOfPresentationAndSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20220630.xsd#BasisOfPresentationAndSignificantAccountingPoliciesPolicies" roleURI="http://www.anchiano.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20220630.xsd#General.Tables" roleURI="http://www.anchiano.com/role/General.Tables"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20220630.xsd#General.Details" roleURI="http://www.anchiano.com/role/General.Details"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20220630.xsd#General.-EstimatedFairValueOfAssetsAcquiredDetails" roleURI="http://www.anchiano.com/role/General.-EstimatedFairValueOfAssetsAcquiredDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20220630.xsd#Contingencies" roleURI="http://www.anchiano.com/role/Contingencies"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/DocumentDocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_AmericanDepositarySharesMember" xlink:label="loc_cmmb_AmericanDepositarySharesMember_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_OrdinarySharesNoParValuePerShareMember" xlink:label="loc_cmmb_OrdinarySharesNoParValuePerShareMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="loc_dei_EntityInformationFormerLegalOrRegisteredName_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_dei_NoTradingSymbolFlag_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_37"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1" xlink:to="loc_us-gaap_ClassOfStockDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_cmmb_AmericanDepositarySharesMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_cmmb_OrdinarySharesNoParValuePerShareMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_DocumentType_5" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_EntityCentralIndexKey_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_DocumentPeriodEndDate_7" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_CurrentFiscalYearEndDate_8" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_DocumentFiscalYearFocus_9" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_DocumentFiscalPeriodFocus_10" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_AmendmentFlag_11" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_DocumentQuarterlyReport_12" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_DocumentTransitionReport_13" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_EntityFileNumber_14" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_EntityRegistrantName_15" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_EntityIncorporationStateCountryCode_16" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_EntityTaxIdentificationNumber_17" order="120" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_EntityAddressAddressLine1_18" order="130" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_EntityAddressAddressLine2_19" order="140" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_EntityAddressCityOrTown_20" order="150" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_EntityAddressPostalZipCode_21" order="160" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_EntityAddressCountry_22" order="170" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_CityAreaCode_23" order="180" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_LocalPhoneNumber_24" order="190" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_EntityInformationFormerLegalOrRegisteredName_25" order="200" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_Security12bTitle_26" order="210" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_TradingSymbol_27" order="220" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_NoTradingSymbolFlag_28" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_SecurityExchangeName_29" order="240" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_EntityCurrentReportingStatus_30" order="250" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_EntityInteractiveDataCurrent_31" order="260" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_EntityFilerCategory_32" order="270" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_EntitySmallBusiness_33" order="280" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_EntityEmergingGrowthCompany_34" order="290" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_EntityExTransitionPeriod_35" order="300" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_EntityShellCompany_36" order="310" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_37" order="320" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaap_DepositsAssetsCurrent_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_31"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_AssetsAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_DepositsAssetsCurrent_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_AssetsCurrent_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_6" xlink:to="loc_us-gaap_DepositsAssetsNoncurrent_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_6" xlink:to="loc_us-gaap_PrepaidExpenseNoncurrent_7" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_6" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_9" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_6" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_10" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_6" xlink:to="loc_us-gaap_AssetsNoncurrent_11" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_Assets_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_15" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_15" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_16" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_17" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_18" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15" xlink:to="loc_us-gaap_LiabilitiesCurrent_19" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_21" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_21" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_21" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_21" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_22" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" xlink:to="loc_us-gaap_CommitmentsAndContingencies_24" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" xlink:to="loc_us-gaap_Liabilities_25" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_26" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_26" xlink:to="loc_us-gaap_CommonStockValue_26" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_26" xlink:to="loc_us-gaap_AdditionalPaidInCapital_27" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_26" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_28" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_26" xlink:to="loc_us-gaap_StockholdersEquity_29" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_31" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/BalanceSheetsParenthetical">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNoParValue" xlink:label="loc_us-gaap_CommonStockNoParValue_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockNoParValue_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4" order="30" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_3"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_FinanceIncomeExpensesNet" xlink:label="loc_cmmb_FinanceIncomeExpensesNet_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_12"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_OperatingExpenses_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_cmmb_FinanceIncomeExpensesNet_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NetIncomeLoss_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareBasic_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_12" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/InterimStatementsOfChangesInEquity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_12"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_EffectOfReverseCapitalizationTransaction" xlink:label="loc_cmmb_EffectOfReverseCapitalizationTransaction_13"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_EffectOfReverseCapitalizationTransactionShares" xlink:label="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_14"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues" xlink:label="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_15"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_StockAndWarrantIssuedDuringPeriodNewIssues" xlink:label="loc_cmmb_StockAndWarrantIssuedDuringPeriodNewIssues_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_19"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_CommonStockMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_RetainedEarningsMember_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_StockholdersEquity_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_SharesOutstanding_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_8" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_11" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_12" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_cmmb_EffectOfReverseCapitalizationTransaction_13" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_14" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_15" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_cmmb_StockAndWarrantIssuedDuringPeriodNewIssues_16" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_NetIncomeLoss_17" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_StockholdersEquity_18" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_SharesOutstanding_19" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_13"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_PaymentsToPurchaseOfDeposits" xlink:label="loc_cmmb_PaymentsToPurchaseOfDeposits_13"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_ProceedsFromSaleOfDeposits" xlink:label="loc_cmmb_ProceedsFromSaleOfDeposits_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyHeldForSale" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyHeldForSale_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_19"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_CashAcquiredInReverseRecapitalization" xlink:label="loc_cmmb_CashAcquiredInReverseRecapitalization_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_20"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_IssuanceOfSharesNetOfIssuanceCosts" xlink:label="loc_cmmb_IssuanceOfSharesNetOfIssuanceCosts_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="loc_us-gaap_ProceedsFromOtherEquity_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_28"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_LiabilitiesAssumedNetOfNonCashAssetsReceivedInReverseMerger" xlink:label="loc_cmmb_LiabilitiesAssumedNetOfNonCashAssetsReceivedInReverseMerger_28"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_AccountReceivableDueToExerciseOfOptions" xlink:label="loc_cmmb_AccountReceivableDueToExerciseOfOptions_29"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_AccruedShareIssuanceExpenses" xlink:label="loc_cmmb_AccruedShareIssuanceExpenses_30"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_ProfitLoss_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_Depreciation_2" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_5" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_6" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_7" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_ShareBasedCompensation_8" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_9" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_10" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_13" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_13" xlink:to="loc_cmmb_PaymentsToPurchaseOfDeposits_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_13" xlink:to="loc_cmmb_ProceedsFromSaleOfDeposits_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_13" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyHeldForSale_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_13" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_16" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_13" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_17" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_19" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_19" xlink:to="loc_cmmb_CashAcquiredInReverseRecapitalization_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_19" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_20" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_19" xlink:to="loc_cmmb_IssuanceOfSharesNetOfIssuanceCosts_21" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_19" xlink:to="loc_us-gaap_ProceedsFromOtherEquity_22" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_19" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_23" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_25" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_26" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_27" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_28" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_28" xlink:to="loc_cmmb_LiabilitiesAssumedNetOfNonCashAssetsReceivedInReverseMerger_28" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_28" xlink:to="loc_cmmb_AccountReceivableDueToExerciseOfOptions_29" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_28" xlink:to="loc_cmmb_AccruedShareIssuanceExpenses_30" order="20" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/General.">
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_NatureOfOperationsDisclosureAbstract" xlink:label="loc_cmmb_NatureOfOperationsDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_0" xlink:to="loc_us-gaap_NatureOfOperations_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/BasisOfPresentationAndSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_UseOfEstimates_2" order="10" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/General.Tables">
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_NatureOfOperationsDisclosureAbstract" xlink:label="loc_cmmb_NatureOfOperationsDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/General.Details">
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_NatureOfOperationsDisclosureAbstract" xlink:label="loc_cmmb_NatureOfOperationsDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_MergerAgreementWithChemomabIsraeliLimitedCompanyAndClinicalStageBiotechCompanyMember" xlink:label="loc_cmmb_MergerAgreementWithChemomabIsraeliLimitedCompanyAndClinicalStageBiotechCompanyMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_FormerChemomabSecurityHoldersMember" xlink:label="loc_cmmb_FormerChemomabSecurityHoldersMember_4"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_OneEmployeeOneOfficerConsultantAndSixBoardMember" xlink:label="loc_cmmb_OneEmployeeOneOfficerConsultantAndSixBoardMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_8"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_TwoThousandFifteenPlanMember" xlink:label="loc_cmmb_TwoThousandFifteenPlanMember_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_11"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_AmericanDepositorySharesMember" xlink:label="loc_cmmb_AmericanDepositorySharesMember_11"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_OrdinarySharesMember" xlink:label="loc_cmmb_OrdinarySharesMember_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_19"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_AtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember" xlink:label="loc_cmmb_AtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_22"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_ShareholdingPercentageImmediatelyFollowingMerger" xlink:label="loc_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_22"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_NumberOfOrdinarySharesForEachPreferredShareConvertedPriorToDateOfMerger" xlink:label="loc_cmmb_NumberOfOrdinarySharesForEachPreferredShareConvertedPriorToDateOfMerger_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_24"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_NumberOfOrdinarySharesConsistedInDS" xlink:label="loc_cmmb_NumberOfOrdinarySharesConsistedInDS_25"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger" xlink:label="loc_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_26"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_NumberOfSharesDilutedAfterMerger" xlink:label="loc_cmmb_NumberOfSharesDilutedAfterMerger_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Capital" xlink:label="loc_us-gaap_Capital_28"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_SharesConvertiblePerShareOfAcquireeEntity" xlink:label="loc_cmmb_SharesConvertiblePerShareOfAcquireeEntity_29"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_RetainedEarningsAccumulatedDeficits" xlink:label="loc_cmmb_RetainedEarningsAccumulatedDeficits_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_40"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_WarrantsExercisablePeriod" xlink:label="loc_cmmb_WarrantsExercisablePeriod_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_42"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_AmountOfTotalSaleAndTransferOfCompoundsAndProductsKestrelPaid" xlink:label="loc_cmmb_AmountOfTotalSaleAndTransferOfCompoundsAndProductsKestrelPaid_43"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" xlink:to="loc_cmmb_MergerAgreementWithChemomabIsraeliLimitedCompanyAndClinicalStageBiotechCompanyMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_4" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4" xlink:to="loc_cmmb_FormerChemomabSecurityHoldersMember_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4" xlink:to="loc_cmmb_OneEmployeeOneOfficerConsultantAndSixBoardMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1" xlink:to="loc_us-gaap_PlanNameAxis_8" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_8" xlink:to="loc_us-gaap_PlanNameDomain_8" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_8" xlink:to="loc_cmmb_TwoThousandFifteenPlanMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_11" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_11" xlink:to="loc_us-gaap_ClassOfStockDomain_11" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_11" xlink:to="loc_cmmb_AmericanDepositorySharesMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_11" xlink:to="loc_cmmb_OrdinarySharesMember_12" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1" xlink:to="loc_srt_RangeAxis_15" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_15" xlink:to="loc_srt_RangeMember_15" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_15" xlink:to="loc_srt_MinimumMember_15" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_15" xlink:to="loc_srt_MaximumMember_16" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_19" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_19" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_19" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_19" xlink:to="loc_cmmb_AtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_22" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_22" xlink:to="loc_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_22" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_22" xlink:to="loc_cmmb_NumberOfOrdinarySharesForEachPreferredShareConvertedPriorToDateOfMerger_23" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_22" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_24" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_22" xlink:to="loc_cmmb_NumberOfOrdinarySharesConsistedInDS_25" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_22" xlink:to="loc_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_26" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_22" xlink:to="loc_cmmb_NumberOfSharesDilutedAfterMerger_27" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_22" xlink:to="loc_us-gaap_Capital_28" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_22" xlink:to="loc_cmmb_SharesConvertiblePerShareOfAcquireeEntity_29" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_22" xlink:to="loc_cmmb_RetainedEarningsAccumulatedDeficits_30" order="80" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_31" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_32" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_33" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_22" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_34" order="120" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_22" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_35" order="130" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_22" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_36" order="140" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_22" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_37" order="150" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_38" order="160" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_22" xlink:to="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_39" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_22" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_40" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_22" xlink:to="loc_cmmb_WarrantsExercisablePeriod_41" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_22" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_42" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_22" xlink:to="loc_cmmb_AmountOfTotalSaleAndTransferOfCompoundsAndProductsKestrelPaid_43" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/General.-EstimatedFairValueOfAssetsAcquiredDetails">
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_NatureOfOperationsDisclosureAbstract" xlink:label="loc_cmmb_NatureOfOperationsDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale" xlink:label="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_3"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:label="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_4"/>
    <loc xlink:type="locator" xlink:href="cmmb-20220630.xsd#cmmb_EstimatedFairValueOfNetAssetsAcquired" xlink:label="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_0" xlink:to="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_0" xlink:to="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_0" xlink:to="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/Contingencies">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140460993844576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Aug. 11, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001534248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Chemomab Therapeutics Ltd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">L3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-3676773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Kiryat Atidim<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Building 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Tel Aviv<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">6158002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">77-331-0156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,431,656<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cmmb_AmericanDepositarySharesMember', window );">American Depositary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American Depositary Shares, each representing twenty (20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CMMB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Name of Exchange on which Security is Registered</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cmmb_OrdinarySharesNoParValuePerShareMember', window );">Ordinary Shares, No Par Value Per Share [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary shares, no par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">n/a <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Name of Exchange on which Security is Registered</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cmmb_AmericanDepositarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cmmb_AmericanDepositarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cmmb_OrdinarySharesNoParValuePerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cmmb_OrdinarySharesNoParValuePerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140460993906480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 9,883<span></span>
</td>
<td class="nump">$ 15,186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Short term bank deposits</a></td>
<td class="nump">41,841<span></span>
</td>
<td class="nump">45,975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other receivables and prepaid expenses</a></td>
<td class="nump">3,106<span></span>
</td>
<td class="nump">1,527<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">54,830<span></span>
</td>
<td class="nump">62,688<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Long term prepaid expenses</a></td>
<td class="nump">821<span></span>
</td>
<td class="nump">908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">355<span></span>
</td>
<td class="nump">357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">295<span></span>
</td>
<td class="nump">345<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">1,548<span></span>
</td>
<td class="nump">1,665<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">56,378<span></span>
</td>
<td class="nump">64,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade payables</a></td>
<td class="nump">1,433<span></span>
</td>
<td class="nump">1,336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">1,712<span></span>
</td>
<td class="nump">555<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee and related expenses</a></td>
<td class="nump">1,117<span></span>
</td>
<td class="nump">653<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">132<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">4,394<span></span>
</td>
<td class="nump">2,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities - long term</a></td>
<td class="nump">148<span></span>
</td>
<td class="nump">237<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">148<span></span>
</td>
<td class="nump">237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingent liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">4,542<span></span>
</td>
<td class="nump">2,887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares no par value - Authorized: 650,000,000 shares as of June 30, 2022 and as of December 31, 2021; Issued and outstanding: 228,633,120 ordinary shares as of June 30, 2022 and 228,090,300 as of December 31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="nump">99,303<span></span>
</td>
<td class="nump">97,639<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(47,467)<span></span>
</td>
<td class="num">(36,173)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">51,836<span></span>
</td>
<td class="nump">61,466<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 56,378<span></span>
</td>
<td class="nump">$ 64,353<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140460993994752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common Stock, No Par Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">650,000,000<span></span>
</td>
<td class="nump">650,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">228,633,120<span></span>
</td>
<td class="nump">228,090,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">228,633,120<span></span>
</td>
<td class="nump">228,090,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140460993766128">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Interim Statements of Operations (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,914<span></span>
</td>
<td class="nump">$ 1,307<span></span>
</td>
<td class="nump">$ 5,659<span></span>
</td>
<td class="nump">$ 2,464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,340<span></span>
</td>
<td class="nump">1,446<span></span>
</td>
<td class="nump">5,915<span></span>
</td>
<td class="nump">1,988<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,254<span></span>
</td>
<td class="nump">2,753<span></span>
</td>
<td class="nump">11,574<span></span>
</td>
<td class="nump">4,452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cmmb_FinanceIncomeExpensesNet', window );">Financing expense, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">480<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">264<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,734<span></span>
</td>
<td class="nump">2,770<span></span>
</td>
<td class="nump">11,838<span></span>
</td>
<td class="nump">4,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Taxes on income (benefit)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(544)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(544)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6,190<span></span>
</td>
<td class="nump">$ 2,770<span></span>
</td>
<td class="nump">$ 11,294<span></span>
</td>
<td class="nump">$ 4,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per Ordinary Share</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">$ 0.027<span></span>
</td>
<td class="nump">$ 0.013<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="nump">$ 0.024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per Ordinary Share</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">$ 0.027<span></span>
</td>
<td class="nump">$ 0.013<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="nump">$ 0.024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of Ordinary Shares outstanding, basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">228,173,276<span></span>
</td>
<td class="nump">216,266,993<span></span>
</td>
<td class="nump">228,132,249<span></span>
</td>
<td class="nump">186,840,022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of Ordinary Shares outstanding, diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">228,173,276<span></span>
</td>
<td class="nump">216,266,993<span></span>
</td>
<td class="nump">228,132,249<span></span>
</td>
<td class="nump">186,840,022<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">20 Ordinary Shares are equal to 1 American Depositary Share (ADS).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Number of shares has been retroactively adjusted to reflect the share reverse split effected on March 16, 2021 (refer to Note 1B).</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_FinanceIncomeExpensesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of finance income earned and finance expenses incurred during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_FinanceIncomeExpensesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140460992141360">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Interim Statements of Changes in Equity (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2"><div>Ordinary shares [Member]</div></th>
<th class="th"><div>Additional paid in capital [Member]</div></th>
<th class="th"><div>Accumulated deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 34,497<span></span>
</td>
<td class="num">$ (23,695)<span></span>
</td>
<td class="nump">$ 10,802<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (In shares) at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">9,274,838<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">43<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cmmb_EffectOfReverseCapitalizationTransaction', window );">Effect of reverse capitalization transaction</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,476<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cmmb_EffectOfReverseCapitalizationTransactionShares', window );">Effect of reverse capitalization transaction (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">152,299,702<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues', window );">Issuance of shares and warrants, net of issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">43,547<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">43,547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cmmb_StockAndWarrantIssuedDuringPeriodNewIssues', window );">Issuance of shares and warrants, net of issuance costs (In shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">52,385,400<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,704)<span></span>
</td>
<td class="num">(1,704)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">80,563<span></span>
</td>
<td class="num">(25,399)<span></span>
</td>
<td class="nump">55,164<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">213,959,940<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">34,497<span></span>
</td>
<td class="num">(23,695)<span></span>
</td>
<td class="nump">10,802<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (In shares) at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">9,274,838<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,474)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">96,208<span></span>
</td>
<td class="num">(28,169)<span></span>
</td>
<td class="nump">68,039<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">227,956,060<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">80,563<span></span>
</td>
<td class="num">(25,399)<span></span>
</td>
<td class="nump">55,164<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (In shares) at Mar. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">213,959,940<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">527<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 527<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of shares, net of issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">15,118<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares, net of issuance costs (In shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,996,120<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,770)<span></span>
</td>
<td class="num">$ (2,770)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">96,208<span></span>
</td>
<td class="num">(28,169)<span></span>
</td>
<td class="nump">68,039<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">227,956,060<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">97,639<span></span>
</td>
<td class="num">(36,173)<span></span>
</td>
<td class="nump">61,466<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (In shares) at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">228,090,300<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">874<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,104)<span></span>
</td>
<td class="num">(5,104)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">98,513<span></span>
</td>
<td class="num">(41,277)<span></span>
</td>
<td class="nump">57,236<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">228,090,300<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">97,639<span></span>
</td>
<td class="num">(36,173)<span></span>
</td>
<td class="nump">61,466<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (In shares) at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">228,090,300<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,294)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">99,303<span></span>
</td>
<td class="num">(47,467)<span></span>
</td>
<td class="nump">51,836<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">228,633,120<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">98,513<span></span>
</td>
<td class="num">(41,277)<span></span>
</td>
<td class="nump">57,236<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (In shares) at Mar. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">228,090,300<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">761<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of Options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">29<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of Options (In shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">542,820<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,190)<span></span>
</td>
<td class="num">(6,190)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 99,303<span></span>
</td>
<td class="num">$ (47,467)<span></span>
</td>
<td class="nump">$ 51,836<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">228,633,120<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Number of shares has been retroactively adjusted to reflect the share reverse split effected on March 16, 2021 (refer to Note 1B).</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_EffectOfReverseCapitalizationTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of effect due reverse capitalization transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_EffectOfReverseCapitalizationTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_EffectOfReverseCapitalizationTransactionShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares isued due to effect of reverse capitalization transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_EffectOfReverseCapitalizationTransactionShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_StockAndWarrantIssuedDuringPeriodNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>it represents number of shares and warrants issued during period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_StockAndWarrantIssuedDuringPeriodNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140460993402048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Interim Statements of Cash flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss for the period</a></td>
<td class="num">$ (11,294)<span></span>
</td>
<td class="num">$ (4,474)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments for operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Change in other receivables and prepaid expenses</a></td>
<td class="num">(1,483)<span></span>
</td>
<td class="num">(2,529)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Change in operating lease liability</a></td>
<td class="num">(15)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Change in trade payables</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Change in accrued expenses</a></td>
<td class="nump">1,157<span></span>
</td>
<td class="num">(993)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Change in employees and related expenses</a></td>
<td class="nump">464<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">1,635<span></span>
</td>
<td class="nump">570<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities', window );">Adjustments for operating activities</a></td>
<td class="nump">1,882<span></span>
</td>
<td class="num">(2,426)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(9,412)<span></span>
</td>
<td class="num">(6,900)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cmmb_PaymentsToPurchaseOfDeposits', window );">Increase in deposits</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(21,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cmmb_ProceedsFromSaleOfDeposits', window );">Decrease in deposits</a></td>
<td class="nump">4,134<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyHeldForSale', window );">Sale of asset held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(105)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">4,109<span></span>
</td>
<td class="num">(20,605)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cmmb_CashAcquiredInReverseRecapitalization', window );">Cash acquired in reverse recapitalization</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Exercise of options</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cmmb_IssuanceOfSharesNetOfIssuanceCosts', window );">Issuance of shares, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherEquity', window );">Issuance of shares and warrants, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">43,557<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">61,227<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Change in cash, cash equivalents and restricted cash</a></td>
<td class="num">(5,281)<span></span>
</td>
<td class="nump">33,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">15,241<span></span>
</td>
<td class="nump">11,727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">9,960<span></span>
</td>
<td class="nump">45,449<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cmmb_LiabilitiesAssumedNetOfNonCashAssetsReceivedInReverseMerger', window );">Liabilities assumed, net of non-cash assets received in reverse merger</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cmmb_AccountReceivableDueToExerciseOfOptions', window );">Receivable related to exercise of options</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cmmb_AccruedShareIssuanceExpenses', window );">Accrued share issuance expenses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 135<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_AccountReceivableDueToExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of account receivable due to exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_AccountReceivableDueToExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_AccruedShareIssuanceExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of accrued issuance expenses non-cash investing and financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_AccruedShareIssuanceExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_CashAcquiredInReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>represents cash acquired from acquisition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_CashAcquiredInReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_IssuanceOfSharesNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares net, of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_IssuanceOfSharesNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_LiabilitiesAssumedNetOfNonCashAssetsReceivedInReverseMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities assumed, net of non-cash assets received in reverse merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_LiabilitiesAssumedNetOfNonCashAssetsReceivedInReverseMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_PaymentsToPurchaseOfDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to purchase of deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_PaymentsToPurchaseOfDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ProceedsFromSaleOfDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ProceedsFromSaleOfDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the issuance of equity classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of formerly productive land held for sale, anything permanently fixed to it, including buildings, structures on it, and so forth.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140460995662928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cmmb_NatureOfOperationsDisclosureAbstract', window );"><strong>Nature Of Operations Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">General.</a></td>
<td class="text">
    <div>
      <div>
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><span><span>Note 1 - General.</span></span></strong></span></span></span></span></div>
        <div>
          <div>
            <div>
              <div>
                <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                <div>
                  <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                      <tr>
                        <td style="width:72pt;vertical-align:top;font-family:'Times New Roman',Times,serif">
                          <div style="margin-left:36pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>A.</span></span></span></span></span></span></div>
                        </td>
                        <td style="width:auto;vertical-align:top;font-family:'Times New Roman',Times,serif">
                          <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chemomab Therapeutics Ltd. (the &#8220;Company") is an Israeli -based company incorporated under the laws of the State of Israel in September 2011. The Company&#8217;s registered office is located in Kiryat Atidim, Tel Aviv, Israel. The Company is a clinical-stage biotech company discovering and developing innovative therapeutics for conditions with high-unmet medical need that involve inflammation and fibrosis.</span></span></p>
                        </td>
                      </tr>

                  </table>
                </div>
                <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                <div>
                  <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                      <tr>
                        <td style="width:72pt;vertical-align:top;font-family:'Times New Roman',Times,serif">
                          <div style="margin-left:36pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>B.</span></span></span></span></span></span></div>
                        </td>
                        <td style="width:auto;vertical-align:top;font-family:'Times New Roman',Times,serif">
                          <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On March&#160;16, 2021, the Company, then known as Anchiano Therapeutics Ltd. (&#8220;Anchiano&#8221;), completed its merger with Chemomab Ltd., a privately-held Israeli limited company (&#8220;Chemomab Ltd.&#8221;). Pursuant to the Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) dated as of December&#160;14, 2020, by and among Anchiano, CMB Acquisition Ltd., an Israeli limited company and wholly-owned subsidiary of Anchiano (&#8220;Merger Sub&#8221;), and Chemomab Ltd., Merger Sub merged with and into Chemomab Ltd., with Chemomab Ltd. being the surviving entity and becoming a wholly owned subsidiary of Anchiano (the &#8220;Merger&#8221;).&#160; Upon consummation of the Merger, the Company changed its name from &#8220;Anchiano Therapeutics Ltd.&#8221; to &#8220;Chemomab Therapeutics Ltd.&#8221; and the business conducted by Chemomab Ltd. became primarily the business conducted by the Company.</span></span></p>
                        </td>
                      </tr>

                  </table>
                </div>
                <div style="text-align:justify;margin-left:72pt;line-height:1.25">&#160;</div>
                <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For accounting purposes, Chemomab Ltd. is considered to have acquired Anchiano based upon the terms of the Merger as well as other factors including: (i) Chemomab Ltd.'s former shareholders owned approximately<span><span><span><span><span><span>&#160;90% </span></span></span></span></span></span>of the combined Company&#8217;s outstanding ordinary shares immediately following the closing of the Merger and (ii) Chemomab Ltd. management holds key management positions of the combined Company. The Merger has been accounted for as an asset acquisition (reverse recapitalization transaction) rather than a business combination, as the assets acquired and the liabilities assumed by Chemomab Ltd. do not meet the definition of a business under accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;). The net assets acquired in connection with the Merger were recorded at their estimated acquisition date fair market value as of March 16, 2021, the date of completion of the Merger.</span></span></div>
                <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Immediately prior to the effective date of the Merger, all preferred shares of Chemomab Ltd. were converted into ordinary shares of Chemomab Ltd. on a one-for-one basis.</span></span></span></span></span></span></div>
                <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>In connection with the Merger, and following the effective time of the Merger, the Company effected a reverse share split of the Company&#8217;s ordinary shares at a ratio of 4:1 (the &#8220;Reverse Split&#8221;) and increased the number of ordinary shares underlying each American Depositary Share ("ADS") from 5 to 20. At the effective time of the Merger, each Chemomab Ltd. ordinary share outstanding immediately prior to the effective time of the Merger automatically converted into the right to receive approximately 12.86 ADSs, each representing 20 Anchiano ordinary shares, plus a warrant to purchase ADSs that may become exercisable only under certain circumstances.</span></span></span></span></span></span></div>
                <div style="text-align:justify;margin-left:72pt;line-height:1.25">&#160;</div>
                <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The exchange ratio was calculated by a formula that was determined through arms-length negotiations between the Company and Chemomab Ltd. The combined Company assumed all of the outstanding options of Chemomab Ltd., vested and unvested, under the Chemomab Share Incentive Plan (the &#8220;2015 Plan&#8221;), with such options representing the right to purchase a number of ADSs equal to approximately 12.86 multiplied by the number of Chemomab Ltd. ordinary shares previously represented by such options.</span></span></div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div>
        <div/>
        <div>
          <div>
            <p style="margin:0pt">&#160;</p>
            <p style="margin-top:0pt;margin-left:72pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>The accompanying unaudited condensed consolidated financial statements and notes to the unaudited condensed consolidated financial statements give retroactive effect to the exchange ratio and the Reverse Split for all periods presented.</span></span></span></span></span></span></p>
            <div>
              <div>
                <div style="text-align:justify;margin-left:72pt;line-height:1.25">&#160;</div>
                <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>The equity structure reflects the legal acquirer's equity structure. The balance sheet has been adjusted to reflect the par value of the outstanding shares of the legal acquirer, including the number of shares issued in the Merger. Any difference is recognized as an adjustment to the additional paid in capital.</span></span></span></span></span></span></div>
                <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Immediately after completion of the Merger, on March 16, 2021, the Company had 8,078,727 ADS issued and outstanding (9,003,357 on a fully diluted basis). In addition, immediately after the Merger, Chemomab Ltd. former shareholders owned approximately 90% of the number of issued and outstanding ordinary shares of the Company and the shareholders of the Company immediately prior to the Merger owned approximately 10% </span></span></span></span></span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">of the number of issued and outstanding ordinary shares of the Company (all on a fully diluted basis).</span></span></div>
                <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>On March 16, 2021, immediately prior to the effectiveness of the Merger, Anchiano had 65,675,904 ordinary shares outstanding (prior to the effect of the Reverse Split) and a market capitalization of $58.7 million. The estimated fair value of the net assets of Anchiano on March 16, 2021, prior to the Merger, was approximately $2.5 million. The fair value of ordinary shares on the Merger closing date, prior to the Merger, was above the fair value of the Company&#8217;s net assets. As the Company&#8217;s net assets were predominantly composed of cash offset against current liabilities, the fair value of the Company&#8217;s net assets as of March 16, 2021, prior to the Merger, is considered to be the best indicator of the fair value and, therefore, the estimated preliminary purchase consideration.</span></span></span></span></span></span></div>
                <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>The following table summarizes the net assets acquired based on their estimated fair values as of March 16, 2021, immediately prior to completion of the Merger (in thousands):</span></span></span></span></span></span></div>
                <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                <div>
                  <div style="margin-left:72pt">

                      <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:90%">

                          <tr>
                            <td style="vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;width:88%" valign="bottom">
                              <div style="text-indent:-12pt;margin-left:12pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Cash and cash equivalents</span></span></span></span></span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>$</span></span></span></span></span></span></div>
                            </td>
                            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>2,427</span></span></span></span></span></span></div>
                            </td>
                            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%" valign="bottom">
                              <div style="text-indent:-12pt;margin-left:12pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Asset held for sale</span></span></span></span></span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>1,000</span></span></span></span></span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%;background-color:rgb(204, 238, 255)" valign="bottom">
                              <div style="text-indent:-12pt;margin-left:12pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Prepaid and other assets</span></span></span></span></span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>236</span></span></span></span></span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%;padding-bottom:2px" valign="bottom">
                              <div style="text-indent:-12pt;margin-left:12pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Accrued liabilities</span></span></span></span></span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>(1,187</span></span></span></span></span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>)</span></span></span></span></span></span></div>
                            </td>
                          </tr>
                          <tr>
                            <td colspan="1" style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%;background-color:rgb(204, 238, 255)" valign="bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Net acquired assets</span></span></span></span></span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>$</span></span></span></span></span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>2,476</span></span></span></span></span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                          </tr>

                      </table>

                  </div>
                </div>
                <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
                <div>
                  <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                      <tr>
                        <td style="width:72pt;vertical-align:top;font-family:'Times New Roman',Times,serif">
                          <div style="margin-left:36pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>C.</span></span></span></span></span></span></div>
                        </td>
                        <td style="width:auto;vertical-align:top;font-family:'Times New Roman',Times,serif">
                          <div style="text-align:justify;line-height:1.25">In connection with the Merger, on March 15, 2021, Anchiano entered into Securities Purchase Agreements with certain purchasers for the issuance and sale by Anchiano in a private placement (the &#8220;Private Placement&#8221;) of approximately<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span> $45.5 million </span></span></span></span></span></span>of its ADSs and accompanying warrants to purchase ADSs. The warrants have an exercise price of approximately<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span> $17.35&#160;</span></span></span></span></span></span>per ADS, expire<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>&#160;five years&#160;</span></span></span></span></span></span>from the date of issuance, and if exercised in full, will provide additional proceeds to the Company of approximately<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span> $4.5 million. </span></span></span></span></span></span>The Private Placement closed on March 22, 2021.</div>
                        </td>
                      </tr>

                  </table>
                </div>
              </div>
            </div>
            <div style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</div>
            <div/>
            <div style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</div>
            <div>
              <div>
                <div>
                  <div>
                    <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                        <tr>
                          <td style="width:72pt;vertical-align:top;font-family:'Times New Roman',Times,serif">
                            <div style="margin-left:36pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>D.</span></span></span></span></span></span></div>
                          </td>
                          <td style="width:auto;vertical-align:top;font-family:'Times New Roman',Times,serif">
                            <div style="text-align:justify;line-height:1.25">Pursuant to an Asset Purchase and Assignment Agreement dated as of March 16, 2021, as amended on March 31, 2021, between the Company&#8217;s wholly owned subsidiary, Anchiano Therapeutics, Inc., a Delaware corporation (&#8220;Anchiano Delaware&#8221;) and Kestrel Therapeutics, Inc., a Delaware corporation (&#8220;Kestrel&#8221;), Anchiano Delaware agreed to sell to Kestrel all of the its rights and obligations in its business to the extent related to the research, development and commercialization of the Compounds and Products (as such terms are defined in the Collaboration and License Agreement entered into as of September 13, 2019, by and between ADT Pharmaceuticals, LLC and Anchiano Delaware), also known as the pan-RAS and PDE10/&#946;-catenin programs. In consideration of the sale and transfer of the Compounds and Products, Kestrel paid the Company a total of $<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>1.0 million.</span></span></span></span></span></span></div>
                          </td>
                        </tr>

                    </table>
                  </div>
                  <div style="text-align:justify;margin-left:72pt;line-height:1.25">&#160;</div>
                  <div>
                    <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                        <tr>
                          <td style="width:72pt;vertical-align:top;font-family:'Times New Roman',Times,serif">
                            <div style="margin-left:36pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>E.</span></span></span></span></span></span></div>
                          </td>
                          <td style="width:auto;vertical-align:top;font-family:'Times New Roman',Times,serif">
                            <div style="text-align:justify;line-height:1.25">On April 30, 2021, the Company entered into an At the Market Offering Agreement (the "ATM Agreement") with Cantor Fitzgerald &amp; Co., ("Cantor"). According to the ATM Agreement, the Company may offer and sell, from time to time, its ADSs having an aggregate offering price of up to<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>&#160;$75.0 </span></span></span></span></span></span>million through Cantor pursuant to the ATM Agreement. From April 30, 2021 through June 30, 2022, the Company sold<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span> 699,806 ADSs at an average price of $22.75 </span></span></span></span></span></span>per ADS under the ATM Agreement, resulting in gross proceeds of approximately<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span> $15.9 </span></span></span></span></span></span>million<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>. </span></span></span></span></span></span>The offer and sale of ADSs under the ATM Agreement has been registered under the Company&#8217;s effective registration statement on Form S-3 (File No. 333-255658), together with a prospectus forming a part thereof, filed with the SEC under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). Sales, if any, of ADS pursuant to the ATM Agreement may be made in any transactions that are deemed to be &#8220;at the market&#8221; offerings as defined in Rule 415(a)(4) under the Securities Act. The Company is not obligated to sell any ADSs under the ATM Agreement.</div>
                          </td>
                        </tr>

                    </table>
                  </div>
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                  <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On April 25, 2022, the Company filed with the SEC a prospectus supplement to the above mentioned registration statement for the issuance and sale of up to</span></span><span><span><span><span><span><span> $18,125,000 </span></span></span></span></span></span>of the Company's ADSs under the ATM Agreement, which is within the $75 million maximum permitted under the ATM Agreement.</span></span></div>
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                  <div>
                    <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                        <tr>
                          <td style="width:72pt;vertical-align:top;font-family:'Times New Roman',Times,serif">
                            <div style="margin-left:36pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>F.</span></span></span></span></span></span></div>
                          </td>
                          <td style="width:auto;vertical-align:top;font-family:'Times New Roman',Times,serif">
                            <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Since January 2020, the COVID-19 outbreak has dramatically expanded into a worldwide pandemic creating macro-economic uncertainty and disruption in the business and financial markets. Many countries around the world, including Israel, have been taking measures designated to limit the continued spread of the Coronavirus, including the closure of workplaces, restricting travel, prohibiting assembling, closing international borders and quarantining populated areas. The Company's clinical trial sites have been affected by the COVID-19 pandemic, and as a result, commencement of the enrollment of Company&#8217;s clinical trials of CM-101 in PSC was delayed and the enrollment rate has been affected as well. As a result, the Company extended patients recruiting to additional territories with significant recruitment potential. In addition, after enrollment in these trials, patients may drop out of the Company's trials because of the COVID-19 possible implications.</span></span></span></span></span></span></div>
                          </td>
                        </tr>

                    </table>
                  </div>
                  <div style="text-align:justify;margin-left:72pt;line-height:1.25">&#160;</div>
                  <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Based on management&#8217;s assessment, the extent to which the coronavirus will further impact the Company&#8217;s operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration and severity of the outbreak, and the actions that may be required to contain the coronavirus or treat its impact. The Company is carefully monitoring the restrictions due to the COVID-19 outbreak and will adjust activities accordingly.</span></span></span></span></span></span>
                    <p style="margin:0pt">&#160;</p>
                  </div>
                  <div/>
                  <div style="text-align:justify;margin-left:72pt;line-height:1.25">
                    <p style="margin:0pt">&#160;</p><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>On March 27, 2020 and December 27, 2020, the President of the United States signed and enacted into law the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) and the Consolidated Appropriations Act, 2021 (CAA). Among other provisions, the CARES Act and the CAA provide relief to U.S. federal corporate taxpayers through temporary adjustments to net operating loss rules, changes to limitations on interest expense deductibility, and the acceleration of available refunds for minimum tax credit carryforwards. The CARES Act also includes provisions for a carryback of any net operating loss (NOL) arising in a taxable year beginning after December 31, 2017, and before January 1, 2021, to each of the five taxable years preceding the taxable year in which the loss arises (carryback period).</span></span></span></span></span></span>
                  </div>
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                  <div style="text-align:justify;margin-left:72pt;line-height:1.25">
                    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chemomab Therapeutics Inc., a wholly owned subsidiary of the Company, filed an application with the US Internal Revenue Service to carryback net operating losses. The Company expects to receive the refund during the second half of 2022.</span></span></p>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_NatureOfOperationsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_NatureOfOperationsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140460993714800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Significant Accounting Policies</a></td>
<td class="text">
      <div>
        <p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong><span>Note 2 - Basis of Presentation and Significant Accounting Policies </span></strong></span></span></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

          <div>
            <p style="margin-top:0pt;margin-left:36pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>A.&#160; &#160; &#160; &#160; &#160; Basis of Preparation</strong></span></span></span></p>
            <p style="margin-top:0pt;margin-left:48px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
            <p style="margin-top:0pt;margin-left:36pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">The condensed interim consolidated financial statements included in this quarterly report are unaudited. These financial statements have been prepared in accordance with U.S. GAAP and applicable rules and regulations of the SEC regarding interim financial reporting and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for a fair statement of the Company&#8217;s financial position as of June 30, 2022, and its results of operations for the three and six months ended June 30, 2022, and 2021, changes in shareholders&#8217; equity for the six months ended June 30, 2022 and 2021, and cash flows for the six months ended June 30, 2022 and 2021. The results of operations for the three and six months ended June 30, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022 or for any other future annual or interim period. These financial statements should be read in conjunction with the audited financial statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC. The Company&#8217;s significant accounting policies are disclosed in the audited financial statements for the year ended December 31, 2021 included in the Company&#8217;s Annual Report on Form 10-K. Since the date of such financial statements, there have been no changes to the Company&#8217;s significant accounting policies.</p>
          </div>

        <p style="margin-top:0pt;margin-left:48px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

          <div>
            <p style="margin-top:0pt;margin-left:36pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>B.&#160; &#160; &#160; &#160; &#160; Use of estimates</strong></span></span></span></p>
            <p style="margin:0pt">&#160;</p>
            <p style="margin-top:0pt;margin-left:36pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.</span></span></span></p>
          </div>

      </div>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140460995688624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Contingencies</a></td>
<td class="text">
    <div>
      <div style="margin-top:0px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note 3 - Contingencies</span></span></strong></div>
      <div>
        <div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>During 2022, </span></span>the Israeli tax authority ("ITA&#8221;) notified the Company that it had initiated a routine VAT audit to include tax years 2017 through 2020. The ITA raised several claims, mainly in respect with the recoverability of VAT with respect to Merger Agreement related expenses and the classification of the Company as a holding company. On July 2022, the ITA proposed a settlement, which the Company rejected. As a result, the ITA issued an assessment. The Company plans to appeal the ITA&#8217;s assessment. The Company has recorded a provision which is inherently subjective due to the inherent uncertainty of these matters and the judicial process. Therefore, the final outcome may differ from the estimated liability recorded by the Company during the period<span><span>.</span></span></span></span></div>
        </div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140460992532032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Preparation</a></td>
<td class="text">
          <div>
            <p style="margin-top:0pt;margin-left:36pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>A.&#160; &#160; &#160; &#160; &#160; Basis of Preparation</strong></span></span></span></p>
            <p style="margin-top:0pt;margin-left:48px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
            <p style="margin-top:0pt;margin-left:36pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">The condensed interim consolidated financial statements included in this quarterly report are unaudited. These financial statements have been prepared in accordance with U.S. GAAP and applicable rules and regulations of the SEC regarding interim financial reporting and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for a fair statement of the Company&#8217;s financial position as of June 30, 2022, and its results of operations for the three and six months ended June 30, 2022, and 2021, changes in shareholders&#8217; equity for the six months ended June 30, 2022 and 2021, and cash flows for the six months ended June 30, 2022 and 2021. The results of operations for the three and six months ended June 30, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022 or for any other future annual or interim period. These financial statements should be read in conjunction with the audited financial statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC. The Company&#8217;s significant accounting policies are disclosed in the audited financial statements for the year ended December 31, 2021 included in the Company&#8217;s Annual Report on Form 10-K. Since the date of such financial statements, there have been no changes to the Company&#8217;s significant accounting policies.</p>
          </div>
        <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text">
          <div>
            <p style="margin-top:0pt;margin-left:36pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>B.&#160; &#160; &#160; &#160; &#160; Use of estimates</strong></span></span></span></p>
            <p style="margin:0pt">&#160;</p>
            <p style="margin-top:0pt;margin-left:36pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.</span></span></span></p>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140460992132320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cmmb_NatureOfOperationsDisclosureAbstract', window );"><strong>Nature Of Operations Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of net assets acquired based on their estimated fair value</a></td>
<td class="text">
                      <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:90%">

                          <tr>
                            <td style="vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;width:88%" valign="bottom">
                              <div style="text-indent:-12pt;margin-left:12pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Cash and cash equivalents</span></span></span></span></span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>$</span></span></span></span></span></span></div>
                            </td>
                            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>2,427</span></span></span></span></span></span></div>
                            </td>
                            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%" valign="bottom">
                              <div style="text-indent:-12pt;margin-left:12pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Asset held for sale</span></span></span></span></span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>1,000</span></span></span></span></span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%;background-color:rgb(204, 238, 255)" valign="bottom">
                              <div style="text-indent:-12pt;margin-left:12pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Prepaid and other assets</span></span></span></span></span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>236</span></span></span></span></span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%;padding-bottom:2px" valign="bottom">
                              <div style="text-indent:-12pt;margin-left:12pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Accrued liabilities</span></span></span></span></span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>(1,187</span></span></span></span></span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>)</span></span></span></span></span></span></div>
                            </td>
                          </tr>
                          <tr>
                            <td colspan="1" style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%;background-color:rgb(204, 238, 255)" valign="bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Net acquired assets</span></span></span></span></span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>$</span></span></span></span></span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>2,476</span></span></span></span></span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                          </tr>

                      </table>
                    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_NatureOfOperationsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_NatureOfOperationsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140460993313008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General (Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">14 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 16, 2021</div></th>
<th class="th"><div>Mar. 15, 2021</div></th>
<th class="th"><div>Apr. 25, 2022</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cmmb_NumberOfOrdinarySharesForEachPreferredShareConvertedPriorToDateOfMerger', window );">Number of common shares for each preferred share converted</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split conversion ratio</a></td>
<td class="nump">0.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Capital', window );">Market capitalization amount</a></td>
<td class="nump">$ 58,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Isuuance and sale value of ADSs and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cmmb_WarrantsExercisablePeriod', window );">Warrants exercisable period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cmmb_AmountOfTotalSaleAndTransferOfCompoundsAndProductsKestrelPaid', window );">Amount of total sale and transfer of compounds and products kestrel paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cmmb_AmericanDepositorySharesMember', window );">American Depositary Share ("ADS") [Member] | At The Market Offering Agreement With Cantor Fitzgerald &amp; Co. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">699,806<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Average price of shares issued under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Gross proceeds from sale under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cmmb_AmericanDepositorySharesMember', window );">American Depositary Share ("ADS") [Member] | Maximum [Member] | At The Market Offering Agreement With Cantor Fitzgerald &amp; Co. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cmmb_FormerChemomabSecurityHoldersMember', window );">Former Chemomab Security Holders [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cmmb_ShareholdingPercentageImmediatelyFollowingMerger', window );">Shareholding percentage immediately following the merger</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cmmb_NumberOfOrdinarySharesForEachPreferredShareConvertedPriorToDateOfMerger', window );">Number of common shares for each preferred share converted</a></td>
<td class="nump">65,675,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cmmb_RetainedEarningsAccumulatedDeficits', window );">Accumulated deficit</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cmmb_MergerAgreementWithChemomabIsraeliLimitedCompanyAndClinicalStageBiotechCompanyMember', window );">Merger agreement with Chemomab, an Israeli limited company and a clinical-stage biotech company [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cmmb_NumberOfOrdinarySharesConsistedInDS', window );">Number of ordinary shares represented by each ADS (in shares)</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger', window );">Number of ADS issued and outstanding after the merger</a></td>
<td class="nump">12.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cmmb_NumberOfSharesDilutedAfterMerger', window );">Number of shares diluted after the merger</a></td>
<td class="nump">8,078,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cmmb_SharesConvertiblePerShareOfAcquireeEntity', window );">Number of shares after merger for each share of Chemomab</a></td>
<td class="nump">9,003,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_AmountOfTotalSaleAndTransferOfCompoundsAndProductsKestrelPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of total sale and transfer of compounds and products kestrel paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_AmountOfTotalSaleAndTransferOfCompoundsAndProductsKestrelPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of ADS issued and outstanding after the merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_NumberOfOrdinarySharesConsistedInDS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the number of ordinary shares consisted in one American depository share (ADS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_NumberOfOrdinarySharesConsistedInDS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_NumberOfOrdinarySharesForEachPreferredShareConvertedPriorToDateOfMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock for each preferred share converted before merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_NumberOfOrdinarySharesForEachPreferredShareConvertedPriorToDateOfMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_NumberOfSharesDilutedAfterMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares diluted after the merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_NumberOfSharesDilutedAfterMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_RetainedEarningsAccumulatedDeficits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_RetainedEarningsAccumulatedDeficits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ShareholdingPercentageImmediatelyFollowingMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>shareholding percentage immediately following the merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ShareholdingPercentageImmediatelyFollowingMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_SharesConvertiblePerShareOfAcquireeEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the shares convertible in merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_SharesConvertiblePerShareOfAcquireeEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_WarrantsExercisablePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the warrants exercisable period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_WarrantsExercisablePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Capital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of total capital as defined by regulatory framework.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 505<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=117337116&amp;loc=SL5958568-112826<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Capital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of preferred stock and warrants for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cmmb_AmericanDepositorySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cmmb_AmericanDepositorySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cmmb_AtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cmmb_AtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cmmb_FormerChemomabSecurityHoldersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cmmb_FormerChemomabSecurityHoldersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cmmb_MergerAgreementWithChemomabIsraeliLimitedCompanyAndClinicalStageBiotechCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cmmb_MergerAgreementWithChemomabIsraeliLimitedCompanyAndClinicalStageBiotechCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140460991871376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>General - Estimated fair value of assets acquired (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 16, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cmmb_NatureOfOperationsDisclosureAbstract', window );"><strong>Nature Of Operations Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale', window );">Asset held for sale</a></td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid and other assets</a></td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses', window );">Accrued liabilities</a></td>
<td class="num">(1,187)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cmmb_EstimatedFairValueOfNetAssetsAcquired', window );">Net acquired assets</a></td>
<td class="nump">$ 2,476<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of of asset held for sale recogized prior to the completion of merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued liabilities to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_EstimatedFairValueOfNetAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated fair value of the net assets acquired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_EstimatedFairValueOfNetAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_NatureOfOperationsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_NatureOfOperationsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>zk2228232_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cmmb="http://www.anchiano.com/20220630"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cmmb-20220630.xsd" xlink:type="simple"/>
    <context id="C_20220401to20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_20210401to20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_20220101to20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_20210101to20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_20210101to20210331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20210331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_20210331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_20210630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_20210331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_20210331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_20210401to20210630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_20210401to20210630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_20210630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_20210630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_20210101to20210331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_20210401to20210630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_20220331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_20220331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_20220331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_20220101to20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20220331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20220331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20220331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_20210316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <instant>2021-03-16</instant>
        </period>
    </context>
    <context id="C_20210316_usgaapBusinessAcquisitionAxis_cmmbMergerAgreementWithChemomabIsraeliLimitedCompanyAndClinicalStageBiotechCompanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cmmb:MergerAgreementWithChemomabIsraeliLimitedCompanyAndClinicalStageBiotechCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-16</instant>
        </period>
    </context>
    <context id="C_20210314to20210316_usgaapBusinessAcquisitionAxis_cmmbMergerAgreementWithChemomabIsraeliLimitedCompanyAndClinicalStageBiotechCompanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cmmb:MergerAgreementWithChemomabIsraeliLimitedCompanyAndClinicalStageBiotechCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-14</startDate>
            <endDate>2021-03-16</endDate>
        </period>
    </context>
    <context id="C_20210314to20210316_srtTitleOfIndividualAxis_cmmbFormerChemomabSecurityHoldersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cmmb:FormerChemomabSecurityHoldersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-14</startDate>
            <endDate>2021-03-16</endDate>
        </period>
    </context>
    <context id="C_20210316_srtTitleOfIndividualAxis_cmmbFormerChemomabSecurityHoldersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cmmb:FormerChemomabSecurityHoldersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-16</instant>
        </period>
    </context>
    <context id="C_20210301to20210315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-15</endDate>
        </period>
    </context>
    <context id="C_20210401to20210430_usgaapStatementClassOfStockAxis_cmmbAmericanDepositorySharesMember_usgaapSubsidiarySaleOfStockAxis_cmmbAtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmmb:AmericanDepositorySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:AtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="C_20210501to20220630_usgaapStatementClassOfStockAxis_cmmbAmericanDepositorySharesMember_usgaapSubsidiarySaleOfStockAxis_cmmbAtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmmb:AmericanDepositorySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:AtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_20220630_usgaapStatementClassOfStockAxis_cmmbAmericanDepositorySharesMember_usgaapSubsidiarySaleOfStockAxis_cmmbAtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmmb:AmericanDepositorySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:AtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_20220401to20220425_srtRangeAxis_srtMaximumMember_usgaapStatementClassOfStockAxis_cmmbAmericanDepositorySharesMember_usgaapSubsidiarySaleOfStockAxis_cmmbAtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmmb:AmericanDepositorySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:AtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-25</endDate>
        </period>
    </context>
    <context id="C_20210314to20210316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <startDate>2021-03-14</startDate>
            <endDate>2021-03-16</endDate>
        </period>
    </context>
    <context id="C_20210315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <instant>2021-03-15</instant>
        </period>
    </context>
    <context id="C_20220101to20220630_usgaapStatementClassOfStockAxis_cmmbAmericanDepositarySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmmb:AmericanDepositarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_20220101to20220630_usgaapStatementClassOfStockAxis_cmmbOrdinarySharesNoParValuePerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmmb:OrdinarySharesNoParValuePerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_20220811">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <instant>2022-08-11</instant>
        </period>
    </context>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Share">
        <measure>shares</measure>
    </unit>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="USD_per_share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="C_20220101to20220630" id="FFact_288">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="C_20220101to20220630" id="FFact_289">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="C_20220101to20220630" id="FFact_290">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="C_20220101to20220630" id="FFact_292">0001534248</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="C_20220101to20220630" id="FFact_1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="C_20220101to20220630" id="FFact_2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="C_20220101to20220630" id="FFact_3">2022-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_20220101to20220630"
      id="Fxbrl_20220509210752112">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="C_20220101to20220630" id="FFact_4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="C_20220101to20220630" id="FFact_5">001-38807</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="C_20220101to20220630" id="FFact_6">Chemomab Therapeutics Ltd.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_20220101to20220630" id="FFact_7">L3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="C_20220101to20220630" id="FFact_8">81-3676773</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_20220101to20220630" id="FFact_9">Kiryat Atidim</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="C_20220101to20220630" id="FFact_10">Building 7</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="C_20220101to20220630" id="FFact_11">Tel Aviv</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="C_20220101to20220630" id="FFact_12">IL</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="C_20220101to20220630" id="FFact_13">6158002</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_20220101to20220630" id="FFact_14">972</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_20220101to20220630" id="FFact_15">77-331-0156</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_20220101to20220630_usgaapStatementClassOfStockAxis_cmmbAmericanDepositarySharesMember"
      id="FFact_16">American Depositary Shares, each representing twenty (20)</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_20220101to20220630_usgaapStatementClassOfStockAxis_cmmbAmericanDepositarySharesMember"
      id="FFact_17">CMMB</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_20220101to20220630_usgaapStatementClassOfStockAxis_cmmbAmericanDepositarySharesMember"
      id="FFact_18">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="C_20220101to20220630_usgaapStatementClassOfStockAxis_cmmbOrdinarySharesNoParValuePerShareMember"
      id="FFact_19">Ordinary shares, no par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_20220101to20220630_usgaapStatementClassOfStockAxis_cmmbOrdinarySharesNoParValuePerShareMember"
      id="Fxbrl_20220810212313319">n/a </dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_20220101to20220630_usgaapStatementClassOfStockAxis_cmmbOrdinarySharesNoParValuePerShareMember"
      id="Fxbrl_20220810204332751">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="C_20220101to20220630" id="FFact_22">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="C_20220101to20220630" id="FFact_23">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="C_20220101to20220630" id="FFact_24">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="C_20220101to20220630" id="FFact_25">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="C_20220101to20220630" id="FFact_26">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="C_20220101to20220630" id="FFact_27">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany contextRef="C_20220101to20220630" id="FFact_28">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_20220811"
      decimals="INF"
      id="Fxbrl_20220720131522106"
      unitRef="Share">11431656</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20220630"
      decimals="-3"
      id="FFact_30"
      unitRef="USD">9883000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_31"
      unitRef="USD">15186000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DepositsAssetsCurrent
      contextRef="C_20220630"
      decimals="-3"
      id="FFact_32"
      unitRef="USD">41841000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_33"
      unitRef="USD">45975000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20220630"
      decimals="-3"
      id="FFact_34"
      unitRef="USD">3106000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_35"
      unitRef="USD">1527000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_20220630"
      decimals="-3"
      id="FFact_36"
      unitRef="USD">54830000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_37"
      unitRef="USD">62688000</us-gaap:AssetsCurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="C_20220630"
      decimals="-3"
      id="Fxbrl_20220504175928392"
      unitRef="USD">821000</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_40"
      unitRef="USD">908000</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20220630"
      decimals="-3"
      id="FFact_42"
      unitRef="USD">355000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_43"
      unitRef="USD">357000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_20220630"
      decimals="-3"
      id="FFact_44"
      unitRef="USD">77000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_45"
      unitRef="USD">55000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20220630"
      decimals="-3"
      id="FFact_46"
      unitRef="USD">295000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_47"
      unitRef="USD">345000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:AssetsNoncurrent
      contextRef="C_20220630"
      decimals="-3"
      id="FFact_48"
      unitRef="USD">1548000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_49"
      unitRef="USD">1665000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_20220630"
      decimals="-3"
      id="FFact_50"
      unitRef="USD">56378000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_51"
      unitRef="USD">64353000</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="C_20220630"
      decimals="-3"
      id="FFact_52"
      unitRef="USD">1433000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_53"
      unitRef="USD">1336000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_20220630"
      decimals="-3"
      id="FFact_54"
      unitRef="USD">1712000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_55"
      unitRef="USD">555000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_20220630"
      decimals="-3"
      id="FFact_56"
      unitRef="USD">1117000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_57"
      unitRef="USD">653000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20220630"
      decimals="-3"
      id="FFact_58"
      unitRef="USD">132000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_59"
      unitRef="USD">106000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_20220630"
      decimals="-3"
      id="FFact_60"
      unitRef="USD">4394000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_61"
      unitRef="USD">2650000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20220630"
      decimals="-3"
      id="FFact_62"
      unitRef="USD">148000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_63"
      unitRef="USD">237000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_20220630"
      decimals="-3"
      id="FFact_64"
      unitRef="USD">148000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_65"
      unitRef="USD">237000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_20220630"
      id="Fxbrl_20220801213051011"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_20211231"
      id="Fxbrl_20220801213059987"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Liabilities
      contextRef="C_20220630"
      decimals="-3"
      id="FFact_66"
      unitRef="USD">4542000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_67"
      unitRef="USD">2887000</us-gaap:Liabilities>
    <us-gaap:CommonStockNoParValue
      contextRef="C_20211231"
      decimals="INF"
      id="Fxbrl_20220505092446513"
      unitRef="USD_per_share">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockNoParValue
      contextRef="C_20220630"
      decimals="INF"
      id="Fxbrl_20220719155003261"
      unitRef="USD_per_share">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_20211231"
      decimals="INF"
      id="Fxbrl_20220505092709497"
      unitRef="Share">650000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_20220630"
      decimals="INF"
      id="Fxbrl_20220719155025581"
      unitRef="Share">650000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_20220630"
      decimals="INF"
      id="Fxbrl_20220808225957738"
      unitRef="Share">228633120</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20220630"
      decimals="INF"
      id="Fxbrl_20220719155109723"
      unitRef="Share">228633120</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_20211231"
      decimals="INF"
      id="Fxbrl_20220808230014261"
      unitRef="Share">228090300</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20211231"
      decimals="INF"
      id="Fxbrl_20220719155156785"
      unitRef="Share">228090300</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_20220630"
      decimals="-3"
      id="Fxbrl_20220505093047469"
      unitRef="USD">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20220505093055381"
      unitRef="USD">0</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_20220630"
      decimals="-3"
      id="FFact_78"
      unitRef="USD">99303000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_79"
      unitRef="USD">97639000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20220630"
      decimals="-3"
      id="FFact_80"
      unitRef="USD">-47467000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_81"
      unitRef="USD">-36173000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_20220630"
      decimals="-3"
      id="Fxbrl_20220719200901554_Fact_84"
      unitRef="USD">51836000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20220719200901554_Fact_85"
      unitRef="USD">61466000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_20220630"
      decimals="-3"
      id="FFact_84"
      unitRef="USD">56378000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_85"
      unitRef="USD">64353000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20220401to20220630"
      decimals="-3"
      id="FFact_88"
      unitRef="USD">2914000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20210401to20210630"
      decimals="-3"
      id="FFact_89"
      unitRef="USD">1307000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20220719164443341"
      unitRef="USD">5659000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="Fxbrl_20220719164445428"
      unitRef="USD">2464000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20220401to20220630"
      decimals="-3"
      id="FFact_92"
      unitRef="USD">3340000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20210401to20210630"
      decimals="-3"
      id="FFact_93"
      unitRef="USD">1446000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20220719164450381"
      unitRef="USD">5915000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="Fxbrl_20220719164452278"
      unitRef="USD">1988000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_20220401to20220630"
      decimals="-3"
      id="FFact_96"
      unitRef="USD">6254000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_20210401to20210630"
      decimals="-3"
      id="FFact_97"
      unitRef="USD">2753000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20220719164501750"
      unitRef="USD">11574000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="Fxbrl_20220719164503934"
      unitRef="USD">4452000</us-gaap:OperatingExpenses>
    <cmmb:FinanceIncomeExpensesNet
      contextRef="C_20220401to20220630"
      decimals="-3"
      id="Fxbrl_20220719180539700_xbrl_20220719164540689"
      unitRef="USD">-480000</cmmb:FinanceIncomeExpensesNet>
    <cmmb:FinanceIncomeExpensesNet
      contextRef="C_20210401to20210630"
      decimals="-3"
      id="Fxbrl_20220719180539700_xbrl_20220719164542506"
      unitRef="USD">-17000</cmmb:FinanceIncomeExpensesNet>
    <cmmb:FinanceIncomeExpensesNet
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20220719180539700_xbrl_20220719164544402"
      unitRef="USD">-264000</cmmb:FinanceIncomeExpensesNet>
    <cmmb:FinanceIncomeExpensesNet
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="Fxbrl_20220719180539700_xbrl_20220719164546402"
      unitRef="USD">-22000</cmmb:FinanceIncomeExpensesNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20220401to20220630"
      decimals="-3"
      id="Fxbrl_20220808224756229"
      unitRef="USD">-6734000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20210401to20210630"
      decimals="-3"
      id="Fxbrl_20220808224804527"
      unitRef="USD">-2770000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20220808224806687"
      unitRef="USD">-11838000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="Fxbrl_20220808224808919"
      unitRef="USD">-4474000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20220401to20220630"
      decimals="-3"
      id="Fxbrl_20220728231430174"
      unitRef="USD">-544000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20210401to20210630"
      decimals="-3"
      id="FFact_101"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20220728231438213"
      unitRef="USD">-544000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="Fxbrl_20220719164514240"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220401to20220630"
      decimals="-3"
      id="FFact_104"
      unitRef="USD">-6190000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210401to20210630"
      decimals="-3"
      id="FFact_105"
      unitRef="USD">-2770000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20220719164519088"
      unitRef="USD">-11294000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="Fxbrl_20220719164521040"
      unitRef="USD">-4474000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20220401to20220630"
      decimals="3"
      id="Fxbrl_20220801220211119"
      unitRef="USD_per_share">0.027</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20220401to20220630"
      decimals="3"
      id="Fxbrl_20220809022126183"
      unitRef="USD_per_share">0.027</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20210401to20210630"
      decimals="3"
      id="Fxbrl_20220801220307005"
      unitRef="USD_per_share">0.013</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20210401to20210630"
      decimals="3"
      id="Fxbrl_20220809022138581"
      unitRef="USD_per_share">0.013</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20220101to20220630"
      decimals="3"
      id="Fxbrl_20220801220408934"
      unitRef="USD_per_share">0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20220101to20220630"
      decimals="3"
      id="Fxbrl_20220809022148798"
      unitRef="USD_per_share">0.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20210101to20210630"
      decimals="3"
      id="Fxbrl_20220801220459941"
      unitRef="USD_per_share">0.024</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20210101to20210630"
      decimals="3"
      id="Fxbrl_20220809022201676"
      unitRef="USD_per_share">0.024</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20220401to20220630"
      decimals="INF"
      id="Fxbrl_20220720153627242"
      unitRef="Share">228173276</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20220401to20220630"
      decimals="INF"
      id="Fxbrl_20220809022343739"
      unitRef="Share">228173276</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20210401to20210630"
      decimals="INF"
      id="Fxbrl_20220720153632498"
      unitRef="Share">216266993</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20210401to20210630"
      decimals="INF"
      id="Fxbrl_20220809022355319"
      unitRef="Share">216266993</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20220101to20220630"
      decimals="INF"
      id="Fxbrl_20220720153639507"
      unitRef="Share">228132249</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20220101to20220630"
      decimals="INF"
      id="Fxbrl_20220809022408661"
      unitRef="Share">228132249</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20210101to20210630"
      decimals="INF"
      id="Fxbrl_20220720153641684"
      unitRef="Share">186840022</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20210101to20210630"
      decimals="INF"
      id="Fxbrl_20220809022503184"
      unitRef="Share">186840022</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20220719171142064_xbrl_20220504161436664"
      unitRef="Share">228090300</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20220719171142064_xbrl_20220505093740414"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220719171142064_xbrl_20220504161607482"
      unitRef="USD">97639000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220719171142064_xbrl_20220504161812745"
      unitRef="USD">-36173000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20220719171142064_xbrl_20220504161847247"
      unitRef="USD">61466000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20220101to20220331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20220719171155021_xbrl_20220505093821193"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20220101to20220331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220719171155021_xbrl_20220504161917493"
      unitRef="USD">874000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20220101to20220331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220719171155021_xbrl_20220505093815054"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20220101to20220331"
      decimals="-3"
      id="Fxbrl_20220719171155021_xbrl_20220504161939600"
      unitRef="USD">874000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20220331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20220719171210751_xbrl_20220505093843525"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20220331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220719171210751_xbrl_20220505093847704"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20220331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220719171210751_xbrl_20220504162015389"
      unitRef="USD">-5104000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20220331"
      decimals="-3"
      id="Fxbrl_20220719171210751_xbrl_20220504162029289"
      unitRef="USD">-5104000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_20220331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20220719171143948_xbrl_20220504161436664"
      unitRef="Share">228090300</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20220331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20220719171143948_xbrl_20220505093740414"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20220331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220719171143948_xbrl_20220504161607482"
      unitRef="USD">98513000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20220331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220719171143948_xbrl_20220504161812745"
      unitRef="USD">-41277000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20220331"
      decimals="-3"
      id="Fxbrl_20220719171143948_xbrl_20220504161847247"
      unitRef="USD">57236000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20220719171157157_xbrl_20220505093821193"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220719171157157_xbrl_20220504161917493"
      unitRef="USD">761000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220719171157157_xbrl_20220505093815054"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20220401to20220630"
      decimals="-3"
      id="Fxbrl_20220719171157157_xbrl_20220504161939600"
      unitRef="USD">761000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20220719171227712"
      unitRef="Share">542820</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20220719171215975_xbrl_20220505093843525"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220719171215975_xbrl_20220505093847704"
      unitRef="USD">29000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220719171215975_xbrl_20220504162015389"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20220401to20220630"
      decimals="-3"
      id="Fxbrl_20220719171215975_xbrl_20220504162029289"
      unitRef="USD">29000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20220719171212527_xbrl_20220505093843525"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220719171212527_xbrl_20220505093847704"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220719171212527_xbrl_20220504162015389"
      unitRef="USD">-6190000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220401to20220630"
      decimals="-3"
      id="Fxbrl_20220719171212527_xbrl_20220504162029289"
      unitRef="USD">-6190000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20220719171146108_xbrl_20220504161436664"
      unitRef="Share">228633120</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20220719171146108_xbrl_20220505093740414"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220719171146108_xbrl_20220504161607482"
      unitRef="USD">99303000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220719171146108_xbrl_20220504161812745"
      unitRef="USD">-47467000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20220630"
      decimals="-3"
      id="Fxbrl_20220719171146108_xbrl_20220504161847247"
      unitRef="USD">51836000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20220504161436664"
      unitRef="Share">9274838</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20220505093740414"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220504161607482"
      unitRef="USD">34497000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220504161812745"
      unitRef="USD">-23695000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20201231"
      decimals="-3"
      id="Fxbrl_20220504161847247"
      unitRef="USD">10802000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20210101to20210331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20220505093821193"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20210101to20210331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220504161917493"
      unitRef="USD">43000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20210101to20210331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220505093815054"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20210101to20210331"
      decimals="-3"
      id="Fxbrl_20220504161939600"
      unitRef="USD">43000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <cmmb:EffectOfReverseCapitalizationTransactionShares
      contextRef="C_20210101to20210331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20220719171018175_xbrl_20220509163550193"
      unitRef="Share">152299702</cmmb:EffectOfReverseCapitalizationTransactionShares>
    <cmmb:EffectOfReverseCapitalizationTransaction
      contextRef="C_20210101to20210331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20220719171018175_xbrl_20220509172328807"
      unitRef="USD">0</cmmb:EffectOfReverseCapitalizationTransaction>
    <cmmb:EffectOfReverseCapitalizationTransaction
      contextRef="C_20210101to20210331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220719171018175_xbrl_20220509172946846"
      unitRef="USD">2476000</cmmb:EffectOfReverseCapitalizationTransaction>
    <cmmb:EffectOfReverseCapitalizationTransaction
      contextRef="C_20210101to20210331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220719171018175_xbrl_20220509164008995"
      unitRef="USD">0</cmmb:EffectOfReverseCapitalizationTransaction>
    <cmmb:EffectOfReverseCapitalizationTransaction
      contextRef="C_20210101to20210331"
      decimals="-3"
      id="Fxbrl_20220719171018175_xbrl_20220509163651908"
      unitRef="USD">2476000</cmmb:EffectOfReverseCapitalizationTransaction>
    <cmmb:StockAndWarrantIssuedDuringPeriodNewIssues
      contextRef="C_20210101to20210331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20220719171029396_xbrl_20220509163909641"
      unitRef="Share">52385400</cmmb:StockAndWarrantIssuedDuringPeriodNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20210101to20210331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20220719171029396_xbrl_20220509165714258"
      unitRef="USD">0</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20210101to20210331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220719171029396_xbrl_20220509163916692"
      unitRef="USD">43547000</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20210101to20210331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220719171029396_xbrl_20220509164000245"
      unitRef="USD">0</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20210101to20210331"
      decimals="-3"
      id="Fxbrl_20220719171029396_xbrl_20220509163919739"
      unitRef="USD">43547000</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210101to20210331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20220505093843525"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210101to20210331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220505093847704"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210101to20210331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220504162015389"
      unitRef="USD">-1704000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210101to20210331"
      decimals="-3"
      id="Fxbrl_20220504162029289"
      unitRef="USD">-1704000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_20210331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20220504162054050"
      unitRef="Share">213959940</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20210331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20220505093917037"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20210331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220504162134224"
      unitRef="USD">80563000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20210331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220504162140381"
      unitRef="USD">-25399000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20210331"
      decimals="-3"
      id="Fxbrl_20220504162145961"
      unitRef="USD">55164000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20210401to20210630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20220505094011117"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20210401to20210630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220504162242016"
      unitRef="USD">527000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20210401to20210630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220505094006095"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20210401to20210630"
      decimals="-3"
      id="Fxbrl_20220504162250216"
      unitRef="USD">527000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_20210401to20210630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20220509163909641"
      unitRef="Share">13996120</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_20210401to20210630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20220509165714258"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_20210401to20210630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220509163916692"
      unitRef="USD">15118000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_20210401to20210630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220509164000245"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_20210401to20210630"
      decimals="INF"
      id="Fxbrl_20220509163919739"
      unitRef="Share">15118</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210401to20210630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20220505094033172"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210401to20210630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220505094023997"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210401to20210630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220504162305425"
      unitRef="USD">-2770000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210401to20210630"
      decimals="-3"
      id="Fxbrl_20220504162313633"
      unitRef="USD">-2770000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_20210630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20220504162109962"
      unitRef="Share">227956060</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20210630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20220505094051101"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20210630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220504162332928"
      unitRef="USD">96208000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20210630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220504162338080"
      unitRef="USD">-28169000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20210630"
      decimals="-3"
      id="Fxbrl_20220504162343720"
      unitRef="USD">68039000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_193"
      unitRef="USD">-11294000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_194"
      unitRef="USD">-4474000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_195"
      unitRef="USD">27000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_196"
      unitRef="USD">14000</us-gaap:Depreciation>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_197"
      unitRef="USD">1483000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="Fxbrl_20220719185926153"
      unitRef="USD">2529000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20220719190053059"
      unitRef="USD">-15000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="Fxbrl_20220504154924941"
      unitRef="USD">0</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_199"
      unitRef="USD">97000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_200"
      unitRef="USD">312000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_201"
      unitRef="USD">1157000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_202"
      unitRef="USD">-993000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_203"
      unitRef="USD">464000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_204"
      unitRef="USD">200000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_205"
      unitRef="USD">1635000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_206"
      unitRef="USD">570000</us-gaap:ShareBasedCompensation>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_207"
      unitRef="USD">1882000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="Fxbrl_20220719185858022"
      unitRef="USD">-2426000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_209"
      unitRef="USD">-9412000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_210"
      unitRef="USD">-6900000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <cmmb:PaymentsToPurchaseOfDeposits
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20220801194023381_Fact_211"
      unitRef="USD">0</cmmb:PaymentsToPurchaseOfDeposits>
    <cmmb:PaymentsToPurchaseOfDeposits
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="Fxbrl_20220801194023381_xbrl_20220719190124821"
      unitRef="USD">21500000</cmmb:PaymentsToPurchaseOfDeposits>
    <cmmb:ProceedsFromSaleOfDeposits
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_211"
      unitRef="USD">4134000</cmmb:ProceedsFromSaleOfDeposits>
    <cmmb:ProceedsFromSaleOfDeposits
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="Fxbrl_20220719190124821"
      unitRef="USD">0</cmmb:ProceedsFromSaleOfDeposits>
    <us-gaap:ProceedsFromSaleOfPropertyHeldForSale
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20220719180938189_Fact_211"
      unitRef="USD">0</us-gaap:ProceedsFromSaleOfPropertyHeldForSale>
    <us-gaap:ProceedsFromSaleOfPropertyHeldForSale
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="Fxbrl_20220719180938189_Fact_212"
      unitRef="USD">1000000</us-gaap:ProceedsFromSaleOfPropertyHeldForSale>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_215"
      unitRef="USD">25000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_216"
      unitRef="USD">105000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_217"
      unitRef="USD">4109000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_218"
      unitRef="USD">-20605000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <cmmb:CashAcquiredInReverseRecapitalization
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20220504155015779"
      unitRef="USD">0</cmmb:CashAcquiredInReverseRecapitalization>
    <cmmb:CashAcquiredInReverseRecapitalization
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_221"
      unitRef="USD">2427000</cmmb:CashAcquiredInReverseRecapitalization>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20220719180719914_Fact_209"
      unitRef="USD">22000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="Fxbrl_20220719180719914_Fact_210"
      unitRef="USD">0</us-gaap:ProceedsFromStockOptionsExercised>
    <cmmb:IssuanceOfSharesNetOfIssuanceCosts
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20220719180724993_Fact_209"
      unitRef="USD">0</cmmb:IssuanceOfSharesNetOfIssuanceCosts>
    <cmmb:IssuanceOfSharesNetOfIssuanceCosts
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="Fxbrl_20220719180724993_Fact_210"
      unitRef="USD">15243000</cmmb:IssuanceOfSharesNetOfIssuanceCosts>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_227"
      unitRef="USD">0</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_228"
      unitRef="USD">43557000</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_229"
      unitRef="USD">22000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_230"
      unitRef="USD">61227000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_231"
      unitRef="USD">-5281000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_232"
      unitRef="USD">33722000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_233"
      unitRef="USD">15241000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20201231"
      decimals="-3"
      id="FFact_234"
      unitRef="USD">11727000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20220630"
      decimals="-3"
      id="FFact_235"
      unitRef="USD">9960000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20210630"
      decimals="-3"
      id="FFact_236"
      unitRef="USD">45449000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <cmmb:LiabilitiesAssumedNetOfNonCashAssetsReceivedInReverseMerger
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20220505095521944"
      unitRef="USD">0</cmmb:LiabilitiesAssumedNetOfNonCashAssetsReceivedInReverseMerger>
    <cmmb:LiabilitiesAssumedNetOfNonCashAssetsReceivedInReverseMerger
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_237"
      unitRef="USD">49000</cmmb:LiabilitiesAssumedNetOfNonCashAssetsReceivedInReverseMerger>
    <cmmb:AccountReceivableDueToExerciseOfOptions
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20220719180738568_Fact_209"
      unitRef="USD">7000</cmmb:AccountReceivableDueToExerciseOfOptions>
    <cmmb:AccountReceivableDueToExerciseOfOptions
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="Fxbrl_20220719180738568_Fact_210"
      unitRef="USD">0</cmmb:AccountReceivableDueToExerciseOfOptions>
    <cmmb:AccruedShareIssuanceExpenses
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20220505095540169"
      unitRef="USD">0</cmmb:AccruedShareIssuanceExpenses>
    <cmmb:AccruedShareIssuanceExpenses
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_239"
      unitRef="USD">135000</cmmb:AccruedShareIssuanceExpenses>
    <us-gaap:NatureOfOperations
      contextRef="C_20220101to20220630"
      id="Fxbrl_20220505134250696">
    &lt;div&gt;
      &lt;div&gt;
        &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;span&gt;&lt;span&gt;Note 1 - General.&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div&gt;
          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
                &lt;div&gt;
                  &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                      &lt;tr&gt;
                        &lt;td style="width:72pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;
                          &lt;div style="margin-left:36pt;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;A.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style="width:auto;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;
                          &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Chemomab Therapeutics Ltd. (the &#x201c;Company") is an Israeli -based company incorporated under the laws of the State of Israel in September 2011. The Company&#x2019;s registered office is located in Kiryat Atidim, Tel Aviv, Israel. The Company is a clinical-stage biotech company discovering and developing innovative therapeutics for conditions with high-unmet medical need that involve inflammation and fibrosis.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;

                  &lt;/table&gt;
                &lt;/div&gt;
                &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
                &lt;div&gt;
                  &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                      &lt;tr&gt;
                        &lt;td style="width:72pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;
                          &lt;div style="margin-left:36pt;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;B.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style="width:auto;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;
                          &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On March&#160;16, 2021, the Company, then known as Anchiano Therapeutics Ltd. (&#x201c;Anchiano&#x201d;), completed its merger with Chemomab Ltd., a privately-held Israeli limited company (&#x201c;Chemomab Ltd.&#x201d;). Pursuant to the Agreement and Plan of Merger (the &#x201c;Merger Agreement&#x201d;) dated as of December&#160;14, 2020, by and among Anchiano, CMB Acquisition Ltd., an Israeli limited company and wholly-owned subsidiary of Anchiano (&#x201c;Merger Sub&#x201d;), and Chemomab Ltd., Merger Sub merged with and into Chemomab Ltd., with Chemomab Ltd. being the surviving entity and becoming a wholly owned subsidiary of Anchiano (the &#x201c;Merger&#x201d;).&#160; Upon consummation of the Merger, the Company changed its name from &#x201c;Anchiano Therapeutics Ltd.&#x201d; to &#x201c;Chemomab Therapeutics Ltd.&#x201d; and the business conducted by Chemomab Ltd. became primarily the business conducted by the Company.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;

                  &lt;/table&gt;
                &lt;/div&gt;
                &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
                &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;For accounting purposes, Chemomab Ltd. is considered to have acquired Anchiano based upon the terms of the Merger as well as other factors including: (i) Chemomab Ltd.'s former shareholders owned approximately&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&#160;90% &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;of the combined Company&#x2019;s outstanding ordinary shares immediately following the closing of the Merger and (ii) Chemomab Ltd. management holds key management positions of the combined Company. The Merger has been accounted for as an asset acquisition (reverse recapitalization transaction) rather than a business combination, as the assets acquired and the liabilities assumed by Chemomab Ltd. do not meet the definition of a business under accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;). The net assets acquired in connection with the Merger were recorded at their estimated acquisition date fair market value as of March 16, 2021, the date of completion of the Merger.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
                &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Immediately prior to the effective date of the Merger, all preferred shares of Chemomab Ltd. were converted into ordinary shares of Chemomab Ltd. on a one-for-one basis.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
                &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;In connection with the Merger, and following the effective time of the Merger, the Company effected a reverse share split of the Company&#x2019;s ordinary shares at a ratio of 4:1 (the &#x201c;Reverse Split&#x201d;) and increased the number of ordinary shares underlying each American Depositary Share ("ADS") from 5 to 20. At the effective time of the Merger, each Chemomab Ltd. ordinary share outstanding immediately prior to the effective time of the Merger automatically converted into the right to receive approximately 12.86 ADSs, each representing 20 Anchiano ordinary shares, plus a warrant to purchase ADSs that may become exercisable only under certain circumstances.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
                &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The exchange ratio was calculated by a formula that was determined through arms-length negotiations between the Company and Chemomab Ltd. The combined Company assumed all of the outstanding options of Chemomab Ltd., vested and unvested, under the Chemomab Share Incentive Plan (the &#x201c;2015 Plan&#x201d;), with such options representing the right to purchase a number of ADSs equal to approximately 12.86 multiplied by the number of Chemomab Ltd. ordinary shares previously represented by such options.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
      &lt;div&gt;
        &lt;div/&gt;
        &lt;div&gt;
          &lt;div&gt;
            &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
            &lt;p style="margin-top:0pt;margin-left:72pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The accompanying unaudited condensed consolidated financial statements and notes to the unaudited condensed consolidated financial statements give retroactive effect to the exchange ratio and the Reverse Split for all periods presented.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
                &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The equity structure reflects the legal acquirer's equity structure. The balance sheet has been adjusted to reflect the par value of the outstanding shares of the legal acquirer, including the number of shares issued in the Merger. Any difference is recognized as an adjustment to the additional paid in capital.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
                &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Immediately after completion of the Merger, on March 16, 2021, the Company had 8,078,727 ADS issued and outstanding (9,003,357 on a fully diluted basis). In addition, immediately after the Merger, Chemomab Ltd. former shareholders owned approximately 90% of the number of issued and outstanding ordinary shares of the Company and the shareholders of the Company immediately prior to the Merger owned approximately 10% &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;of the number of issued and outstanding ordinary shares of the Company (all on a fully diluted basis).&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
                &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;On March 16, 2021, immediately prior to the effectiveness of the Merger, Anchiano had 65,675,904 ordinary shares outstanding (prior to the effect of the Reverse Split) and a market capitalization of $58.7 million. The estimated fair value of the net assets of Anchiano on March 16, 2021, prior to the Merger, was approximately $2.5 million. The fair value of ordinary shares on the Merger closing date, prior to the Merger, was above the fair value of the Company&#x2019;s net assets. As the Company&#x2019;s net assets were predominantly composed of cash offset against current liabilities, the fair value of the Company&#x2019;s net assets as of March 16, 2021, prior to the Merger, is considered to be the best indicator of the fair value and, therefore, the estimated preliminary purchase consideration.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
                &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The following table summarizes the net assets acquired based on their estimated fair values as of March 16, 2021, immediately prior to completion of the Merger (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
                &lt;div&gt;
                  &lt;div style="margin-left:72pt"&gt;

                      &lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:90%"&gt;

                          &lt;tr&gt;
                            &lt;td style="vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;width:88%" valign="bottom"&gt;
                              &lt;div style="text-indent:-12pt;margin-left:12pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Cash and cash equivalents&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2,427&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%" valign="bottom"&gt;
                              &lt;div style="text-indent:-12pt;margin-left:12pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Asset held for sale&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                              &lt;div style="text-indent:-12pt;margin-left:12pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Prepaid and other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;236&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%;padding-bottom:2px" valign="bottom"&gt;
                              &lt;div style="text-indent:-12pt;margin-left:12pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;(1,187&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td colspan="1" style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Net acquired assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2,476&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;

                      &lt;/table&gt;

                  &lt;/div&gt;
                &lt;/div&gt;
                &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both"&gt;&#160;&lt;/div&gt;
                &lt;div&gt;
                  &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                      &lt;tr&gt;
                        &lt;td style="width:72pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;
                          &lt;div style="margin-left:36pt;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;C.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style="width:auto;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;
                          &lt;div style="text-align:justify;line-height:1.25"&gt;In connection with the Merger, on March 15, 2021, Anchiano entered into Securities Purchase Agreements with certain purchasers for the issuance and sale by Anchiano in a private placement (the &#x201c;Private Placement&#x201d;) of approximately&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt; $45.5 million &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;of its ADSs and accompanying warrants to purchase ADSs. The warrants have an exercise price of approximately&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt; $17.35&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;per ADS, expire&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&#160;five years&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;from the date of issuance, and if exercised in full, will provide additional proceeds to the Company of approximately&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt; $4.5 million. &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;The Private Placement closed on March 22, 2021.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;

                  &lt;/table&gt;
                &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif"&gt;&#160;&lt;/div&gt;
            &lt;div/&gt;
            &lt;div style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif"&gt;&#160;&lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div&gt;
                  &lt;div&gt;
                    &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                        &lt;tr&gt;
                          &lt;td style="width:72pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;
                            &lt;div style="margin-left:36pt;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;D.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td style="width:auto;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;
                            &lt;div style="text-align:justify;line-height:1.25"&gt;Pursuant to an Asset Purchase and Assignment Agreement dated as of March 16, 2021, as amended on March 31, 2021, between the Company&#x2019;s wholly owned subsidiary, Anchiano Therapeutics, Inc., a Delaware corporation (&#x201c;Anchiano Delaware&#x201d;) and Kestrel Therapeutics, Inc., a Delaware corporation (&#x201c;Kestrel&#x201d;), Anchiano Delaware agreed to sell to Kestrel all of the its rights and obligations in its business to the extent related to the research, development and commercialization of the Compounds and Products (as such terms are defined in the Collaboration and License Agreement entered into as of September 13, 2019, by and between ADT Pharmaceuticals, LLC and Anchiano Delaware), also known as the pan-RAS and PDE10/&#x3b2;-catenin programs. In consideration of the sale and transfer of the Compounds and Products, Kestrel paid the Company a total of $&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1.0 million.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                        &lt;/tr&gt;

                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
                  &lt;div&gt;
                    &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                        &lt;tr&gt;
                          &lt;td style="width:72pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;
                            &lt;div style="margin-left:36pt;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;E.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td style="width:auto;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;
                            &lt;div style="text-align:justify;line-height:1.25"&gt;On April 30, 2021, the Company entered into an At the Market Offering Agreement (the "ATM Agreement") with Cantor Fitzgerald &amp;amp; Co., ("Cantor"). According to the ATM Agreement, the Company may offer and sell, from time to time, its ADSs having an aggregate offering price of up to&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&#160;$75.0 &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;million through Cantor pursuant to the ATM Agreement. From April 30, 2021 through June 30, 2022, the Company sold&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt; 699,806 ADSs at an average price of $22.75 &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;per ADS under the ATM Agreement, resulting in gross proceeds of approximately&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt; $15.9 &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;million&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;. &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;The offer and sale of ADSs under the ATM Agreement has been registered under the Company&#x2019;s effective registration statement on Form S-3 (File No. 333-255658), together with a prospectus forming a part thereof, filed with the SEC under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;). Sales, if any, of ADS pursuant to the ATM Agreement may be made in any transactions that are deemed to be &#x201c;at the market&#x201d; offerings as defined in Rule 415(a)(4) under the Securities Act. The Company is not obligated to sell any ADSs under the ATM Agreement.&lt;/div&gt;
                          &lt;/td&gt;
                        &lt;/tr&gt;

                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
                  &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;On April 25, 2022, the Company filed with the SEC a prospectus supplement to the above mentioned registration statement for the issuance and sale of up to&lt;/span&gt;&lt;/span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt; $18,125,000 &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;of the Company's ADSs under the ATM Agreement, which is within the $75 million maximum permitted under the ATM Agreement.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
                  &lt;div&gt;
                    &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                        &lt;tr&gt;
                          &lt;td style="width:72pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;
                            &lt;div style="margin-left:36pt;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;F.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td style="width:auto;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;
                            &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Since January 2020, the COVID-19 outbreak has dramatically expanded into a worldwide pandemic creating macro-economic uncertainty and disruption in the business and financial markets. Many countries around the world, including Israel, have been taking measures designated to limit the continued spread of the Coronavirus, including the closure of workplaces, restricting travel, prohibiting assembling, closing international borders and quarantining populated areas. The Company's clinical trial sites have been affected by the COVID-19 pandemic, and as a result, commencement of the enrollment of Company&#x2019;s clinical trials of CM-101 in PSC was delayed and the enrollment rate has been affected as well. As a result, the Company extended patients recruiting to additional territories with significant recruitment potential. In addition, after enrollment in these trials, patients may drop out of the Company's trials because of the COVID-19 possible implications.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                        &lt;/tr&gt;

                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
                  &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Based on management&#x2019;s assessment, the extent to which the coronavirus will further impact the Company&#x2019;s operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration and severity of the outbreak, and the actions that may be required to contain the coronavirus or treat its impact. The Company is carefully monitoring the restrictions due to the COVID-19 outbreak and will adjust activities accordingly.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;
                    &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
                  &lt;/div&gt;
                  &lt;div/&gt;
                  &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;
                    &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;On March 27, 2020 and December 27, 2020, the President of the United States signed and enacted into law the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) and the Consolidated Appropriations Act, 2021 (CAA). Among other provisions, the CARES Act and the CAA provide relief to U.S. federal corporate taxpayers through temporary adjustments to net operating loss rules, changes to limitations on interest expense deductibility, and the acceleration of available refunds for minimum tax credit carryforwards. The CARES Act also includes provisions for a carryback of any net operating loss (NOL) arising in a taxable year beginning after December 31, 2017, and before January 1, 2021, to each of the five taxable years preceding the taxable year in which the loss arises (carryback period).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
                  &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;
                    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Chemomab Therapeutics Inc., a wholly owned subsidiary of the Company, filed an application with the US Internal Revenue Service to carryback net operating losses. The Company expects to receive the refund during the second half of 2022.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:NatureOfOperations>
    <cmmb:ShareholdingPercentageImmediatelyFollowingMerger
      contextRef="C_20210314to20210316_srtTitleOfIndividualAxis_cmmbFormerChemomabSecurityHoldersMember"
      decimals="2"
      id="Fxbrl_20220801194753103"
      unitRef="Pure">0.90</cmmb:ShareholdingPercentageImmediatelyFollowingMerger>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_20210314to20210316"
      decimals="2"
      id="Fxbrl_20220801211724341"
      unitRef="Pure">0.04</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <cmmb:NumberOfOrdinarySharesForEachPreferredShareConvertedPriorToDateOfMerger
      contextRef="C_20210314to20210316"
      decimals="INF"
      id="Fxbrl_20220801211728344"
      unitRef="Share">1</cmmb:NumberOfOrdinarySharesForEachPreferredShareConvertedPriorToDateOfMerger>
    <cmmb:NumberOfAdsIssuedAndOutstandingAfterMerger
      contextRef="C_20210316_usgaapBusinessAcquisitionAxis_cmmbMergerAgreementWithChemomabIsraeliLimitedCompanyAndClinicalStageBiotechCompanyMember"
      decimals="INF"
      id="Fxbrl_20220719155933012"
      unitRef="Share">12.86</cmmb:NumberOfAdsIssuedAndOutstandingAfterMerger>
    <cmmb:NumberOfOrdinarySharesConsistedInDS
      contextRef="C_20210314to20210316_usgaapBusinessAcquisitionAxis_cmmbMergerAgreementWithChemomabIsraeliLimitedCompanyAndClinicalStageBiotechCompanyMember"
      decimals="INF"
      id="Fxbrl_20220801195039967"
      unitRef="Share">20</cmmb:NumberOfOrdinarySharesConsistedInDS>
    <cmmb:NumberOfSharesDilutedAfterMerger
      contextRef="C_20210316_usgaapBusinessAcquisitionAxis_cmmbMergerAgreementWithChemomabIsraeliLimitedCompanyAndClinicalStageBiotechCompanyMember"
      decimals="INF"
      id="Fxbrl_20220719160013200"
      unitRef="Share">8078727</cmmb:NumberOfSharesDilutedAfterMerger>
    <cmmb:SharesConvertiblePerShareOfAcquireeEntity
      contextRef="C_20210314to20210316_usgaapBusinessAcquisitionAxis_cmmbMergerAgreementWithChemomabIsraeliLimitedCompanyAndClinicalStageBiotechCompanyMember"
      decimals="INF"
      id="Fxbrl_20220719160028273"
      unitRef="Share">9003357</cmmb:SharesConvertiblePerShareOfAcquireeEntity>
    <cmmb:ShareholdingPercentageImmediatelyFollowingMerger
      contextRef="C_20210314to20210316_srtTitleOfIndividualAxis_cmmbFormerChemomabSecurityHoldersMember"
      decimals="2"
      id="Fxbrl_20220719160036138"
      unitRef="Pure">0.90</cmmb:ShareholdingPercentageImmediatelyFollowingMerger>
    <cmmb:NumberOfOrdinarySharesForEachPreferredShareConvertedPriorToDateOfMerger
      contextRef="C_20210314to20210316_srtTitleOfIndividualAxis_cmmbFormerChemomabSecurityHoldersMember"
      decimals="INF"
      id="Fxbrl_20220719160047972"
      unitRef="Share">65675904</cmmb:NumberOfOrdinarySharesForEachPreferredShareConvertedPriorToDateOfMerger>
    <us-gaap:Capital
      contextRef="C_20210316"
      decimals="-5"
      id="Fxbrl_20220719160056244"
      unitRef="USD">58700000</us-gaap:Capital>
    <cmmb:RetainedEarningsAccumulatedDeficits
      contextRef="C_20210316_srtTitleOfIndividualAxis_cmmbFormerChemomabSecurityHoldersMember"
      decimals="-5"
      id="Fxbrl_20220719160102341"
      unitRef="USD">-2500000</cmmb:RetainedEarningsAccumulatedDeficits>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="C_20220101to20220630"
      id="Fxbrl_20220801194203792">
                      &lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:90%"&gt;

                          &lt;tr&gt;
                            &lt;td style="vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;width:88%" valign="bottom"&gt;
                              &lt;div style="text-indent:-12pt;margin-left:12pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Cash and cash equivalents&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2,427&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%" valign="bottom"&gt;
                              &lt;div style="text-indent:-12pt;margin-left:12pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Asset held for sale&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                              &lt;div style="text-indent:-12pt;margin-left:12pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Prepaid and other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;236&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%;padding-bottom:2px" valign="bottom"&gt;
                              &lt;div style="text-indent:-12pt;margin-left:12pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;(1,187&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td colspan="1" style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Net acquired assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2,476&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;

                      &lt;/table&gt;
                    </us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="C_20210316"
      decimals="-3"
      id="FFact_251"
      unitRef="USD">2427000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <cmmb:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale
      contextRef="C_20210316"
      decimals="-3"
      id="FFact_252"
      unitRef="USD">1000000</cmmb:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="C_20210316"
      decimals="-3"
      id="FFact_253"
      unitRef="USD">236000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <cmmb:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses
      contextRef="C_20210316"
      decimals="-3"
      id="FFact_254"
      unitRef="USD">-1187000</cmmb:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses>
    <cmmb:EstimatedFairValueOfNetAssetsAcquired
      contextRef="C_20210316"
      decimals="-3"
      id="FFact_255"
      unitRef="USD">2476000</cmmb:EstimatedFairValueOfNetAssetsAcquired>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="C_20210301to20210315"
      decimals="-5"
      id="Fxbrl_20220719160118070"
      unitRef="USD">45500000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_20210315"
      decimals="2"
      id="Fxbrl_20220808231241599"
      unitRef="USD_per_share">17.35</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <cmmb:WarrantsExercisablePeriod
      contextRef="C_20210301to20210315"
      id="Fxbrl_20220719160132552">P5Y</cmmb:WarrantsExercisablePeriod>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_20210301to20210315"
      decimals="-5"
      id="Fxbrl_20220719160138785"
      unitRef="USD">4500000</us-gaap:ProceedsFromWarrantExercises>
    <cmmb:AmountOfTotalSaleAndTransferOfCompoundsAndProductsKestrelPaid
      contextRef="C_20210301to20210315"
      decimals="-5"
      id="Fxbrl_20220801230315934"
      unitRef="USD">1000000</cmmb:AmountOfTotalSaleAndTransferOfCompoundsAndProductsKestrelPaid>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_20210401to20210430_usgaapStatementClassOfStockAxis_cmmbAmericanDepositorySharesMember_usgaapSubsidiarySaleOfStockAxis_cmmbAtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember"
      decimals="-5"
      id="Fxbrl_20220719160218493"
      unitRef="USD">75000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_20210501to20220630_usgaapStatementClassOfStockAxis_cmmbAmericanDepositorySharesMember_usgaapSubsidiarySaleOfStockAxis_cmmbAtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember"
      decimals="INF"
      id="Fxbrl_20220719160226621"
      unitRef="Share">699806</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_20220630_usgaapStatementClassOfStockAxis_cmmbAmericanDepositorySharesMember_usgaapSubsidiarySaleOfStockAxis_cmmbAtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember"
      decimals="2"
      id="Fxbrl_20220719160233894"
      unitRef="USD_per_share">22.75</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="C_20210501to20220630_usgaapStatementClassOfStockAxis_cmmbAmericanDepositorySharesMember_usgaapSubsidiarySaleOfStockAxis_cmmbAtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember"
      decimals="-5"
      id="Fxbrl_20220719160245351"
      unitRef="USD">15900000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_20220401to20220425_srtRangeAxis_srtMaximumMember_usgaapStatementClassOfStockAxis_cmmbAmericanDepositorySharesMember_usgaapSubsidiarySaleOfStockAxis_cmmbAtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember"
      decimals="0"
      id="Fxbrl_20220720110354187"
      unitRef="USD">18125000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_20220101to20220630"
      id="Fxbrl_20220505134338955">
      &lt;div&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;&lt;span&gt;Note 2 - Basis of Presentation and Significant Accounting Policies &lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

          &lt;div&gt;
            &lt;p style="margin-top:0pt;margin-left:36pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;A.&#160; &#160; &#160; &#160; &#160; Basis of Preparation&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
            &lt;p style="margin-top:0pt;margin-left:48px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;
            &lt;p style="margin-top:0pt;margin-left:36pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;The condensed interim consolidated financial statements included in this quarterly report are unaudited. These financial statements have been prepared in accordance with U.S. GAAP and applicable rules and regulations of the SEC regarding interim financial reporting and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for a fair statement of the Company&#x2019;s financial position as of June 30, 2022, and its results of operations for the three and six months ended June 30, 2022, and 2021, changes in shareholders&#x2019; equity for the six months ended June 30, 2022 and 2021, and cash flows for the six months ended June 30, 2022 and 2021. The results of operations for the three and six months ended June 30, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022 or for any other future annual or interim period. These financial statements should be read in conjunction with the audited financial statements included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC. The Company&#x2019;s significant accounting policies are disclosed in the audited financial statements for the year ended December 31, 2021 included in the Company&#x2019;s Annual Report on Form 10-K. Since the date of such financial statements, there have been no changes to the Company&#x2019;s significant accounting policies.&lt;/p&gt;
          &lt;/div&gt;

        &lt;p style="margin-top:0pt;margin-left:48px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

          &lt;div&gt;
            &lt;p style="margin-top:0pt;margin-left:36pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;B.&#160; &#160; &#160; &#160; &#160; Use of estimates&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
            &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
            &lt;p style="margin-top:0pt;margin-left:36pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
          &lt;/div&gt;

      &lt;/div&gt;
    </us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_20220101to20220630"
      id="Fxbrl_20220505104021668">
          &lt;div&gt;
            &lt;p style="margin-top:0pt;margin-left:36pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;A.&#160; &#160; &#160; &#160; &#160; Basis of Preparation&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
            &lt;p style="margin-top:0pt;margin-left:48px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;
            &lt;p style="margin-top:0pt;margin-left:36pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;The condensed interim consolidated financial statements included in this quarterly report are unaudited. These financial statements have been prepared in accordance with U.S. GAAP and applicable rules and regulations of the SEC regarding interim financial reporting and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for a fair statement of the Company&#x2019;s financial position as of June 30, 2022, and its results of operations for the three and six months ended June 30, 2022, and 2021, changes in shareholders&#x2019; equity for the six months ended June 30, 2022 and 2021, and cash flows for the six months ended June 30, 2022 and 2021. The results of operations for the three and six months ended June 30, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022 or for any other future annual or interim period. These financial statements should be read in conjunction with the audited financial statements included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC. The Company&#x2019;s significant accounting policies are disclosed in the audited financial statements for the year ended December 31, 2021 included in the Company&#x2019;s Annual Report on Form 10-K. Since the date of such financial statements, there have been no changes to the Company&#x2019;s significant accounting policies.&lt;/p&gt;
          &lt;/div&gt;
        </us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_20220101to20220630"
      id="Fxbrl_20220505104106171">
          &lt;div&gt;
            &lt;p style="margin-top:0pt;margin-left:36pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;B.&#160; &#160; &#160; &#160; &#160; Use of estimates&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
            &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
            &lt;p style="margin-top:0pt;margin-left:36pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
          &lt;/div&gt;
        </us-gaap:UseOfEstimates>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_20220101to20220630"
      id="Fxbrl_20220728222325384">
    &lt;div&gt;
      &lt;div style="margin-top:0px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Note 3 - Contingencies&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
      &lt;div&gt;
        &lt;div&gt;
          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;During 2022, &lt;/span&gt;&lt;/span&gt;the Israeli tax authority ("ITA&#x201d;) notified the Company that it had initiated a routine VAT audit to include tax years 2017 through 2020. The ITA raised several claims, mainly in respect with the recoverability of VAT with respect to Merger Agreement related expenses and the classification of the Company as a holding company. On July 2022, the ITA proposed a settlement, which the Company rejected. As a result, the ITA issued an assessment. The Company plans to appeal the ITA&#x2019;s assessment. The Company has recorded a provision which is inherently subjective due to the inherent uncertainty of these matters and the judicial process. Therefore, the final outcome may differ from the estimated liability recorded by the Company during the period&lt;span&gt;&lt;span&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fxbrl_20220720153627242"
          xlink:label="Fxbrl_20220720153627242"
          xlink:type="locator"/>
        <link:footnote id="FN20220809003109592" xlink:label="FN20220809003109592" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Number of shares has been retroactively adjusted to reflect the share reverse split effected on March 16, 2021 (refer to Note 1B).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220720153627242"
          xlink:to="FN20220809003109592"
          xlink:type="arc"/>
        <link:footnote id="FN20220809022016820" xlink:label="FN20220809022016820" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">20 Ordinary Shares are equal to 1 American Depositary Share (ADS).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220720153627242"
          xlink:to="FN20220809022016820"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220720153632498"
          xlink:label="Fxbrl_20220720153632498"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220720153632498"
          xlink:to="FN20220809003109592"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220720153632498"
          xlink:to="FN20220809022016820"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220720153639507"
          xlink:label="Fxbrl_20220720153639507"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220720153639507"
          xlink:to="FN20220809003109592"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220720153639507"
          xlink:to="FN20220809022016820"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220720153641684"
          xlink:label="Fxbrl_20220720153641684"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220720153641684"
          xlink:to="FN20220809003109592"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220720153641684"
          xlink:to="FN20220809022016820"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220801220211119"
          xlink:label="Fxbrl_20220801220211119"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220801220211119"
          xlink:to="FN20220809003109592"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220801220211119"
          xlink:to="FN20220809022016820"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220801220307005"
          xlink:label="Fxbrl_20220801220307005"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220801220307005"
          xlink:to="FN20220809003109592"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220801220307005"
          xlink:to="FN20220809022016820"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220801220408934"
          xlink:label="Fxbrl_20220801220408934"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220801220408934"
          xlink:to="FN20220809003109592"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220801220408934"
          xlink:to="FN20220809022016820"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220801220459941"
          xlink:label="Fxbrl_20220801220459941"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220801220459941"
          xlink:to="FN20220809003109592"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220801220459941"
          xlink:to="FN20220809022016820"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220809022126183"
          xlink:label="Fxbrl_20220809022126183"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220809022126183"
          xlink:to="FN20220809003109592"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220809022126183"
          xlink:to="FN20220809022016820"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220809022138581"
          xlink:label="Fxbrl_20220809022138581"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220809022138581"
          xlink:to="FN20220809003109592"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220809022138581"
          xlink:to="FN20220809022016820"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220809022148798"
          xlink:label="Fxbrl_20220809022148798"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220809022148798"
          xlink:to="FN20220809003109592"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220809022148798"
          xlink:to="FN20220809022016820"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220809022201676"
          xlink:label="Fxbrl_20220809022201676"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220809022201676"
          xlink:to="FN20220809003109592"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220809022201676"
          xlink:to="FN20220809022016820"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220809022343739"
          xlink:label="Fxbrl_20220809022343739"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220809022343739"
          xlink:to="FN20220809003109592"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220809022343739"
          xlink:to="FN20220809022016820"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220809022355319"
          xlink:label="Fxbrl_20220809022355319"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220809022355319"
          xlink:to="FN20220809003109592"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220809022355319"
          xlink:to="FN20220809022016820"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220809022408661"
          xlink:label="Fxbrl_20220809022408661"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220809022408661"
          xlink:to="FN20220809003109592"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220809022408661"
          xlink:to="FN20220809022016820"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220809022503184"
          xlink:label="Fxbrl_20220809022503184"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220809022503184"
          xlink:to="FN20220809003109592"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220809022503184"
          xlink:to="FN20220809022016820"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220504161436664"
          xlink:label="Fxbrl_20220504161436664"
          xlink:type="locator"/>
        <link:footnote id="FN20220719183112561" xlink:label="FN20220719183112561" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Number of shares has been retroactively adjusted to reflect the share reverse split effected on March 16, 2021 (refer to Note 1B).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220504161436664"
          xlink:to="FN20220719183112561"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220504161607482"
          xlink:label="Fxbrl_20220504161607482"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220504161607482"
          xlink:to="FN20220719183112561"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220504161812745"
          xlink:label="Fxbrl_20220504161812745"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220504161812745"
          xlink:to="FN20220719183112561"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220504161847247"
          xlink:label="Fxbrl_20220504161847247"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220504161847247"
          xlink:to="FN20220719183112561"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220504162054050"
          xlink:label="Fxbrl_20220504162054050"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220504162054050"
          xlink:to="FN20220719183112561"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220504162109962"
          xlink:label="Fxbrl_20220504162109962"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220504162109962"
          xlink:to="FN20220719183112561"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220505093740414"
          xlink:label="Fxbrl_20220505093740414"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220505093740414"
          xlink:to="FN20220719183112561"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220505093821193"
          xlink:label="Fxbrl_20220505093821193"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220505093821193"
          xlink:to="FN20220719183112561"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220505093843525"
          xlink:label="Fxbrl_20220505093843525"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220505093843525"
          xlink:to="FN20220719183112561"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220505093917037"
          xlink:label="Fxbrl_20220505093917037"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220505093917037"
          xlink:to="FN20220719183112561"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220505094011117"
          xlink:label="Fxbrl_20220505094011117"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220505094011117"
          xlink:to="FN20220719183112561"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220505094033172"
          xlink:label="Fxbrl_20220505094033172"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220505094033172"
          xlink:to="FN20220719183112561"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220505094051101"
          xlink:label="Fxbrl_20220505094051101"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220505094051101"
          xlink:to="FN20220719183112561"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220509163909641"
          xlink:label="Fxbrl_20220509163909641"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220509163909641"
          xlink:to="FN20220719183112561"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220509165714258"
          xlink:label="Fxbrl_20220509165714258"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220509165714258"
          xlink:to="FN20220719183112561"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220719171018175_xbrl_20220509172328807"
          xlink:label="Fxbrl_20220719171018175_xbrl_20220509172328807"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220719171018175_xbrl_20220509172328807"
          xlink:to="FN20220719183112561"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220719171018175_xbrl_20220509163550193"
          xlink:label="Fxbrl_20220719171018175_xbrl_20220509163550193"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220719171018175_xbrl_20220509163550193"
          xlink:to="FN20220719183112561"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220719171029396_xbrl_20220509165714258"
          xlink:label="Fxbrl_20220719171029396_xbrl_20220509165714258"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220719171029396_xbrl_20220509165714258"
          xlink:to="FN20220719183112561"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220719171029396_xbrl_20220509163909641"
          xlink:label="Fxbrl_20220719171029396_xbrl_20220509163909641"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220719171029396_xbrl_20220509163909641"
          xlink:to="FN20220719183112561"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>25
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M79?VS1#\;/-8DHZ+@\H8>B+,,6-R 2,EM%.NUAN+?]\*@PC_6/V]$<@4_IK
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MC I*Q*1<4"*G(8-P8(/P:]-!0P,J"SZ7$.KAK2/>*25TA3;VW4 *H9ZI621
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MW+8_-S1):=4(\.?W)1]U=]$TT!^WOO@/4$L#!!0    ( - [#%435J@*4P8
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MV[@5?M>OP&C3K3U#RY)\SVU&L;-MVF3CB3?M0Z</$ E):$B "Y!6O+^^WSD
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M!_&/.H(81_B?-(5T*#ZPYYF(VC@,!AQ1[H1WVVT3#)T$%>#B<YX:5I)^4&S
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M\'YE43+C#SJ@_;3Q[;\!4$L#!!0    ( - [#%5,?[F*X00  -@,   8
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M*G&/>_1BVW8T?=:I1%-3+ HJH::VV,^$*BKFDMJJ<^B3J))B*15UOP:J28C
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M#&B7@.L'A2Z&P&TP/EKY7U!+ P04    " #0.PQ5=,5&PNT$  #_#   &0
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M(AB70.>%UK@+7(/^FDW_ E!+ P04    " #0.PQ5[#(O%?('   4/   &0
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M!;5ZHWA>;IE\X$KQM'RY9S1B0I\ GV\YU.OU&]W <2/PZO]02P,$%     @
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M1AS!%( &#$D2=P[NG$?QZIR*U___#'\!4$L#!!0    ( - [#%67BKL<P
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MPI-I3G>ZJJ6\(]L/_<UPT7<@??=T\P=02P,$%     @ T#L,51@1BF7X
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M4$L! A0#%     @ T#L,58\V8%:8 @  . <  !@              ("!OQ0
M 'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( - [#%5!P7*1
M/P4  #84   8              " @8T7  !X;"]W;W)K<VAE971S+W-H965T
M-"YX;6Q02P$"% ,4    " #0.PQ5*^:VTP4)  !Z/0  &
M@($"'0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ T#L,
M51-6J I3!@  L1L  !@              ("!/28  'AL+W=O<FMS:&5E=',O
M<VAE970V+GAM;%!+ 0(4 Q0    ( - [#%6/"CN^N \  .8H   8
M      " @<8L  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M" #0.PQ53'^YBN$$  #8#   &               @(&T/   >&PO=V]R:W-H
M965T<R]S:&5E=#@N>&UL4$L! A0#%     @ T#L,5?M_B[X6 @  P 0  !@
M             ("!RT$  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4
M Q0    ( - [#%5TQ4;"[00  /\,   9              " @1=$  !X;"]W
M;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ T#L,5?0(VV&. @
M<@4  !D              ("!.TD  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX
M;6Q02P$"% ,4    " #0.PQ5[#(O%?('   4/   &0              @($
M3   >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( - [#%6R
MH)D]DP(  #L&   9              " @2E4  !X;"]W;W)K<VAE971S+W-H
M965T,3,N>&UL4$L! A0#%     @ T#L,55B;H'(G P  #!(   T
M     ( !\U8  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #0.PQ5EXJ[',
M   3 @  "P              @ %%6@  7W)E;',O+G)E;'-02P$"% ,4
M" #0.PQ5\EY J1,"  #!"0  #P              @ $N6P  >&PO=V]R:V)O
M;VLN>&UL4$L! A0#%     @ T#L,51@1BF7X    S@@  !H
M ( !;ET  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @
MT#L,5<0]0[)) 0  ,PH  !,              ( !GEX  %M#;VYT96YT7U1Y
><&5S72YX;6Q02P4&     !4 %0"*!0  &&

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>57</ContextCount>
  <ElementCount>134</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>10</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="zk2228232.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="zk2228232.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="zk2228232.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="zk2228232.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0004 - Statement - Condensed Consolidated Interim Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Interim Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="zk2228232.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0005 - Statement - Condensed Consolidated Interim Statements of Changes in Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/InterimStatementsOfChangesInEquity</Role>
      <ShortName>Condensed Consolidated Interim Statements of Changes in Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="zk2228232.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0006 - Statement - Condensed Consolidated Interim Statements of Cash flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Interim Statements of Cash flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="zk2228232.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0007 - Disclosure - General</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/General.</Role>
      <ShortName>General</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="zk2228232.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0008 - Disclosure - Basis of Presentation and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/BasisOfPresentationAndSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="zk2228232.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0009 - Disclosure - Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/Contingencies</Role>
      <ShortName>Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="zk2228232.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0010 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/BasisOfPresentationAndSignificantAccountingPolicies</ParentRole>
      <Position>10</Position>
    </Report>
    <Report instance="zk2228232.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0011 - Disclosure - General (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/General.Tables</Role>
      <ShortName>General (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/General.</ParentRole>
      <Position>11</Position>
    </Report>
    <Report instance="zk2228232.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0012 - Disclosure - General (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/General.Details</Role>
      <ShortName>General (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/General.Tables</ParentRole>
      <Position>12</Position>
    </Report>
    <Report instance="zk2228232.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0013 - Disclosure - General - Estimated fair value of assets acquired (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/General.-EstimatedFairValueOfAssetsAcquiredDetails</Role>
      <ShortName>General - Estimated fair value of assets acquired (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="zk2228232.htm">zk2228232.htm</File>
    <File>cmmb-20220630.xsd</File>
    <File>cmmb-20220630_cal.xml</File>
    <File>cmmb-20220630_def.xml</File>
    <File>cmmb-20220630_lab.xml</File>
    <File>cmmb-20220630_pre.xml</File>
    <File>exhibit_31-1.htm</File>
    <File>exhibit_31-2.htm</File>
    <File>exhibit_32-1.htm</File>
    <File>exhibit_32-2.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="224">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="34">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>30
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "zk2228232.htm": {
   "axisCustom": 0,
   "axisStandard": 6,
   "contextCount": 57,
   "dts": {
    "calculationLink": {
     "local": [
      "cmmb-20220630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cmmb-20220630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "zk2228232.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cmmb-20220630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cmmb-20220630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cmmb-20220630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 194,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 4
   },
   "keyCustom": 24,
   "keyStandard": 110,
   "memberCustom": 6,
   "memberStandard": 4,
   "nsprefix": "cmmb",
   "nsuri": "http://www.anchiano.com/20220630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2228232.htm",
      "contextRef": "C_20220101to20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001 - Document - Document and Entity Information",
     "role": "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2228232.htm",
      "contextRef": "C_20220101to20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2228232.htm",
      "contextRef": "C_20220101to20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0010 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)",
     "role": "http://www.anchiano.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2228232.htm",
      "contextRef": "C_20220101to20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2228232.htm",
      "contextRef": "C_20220101to20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0011 - Disclosure - General (Tables)",
     "role": "http://www.anchiano.com/role/General.Tables",
     "shortName": "General (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2228232.htm",
      "contextRef": "C_20220101to20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2228232.htm",
      "contextRef": "C_20210314to20210316",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "cmmb:NumberOfOrdinarySharesForEachPreferredShareConvertedPriorToDateOfMerger",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0012 - Disclosure - General (Detail Textuals)",
     "role": "http://www.anchiano.com/role/General.Details",
     "shortName": "General (Detail Textuals)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2228232.htm",
      "contextRef": "C_20210314to20210316",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "cmmb:NumberOfOrdinarySharesForEachPreferredShareConvertedPriorToDateOfMerger",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2228232.htm",
      "contextRef": "C_20210316",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0013 - Disclosure - General - Estimated fair value of assets acquired (Details)",
     "role": "http://www.anchiano.com/role/General.-EstimatedFairValueOfAssetsAcquiredDetails",
     "shortName": "General - Estimated fair value of assets acquired (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2228232.htm",
      "contextRef": "C_20210316",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2228232.htm",
      "contextRef": "C_20220630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2228232.htm",
      "contextRef": "C_20220630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockNoParValue",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2228232.htm",
      "contextRef": "C_20220630",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockNoParValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD_per_share",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.anchiano.com/role/BalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockNoParValue",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2228232.htm",
      "contextRef": "C_20220630",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockNoParValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD_per_share",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2228232.htm",
      "contextRef": "C_20220401to20220630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0004 - Statement - Condensed Consolidated Interim Statements of Operations (Unaudited)",
     "role": "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations",
     "shortName": "Condensed Consolidated Interim Statements of Operations (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2228232.htm",
      "contextRef": "C_20220401to20220630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2228232.htm",
      "contextRef": "C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0005 - Statement - Condensed Consolidated Interim Statements of Changes in Equity (Unaudited)",
     "role": "http://www.anchiano.com/role/InterimStatementsOfChangesInEquity",
     "shortName": "Condensed Consolidated Interim Statements of Changes in Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2228232.htm",
      "contextRef": "C_20210101to20210331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2228232.htm",
      "contextRef": "C_20220101to20220630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0006 - Statement - Condensed Consolidated Interim Statements of Cash flows (Unaudited)",
     "role": "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows",
     "shortName": "Condensed Consolidated Interim Statements of Cash flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2228232.htm",
      "contextRef": "C_20220101to20220630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2228232.htm",
      "contextRef": "C_20220101to20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0007 - Disclosure - General",
     "role": "http://www.anchiano.com/role/General.",
     "shortName": "General",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2228232.htm",
      "contextRef": "C_20220101to20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2228232.htm",
      "contextRef": "C_20220101to20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0008 - Disclosure - Basis of Presentation and Significant Accounting Policies",
     "role": "http://www.anchiano.com/role/BasisOfPresentationAndSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2228232.htm",
      "contextRef": "C_20220101to20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2228232.htm",
      "contextRef": "C_20220101to20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0009 - Disclosure - Contingencies",
     "role": "http://www.anchiano.com/role/Contingencies",
     "shortName": "Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2228232.htm",
      "contextRef": "C_20220101to20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 10,
   "tag": {
    "cmmb_AccountReceivableDueToExerciseOfOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the amount of account receivable due to exercise of options.",
        "label": "Account Receivable Due To Exercise Of Options",
        "terseLabel": "Account receivable Due to Exercise of Options",
        "verboseLabel": "Receivable related to exercise of options"
       }
      }
     },
     "localname": "AccountReceivableDueToExerciseOfOptions",
     "nsuri": "http://www.anchiano.com/20220630",
     "presentation": [
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_AccruedShareIssuanceExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of accrued issuance expenses non-cash investing and financing activities.",
        "label": "Accrued share issuance expenses"
       }
      }
     },
     "localname": "AccruedShareIssuanceExpenses",
     "nsuri": "http://www.anchiano.com/20220630",
     "presentation": [
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_AmericanDepositarySharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "American Depositary Shares [Member]",
        "label": "American Depositary Shares [Member]"
       }
      }
     },
     "localname": "AmericanDepositarySharesMember",
     "nsuri": "http://www.anchiano.com/20220630",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "cmmb_AmericanDepositorySharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for American Depository Shares.",
        "label": "American Depository Shares [Member]",
        "terseLabel": "American Depositary Share (\"ADS\") [Member]"
       }
      }
     },
     "localname": "AmericanDepositorySharesMember",
     "nsuri": "http://www.anchiano.com/20220630",
     "presentation": [
      "http://www.anchiano.com/role/General.Details"
     ],
     "xbrltype": "domainItemType"
    },
    "cmmb_AmountOfTotalSaleAndTransferOfCompoundsAndProductsKestrelPaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of total sale and transfer of compounds and products kestrel paid.",
        "label": "Amount Of Total Sale And Transfer Of Compounds And Products Kestrel Paid",
        "terseLabel": "Amount of total sale and transfer of compounds and products kestrel paid"
       }
      }
     },
     "localname": "AmountOfTotalSaleAndTransferOfCompoundsAndProductsKestrelPaid",
     "nsuri": "http://www.anchiano.com/20220630",
     "presentation": [
      "http://www.anchiano.com/role/General.Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_AtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for At the Market Offering Agreement with Cantor Fitzgerald &amp; Co.",
        "label": "At Market Offering Agreement With Cantor Fitzgerald And Co [Member]",
        "terseLabel": "At The Market Offering Agreement With Cantor Fitzgerald &amp; Co. [Member]"
       }
      }
     },
     "localname": "AtMarketOfferingAgreementWithCantorFitzgeraldAndCoMember",
     "nsuri": "http://www.anchiano.com/20220630",
     "presentation": [
      "http://www.anchiano.com/role/General.Details"
     ],
     "xbrltype": "domainItemType"
    },
    "cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of of asset held for sale recogized prior to the completion of merger.",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Asset Held For Sale",
        "terseLabel": "Asset held for sale"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale",
     "nsuri": "http://www.anchiano.com/20220630",
     "presentation": [
      "http://www.anchiano.com/role/General.-EstimatedFairValueOfAssetsAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued liabilities to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accrued Expenses",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses",
     "nsuri": "http://www.anchiano.com/20220630",
     "presentation": [
      "http://www.anchiano.com/role/General.-EstimatedFairValueOfAssetsAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_CashAcquiredInReverseRecapitalization": {
     "auth_ref": [],
     "calculation": {
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "represents cash acquired from acquisition",
        "label": "Cash acquired in reverse recapitalization",
        "terseLabel": "Cash acquired in reverse recapitalization"
       }
      }
     },
     "localname": "CashAcquiredInReverseRecapitalization",
     "nsuri": "http://www.anchiano.com/20220630",
     "presentation": [
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_EffectOfReverseCapitalizationTransaction": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of effect due reverse capitalization transaction.",
        "label": "Effect of reverse capitalization transaction"
       }
      }
     },
     "localname": "EffectOfReverseCapitalizationTransaction",
     "nsuri": "http://www.anchiano.com/20220630",
     "presentation": [
      "http://www.anchiano.com/role/InterimStatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_EffectOfReverseCapitalizationTransactionShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares isued due to effect of reverse capitalization transaction.",
        "label": "Effect Of Reverse Capitalization Transaction Shares",
        "terseLabel": "Effect of reverse capitalization transaction (in shares)"
       }
      }
     },
     "localname": "EffectOfReverseCapitalizationTransactionShares",
     "nsuri": "http://www.anchiano.com/20220630",
     "presentation": [
      "http://www.anchiano.com/role/InterimStatementsOfChangesInEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "cmmb_EstimatedFairValueOfNetAssetsAcquired": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of estimated fair value of the net assets acquired.",
        "label": "Estimated Fair Value Of Net Assets Acquired",
        "terseLabel": "Net acquired assets"
       }
      }
     },
     "localname": "EstimatedFairValueOfNetAssetsAcquired",
     "nsuri": "http://www.anchiano.com/20220630",
     "presentation": [
      "http://www.anchiano.com/role/General.-EstimatedFairValueOfAssetsAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_FinanceIncomeExpensesNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of finance income earned and finance expenses incurred during the period.",
        "label": "Finance Income Expenses Net",
        "negatedLabel": "Financing expense, net",
        "terseLabel": "Financing expenses (income), net"
       }
      }
     },
     "localname": "FinanceIncomeExpensesNet",
     "nsuri": "http://www.anchiano.com/20220630",
     "presentation": [
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_FormerChemomabSecurityHoldersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This represents former Chemomab security holders.",
        "label": "Former Chemomab Security Holders [Member]"
       }
      }
     },
     "localname": "FormerChemomabSecurityHoldersMember",
     "nsuri": "http://www.anchiano.com/20220630",
     "presentation": [
      "http://www.anchiano.com/role/General.Details"
     ],
     "xbrltype": "domainItemType"
    },
    "cmmb_IssuanceOfSharesNetOfIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 30.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of shares net, of issuance costs.",
        "label": "Issuance Of Shares Net Of Issuance Costs",
        "terseLabel": "Issuance of shares net, of issuance costs",
        "verboseLabel": "Issuance of shares, net of issuance costs"
       }
      }
     },
     "localname": "IssuanceOfSharesNetOfIssuanceCosts",
     "nsuri": "http://www.anchiano.com/20220630",
     "presentation": [
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_LiabilitiesAssumedNetOfNonCashAssetsReceivedInReverseMerger": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of liabilities assumed, net of non-cash assets received in reverse merger.",
        "label": "Liabilities Assumed Net Of Non Cash Assets Received In Reverse Merger",
        "terseLabel": "Liabilities assumed, net of non-cash assets received in reverse merger"
       }
      }
     },
     "localname": "LiabilitiesAssumedNetOfNonCashAssetsReceivedInReverseMerger",
     "nsuri": "http://www.anchiano.com/20220630",
     "presentation": [
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_MergerAgreementWithChemomabIsraeliLimitedCompanyAndClinicalStageBiotechCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This represents Merger Agreement with Chemomab, an Israeli limited company and a clinical-stage biotech company inclued proposed merger of CMB Acquisition Ltd, wholly owned subsidiary of our company.",
        "label": "Merger Agreement With Chemomab Israeli Limited Company And Clinical Stage Biotech Company [Member]",
        "terseLabel": "Merger agreement with Chemomab, an Israeli limited company and a clinical-stage biotech company [Member]"
       }
      }
     },
     "localname": "MergerAgreementWithChemomabIsraeliLimitedCompanyAndClinicalStageBiotechCompanyMember",
     "nsuri": "http://www.anchiano.com/20220630",
     "presentation": [
      "http://www.anchiano.com/role/General.Details"
     ],
     "xbrltype": "domainItemType"
    },
    "cmmb_NatureOfOperationsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Nature Of Operations Disclosure [Abstract]"
       }
      }
     },
     "localname": "NatureOfOperationsDisclosureAbstract",
     "nsuri": "http://www.anchiano.com/20220630",
     "xbrltype": "stringItemType"
    },
    "cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of ADS issued and outstanding after the merger.",
        "label": "Number of ADS issued and outstanding after the merger"
       }
      }
     },
     "localname": "NumberOfAdsIssuedAndOutstandingAfterMerger",
     "nsuri": "http://www.anchiano.com/20220630",
     "presentation": [
      "http://www.anchiano.com/role/General.Details"
     ],
     "xbrltype": "sharesItemType"
    },
    "cmmb_NumberOfOrdinarySharesConsistedInDS": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the number of ordinary shares consisted in one American depository share (ADS).",
        "label": "Number Of Ordinary Shares Consisted In D S",
        "terseLabel": "Number of ordinary shares represented by each ADS (in shares)"
       }
      }
     },
     "localname": "NumberOfOrdinarySharesConsistedInDS",
     "nsuri": "http://www.anchiano.com/20220630",
     "presentation": [
      "http://www.anchiano.com/role/General.Details"
     ],
     "xbrltype": "sharesItemType"
    },
    "cmmb_NumberOfOrdinarySharesForEachPreferredShareConvertedPriorToDateOfMerger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock for each preferred share converted before merger.",
        "label": "Number Of Ordinary Shares For Each Preferred Share Converted Prior To Date Of Merger",
        "terseLabel": "Number of common shares for each preferred share converted"
       }
      }
     },
     "localname": "NumberOfOrdinarySharesForEachPreferredShareConvertedPriorToDateOfMerger",
     "nsuri": "http://www.anchiano.com/20220630",
     "presentation": [
      "http://www.anchiano.com/role/General.Details"
     ],
     "xbrltype": "sharesItemType"
    },
    "cmmb_NumberOfSharesDilutedAfterMerger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares diluted after the merger.",
        "label": "Number of shares diluted after the merger"
       }
      }
     },
     "localname": "NumberOfSharesDilutedAfterMerger",
     "nsuri": "http://www.anchiano.com/20220630",
     "presentation": [
      "http://www.anchiano.com/role/General.Details"
     ],
     "xbrltype": "sharesItemType"
    },
    "cmmb_OneEmployeeOneOfficerConsultantAndSixBoardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One employee one officer consultant and six Board [Member]",
        "label": "One Employee One Officer Consultant And Six Board [Member]",
        "verboseLabel": "One employee one officer consultant and six Board [Member]"
       }
      }
     },
     "localname": "OneEmployeeOneOfficerConsultantAndSixBoardMember",
     "nsuri": "http://www.anchiano.com/20220630",
     "presentation": [
      "http://www.anchiano.com/role/General.Details"
     ],
     "xbrltype": "domainItemType"
    },
    "cmmb_OrdinarySharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ordinary Shares [Member]",
        "label": "Ordinary Shares [Member]"
       }
      }
     },
     "localname": "OrdinarySharesMember",
     "nsuri": "http://www.anchiano.com/20220630",
     "presentation": [
      "http://www.anchiano.com/role/General.Details"
     ],
     "xbrltype": "domainItemType"
    },
    "cmmb_OrdinarySharesNoParValuePerShareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ordinary Shares, No Par Value Per Share [Member]",
        "label": "Ordinary Shares, No Par Value Per Share [Member]"
       }
      }
     },
     "localname": "OrdinarySharesNoParValuePerShareMember",
     "nsuri": "http://www.anchiano.com/20220630",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "cmmb_PaymentsToPurchaseOfDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 30.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to purchase of deposits.",
        "label": "Payments To Purchase Of Deposits",
        "negatedLabel": "Increase in deposits"
       }
      }
     },
     "localname": "PaymentsToPurchaseOfDeposits",
     "nsuri": "http://www.anchiano.com/20220630",
     "presentation": [
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_ProceedsFromSaleOfDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of deposits.",
        "label": "Proceeds From Sale Of Deposits",
        "terseLabel": "Decrease in deposits"
       }
      }
     },
     "localname": "ProceedsFromSaleOfDeposits",
     "nsuri": "http://www.anchiano.com/20220630",
     "presentation": [
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_RetainedEarningsAccumulatedDeficits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficits.",
        "label": "Retained Earnings Accumulated Deficits",
        "negatedLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficits",
     "nsuri": "http://www.anchiano.com/20220630",
     "presentation": [
      "http://www.anchiano.com/role/General.Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_ShareholdingPercentageImmediatelyFollowingMerger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "shareholding percentage immediately following the merger.",
        "label": "Shareholding percentage immediately following the merger"
       }
      }
     },
     "localname": "ShareholdingPercentageImmediatelyFollowingMerger",
     "nsuri": "http://www.anchiano.com/20220630",
     "presentation": [
      "http://www.anchiano.com/role/General.Details"
     ],
     "xbrltype": "percentItemType"
    },
    "cmmb_SharesConvertiblePerShareOfAcquireeEntity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the shares convertible in merger.",
        "label": "Shares Convertible Per Share Of Acquiree Entity",
        "terseLabel": "Number of shares after merger for each share of Chemomab"
       }
      }
     },
     "localname": "SharesConvertiblePerShareOfAcquireeEntity",
     "nsuri": "http://www.anchiano.com/20220630",
     "presentation": [
      "http://www.anchiano.com/role/General.Details"
     ],
     "xbrltype": "sharesItemType"
    },
    "cmmb_StockAndWarrantIssuedDuringPeriodNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "it represents number of shares and warrants issued during period",
        "label": "Stock And Warrant Issued During Period New Issues",
        "terseLabel": "Issuance of shares and warrants, net of issuance costs (In shares)"
       }
      }
     },
     "localname": "StockAndWarrantIssuedDuringPeriodNewIssues",
     "nsuri": "http://www.anchiano.com/20220630",
     "presentation": [
      "http://www.anchiano.com/role/InterimStatementsOfChangesInEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock And Warrants Issued During Period Value New Issues",
        "terseLabel": "Issuance of shares and warrants, net of issuance costs"
       }
      }
     },
     "localname": "StockAndWarrantsIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://www.anchiano.com/20220630",
     "presentation": [
      "http://www.anchiano.com/role/InterimStatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_TwoThousandFifteenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2015 Plan [Member]",
        "label": "Two Thousand Fifteen Plan [Member]",
        "terseLabel": "2015 Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandFifteenPlanMember",
     "nsuri": "http://www.anchiano.com/20220630",
     "presentation": [
      "http://www.anchiano.com/role/General.Details"
     ],
     "xbrltype": "domainItemType"
    },
    "cmmb_WarrantsExercisablePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the warrants exercisable period.",
        "label": "Warrants exercisable period",
        "terseLabel": "Warrants exercisable period"
       }
      }
     },
     "localname": "WarrantsExercisablePeriod",
     "nsuri": "http://www.anchiano.com/20220630",
     "presentation": [
      "http://www.anchiano.com/role/General.Details"
     ],
     "xbrltype": "durationItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Former Legal or Registered Name of an entity",
        "label": "Entity Information, Former Legal or Registered Name"
       }
      }
     },
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Name of Exchange on which Security is Registered"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r121",
      "r134",
      "r137",
      "r146",
      "r148",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r246",
      "r247",
      "r255",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.anchiano.com/role/General.Details"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r121",
      "r134",
      "r137",
      "r146",
      "r148",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r246",
      "r247",
      "r255",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.anchiano.com/role/General.Details"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r107",
      "r118",
      "r119",
      "r120",
      "r121",
      "r134",
      "r137",
      "r144",
      "r146",
      "r148",
      "r171",
      "r172",
      "r173",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r246",
      "r247",
      "r255",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.anchiano.com/role/General.Details"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r107",
      "r118",
      "r119",
      "r120",
      "r121",
      "r134",
      "r137",
      "r144",
      "r146",
      "r148",
      "r171",
      "r172",
      "r173",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r246",
      "r247",
      "r255",
      "r256"
     ],
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.anchiano.com/role/General.Details"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r101",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.anchiano.com/role/General.Details"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.anchiano.com/role/General.Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "auth_ref": [
      "r5",
      "r24"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Trade payables"
       }
      }
     },
     "localname": "AccountsPayableTradeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r17",
      "r217"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional paid in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r55",
      "r56",
      "r57",
      "r176",
      "r177",
      "r178",
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional paid in capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/InterimStatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Adjustments for operating activities"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r11",
      "r52",
      "r93",
      "r95",
      "r99",
      "r103",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r191",
      "r195",
      "r202",
      "r215",
      "r217",
      "r228",
      "r237"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets [Default Label]",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r23",
      "r52",
      "r103",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r191",
      "r195",
      "r202",
      "r215",
      "r217"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r52",
      "r103",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r191",
      "r195",
      "r202",
      "r215"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Preparation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r145",
      "r147",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/General.Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r145",
      "r147",
      "r185",
      "r186",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/General.Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r187"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/General.-EstimatedFairValueOfAssetsAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "auth_ref": [
      "r187"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Prepaid and other assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/General.-EstimatedFairValueOfAssetsAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Capital": {
     "auth_ref": [
      "r236"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of total capital as defined by regulatory framework.",
        "label": "Market capitalization amount"
       }
      }
     },
     "localname": "Capital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/General.Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r9",
      "r48"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r43",
      "r48",
      "r49"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r43",
      "r203"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Change in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r51",
      "r52",
      "r70",
      "r71",
      "r72",
      "r74",
      "r76",
      "r80",
      "r81",
      "r82",
      "r103",
      "r123",
      "r127",
      "r128",
      "r129",
      "r132",
      "r133",
      "r135",
      "r136",
      "r138",
      "r139",
      "r140",
      "r202",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation",
      "http://www.anchiano.com/role/General.Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrant exercise price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/General.Details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r28",
      "r230",
      "r241"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and contingent liabilities"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r122",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/Contingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r55",
      "r56",
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Ordinary shares [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/InterimStatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNoParValue": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount per share of no-par value common stock.",
        "label": "Common Stock, No Par Value"
       }
      }
     },
     "localname": "CommonStockNoParValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r16",
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r16",
      "r217"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Ordinary shares no par value - Authorized: 650,000,000 shares as of September 30, 2021 and 500,000,000 shares as of December 31, 2020; Issued and outstanding: 227,956,060 ordinary shares at September 30, 2021 and 9,274,838 ordinary shares at December 31, 2020",
        "terseLabel": "Ordinary shares no par value - Authorized: 650,000,000 shares as of March 31, 2022 and as of December 31, 2021; Issued and outstanding: 228,090,300 ordinary shares at March 31, 2022 as of December 31, 2021",
        "verboseLabel": "Ordinary shares no par value - Authorized: 650,000,000 shares as of June 30, 2022 and as of December 31, 2021; Issued and outstanding: 228,633,120 ordinary shares as of June 30, 2022 and 228,090,300 as of December 31, 2021"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositsAssetsCurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.",
        "label": "Short term bank deposits"
       }
      }
     },
     "localname": "DepositsAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositsAssetsNoncurrent": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.",
        "label": "Long term deposit"
       }
      }
     },
     "localname": "DepositsAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r46",
      "r105"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r37",
      "r60",
      "r61",
      "r62",
      "r63",
      "r64",
      "r68",
      "r70",
      "r74",
      "r75",
      "r76",
      "r77",
      "r78",
      "r200",
      "r201",
      "r233",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Basic and diluted loss per Ordinary Share",
        "terseLabel": "Basic loss per Ordinary Share"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r37",
      "r60",
      "r61",
      "r62",
      "r63",
      "r64",
      "r70",
      "r74",
      "r75",
      "r76",
      "r77",
      "r78",
      "r200",
      "r201",
      "r233",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted loss per Ordinary Share"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee and related expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r32",
      "r33",
      "r34",
      "r55",
      "r56",
      "r57",
      "r59",
      "r65",
      "r67",
      "r79",
      "r104",
      "r140",
      "r142",
      "r176",
      "r177",
      "r178",
      "r181",
      "r182",
      "r199",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r213",
      "r248",
      "r249",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/InterimStatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 10.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r35",
      "r93",
      "r94",
      "r97",
      "r98",
      "r100",
      "r227",
      "r231",
      "r234",
      "r244"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "negatedTotalLabel": "Loss before taxes",
        "totalLabel": "Loss before taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r53",
      "r66",
      "r67",
      "r92",
      "r180",
      "r183",
      "r184",
      "r245"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 10.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Taxes Expenses (Income)",
        "terseLabel": "Taxes Expenses (Income)",
        "verboseLabel": "Taxes on income (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 30.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
        "label": "Change in trade payables"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 40.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Change in accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 50.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Change in employees and related expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r45",
      "r212"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Change in operating lease liability",
        "verboseLabel": "Change in operating lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Change in other receivables and prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r25",
      "r52",
      "r96",
      "r103",
      "r123",
      "r124",
      "r125",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r192",
      "r195",
      "r196",
      "r202",
      "r215",
      "r216"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r21",
      "r52",
      "r103",
      "r202",
      "r217",
      "r229",
      "r239"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND SHAREHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r4",
      "r27",
      "r52",
      "r103",
      "r123",
      "r124",
      "r125",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r192",
      "r195",
      "r196",
      "r202",
      "r215",
      "r216",
      "r217"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r12",
      "r13",
      "r52",
      "r103",
      "r123",
      "r124",
      "r125",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r192",
      "r195",
      "r196",
      "r202",
      "r215",
      "r216"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total non-current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r83",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "verboseLabel": "General."
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/General."
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r43",
      "r44",
      "r47"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r30",
      "r31",
      "r34",
      "r36",
      "r47",
      "r52",
      "r58",
      "r60",
      "r61",
      "r62",
      "r63",
      "r66",
      "r67",
      "r73",
      "r93",
      "r94",
      "r97",
      "r98",
      "r100",
      "r103",
      "r123",
      "r124",
      "r125",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r201",
      "r202",
      "r232",
      "r242"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss for the period",
        "negatedTotalLabel": "Net loss for the period",
        "totalLabel": "Net loss for the period"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/InterimStatementsOfChangesInEquity",
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 10.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "negatedTotalLabel": "Total operating expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r211"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 30.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r211"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating lease liabilities - long term"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r210"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/General.Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/General.Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Other receivables and prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseNoncurrent": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 30.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.",
        "label": "Long term prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromOtherEquity": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from the issuance of equity classified as other.",
        "label": "Proceeds from Other Equity",
        "verboseLabel": "Issuance of shares and warrants, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromOtherEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyHeldForSale": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of formerly productive land held for sale, anything permanently fixed to it, including buildings, structures on it, and so forth.",
        "label": "Proceeds from Sale of Property Held-for-sale",
        "terseLabel": "Sale of asset held for sale"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyHeldForSale",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r41",
      "r175"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Exercise of options",
        "terseLabel": "Exercise of Shares",
        "verboseLabel": "Exercise of options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r41"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/General.Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r30",
      "r31",
      "r34",
      "r42",
      "r52",
      "r58",
      "r66",
      "r67",
      "r93",
      "r94",
      "r97",
      "r98",
      "r100",
      "r103",
      "r123",
      "r124",
      "r125",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r190",
      "r193",
      "r194",
      "r197",
      "r198",
      "r201",
      "r202",
      "r234"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "verboseLabel": "Net loss for the period"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r106",
      "r217",
      "r235",
      "r240"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 40.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r179",
      "r225",
      "r257"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r10",
      "r49",
      "r253"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/General.Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r18",
      "r142",
      "r217",
      "r238",
      "r251",
      "r252"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r55",
      "r56",
      "r57",
      "r59",
      "r65",
      "r67",
      "r104",
      "r176",
      "r177",
      "r178",
      "r181",
      "r182",
      "r199",
      "r248",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/InterimStatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Aggregate offering price"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/General.Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.",
        "label": "Gross proceeds from sale under agreement"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/General.Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/General.Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Shares issued under agreement"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/General.Details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Average price of shares issued under agreement"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/General.Details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of net assets acquired based on their estimated fair value"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/General.Tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r108",
      "r109",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/General.Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 60.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based compensation expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share based payment options vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/General.Details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Number of shares authorized, increase"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/General.Details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Options to purchase ADs"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/General.Details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Exercise price per ADs",
        "verboseLabel": "Value of ADS"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/General.Details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (In shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/InterimStatementsOfChangesInEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r50",
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/BasisOfPresentationAndSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r51",
      "r52",
      "r70",
      "r71",
      "r72",
      "r74",
      "r76",
      "r80",
      "r81",
      "r82",
      "r103",
      "r123",
      "r127",
      "r128",
      "r129",
      "r132",
      "r133",
      "r135",
      "r136",
      "r138",
      "r139",
      "r140",
      "r202",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation",
      "http://www.anchiano.com/role/General.Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r29",
      "r32",
      "r33",
      "r34",
      "r55",
      "r56",
      "r57",
      "r59",
      "r65",
      "r67",
      "r79",
      "r104",
      "r140",
      "r142",
      "r176",
      "r177",
      "r178",
      "r181",
      "r182",
      "r199",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r213",
      "r248",
      "r249",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/InterimStatementsOfChangesInEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation",
      "http://www.anchiano.com/role/InterimStatementsOfChangesInEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r55",
      "r56",
      "r57",
      "r79",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation",
      "http://www.anchiano.com/role/InterimStatementsOfChangesInEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of preferred stock and warrants for common stock issued.",
        "label": "Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants",
        "terseLabel": "Isuuance and sale value of ADSs and warrants"
       }
      }
     },
     "localname": "StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/General.Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r15",
      "r16",
      "r140",
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Issuance of shares, net of issuance costs, shares",
        "terseLabel": "Issuance of shares, net of issuance costs (In shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/InterimStatementsOfChangesInEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r15",
      "r16",
      "r140",
      "r142",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "terseLabel": "Exercise of Options (In shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/InterimStatementsOfChangesInEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r15",
      "r16",
      "r140",
      "r142"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Issuance of shares, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/InterimStatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r15",
      "r16",
      "r142",
      "r166"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Share-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/InterimStatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r29",
      "r140",
      "r142"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Exercise of Options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/InterimStatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r16",
      "r19",
      "r20",
      "r52",
      "r102",
      "r103",
      "r202",
      "r217"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/InterimStatementsOfChangesInEquity",
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Reverse stock split conversion ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/General.Details"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/General.Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r84",
      "r85",
      "r86",
      "r87",
      "r88",
      "r89",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r69",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average number of Ordinary Shares outstanding, diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r68",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted average number of Ordinary Shares outstanding, basic, and diluted",
        "terseLabel": "Weighted average number of Ordinary Shares outstanding, basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(c)(1)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=117337116&loc=SL5958568-112826"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r258": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r259": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r261": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r262": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r263": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r264": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r265": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>31
<FILENAME>0001178913-22-003074-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001178913-22-003074-xbrl.zip
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MM%7>&N_'>NZH)!+7.6$_W1UK<O-/LD3T=&W]TVK.=<?CQ_^%X-/_4$L#!!0
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MGZ2^@/E37\)8B!7YE_\!4$L#!!0    ( - [#%4J-[HKH$8  ( ] P 5
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M3V[:P#:0SC[THVUWC/)C/[IPURC[T53ZIF S>>H']U= 21B3KI70/IA.^&J
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M6?IQK#)?-(,KEP1T0^BH6_]9)=X(^.2P6%H--(!XMWKJ@N(!PCU-FM?_]6*
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ML]MX#'!8.P*(2]("$^].3D<A:W[JI:O@GJNW"*9A0KP7XH-)P/@,32A;@LE
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MULHXPBD\$P_#$ R^5/YS$25D'T#7%&8SP<@XF  '6OUI)A@#!Z@TI^R6/B6
M7ZM63<5'@1X?FC&PMNJ18HUEQX#[BL)6)_ZOZ$'8,_4XKBT43GDXAC6$^?%Y
M$I+GOQ+H_'HT57-AM\CI<DD3;G]K-JCUV*:6E&YY$A:D4#^ YB;S,S1WZF%+
M6VF<\G&Z)&P!6'YF]"E3D6"!#:WZ;2)QR\5S81$H/ZQZ0-/&\D[QGT4Q$>&S
M '>#0BZ5<XZ7'8/9NZ"H!NHQ2$U%G:+&NR<&<X]?9^+D(U(Y2770H(>;21US
M-:=LR8&)E!\79.''4W9-%AAYDI'PTE\B>PVZVK(.QWP"$$P ]DA@P^7+Q72V
M7P\SVDKCE _1I^@+*L:E'D_46-8I[IM[$L>Y@JB' C64=(MYZ<>QRH(+H!N4
M<[6H4]2W_K-*SAOP.:E40SV"9CN1(TXN*)Y+W=,DUVOU,)C:<H[P7E*P"-"L
MO'E9WM%8G,S6 UV:BCI"K;(Z[4_N;J,LQM5$JXIKY1SC/7T.[OUD0>0*J%6\
MVK*.<%<&' !K56FUD .D*<MFG_WG:+E:JK<M]9"0]4*ND$9)!6E-#=8+.4)Z
MC>)W^!R!!JF'=ZP6<(203^KI'+;[T6,4KOQ8HJWI.W-AA_>G,G(1ON2C<11@
M?J$\ 4,].*,%E7M>TBO_!9_XX)I <E.U'IK1ALPM-VQ%PE+FIX(7XT6KF<@E
M)V'(=_M@;/A1>)[(Y,+ A]$[RT0R/B[R-=3H5]5,Z)2C_UZ)>'3I+;TF2(5G
M'&5'T5N*7DU7C,)J1<*CEU]33*>0>PB68_75PSGNI)VOIK_JX2%WT\[7T5^%
M5JK'E]QI>R[E3;[!JH>67"LQ!HQ&?S'W+\EDJO!"@LQV3;6D\W[--7X]>J.^
MX(@0FVV4:L&1("Z)A]DJT1(X[W-\^9-WN]D,62\[+MQFZZ%6=CRX"Z&I!U9L
MI7'8_T=^&J48/*NRC7L1?]^2Y^P(2G\!KHRZUK(&ESS*\V3^%E9<-XJ=>3T(
M8AO)"+@XILN[*/&%VU5 %TGT!U@N\M 9MZU2=8F'OYB,KYXR6+Y8J#Q^J(=$
M'*CEK[E/C?;%KEO^2OI4+I2\I Q38 A/4 _[Z!:0TW=A\E2E'B=RO8CCUVN8
M"KGZ5NHP._89>P$UPB.) 0^-[_;:*WBM[_.$0TP]6$<0KT+^(E/<QUS[&3F=
MSPFW/';SH*\[DG^F/M_-D\$-D+CM\[.8/J%E"_\M$EE@S+;$3X+*>8HFP?.D
M'CZSM[I=RF+LIV 9RYAC4W8=+>XS&7F,7,&XD_S'5/Z:[D-G&$WMS2I\A3U@
MM,LWJ]#EW*#+921.(E%7\8 >"Y($/+M+/<JF#9G+\33#TDYKH_G;K:*Q<USL
M<B?U@)P;UO2:>#:;F=UJ<CQ/I8^["BY:#^5I+NQXM"28(NDCH#<;@UJ"<7 @
MWA<<KK)[RG![!GR8#:P&LC%Q(X(DSR;F:)XFDC%Q48E08 [I.;:W(AI<<H*8
M WK6RHX+=Z/14"D[CO54X6XT!JIEW>%6F;:J5U,3<SA-/8%#B:D"*MV63,RQ
M,8TT;OE@)(CX>1U@-RKC2CF'>%7&+)61!.]% @!NU,-Z@A%R8-3 >@*'J\XZ
MH),H7F6H>\T1%TTD(QJ'@@NCVC61N!R+Y4-,7PBY)CQ[G,81<6*.JMA.['!\
M?B8)87X,.YK#<!DE_&T0/FZ2%P' EU%%MY$ZCQ_+7]4MRY?3$W-,1A.)<RYN
M_6?=>80Y1F,3V;BX*>V[S8$;&^G&RX]1QS?2N8T2O'9 KW,A!\Z:@E';U#"J
M"/1UUW+@L"E =#O]J/@S*Y_9Q!P\L5,]H^(W=WJ]P,\*Y@LPVY2YP[*25\)I
M4W8/RTI&M0Z9.6W* &);B3M.JY/1:)F,9*Y5T1JMCW(QAU)4=G=)0EV427-<
MQU;:<8R"B2^CY=%*.^+Q*@S?>LS(SG6,8_SRK6,]HF1#Z9%AKP>3;"@]#OE:
M]W2?U -*6E"-8QS*1Z+UV)+-!"/DP*C/]03CD">-$_RD'FS2CM!EEA _6V'N
MZ2(]"[!A5/.:TF/#;M3OFM)N<YWH7N]I/,* )Z-N[U"+VTPT]KP:]7R'6E[%
MN):6#:,EL$%MXQOGPN.Q-,[UF)D;U/):>&U*%F5;R_AD6H.RD.EZ-,XM:AO?
M..M>IT_J,3LWJ.6U\&HT=3K4,CZ9;GH]/ZE' MVBMC'E_BJQ:)]):U2<5(_W
M\GUJ/:"H)>7X>"KOF.H11NV)1\,9=VV?SF&F<)\=X,IH!C43NLQU&_L)QI/C
M+VLG]0BBVG(N\3:\]\LG33V0:!?RT7!7GC#U**.M-$[YH $A(4^@RGM8'?+6
MXXZVD8R2"Z/I8")QF;F[!.G&QWAW*A'U+R0.SRC#+X$GHVE@5\%(QJF)0W-:
M<JL*QC*&>#\P?>#G/^K550C<F1.1MQ*/9>P,G!EMA7;BD8^9T5ZP(!X'9_*A
MG\(%-D0]T*H5W4AD4,-/@S'10.=6\N91)C)+U\.T:DJY[?L":Y-QH$JY[5>N
M%- 6SF2PCP=TNKQ$X]\<G[61SF'?7Y.4  D^@C\ACR2F'%3N06N.T=I,Z):C
MTEO^LOUL#M)JI''-QRK(5@RVC,<TS42< L(>84><D/.,+'&^&%6^%;U3_C(?
M<(3*9?XP"%;+%??0.R'S*(APQ(QJWX)Z1+RIIZSFB*P&"I=Y?+D1S V/8[ Z
MHE!>.%Z3@$2/))PF/&L0YA/!AT'FX*G=*AHQQU>$55DVI\'N5M,X>!8I)^!#
MZ>GK^=H@F]-G=ZEG'/SR,!7JH0[P9LZO;:)QR4=P3\(5XJK'T"*A102M6^[4
M7CC]FT.P]MW42'JMI!VY9N2Z _5DRO%"CY@3?W>H9A3<JE>!B&R)%AI?C0YQ
MN[+@3X;2HY>BS)7_PI\1/?DL5'UA3B3>6R,N>TH+'=@V6E<&BC'R8+2A#!0.
M=U>M(F22(/[7;^+J7<3LV@?.C=96K^V,;LPM^#CS(Q%OA"_1ZESI@> 6Z 03
MH1!8RS"1]\0<1G?WC;ONV;MVYNZZ,'=+V!+DTAS#=X>MNN[+O@7E-PJ:EE\+
M2SDUFZ8#-/^U].YUE'XY8X3P5)&PS,F^-9O&.V_\-?9LZ7S&''FXA]I?8]^H
MW6&1@Z<>:\H<0WB7S;[&WI170C_S0(OG,GOSSXP?I9NC#N^BN3'WGG'CH>7G
M=X*N.;"7?23,7Y!*5$OHU8Y;@MW ^*?I[8Z;E]W <+DCBA8)3V(+X&LI_DK'
M-^;XQY8UN)0H%;A$1I7E)VW<R>S ')#83#0&3H3+#THF37C43<&-V?!O)!P#
M1X75<6 ."ZPI/0;LT[D*7UWX^QZ8@_XVTHV#'_EVQH^OJ,R*4O!EMCAMZ,?
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M_(G KZ4*VYRXV+?%$#65E<ZPVVG3NJ/N)YSMM/A=4:@[$3A,7NV4T /I*VA
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M[V"7/I+]+M_!E@U-4)SK^>=S'\C.KJ=71[OT_;*[R+_%_C]02P,$%     @
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MI_/$P2( ;ZW[;:# 0<Z"]-W8)B%#!TK>,U_' ")TGW9C@JE,CG2$-?+XF6.
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MO7/+G[9UVVN'=YQ<#EK]OOSA?9+FS&V/]5E+:J8F-$</JU8[L2BU$T6)/*P
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MMB8SURD6+(OJC@-H7/BS(LZ)G;DQM/2JHYYN2^[U&^$)<)3A*,,*RE0-*JF
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MQ<JRN&W7MZ0N7:.:+FJ,D%%+B<]3%Z<((OR771>W_R'GRGPK3%<6:EQ!Q]&
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MEC/9![&C#"1EH*2.=]@']@KPI+<[PX%]!>2IT.(=5<]1=8QFZAO-@[(E$XP
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M-%JDJTP.=CW'T#RLT^\9RU*P[\G6B-1FU_:L:XDDIXX.(1XS^=_-0AT>YII
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M8"KP? &Z+<57H*5-3073'07_A/([/?.ERNG((&Q9#J=LWX.PQ]+I62T._$4
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M\A)L)>A(N$[&9HQ-OP21'!*).35JS)=0E-Q':T/)H\*N,TFO>I.ZD'TZG<Y
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MM%Y$<^;CJB\P'] 26W34I,-<MD**>'@,_\$VD+WALVHP"E$.Q1W%UJ6<=D3
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M  +M?1X2,:=H")!B99<ZD%?)71)+C8.%,/0PJ.9NOZJOWJBO3-LX/BK D?>
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M3A6Y7Z=Z%+ ./1N$=)A+C)7CE?R/>7KJEG7!.14WQL%D/!V7(J05#!P,[@2
MT>TM]9O4+]=+245PZ1T.2IYZ"6>+4)XAA823WXBBTZAUC 1>DP%MK-6HD5#0
MI=#:3D&G0=V(XK5440_;AE"H;2V[.18_+-H?"C8'&Y6,PL.Q#48;NX^3;TN.
MA.K8#BEF\E[?+!H:ORD4G>D";@VRK#OM7!>(';V%E5_R:.#A%UPERN[5WL*:
MIB6_!NH(*'!A/( WDHTXZT!#=ED(9^PJ5>FM%3I,M=0S:OZ,V3&RXLWBP5T+
M$:RPME+A)%7<35%N6K;L"5PR-M?&M>I4;EF%8(E'B1R2:@F8^8,=*V3-%RHG
M1W6C*(%74$%/E<' .AD7LR<,+D0(JLSK-3Q/OQ5RKCD3''M160&X>M66^&RT
M0HIRCF=>"&1TZLW86P"_J$0D3BBB.%O5]_!^'$^T7[R0[5C5'+E>!@GD',;(
M-3MPG5E:MZ-##Z!02664F3R8 &ARWA,<Y1YX;)\A\;,/U"L>Z&(/\'S;Y!HV
MR2G@-)I10NYBIT(.:Q:C[9$M9Y4E$U:KRK> )T-!E26Q5I20<U/_(%=9*0/L
M*X<QNKDLH8J#4_\9Y2=K..M#Q-!R"3ZDQ*,5+K#((V26CRH.3:1??SD6WH#N
MC0;4@UN-M$TU"2[KRSQC8+$JB]-7F]K7<X^B77QJU0WFSHR^7G:A;85A.N6C
M4:$ZS((,B];[LP'49>AT%1@;"XYK67?<8N,O#N7%L57TD93C*QYI^8+,>M7U
M4BP$,QTDN+.7X/)6Q6Y>A:)JJM:+Q5Q9L)')RB@+2%R3G;@*DH&^[Q5!J%SR
MEX*F!EB1.[++X]F-V0OQ8]2_HQIB!=^3_($%3F0EX8KT$!4@%\0!JMIK9T19
MYZBE*0-JK/ @M1S&B16I5>A_)DCSHJ/!:\M*K6Q5Y01RD6(6G.SI61LXUH0%
M+PX+/FO"@C<=%BS#?ZV88(#J)^O.^;JZP&V$Q8Y!L.?J:\%W+%F<C5/GFI("
MJ<6)K./1X7Y\,@D*<7G%%]M;/+*=1"/^"FSWGGM+IOF$ZZ\/E5:IP,7*>U-E
M+C@K/E6U[L1@@_T-]B(9G0%@;8A9"BD;P;1=^7L6.G4L8EGQ[Y1<&\R 7F _
M)_@3*3+]O<Z6E1L%EH!G]N<7[1=K3E;R,^F!SM8=:"$'W8.P:P6\$X9%;$A;
M\2G6>:A6/=K7]V,0KX\1U)!CWR?>=/73WMBU=38U4+/;Q^R67'XK(/]K2:F4
M, IRU>86_9BQEZ#_:RD]RJ$E[</B0,' J9UH_\F#XDL;)0K5.]@FYC17OMZ5
MWTCU^.<CV<!+O-RWV]\H)=FB9/$HT%M"QP\1]%!:WC=8^T&N>S=*]EP]N+E9
M:VAYJ\FH?P0:(?[W\G7U!BL75H6 S5_@3^7;.^![6S;VVACYT(FLNR<G\^-H
MP4+G557KMZZ_"H1/P23^M&\<8E5II#%J[,PD=T3>O3A/L5'99L771L??^6YW
M-5"%T#X#6TG5Q71U=7W]]NVZQ&8+2&K*R2B/:KWE?WW&6]XS2DJ=DU/7Z72Q
M5WVO]W*#TMG*![P<-N:-58[OWS[R-6?8G.'AG>%#=[B#,]P$:]GRM:W,<]B;
MU^O\:0794'JER4>X$ZXS+V)\0](?.S)K=OY@R6#NB#MGV!7E_F%G5%%7>8L7
M^[#%CGM1;1WW.%#8*GELX.UYPUO;[9Z\:N"M@;>=P=M9 V\;'G&O[[O3?8+;
MWODV*S;?4B+Y8RPE^RW.SD^HV?"][X4B]BCL?:1&MD]HW76[IR?K7O #CWHG
M]+T!KWT"K[9[>EI)FVC JP&O38'7^<7:2G8#7@UXK0A>W;5CB+8)7,]2&%Y1
MYMVQGS",T_3YV6D/4:\\.G,[O:<PE.Y\IY7HD ;@G@3@.NZKW@]ARV@ ;B\
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MP9P^E6*$S]OILS>.V#=LQT8T!6@>Y'Z&7M9!@.09,!OP!3_#K[6I.$M I&)
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M"@5,=XXU"448\[6@2Y*J\R#[J=0?XI8)5.WI/M:T4L)C[#4TB'/,ZK;C_?<
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M L>GDRN>(\X"$^:3J6SBB\%?\.\HQD71%@H#Z6N3[C>U?>KV'0"H)=IYF]J
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M+GAS9%!+ 0(4 Q0    ( - [#%6$44X3ZP<  'AA   5              "
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M   0              "  7^+  !E>&AI8FET7S,Q+3(N:'1M4$L! A0#%
M  @ T#L,57.O&5SC!   81D  !               ( !?Y0  &5X:&EB:71?
M,S(M,2YH=&U02P$"% ,4    " #0.PQ5& RTL@L%  !_&   $
M    @ &0F0  97AH:6)I=%\S,BTR+FAT;5!+ 0(4 Q0    ( - [#%7;UGZ'
M,<,  .+<"P -              "  <F>  !Z:S(R,C@R,S(N:'1M4$L%!@
0   *  H ?@(  "5B 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
